PharmGKB_ID,RS_ID,Allele_ID,Allele,Phenotype,phenotype_description,single_drug,gender,score_efficacy,score_toxicity,score_pk,score_dosage,score_plasma_concentration,orientation,auditor
PA166135983,rs10046,1447681814,AA,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of  triglycerides as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.",携带AA基因型的绝经后期乳腺癌妇女，相比AG或GG基因型，血浆甘油三酯浓度可能降低,1,女,,0,,,,plus,郭望
PA166135983,rs10046,1447681815,AG,"Post-menopausal women with the AG genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with GG genotypes and increased levels as compared to women with the AA genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.",携带AG基因型的绝经后期乳腺癌妇女，相比GG基因型，血浆甘油三酯浓度可能降低，相比AA基因型，血浆甘油三酯浓度可能升高,1,女,,1,,,,plus,郭望
PA166135983,rs10046,1447681816,GG,"Post-menopausal women with the GG genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of triglycerides as compared to women with the AA or AG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.",携带GG基因型的绝经后期乳腺癌妇女，相比AG或AA基因型，血浆甘油三酯浓度可能升高,1,女,,2,,,,plus,郭望
PA166136375,rs10210302,1445401327,CC,Patients with the CC genotype and Crohn's disease may have a poorer response to treatment with adalimumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to adalimumab.,携带CC基因型的克罗恩病人，相比CT或TT基因型，药效可能更差,1,,0,,,,,plus,郭望
PA166136375,rs10210302,1445401328,CT,Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.,携带CT基因型的克罗恩病人，相比CC基因型，药效可能更好,1,,2,,,,,plus,郭望
PA166136375,rs10210302,1445401329,TT,Patients with the TT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.,携带TT基因型的克罗恩病人，相比CC基因型，药效可能更好,1,,2,,,,,plus,郭望
PA166135337,rs10264272,1183699863,CC,"Transplant recipients with the CC (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus and require a higher dose of the drug as compared to patients with the CT or TT (*1/*6 or *6/*6) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.携带CC (CYP3A5 *1/*1)基因型的移植患者，相比CT或TT基因型，代谢增加需要较高剂量",携带CC (CYP3A5 *1/*1)基因型的移植患者，相比CT或TT基因型，可能代谢较快需要增加剂量,1,,,,,2,,plus,郭望
PA166135337,rs10264272,1183699864,CT,"Transplant recipients with the CT (CYP3A5 *1/*6) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the CC (*1/*1) genotype, and have increased metabolism and require a higher dose of the drug as compared to patients with the TT (*6/*6) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.",携带CT (CYP3A5 *1/*6)基因型的移植患者，相比CC基因型，可能代谢较慢需要减少剂量，相比于TT基因型，可能代谢较快需要增加剂量,1,,,,,1,,plus,郭望
PA166135337,rs10264272,1183699865,TT,"Transplant recipients with the TT (CYP3A5 *6/*6) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the CT or CC (*1/*6 or *1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.",携带TT (CYP3A5 *6/*6) 基因型的移植患者，相比CC或CT基因型，可能代谢较慢需要减少剂量,1,,,,,0,,plus,郭望
PA166135692,rs10306114,1444667728,AA,Patients with the AA genotype and open-angle glaucoma may have an increased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed. ,携带AA基因型的开角型青光眼患者，相比AG或GG基因型，药效可能增加,1,,2,,,,,plus,郭望
PA166135692,rs10306114,1444667729,AG,Patients with the AG genotype and open-angle glaucoma may have a decreased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost.,携带AG基因型的开角型青光眼患者，相比AA基因型，药效可能降低,1,,0,,,,,plus,郭望
PA166135692,rs10306114,1444667730,GG,Patients with the GG genotype and open-angle glaucoma may have a decreased response to latanoprost  (as determined by a reduction in intraocular pressure) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to latanoprost. *Please note: in the single study listed below individuals of genotype GG were not analyzed. ,携带GG基因型的开角型青光眼患者，相比AA基因型，药效可能降低,1,,0,,,,,plus,郭望
PA166134811,rs10306114,1183685523,AA,"Patients with the AA genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.",携带AA基因型的患者，相比AG或GG基因型，药物无效的风险可能降低,1,,2,,,,,plus,郭望
PA166134811,rs10306114,1183685524,AG,Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带AG基因型的患者，相比AA基因型，药物无效的风险可能增加,1,,0,,,,,plus,郭望
PA166134811,rs10306114,1183685525,GG,Patients with the GG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带GG基因型的患者，相比AA基因型，药物无效的风险可能增加,1,,0,,,,,plus,郭望
PA166136192,rs1042151,1444667544,AA,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带AA基因型的哮喘患者，相比AG或GG基因型，用药诱导的哮喘风险可能降低,1,,,0,,,,plus,郭望
PA166136192,rs1042151,1444667545,AG,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带AG基因型的哮喘患者，相比AA基因型，用药诱导的哮喘风险可能增加；相比GG基因型，用药诱导的哮喘风险可能降低,1,,,1,,,,plus,郭望
PA166136192,rs1042151,1444667546,GG,Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带GG基因型的哮喘患者，相比AA或AG基因型，用药诱导的哮喘风险可能增加,1,,,2,,,,plus,郭望
PA166152861,rs1041983,1447964073,CC,Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.,携带CC基因型的肺结核患者，相比TT基因型，肝毒性风险可能降低,1,,,0,,,,plus,郭望
PA166152861,rs1041983,1447964074,CT,"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.",携带CT基因型的肺结核患者，相比TT基因型，肝毒性风险可能降低；相比CC基因型，肝毒性风险可能增加,1,,,1,,,,plus,郭望
PA166152861,rs1041983,1447964075,TT,Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.,携带TT基因型的肺结核患者，相比CC基因型，肝毒性风险可能增加,1,,,2,,,,plus,郭望
PA166135266,rs10423928,1447952963,AA,Patients with the AA genotype may have increased plasma insulin levels and increased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.,携带AA基因型的精神分裂症患者，相比TT基因型，血浆胰岛素水平可能升高，体重增加的可能性增加,1,,,2,,,,plus,郭望
PA166135266,rs10423928,1447952964,AT,"Patients with the AT genotype may have decreased plasma insulin levels when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. However, patients with the AT genotype may have increased severity of weight gain as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.",携带AT基因型的精神分裂症患者，相比AA基因型，血浆胰岛素水平可能降低，相比TT基因型，体重增加的可能性增加,1,,,2,,,,plus,郭望
PA166135266,rs10423928,1447952965,TT,Patients with the TT genotype may have decreased plasma insulin levels and decreased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype AA. Other genetic and clinical factors may also influence a patient's response to olanzapine.,携带TT基因型的精神分裂症患者，相比AA基因型，血浆胰岛素水平可能降低，体重增加的可能性降低,1,,,0,,,,plus,郭望
PA166135095,rs1042640,1183614869,CC,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带CC基因型的患者，相比CG或GG基因型，无意的药物过量引起的肝衰竭风险可能增加,1,,,2,,,,plus,郭望
PA166135095,rs1042640,1183614870,CG,Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带CG基因型的患者，相比CC基因型，无意的药物过量引起的肝衰竭风险可能降低,1,,,0,,,,plus,郭望
PA166135095,rs1042640,1183614871,GG,Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带GG基因型的患者，相比CC基因型，无意的药物过量引起的肝衰竭风险可能降低,1,,,0,,,,plus,郭望
PA166134349,rs1042522,1448266883,CC,Patients with the CC genotype may have 1) decreased but not absent risk for toxicity 2) increased survival when treated with antineoplastic agents as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.,携带CC基因型的患者，相比CG或GG基因型，毒性风险可能降低，生存期可能延长,1,,,0,,,,minus,郭望
PA166134349,rs1042522,1448266884,CG,Patients with the CG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.,携带CG基因型的患者，相比CC基因型，毒性风险可能增加，生存期可能缩短,1,,,2,,,,minus,郭望
PA166134349,rs1042522,1448266885,GG,Patients with the GG genotype may have 1) increased risk for toxicity 2) decreased survival when treated with antineoplastic agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.,携带GG基因型的患者，相比CC基因型，毒性风险可能增加，生存期可能缩短,1,,,2,,,,minus,郭望
PA166136204,rs10455872,1444827827,AA,Patients with the AA genotype may have an increased response to hmg coa reductase inhibitors and (according to one study) a decreased risk of coronary artery disease as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. ,携带AA基因型的患者，相比AG或GG基因型，药效可能增加，冠状动脉疾病风险可能降低,1,,2,,,,,plus,郭望
PA166136204,rs10455872,1444827828,AG,Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors and (according to one study) a decreased risk of coronary artery disease as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors and an increased risk of coronary artery disease as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. ,携带AG基因型的患者，相比GG基因型，药效可能增加，冠状动脉疾病风险可能降低；相比AA基因型，药效可能降低，冠状动脉疾病风险可能增加,1,,1,,,,,plus,郭望
PA166136204,rs10455872,1444827829,GG,Patients with the GG genotype may have a decreased response to hmg coa reductase inhibitors and (according to one study) an increased risk of coronary artery disease as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors. ,携带GG基因型的患者，相比AG或AA基因型，药效可能降低，冠状动脉疾病风险可能增加,1,,0,,,,,plus,郭望
PA166161948,rs10485058,1448526042,AA,Patients with the AA genotype who are opioid-dependent may have a better response to treatment with methadone as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone response.,携带AA基因型的阿片类药物依赖患者，相比AG或GG基因型，药效可能较好,1,,2,,,,,FWD,郭望
PA166161948,rs10485058,1448526043,AG,Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone response.,携带AG基因型的阿片类药物依赖患者，相比AA基因型，药效可能较差,1,,0,,,,,FWD,郭望
PA166161948,rs10485058,1448526044,GG,Patients with the GG genotype who are opioid-dependent may have a poorer response to treatment with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone response.,携带GG基因型的阿片类药物依赖患者，相比AA基因型，药效可能较差,1,,0,,,,,FWD,郭望
PA166136022,rs10490924,1447946021,GG,"Patients with the GG genotype and age-related macular degeneration who are treated with bevacizumab may have poorer improvement in visual acuity as compared to patients with the GT or TT genotype. However, another study finds that those with the GG genotype have better improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.",携带GG基因型的老年性黄斑变性患者，相比GT或TT基因型，对视力提升作用可能较差,1,,0,,,,,plus,郭望
PA166136022,rs10490924,1447946022,GT,Patients with the GT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.,携带GT基因型的老年性黄斑变性患者，相比GG基因型，对视力提升作用可能较好,1,,2,,,,,plus,郭望
PA166136022,rs10490924,1447946023,TT,"Patients with the TT genotype and age-related macular degeneration who are treated with bevacizumab may have better improvement in visual acuity as compared to patients with the GG genotype. However, another study finds that those with the TT genotype have poorer improvement in visual acuity. Other genetic and clinical factors may also influence a patient's response to bevacizumab treatment.",携带TT基因型的老年性黄斑变性患者，相比GG基因型，对视力提升作用可能较好,1,,2,,,,,plus,郭望
PA166152636,rs10494227,1448106268,AA,Patients with the AA genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.,携带AA基因型的多发性硬化患者，相比GG基因型，药效可能增加,1,,2,,,,,FWD,郭望
PA166152636,rs10494227,1448106269,AG,"Patients with the AG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the GG genotype, or a decreased response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.",携带AG基因型的多发性硬化患者，相比GG基因型，药效可能增加；相比AA基因型，药效可能降低,1,,1,,,,,FWD,郭望
PA166152636,rs10494227,1448106270,GG,Patients with the GG genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.,携带GG基因型的多发性硬化患者，相比AA基因型，药效可能降低,1,,0,,,,,FWD,郭望
PA166134949,rs10494366,1183491002,GG,"Patients with the GG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have a decreased, but not absent, risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.",携带GG基因型的患者，相比TT或GT基因型，手术局部麻醉时，QTc延长风险可能降低,1,,,0,,,,plus,郭望
PA166134949,rs10494366,1183491001,TG,Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.,携带TG基因型的患者，相比GG基因型，手术局部麻醉时，QTc延长风险可能增加,1,,,2,,,,plus,郭望
PA166134949,rs10494366,1183491000,TT,Patients with the TT genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.,携带TT基因型的患者，相比GG基因型，手术局部麻醉时，QTc延长风险可能增加,1,,,2,,,,plus,郭望
PA166134183,rs10494366,655384899,GG,Patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.,携带GG基因型的患者，相比TT基因型， QTc间期延长的风险可能增加,1,,,2,,,,plus,郭望
PA166134183,rs10494366,655384900,GT,"While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype, it was not shown conclusively if heterzygous (GT) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.",GT 基因型研究结果未知,1,,,,,,,plus,郭望
PA166134183,rs10494366,655384901,TT,"Patients with the TT genotype may have a decreased, but not absent, risk for QTc prolongation during verapamil treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.",携带TT基因型的患者，相比GG基因型， QTc间期延长的风险可能降低,1,,,0,,,,plus,郭望
PA166159191,rs10494366,1448103820,GG,Patients with the GG genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.,携带GG基因型的高血压患者，相比TT基因型，心血管不良反应和全因死亡率可能增加,1,,,2,,,,plus,郭望
PA166159191,rs10494366,1448103821,GT,Patients with the GT genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.,携带GT基因型的高血压患者，相比TT基因型，心血管不良反应和全因死亡率可能增加,1,,,2,,,,plus,郭望
PA166159191,rs10494366,1448103822,TT,Patients with the TT genotype and hypertension may have a decreased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.,携带TT基因型的高血压患者，相比TG或GG基因型，心血管不良反应和全因死亡率可能降低,1,,,0,,,,plus,郭望
PA166159203,rs10494366,1448103937,GG,Patients with the GG genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to repaglinide. ,携带GG基因型的II型糖尿病患者，相比TT基因型，药效可能较差,1,,0,,,,,plus,郭望
PA166159203,rs10494366,1448103938,GT,"Patients with the GT genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide. ",携带GT基因型的II型糖尿病患者，相比TT基因型，药效可能较差；相比GG基因型，药效可能较好,1,,1,,,,,plus,郭望
PA166159203,rs10494366,1448103939,TT,Patients with the TT genotype and type 2 diabetes may have a better response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide. ,携带TT基因型的II型糖尿病患者，相比GG基因型，药效可能较好,1,,2,,,,,plus,郭望
PA166158998,rs10509373,1448100663,CC,Patients with the CC genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.,携带CC基因型的乳腺癌患者，相比TT基因型，无瘤生存期可能更短,1,,0,,,,,plus,郭望
PA166158998,rs10509373,1448100664,CT,Patients with the CT genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.,携带CT基因型的乳腺癌患者，相比TT基因型，无瘤生存期可能更短,1,,0,,,,,plus,郭望
PA166158998,rs10509373,1448100665,TT,Patients with the TT genotype and breast cancer may have longer recurrence-free survival times when treated with tamoxifen as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.,携带TT基因型的乳腺癌患者，相比CC或CT基因型，无瘤生存期可能更长,1,,2,,,,,plus,郭望
PA166134867,rs10509680,1043880376,GG,Patients with the GG genotype may require increased dose of warfarin when treated with warfarin as compared to patients with the TT or TG genotype. Other clinical or genetic factors may also influence the dose of warfarin.,携带GG基因型的患者，相比TT或TG基因型，可能需要增加剂量,1,,,,,2,,plus,郭望
PA166134867,rs10509680,1043880377,TG,Patients with the TG genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.,携带TG基因型的患者，相比GG基因型，可能需要减少剂量,1,,,,,0,,plus,郭望
PA166134867,rs10509680,1043880378,TT,Patients with the TT genotype may require decreased dose of warfarin when treated with warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence the dose of warfarin.,携带TT基因型的患者，相比GG基因型，可能需要减少剂量,1,,,,,0,,plus,郭望
PA166134144,rs10509681,1448605617,CC,"Patients with the CC genotype (CYP2C8*3/*3) may have increased metabolism of rosiglitazone, a smaller change in HbA1c, and a decreased risk of edema as compared to patients with the TT genotype (CYP2C8*1/*1). One study found no association with blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels.",携带CC基因型的患者，相比TT基因型，药物代谢可能加快，HbA1c改变可能更小，水肿的风险可能降低,1,,,,2,,,plus,郭望
PA166134144,rs10509681,1448605618,CT,"Patients with the CT (CYP2C8*3/*1) genotype may have increased metabolism of rosiglitazone and a decreased risk of edema compared to patients with the TT genotype (CYP2C8*1/*1). No association was found when considering blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels.",携带CT基因型的患者，相比TT基因型，药物代谢可能加快，水肿的风险可能降低,1,,,,2,,,plus,郭望
PA166134144,rs10509681,1448605619,TT,"Patients with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of rosiglitazone, a larger change in HbA1c, and an increased risk of edema as compared to patients with the CC (CYP2C8*3/*3) or CT (CYP2C8*3/*1) genotype. One study found no association with blood glucose levels. Other genetic and clinical factors may also influence metabolism of rosiglitazone, risk of edema and blood glucose levels.",携带TT (CYP2C8*1/*1)基因型的患者，相比CT或CC基因型，药物代谢可能减慢，HbA1c改变可能更大，水肿的风险可能增加,1,,,,0,,,plus,郭望
PA166134455,rs10509681,978639597,CC,"Individuals with the CC genotype were not studied, however individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide and blood glucose levels.",无CC基因型患者参与研究,1,,,,,,,plus,郭望
PA166134455,rs10509681,978639598,CT,"Individuals with the CT (CYP2C8*3/*1) genotype may have increased metabolism of repaglinide compared to patients with the TT genotype (CYP2C8*1/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.",携带CT基因型的患者，相比TT基因型，药物代谢可能更快,1,,,,2,,,plus,郭望
PA166134455,rs10509681,978639599,TT,"Individuals with the TT (CYP2C8*1/*1) genotype may have decreased metabolism of repaglinide compared to patients with the CT genotype (CYP2C8*3/*1). No association was found with differences in blood glucose lowering efficacy. Please note, the study supporting this annotation was carried out in healthy volunteers. Other genetic and clinical factors may also influence metabolism of repaglinide.",携带TT基因型的患者，相比CT基因型，药物代谢可能更慢,1,,,,0,,,plus,郭望
PA166151938,rs10514475,1447953104,AA,Patients with the AA genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.,携带AA基因型的抑郁症患者，相比AG或GG基因型，药效可能增加,1,,2,,,,,FWD,郭望
PA166151938,rs10514475,1447953105,AG,Patients with the AG genotype and depression may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's respond to SSRIs.,携带AG基因型的抑郁症患者，相比GG基因型，药效可能增加,1,,2,,,,,FWD,郭望
PA166151938,rs10514475,1447953106,GG,Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.,携带GG基因型的抑郁症患者，相比AA或AG基因型，药效可能降低,1,,0,,,,,FWD,郭望
PA166134302,rs1051740,655385990,CC,Patients with the CC genotype who use phenytoin during the first trimester of pregnancy may be less likely to have a child with a craniofacial abnormality as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of having a child with a craniofacial abnormality.,携带CC基因型的患者，相比CT或TT基因型，妊娠前三个月用药，生出颅面异常孩子的可能性更小,1,女,,0,,,,plus,郭望
PA166134302,rs1051740,655385991,CT,Patients with the CT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.,携带CT基因型的患者，相比CC基因型，妊娠前三个月用药，生出颅面异常孩子的可能性更大,1,女,,2,,,,plus,郭望
PA166134302,rs1051740,655385992,TT,Patients with the TT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.,携带TT基因型的患者，相比CC基因型，妊娠前三个月用药，生出颅面异常孩子的可能性更大,1,女,,2,,,,plus,郭望
PA166134607,rs1051740,1447679978,CC,"Patients with the CC genotype and Epilepsy may have higher metabolism of carbamazepine and may require an increased dose of carbamazepine as compared to patients with the the CT or TT genotypes, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.",携带CC基因型的癫痫患者，相比CT或TT基因型，药物代谢可能更快，药物剂量可能需要增加,1,,,,,2,,plus,郭望
PA166134607,rs1051740,1447679979,CT,"Patients with the CT genotype and Epilepsy may have higher metabolism of carbamazepine and may require an increased dose of carbamazepine as compared to patients with the the TT genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.",携带CT基因型的癫痫患者，相比TT基因型，药物代谢可能更快，药物剂量可能需要增加,1,,,,,2,,plus,郭望
PA166134607,rs1051740,1447679980,TT,"Patients with the TT genotype and Epilepsy may have lower metabolism of carbamazepine and may require a decreased dose of carbamazepine as compared to patients with the the CC or CT genotypes, although this is contradicted in some studies. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.",携带TT基因型的癫痫患者，相比CC或CT基因型，药物代谢可能更慢，药物剂量可能需要减少,1,,,,,0,,plus,郭望
PA166152673,rs1051740,1447960240,CC,"Patients with the CC genotype may have a greater likelihood of being overanticoagulated when treated with phenprocoumon, and may require a decreased dose, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.",携带CC基因型的患者，相比CT或TT基因型，过度抗凝的可能性较大，可能需要降低剂量,1,,2,,,,,plus,郭望
PA166152673,rs1051740,1447960241,CT,"Patients with the CT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.",携带CT基因型的患者，相比CC基因型，过度抗凝的可能性较小，可能需要增加剂量,1,,0,,,,,plus,郭望
PA166152673,rs1051740,1447960242,TT,"Patients with the TT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.",携带TT基因型的患者，相比CC基因型，过度抗凝的可能性较小，可能需要增加剂量,1,,0,,,,,plus,郭望
PA166134695,rs1051730,982031884,AA,Patients with the AA genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.,携带AA基因型的尼古丁依赖患者，相比GG基因型，使用替代疗法，戒烟6个月的可能性增加,1,,2,,,,,plus,郭望
PA166134695,rs1051730,982031885,AG,Patients with the AG genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.,携带AG基因型的尼古丁依赖患者，相比GG基因型，使用替代疗法，戒烟7个月的可能性增加,1,,2,,,,,plus,郭望
PA166134695,rs1051730,982031886,GG,Patients with the GG genotype may have decreased chance of achieving 6 month abstinence if prescribed NRT (nicotiene replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to smoking cessation therapies.,携带GG基因型的尼古丁依赖患者，相比AA基因型，使用替代疗法，戒烟8个月的可能性降低,1,,0,,,,,plus,郭望
PA166135733,rs1051730,1444700406,AA,"Patients with the AA genotype may have an increased risk for nicotine dependency, decreased lung function when exposed to nicotine, but may experience an increased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.",携带AA基因型的尼古丁依赖患者，相比GG基因型，接触尼古丁时，更易成瘾，且肺部功能降低的可能性增加,1,,0,,,,,plus,郭望
PA166135733,rs1051730,1444700407,AG,"Patients with the AG genotype may have an increased risk for nicotine dependency, decreased lung function when exposed to nicotine, but may experience an increased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the GG genotype or a decreased risk for nicotine dependency and decreased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.",携带AG基因型的尼古丁依赖患者，相比GG基因型，接触尼古丁时，更易成瘾，且肺部功能降低的可能性增加,1,,0,,,,,plus,郭望
PA166135733,rs1051730,1444700408,GG,"Patients with the GG genotype may have an decreased risk for nicotine dependency, increased lung function when exposed to nicotine, but may experience decreased chance of achieving 6 month abstinence if prescribed nicotine replacement therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.",携带GG基因型的尼古丁依赖患者，相比AA基因型，接触尼古丁时，成瘾性降低，且肺部功能降低的可能性降低,1,,2,,,,,plus,郭望
PA166159194,rs1051730,1448103841,AA,Patients with the AA genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of alcoholism.,携带AA基因型的人群，相比GG基因型，酗酒可能性降低,1,,,0,,,,plus,郭望
PA166159194,rs1051730,1448103842,AG,"Patients with the AG genotype may have a decreased risk for alcoholism as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.",携带AG基因型的人群，相比GG基因型，酗酒可能性降低,1,,,2,,,,plus,郭望
PA166159194,rs1051730,1448103843,GG,Patients with the GG genotype may have an increased risk for alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.,携带GG基因型的人群，相比AA基因型，酗酒可能性增加,1,,,2,,,,plus,郭望
PA166136295,rs1061170,1448100736,CC,"Patients with the CC genotype and macular degeneration may have a poorer improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CT or TT genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.",携带CC基因型的黄斑变性患者，相比CT或TT患者，视力提升效果可能更小,1,,0,,,,,plus,郭望
PA166136295,rs1061170,1448100737,CT,"Patients with the CT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.",携带CT基因型的黄斑变性患者，相比CC患者，视力提升效果可能更大,1,,2,,,,,plus,郭望
PA166136295,rs1061170,1448100738,TT,"Patients with the TT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.",携带TT基因型的黄斑变性患者，相比CC患者，视力提升效果可能更大,1,,2,,,,,plus,郭望
PA166152675,rs1061170,1447960264,CC,"Patients with the CC genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.",携带CC基因型的老年黄斑变性患者，相比TT基因型，可能具有更好的效果,1,,2,,,,,plus,郭望
PA166152675,rs1061170,1447960265,CT,"Patients with the CT genotype and age-related macular degeneration may have a better response to treatment with photodynamic therapy as compared to patients with the TT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.",携带CT基因型的老年黄斑变性患者，相比TT基因型，可能具有更好的效果,1,,2,,,,,plus,郭望
PA166152675,rs1061170,1447960266,TT,"Patients with the TT genotype and age-related macular degeneration may have a poorer response to treatment with photodynamic therapy as compared to patients with the CC or CT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.",携带TT基因型的老年黄斑变性患者，相比CC或CT基因型，可能具有更差的效果,1,,0,,,,,plus,郭望
PA166136106,rs1061170,1444607329,CC,No patients with the CC genotype available for analysis.,无CC基因型患者参与研究,1,,,,,,,plus,郭望
PA166136106,rs1061170,1444607328,CT,Patients with the CT genotype and age-related macular degeneration may require a greater number of bevacizumab injections as compared to those with the TT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.,携带CT基因型的老年黄斑变性患者，相比TT基因型，注射量可能需要增加,1,,,,,2,,plus,郭望
PA166136106,rs1061170,1444607327,TT,Patients with the TT genotype and age-related macular degeneration may require a fewer number of bevacizumab injections as compared to those with the CT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.,携带TT基因型的老年黄斑变性患者，相比CT基因型，注射量可能需要减少,1,,,,,0,,plus,郭望
PA166135612,rs1063320,1184988841,CC,Patients with asthma and the CC genotype may have an increased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CG and GG genotypes. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.,携带CC基因型的哮喘患者，相比CG或GG基因型，哮喘症状加重可能性增加,1,,0,,,,,minus,郭望
PA166135612,rs1063320,1184988842,CG,Patients with asthma and the CG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.,携带CG基因型的哮喘患者，相比CC基因型，哮喘症状加重可能性降低,1,,2,,,,,minus,郭望
PA166135612,rs1063320,1184988843,GG,Patients with asthma and the GG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.,携带GG基因型的哮喘患者，相比CC基因型，哮喘症状加重可能性降低,1,,2,,,,,minus,郭望
PA166135116,rs1062613,1183630693,CC,Patients with the CC genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.,携带CC基因型的精神分裂症患者，相比TT基因型，药物起效的可能性降低,1,,0,,,,,plus,郭望
PA166135116,rs1062613,1183630694,CT,"Patients with the CT genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype, or may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.",携带CT基因型的精神分裂症患者，相比TT基因型，药物起效的可能性降低；相比CC基因型，药物起效的可能性增加,1,,1,,,,,plus,郭望
PA166135116,rs1062613,1183630695,TT,Patients with the TT genotype and schizophrenia may be more likely to respond to treatment with clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to clozapine.,携带TT基因型的精神分裂症患者，相比CC基因型，药物起效的可能性增加,1,,2,,,,,plus,郭望
PA166135089,rs1065852,1183614831,AA,Patients with the AA genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.,携带AA基因型的精神分裂症患者，相比GG基因型，QTc间隔可能缩短,1,,2,,,,,plus,郭望
PA166135089,rs1065852,1183614832,AG,Patients with the AG genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.,携带AG基因型的精神分裂症患者，相比GG基因型，QTc间隔可能缩短,1,,2,,,,,plus,郭望
PA166135089,rs1065852,1183614833,GG,Patients with the GG genotype and schizophrenia may have an increased QTc interval when treated with iloperidone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence QTc interval.,携带GG基因型的精神分裂症患者，相比AA或AG患者基因型，QTc间隔可能增加,1,,0,,,,,plus,郭望
PA166136114,rs1065852,1444700530,AA,Patients with the AA genotype and depression may have a decreased response and remission rate when treated with escitalopram as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also effect patients response.,携带AA基因型的抑郁症患者，相比AG或GG基因型，药效和缓解作用可能降低,1,,0,,,,,plus,郭望
PA166136114,rs1065852,1444700531,AG,Patients with the AG genotype and depression may have a increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients response.,携带AG基因型的抑郁症患者，相比AA基因型，药效和缓解作用可能增加,1,,2,,,,,plus,郭望
PA166136114,rs1065852,1444700532,GG,Patients with the GG genotype and depression may have a increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients response.,携带GG基因型的抑郁症患者，相比AA基因型，药效和缓解作用可能增加,1,,2,,,,,plus,郭望
PA166135398,rs10757274,1183700537,AA,"Patients with the AA genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.",携带AA基因型的人群，相比GG基因型，急性冠脉综合征的可能性降低,1,,2,,,,,plus,郭望
PA166135398,rs10757274,1183700538,AG,"Patients with the AG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.",携带AG基因型的人群，相比GG基因型，急性冠脉综合征的可能性降低,1,,2,,,,,plus,郭望
PA166135398,rs10757274,1183700539,GG,"Patients with the GG genotype may have increased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.",携带GG基因型的人群，相比AG或AA基因型，急性冠脉综合征的可能性增加,1,,0,,,,,plus,郭望
PA166134413,rs1057910,769181842,AA,Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,携带AA基因型的患者，相比AC或CC基因型，可能需要增加剂量,1,,,,,2,,plus,郭望
PA166134413,rs1057910,769181843,AC,Patients with the AC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,携带AC基因型的患者，相比AA基因型，可能需要减少剂量,1,,,,,0,,plus,郭望
PA166134413,rs1057910,769181844,CC,Patients with the CC genotype may require decreased dose of acenocoumarol or closer INR monitoring as compared to patients with the AA genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,携带CC基因型的患者，相比AA基因型，可能需要减少剂量,1,,,,,0,,plus,郭望
PA166134907,rs1057910,1045153884,AA,Patients with the AA (CYP2C9*1/*1) genotype may have lower plasma levels of fluvastatin as compared to patients with the AC (CYP2C9*1/*3) or CC (CYP2C9*3/*3) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics.,携带AA基因型的患者，相比AC或CC基因型，血药浓度可能较低,1,,,,,,0,plus,郭望
PA166134907,rs1057910,1045153883,AC,Patients with the AC (CYP2C9*1/*3) genotype may have higher plasma levels of fluvastatin as compared to patients with the AA (CYP2C9*1/*1) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics. ,携带AC基因型的患者，相比AA基因型，血药浓度可能较高,1,,,,,,2,plus,郭望
PA166134907,rs1057910,1045153882,CC,Patients with the CC (CYP2C9*3/*3) genotype may have higher plasma levels of fluvastatin as compared to patients with the AC (CYP2C9*1/*3) or AA (CYP2C9*1/*1) genotype. This association does not seem to affect response to fluvastatin treatment or risk of myopathy. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment and pharmacokinetics. ,携带CC基因型的患者，相比AA基因型，血药浓度可能较高,1,,,,,,2,plus,郭望
PA166134154,rs1057910,1448431553,AA,Patients with the AA genotype: 1) may require an increased dose of warfarin as compared to patients with the AC or CC genotype 2) may have a decreased risk for adverse events as compared to patients with the AC or CC genotype. Patients with the AA genotype may still be at risk for adverse events when taking warfarin based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.,携带AA基因型患者，相比AC或CC基因型，可能需要增加药物的剂量，不良反应风险可能降低,1,,,0,,2,,plus,郭望
PA166134154,rs1057910,1448431554,AC,Patients with the AC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.,携带AC基因型患者，相比AA基因型，可能需要减少药物的剂量，不良反应风险可能增加,1,,,2,,0,,plus,郭望
PA166134154,rs1057910,1448431555,CC,Patients with the CC genotype: 1) may require a decreased dose of warfarin as compared to patients with the AA genotype 2) may have an increased risk for adverse events as compared to patients with the AA genotype.,携带CC基因型患者，相比AA基因型，可能需要减少药物的剂量，不良反应风险可能增加,1,,,2,,0,,plus,郭望
PA166134443,rs1057910,1183693355,AA,Patients with the AA (CYP2C9 *1/*1) genotype may have increased metabolism of celecoxib as compared to patients with the AC or CC (*1/*3 or *3/*3) genotype. Other genetic and clinical factors may also influence a metabolism of celecoxib., 携带AA基因型的患者，相比AC或CC基因型，药物代谢可能较快,1,,,,2,,,plus,郭望
PA166134443,rs1057910,1183693356,AC,"Patients with the AC (CYP2C9 *1/*3) genotype may have reduced metabolism of celecoxib as compared to patients with the AA (*1/*1) genotype, and increased metabolism as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence metabolism of celecoxib. ", 携带AC基因型的患者，相比AA基因型，药物代谢可能较慢；相比CC基因型，药物代谢可能较快,1,,,,1,,,plus,郭望
PA166134443,rs1057910,1183693357,CC,Patients with the CC (CYP2C9 *3/*3) genotype may have reduced metabolism of celecoxib as compared to patients with the AA or AC (*1/*1 or *1/*3) genotype. Other genetic and clinical factors may also influence metabolism of celecoxib. , 携带CC基因型的患者，相比AA或CC基因型，药物代谢可能较慢,1,,,,0,,,plus,郭望
PA166134604,rs1057910,981238438,AA,"Patients with the AA genotype who are treated with non-steroid antiinflammatory agents, celecoxib or diclofenac may have a decreased, but not absent, risk of gastrointestinal bleeding as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.",携带AA基因型的患者，相比AC或CC基因型，胃肠道不良反应风险可能降低,1,,,0,,,,plus,郭望
PA166134604,rs1057910,981238439,AC,"Patients with the AC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.",携带AC基因型的患者，相比AA基因型，胃肠道不良反应风险可能增加,1,,,2,,,,plus,郭望
PA166134604,rs1057910,981238440,CC,"Patients with the CC genotype who are treated with non-steroids antiinflammatory agents, celecoxib or diclofenac may have an increased risk of gastrointestinal bleeding as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to Antiinflammatory agents, non-steroids, celecoxib or diclofenac.",携带CC基因型的患者，相比AA基因型，胃肠道不良反应风险可能增加,1,,,2,,,,plus,郭望
PA166134605,rs1057910,1043737391,AA,Subjects with the AA genotype who are treated with losartan may have increased metabolism of losartan as compared to subjects with the CA and CC genotype. Other genetic and clinical factors may also influence metabolism of losartan.,携带AA基因型的患者，相比AC或CC基因型，药物代谢可能较快,1,,,,2,,,plus,郭望
PA166134605,rs1057910,1043737392,AC,Subjects with the AC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.,携带AC基因型的患者，相比AA基因型，药物代谢可能较慢,1,,,,0,,,plus,郭望
PA166134605,rs1057910,1043737393,CC,Subjects with the CC genotype who are treated with losartan may have decreased metabolism of losartan as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence metabolism of losartan.,携带CC基因型的患者，相比AA基因型，药物代谢可能较慢,1,,,,0,,,plus,郭望
PA166134606,rs1057910,981238502,AA,"Patients with the AA genotype and with Epilepsy who are treated with phenytoin may have an increased metabolism, decreased plasma free phenytoin concentration, and decreased, but not absent, risk of Drug Toxicity as compared to patients with the AC and CC genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.",携带AA基因型的癫痫患者，相比AC或CC基因型，药物代谢可能较快，血药浓度可能降低，药物毒性可能降低,1,,2,,,,,plus,郭望
PA166134606,rs1057910,981238503,AC,"Patients with the AC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.",携带AC基因型的癫痫患者，相比AA基因型，药物代谢可能较慢，血药浓度可能增加，药物毒性可能增加,1,,0,,,,,plus,郭望
PA166134606,rs1057910,981238504,CC,"Patients with the CC genotype and with Epilepsy who are treated with phenytoin may have a decreased metabolism, increased plasma free phenytoin concentration, and increased likelihood of Drug Toxicity as compared to patients with the AA genotype. However, these associations are contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.",携带CC基因型的癫痫患者，相比AA基因型，药物代谢可能较慢，血药浓度可能增加，药物毒性可能增加,1,,0,,,,,plus,郭望
PA166134741,rs1057910,1448278850,AA,"Patients with the AA genotype may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AC or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. ",携带AA基因型的，相比AC或CC基因型，抑制血小板凝集作用可能增加，高氯吡格雷血小板反应和药效差的可能性降低,1,,2,,,,,plus,郭望
PA166134741,rs1057910,1448278851,AC,"Patients with the AC genotype may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.  ",携带AC基因型的，相比AA基因型，抑制血小板凝集作用可能降低，高氯吡格雷血小板反应和药效差的可能性增加,1,,0,,,,,plus,郭望
PA166134741,rs1057910,1448278852,CC,"Patients with the CC genotype may have 1) decreased inhibition of platelet aggregation and 2) increased risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with the AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.  ",携带CC基因型的，相比AA基因型，抑制血小板凝集作用可能降低，高氯吡格雷血小板反应和药效差的可能性增加,1,,0,,,,,plus,郭望
PA166134288,rs1057910,1184986535,AA,Patients with the AA genotype who are treated with sulfonylurea: 1) May be less likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be more likely to have failure of therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylurea therapy.,携带AA基因型的患者，相比CC基因型，HbA1c水平小于7%的可能性更小，药物无效的可能性更大,1,,0,,,,,plus,郭望
PA166134288,rs1057910,1184986536,AC,Results from patients with the AC genotype were not statistically significant.,AC基因型患者研究结果无统计学意义,1,,,,,,,plus,郭望
PA166134288,rs1057910,1184986537,CC,Patients with the CC genotype who are treated with sulfonylurea: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the AA genotype 2) May be less likely to have failure of therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylurea therapy.,携带CC基因型的患者，相比AA基因型，HbA1c水平小于7%的可能性更大，药物无效的可能性更小,1,,2,,,,,plus,郭望
PA166153433,rs1057910,1447990145,AA,"Patients with the AA genotype and essential hypertension may have increased metabolism or clearance of irbesartan as compared to patients with the AC genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension. ",携带AA基因型的原发性高血压患者，相比AC基因型，药物的代谢或清除可能较快,1,,,,2,,,plus,郭望
PA166153433,rs1057910,1447990146,AC,"Patients with the AC genotype and essential hypertension may have decreased metabolism or clearance of irbesartan as compared to patients with the AA genotype, but may have no difference in response. Other clinical or genetic factors may also influence concentrations of irbesartan in patients with essential hypertension. ",携带AC基因型的原发性高血压患者，相比AA基因型，药物的代谢或清除可能较慢,1,,,,0,,,plus,郭望
PA166161172,rs10782001,1448423705,AA,Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.,携带AA基因型的牛皮癣患者，相比GG基因型，不良反应的风险可能降低,1,,,0,,,,plus,郭望
PA166161172,rs10782001,1448423706,AG,Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.,携带AG基因型的牛皮癣患者，相比GG基因型，不良反应的风险可能降低,1,,,0,,,,plus,郭望
PA166161172,rs10782001,1448423707,GG,Patients with the GG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.,携带GG基因型的牛皮癣患者，相比AG或AA基因型，不良反应的风险可能增加,1,,,2,,,,plus,郭望
PA166135400,rs1080985,1183700813,CC,Patients with the CC genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine. ,携带CC基因型的患者，相比GG基因型，药物代谢可能较快,1,,,,2,,,minus,郭望
PA166135400,rs1080985,1183700814,CG,Patients with the CG genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype or may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine. ,携带CG基因型的患者，相比GG基因型，药物代谢可能较快；相比CC基因型，药物代谢可能较慢,1,,,,1,,,minus,郭望
PA166135400,rs1080985,1183700815,GG,Patients with the GG genotype may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine. ,携带GG基因型的患者，相比CC基因型，药物代谢可能较慢,1,,,,0,,,minus,郭望
PA166135403,rs1080985,1183701071,CC,Patients with the CC genotype may have a higher thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine ,携带CC基因型的患者，相比CG或GG基因型，硫利达嗪:美索达嗪比值可能更高,1,,,,2,,,minus,郭望
PA166135403,rs1080985,1183701070,CG ,Patients with the CG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.,携带CG基因型的患者，相比CC基因型，硫利达嗪:美索达嗪比值可能更低,1,,,,0,,,minus,郭望
PA166135403,rs1080985,1183701069,GG,Patients with the GG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.,携带GG基因型的患者，相比CC基因型，硫利达嗪:美索达嗪比值可能更低,1,,,,0,,,minus,郭望
PA166134151,rs10811661,655384705,CC,Patients with the CC genotype and at high-risk for type II diabetes who are treated with troglitazone may have increased beta cell function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的II型糖尿病高风险患者，相比TT基因型，可能具有增加β细胞功能的作用,1,,0,,,,,,郭望
PA166134151,rs10811661,655384706,CT,Patients with the CT genotype and at high risk for type II diabetes who are treated with troglitazone may have increased beta call function as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to troglitazone.,携带CT基因型的II型糖尿病高风险患者，相比TT基因型，可能具有增加β细胞功能的作用,1,,0,,,,,,郭望
PA166134151,rs10811661,655384707,TT,Patients with the TT genotype and at high risk for type II diabetes who are treated with troglitazone may have decreased beta cell function as compared to patients with the CT and CC genotype.,携带TT基因型的II型糖尿病高风险患者，相比CT或CC基因型，可能具有降低β细胞功能的作用,1,,2,,,,,,郭望
PA166134276,rs10821936,655385472,CC,Pediatric patients with the CC genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.,携带CC基因型的B-超二倍体急性淋巴细胞白血病患儿，相比TT基因型，多聚谷氨酸化甲氨蝶呤累积风险增加,1,,,2,,,,plus,郭望
PA166134276,rs10821936,655385473,CT,Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.,携带CT基因型的B-超二倍体急性淋巴细胞白血病患儿，相比TT基因型，多聚谷氨酸化甲氨蝶呤累积风险增加,1,,,2,,,,plus,郭望
PA166134276,rs10821936,655385474,TT,Pediatric patients with the TT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have lower methotrexate polyglutamate accumulation as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.,携带TT基因型的B-超二倍体急性淋巴细胞白血病患儿，相比CC或CT基因型，多聚谷氨酸化甲氨蝶呤累积风险降低,1,,,0,,,,plus,郭望
PA166136268,rs10871454,1444700554,CC,Patients with the CC genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage. ,携带CC基因型的患者，相比TT基因型，剂量可能需要增加,1,,,,,2,,plus,郭望
PA166136268,rs10871454,1444700553,CT,Patients with the CT genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage. ,携带CT基因型的患者，相比TT基因型，剂量可能需要增加,1,,,,,2,,plus,郭望
PA166136268,rs10871454,1444700552,TT,Patients with the TT genotype who are treated with phenprocoumon may require a decreased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage. ,携带TT基因型的患者，相比CC基因型，剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134209,rs10871454,655385019,CC,Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype.,携带CC基因型的患者，相比CT或TT基因型，剂量可能需要增加,1,,,,,2,,plus,郭望
PA166134209,rs10871454,655385018,CT,Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.,携带CT基因型的患者，相比CC基因型，剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134209,rs10871454,655385017,TT,Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype.,携带TT基因型的患者，相比CC或CT基因型，剂量可能需要减少,1,,,,,0,,plus,郭望
PA166135088,rs10929303,1183614826,CC,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带CC基因型的患者，相比CT或TT基因型，无意的对乙酰氨基酚过量引起的肝功能衰竭的风险可能增加,1,,,2,,,,FWD,郭望
PA166135088,rs10929303,1183614827,CT,Patients with the CT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带CT基因型的患者，相比CC基因型，无意的对乙酰氨基酚过量引起的肝功能衰竭的风险可能降低,1,,,0,,,,FWD,郭望
PA166135088,rs10929303,1183614828,TT,Patients with the TT genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带TT基因型的患者，相比CC基因型，无意的对乙酰氨基酚过量引起的肝功能衰竭的风险可能降低,1,,,0,,,,FWD,郭望
PA166158981,rs10945919,1448100453,AA,Rheumatoid Arthritis patients with the genotype AA may be more likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的类风湿性关节炎患者，相比GG基因型，药物可能药效较好,1,,2,,,,,plus,郭望
PA166158981,rs10945919,1448100454,AG,"Rheumatoid Arthritis patients with the genotype AG may be more likely to respond to TNF inhibitors compared with patients with genotype GG, or less likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.",携带AG基因型的类风湿性关节炎患者，相比GG基因型，药物可能药效较好；相比AA基因型，药物可能药效较差,1,,1,,,,,plus,郭望
PA166158981,rs10945919,1448100455,GG,Rheumatoid Arthritis patients with the genotype GG may be less likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的类风湿性关节炎患者，相比AA基因型，药物可能药效较差,1,,0,,,,,plus,郭望
PA166158947,rs10997242,1448100167,CC,Patients with the CC genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.,携带CC基因型的重度抑郁症患者，相比TT基因型，药效可能较差,1,,0,,,,,FWD,郭望
PA166158947,rs10997242,1448100168,CT,Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.,携带CT基因型的重度抑郁症患者，相比TT基因型，药效可能较差,1,,0,,,,,FWD,郭望
PA166158947,rs10997242,1448100169,TT,Patients with the TT genotype and major depressive disorder may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.,携带TT基因型的重度抑郁症患者，相比CC或CT基因型，药效可能较好,1,,2,,,,,FWD,郭望
PA166159012,rs10994982,1448100889,AA,Patients with the AA genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate.,携带AA基因型的急性淋巴细胞白血病患者，相比GG基因型，药物的清除可能较慢,1,,,,0,,,plus,郭望
PA166159012,rs10994982,1448100890,AG,"Patients with the AG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.",携带AG基因型的急性淋巴细胞白血病患者，相比GG基因型，药物的清除可能较慢；相比AA基因型，药物的清除可能较快,1,,,,1,,,plus,郭望
PA166159012,rs10994982,1448100891,GG,Patients with the GG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.,携带GG基因型的急性淋巴细胞白血病患者，相比AA基因型，药物的清除可能较快,1,,,,2,,,plus,郭望
PA166135411,rs11030104,1183702970,AA,Patients with the AA genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.,携带AA基因型的精神分裂症患者，相比AG或GG基因型，耐药性可能降低,1,,2,,,,,plus,郭望
PA166135411,rs11030104,1183702971,AG,Patients with the AG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.,携带AG基因型的精神分裂症患者，相比AA基因型，耐药性可能增加,1,,0,,,,,plus,郭望
PA166135411,rs11030104,1183702972,GG,Patients with the GG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.,携带GG基因型的精神分裂症患者，相比AA基因型，耐药性可能增加,1,,0,,,,,plus,郭望
PA166134663,rs10929302,1448531612,AA,"The AA genotype may be associated with a greater risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AG and GG genotypes. ",携带AA基因型的患者，相比AG或GG基因型，3-4级的血液和胃肠道毒性（包括中性粒细胞减少症和腹泻）风险可能增加,1,,0,,,,,plus,郭望
PA166134663,rs10929302,1448531613,AG,"The AG genotype may be associated with a reduced risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AA genotype. ",携带AG基因型的患者，相比AA基因型，3-5级的血液和胃肠道毒性（包括中性粒细胞减少症和腹泻）风险可能降低,1,,2,,,,,plus,郭望
PA166134663,rs10929302,1448531614,GG,"The GG genotype may be associated with a reduced risk for irinotecan-induced grade 3 or 4 hematological and gastrointestinal toxicities, including neutropenia and diarrhea, as compared to the AA genotype. ",携带GG基因型的患者，相比AA基因型，3-6级的血液和胃肠道毒性（包括中性粒细胞减少症和腹泻）风险可能降低,1,,2,,,,,plus,郭望
PA166134132,rs11045819,655384586,AA,Patients with the AA genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may influence also a patient's response to fluvastatin.,携带AA基因型的患者，相比CC基因型，LDL-C降低程度可能更大,1,,2,,,,,plus,郭望
PA166134132,rs11045819,655384585,AC,Patients with the AC genotype who are treated with fluvastatin may have a greater reduction in LDL-C as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin.,携带AC基因型的患者，相比CC基因型，LDL-C降低程度可能更大,1,,2,,,,,plus,郭望
PA166134132,rs11045819,655384584,CC,Patients with the CC genotype who are treated with fluvastatin may have a lesser reduction in LDL-C as compared to patients with the AC and AA genotype.,携带CC基因型的患者，相比AC或AA基因型，LDL-C降低程度可能更小,1,,0,,,,,plus,郭望
PA166158880,rs11045819,1448099120,AA,"No patients with the AA genotype were available for analysis, but patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance. ",无AA基因型的患者参与研究,1,,,,,,,plus,郭望
PA166158880,rs11045819,1448099121,AC,Patients with the AC genotype may have increased clearance of rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rifampin clearance. ,携带AC基因型的患者，相比CC基因型，药物的清除可能较快,1,,,,2,,,plus,郭望
PA166158880,rs11045819,1448099122,CC,Patients with the CC genotype may have decreased clearance of rifampin as compared to patients with the AC genotype. Other genetic and clinical factors may also influence rifampin clearance. ,携带CC基因型的患者，相比AC基因型，药物的清除可能较慢,1,,,,0,,,plus,郭望
PA166135396,rs1105525,1183700525,CC,Patients with the CC genotype may have increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带CC基因型的前体淋巴细胞白血病患者，相比CT或TT基因型，无事件生存率可能增加,1,,2,,,,,FWD,郭望
PA166135396,rs1105525,1183700524,TC,Patients with the TC genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带CT基因型的前体淋巴细胞白血病患者，相比CC基因型，无事件生存率可能减少,1,,0,,,,,FWD,郭望
PA166135396,rs1105525,1183700523,TT,Patients with the TT genotype may have decreased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带TT基因型的前体淋巴细胞白血病患者，相比CC基因型，无事件生存率可能减少,1,,0,,,,,FWD,郭望
PA166134398,rs11045879,1448100856,CC,"Patients with the CC genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the CT or TT genotype 2)  may have a decreased, but not absent, risk for GI toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for GI toxicity when treated with methotrexate.",携带CC基因型的前体淋巴细胞白血病患者，相比CT或TT基因型，药物清除率可能降低，胃肠道毒性可能降低,1,,2,,,,,plus,郭望
PA166134398,rs11045879,1448100857,CT,Patients with the CT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC genotype and decreased clearance as compared to the TT genotype 2) may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC genotype and decreased risk as compared to the TT genotype.,携带CT基因型的前体淋巴细胞白血病患者，相比CC基因型，药物清除率可能增加，胃肠道毒性可能增加；相比TT基因型，药物清除率可能降低，胃肠道毒性可能降低,1,,1,,,,,plus,郭望
PA166134398,rs11045879,1448100858,TT,Patients with the TT genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the CC or CT genotype 2) may have an increased risk for GI toxicity when treated with methotrexate as compared to patients with the CC or CT genotype.,携带TT基因型的前体淋巴细胞白血病患者，相比CC或CT基因型，药物清除率可能增加，胃肠道毒性可能增加,1,,0,,,,,plus,郭望
PA166134584,rs1105879,1448107611,AA,Patients with the AA genotype and Epilepsy who are treated with valproic acid may require a decreased dose as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.,携带AA基因型的癫痫患者，相比AC或CC基因型，药物剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134584,rs1105879,1448107612,AC,Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.,携带AC基因型的癫痫患者，相比AA基因型，药物剂量可能需要增加,1,,,,,2,,plus,郭望
PA166134584,rs1105879,1448107613,CC,Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.,携带CC基因型的癫痫患者，相比AA基因型，药物剂量可能需要增加,1,,,,,2,,plus,郭望
PA166134868,rs11150606,1448105602,CC,Patients with the CC genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.,携带CC基因型的患者，相比TT基因型，药物剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134868,rs11150606,1448105603,CT,Patients with the CT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.,携带CT基因型的患者，相比TT基因型，药物剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134868,rs11150606,1448105604,TT,Patients with the TT genotype may require increased dose of warfarin as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence warfarin dose.,携带TT基因型的患者，相比CT或CC基因型，药物剂量可能需要增加,1,,,,,2,,plus,郭望
PA166135970,rs111888148,1447992177,AA,"Patients with the AA genotype may develop Malignant Hyperthermia (MH) when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.",携带AA基因型的患者，相比GG基因型，可能出现恶性高热,1,,,2,,,,plus,郭望
PA166135970,rs111888148,1447992178,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develop Malignant Hyperthermia.",携带AG基因型的患者，相比GG基因型，可能出现恶性高热,1,,,2,,,,plus,郭望
PA166135970,rs111888148,1447992179,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.",携带GG基因型的患者，相比AG基因型，可能不会出现恶性高热,1,,,0,,,,plus,郭望
PA166135939,rs11155012,1446899666,AA,Women with breast cancer and the AA genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.,携带AA基因型的乳腺癌患者，相比AG或GG基因型，生存的可能性降低,1,,0,,,,,FWD,郭望
PA166135939,rs11155012,1446899667,AG,Women with breast cancer and the AG genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the GG genotypes and an increased likelihood of survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances. ,携带AG基因型的乳腺癌患者，相比GG基因型，生存的可能性降低；相比AA基因型，生存的可能性增加,1,,1,,,,,FWD,郭望
PA166135939,rs11155012,1446899668,GG,Women with breast cancer and the GG genotype may have an increased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or AA genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances. ,携带GG基因型的乳腺癌患者，相比AG或AA基因型，生存的可能性增加,1,,2,,,,,FWD,郭望
PA166135394,rs11189381,1183700515,CC,Patients with the CC genotype may have  decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.,携带CC基因型的患者，相比TT基因型，骨坏死的可能性降低,1,,,0,,,,FWD,郭望
PA166135394,rs11189381,1183700514,TC,Patients with the TC genotype may have  increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.,携带CT基因型的患者，相比CC基因型，骨坏死的可能性增加,1,,,2,,,,FWD,郭望
PA166135394,rs11189381,1183700513,TT,Patients with the TT genotype may have  increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.,携带TT基因型的患者，相比CC基因型，骨坏死的可能性增加,1,,,2,,,,FWD,郭望
PA166152977,rs11200638,1447981097,AA,"Patients with the AA genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.",携带AA基因型的老年黄斑变性患者，相比GG基因型，视力提升作用可能较小,1,,0,,,,,plus,郭望
PA166152977,rs11200638,1447981098,AG,"Patients with the AG genotype and age-related macular degeneration may have greater improvement in visual acuity when treated with bevacizumab as compared to patients with the AA or GG genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.",携带AG基因型的老年黄斑变性患者，相比AA或GG基因型，视力提升作用可能较大,1,,2,,,,,plus,郭望
PA166152977,rs11200638,1447981099,GG,"Patients with the GG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Studies assessing bevacizumab and ranibizumab in a combined analysis, and studies assessing ranibizumab alone, have found no association with visual acuity response. Other genetic and clinical factors may also influence response to bevacizumab.",携带GG基因型的老年黄斑变性患者，相比AA基因型，视力提升作用可能较大,1,,1,,,,,plus,郭望
PA166161169,rs11209026,1448423684,AA,"No patients with the AA genotype were available for analysis, but patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.",无AA基因型的患者参与研究,1,,,,,,,plus,郭望
PA166161169,rs11209026,1448423685,AG,Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.,携带AG基因型的牛皮癣患者，相比GG基因型，不良反应的风险可能增加,1,,,2,,,,plus,郭望
PA166161169,rs11209026,1448423686,GG,Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.,携带GG基因型的牛皮癣患者，相比AG基因型，不良反应的风险可能降低,1,,,0,,,,plus,郭望
PA166134387,rs11188072,982030629,CC,"Patients with the CC genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",携带CC基因型的患者，相比TT基因型，药物剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134387,rs11188072,982030630,CT,"Patients with the CT genotype who are treated with escitalopram may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",携带CT基因型的患者，相比TT基因型，药物剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134387,rs11188072,982030631,TT,"Patients with the TT genotype who are treated with escitalopram may require an increased dose  as compared to patients with the CT or CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",携带TT基因型的患者，相比CC或CT基因型，药物剂量可能需要增加,1,,,,,2,,plus,郭望
PA166134386,rs11188072,655387746,CC,"Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",携带CC基因型的患者，相比TT基因型，药物剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134386,rs11188072,655387747,CT,"Patients with the CT genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",携带CT基因型的患者，相比TT基因型，药物剂量可能需要减少,1,,,,,0,,plus,郭望
PA166134386,rs11188072,655387748,TT,"Patients with the TT genotype who are treated with mephenytoin may require an increased dose as compared to patients with the CC genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.",携带TT基因型的患者，相比CC基因型，药物剂量可能需要增加,1,,,,,2,,plus,郭望
PA166135143,rs11188072,1183631923,CC,"Patients with the CC genotype (CYP2C19*1/*1) and major depressive disorder may have higher dose-corrected plasma concentrations of imipramine as compared to patients with the CT or TT genotype (CYP2C19*1/*17 or *17/*17). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. ",携带CC基因型的重度抑郁症患者，相比CT或TT基因型，药物剂量相关的血药浓度可能更高,1,,,,,,2,plus,郭望
PA166135143,rs11188072,1183631924,CT,"Patients with the CT genotype (CYP2C19*1/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype  (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. ",携带CT基因型的重度抑郁症患者，相比CC基因型，药物剂量相关的血药浓度可能更低,1,,,,,,0,plus,郭望
PA166135143,rs11188072,1183631925,TT,"Patients with the TT genotype (CYP2C19*17/*17) and major depressive disorder may have lower dose-corrected plasma concentrations of imipramine as compared to patients with the CC genotype  (CYP2C19*1/*1). In this case, *17 was defined by 2 variants rs11188072 and rs12248560. Other genetic and clinical factors may also influence a patient's metabolism of imipramine. ",携带TT基因型的重度抑郁症患者，相比CC基因型，药物剂量相关的血药浓度可能更低,1,,,,,,0,plus,郭望
PA166134585,rs11212617,1183574218,AA,"Patients with the AA genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.",携带AA基因型的II型糖尿病患者，相比CC基因型，药效可能较差,1,,0,,,,,plus,郭望
PA166134585,rs11212617,1183574219,AC,"Patients with the AC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype.  An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.",携带AC基因型的II型糖尿病患者，相比AA基因型，药效可能较好；相比CC基因型，药效可能较差,1,,1,,,,,plus,郭望
PA166134585,rs11212617,1183574220,CC,"Patients with the CC genotype with Diabetes Mellitus, Type 2 who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype.  An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.",携带CC基因型的II型糖尿病患者，相比AA基因型，药效可能较好,1,,2,,,,,plus,郭望
PA166134760,rs11252394,1183685519,AA,Patients with AA genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带AA基因型哮喘患者，相比GG基因型，支气管扩张作用可能增加,1,,2,,,,,plus,郭望
PA166134760,rs11252394,1183685520,AG,Patients with AG genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带AG基因型哮喘患者，相比GG基因型，支气管扩张作用可能增加,1,,2,,,,,plus,郭望
PA166134760,rs11252394,1183685521,GG,Patients with GG genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带GG基因型哮喘患者，相比AA基因型，支气管扩张作用可能降低,1,,0,,,,,plus,郭望
PA166136362,rs112563513,1448615838,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. ",携带AA基因型的患者，相比GG基因型，可能出现恶性高热,1,,,2,,,,plus,郭望
PA166136362,rs112563513,1448615839,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG, although this is contradicted in some studies. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. ",携带AG基因型的患者，相比GG基因型，可能出现恶性高热,1,,,2,,,,plus,郭望
PA166136362,rs112563513,1448615840,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG, although this is contradicted in some studies. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia. ",携带GG基因型的患者，相比AG基因型，可能不会出现恶性高热,1,,,0,,,,plus,郭望
PA166136275,rs1126510,1444700643,AA,Patients with the AA genotype and asthma may have increased risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also effect patients' response to aspirin.,携带AA基因型的患者，相比AG或GG基因型，阿司匹林不耐受性哮喘的风险可能增加,1,,,2,,,,plus,郭望
PA166136275,rs1126510,1444700642,AG,"Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.",携带AG基因型的患者，相比AA基因型，阿司匹林不耐受性哮喘的风险可能降低,1,,,0,,,,plus,郭望
PA166136275,rs1126510,1444700641,GG,"Patients with the GG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.",携带GG基因型的患者，相比AA基因型，阿司匹林不耐受性哮喘的风险可能降低,1,,,0,,,,plus,郭望
PA166135664,rs1126757,1444608379,CC,"Patients with the CC genotype and depression may not respond as well to treatment with escitalopram, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to escitalopram.",携带CC基因型的抑郁症患者，相比CT或TT基因型，药物可能无效,1,,0,,,,,plus,郭望
PA166135664,rs1126757,1444608380,CT,"Patients with the CT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.",携带CT基因型的抑郁症患者，相比CC基因型，药物可能更好,1,,2,,,,,plus,郭望
PA166135664,rs1126757,1444608381,TT,"Patients with the TT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.",携带TT基因型的抑郁症患者，相比CC基因型，药物可能更好,1,,2,,,,,plus,郭望
PA166135233,rs1130214,1183630277,AA,"Patients with the AA genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.",携带AA基因型的肺癌患者，相比CC基因型，病情恶化风险可能降低,1,,2,,,,,plus,郭望
PA166135233,rs1130214,1183630278,AC,"Patients with the AC genotype and lung cancer who are treated with carboplatin or cisplatin may have a reduced, but not absent, risk of distant disease progression as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.",携带AC基因型的肺癌患者，相比CC基因型，病情恶化风险可能降低,1,,2,,,,,plus,郭望
PA166135233,rs1130214,1183630279,CC,Patients with the CC genotype and lung cancer who are treated with carboplatin or cisplatin may have a higher risk of distant disease progression as compared to patients with the AC or AA  genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.,携带CC基因型的肺癌患者，相比AC或AA基因型，病情恶化风险可能增加,1,,0,,,,,plus,郭望
PA166134644,rs1137617,982009416,AA,Patients with the AA genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AA genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments. ,携带AA基因型的原发性高血压患者，相比GG基因型，舒张压和平均动脉压降低程度可能更大,1,,2,,,,,plus,郭望
PA166134644,rs1137617,982009417,AG,Patients with the AG genotype with essential hypertension who are treated with calcium channel blockers may have greater reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the GG genotype. Male patients with the AG genotype may also have greater reductions in systolic blood pressure. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments. ,携带AG基因型的原发性高血压患者，相比GG基因型，舒张压和平均动脉压降低程度可能更大,1,,2,,,,,plus,郭望
PA166134644,rs1137617,982009418,GG,Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments. ,携带GG基因型的原发性高血压患者，相比AA或AG基因型，舒张压和平均动脉压降低程度可能更小,1,,0,,,,,plus,郭望
PA166134238,rs1138272,655385167,CC,Patients with the CC genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.,携带CC基因型的患者，相比TT基因型，药物清除率可能较慢,1,,,,0,,,plus,郭望
PA166134238,rs1138272,655385166,CT,Patients with the CT genotype may have decreased clearance of thiotepa as compared to patients with the TT genotype.,携带CT基因型的患者，相比TT基因型，药物清除率可能较慢,1,,,,0,,,plus,郭望
PA166134238,rs1138272,655385165,TT,Patients with the TT genotype may have increased clearance of thiotepa as compared to patients with the CT or TT genotype.,携带TT基因型的患者，相比CC或CT基因型，药物清除率可能较快,1,,,,2,,,plus,郭望
PA166136396,rs1138272,1445402228,CC,"Patients with the CC genotype and cancer may have longer survival times when treated with cisplatin as compared to patients with the CT or TT genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.",携带CC基因型的癌症患者，相比CT或TT基因型，生存时间可能更长,1,,2,,,,,plus,郭望
PA166136396,rs1138272,1445402229,CT,"Patients with the CT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.",携带CT基因型的癌症患者，相比CC基因型，生存时间可能更短,1,,0,,,,,plus,郭望
PA166136396,rs1138272,1445402230,TT,"Patients with the TT genotype and cancer may have shorter survival times when treated with cisplatin as compared to patients with the CC genotype. However, conflicting evidence exists for this association. Other genetic and clinical factors may also influence survival time.",携带TT基因型的癌症患者，相比CC基因型，生存时间可能更短,1,,0,,,,,plus,郭望
PA166151961,rs113993959,1447954385,GG,Patients with the GG genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.,携带GG基因型的囊性纤维化患者，相比GT或TT基因型，药物治疗可能无效,1,,0,,,,,,李晶晶
PA166151961,rs113993959,1447954386,GT,"Patients with the GT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.",携带GT基因型的囊性纤维化患者，相比GG基因型，药效可能增加,1,,2,,,,,,李晶晶
PA166151961,rs113993959,1447954387,TT,"Patients with the TT genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.",携带TT基因型的囊性纤维化患者，相比GG基因型，药效可能增加,1,,2,,,,,,李晶晶
PA166134764,rs114202595,982045147,AA,Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带AA基因型的糖尿病患者，相比GG基因型，对餐后血糖降低作用可能更好,1,,2,,,,,,李晶晶
PA166134764,rs114202595,982045148,AG,Patients with AA + AG genotypes may have better response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带AG基因型的糖尿病患者，相比GG基因型，对餐后血糖降低作用可能更好,1,,2,,,,,,李晶晶
PA166134764,rs114202595,982045149,GG,Patients with GG genotypes may have worse response for postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with AA +AG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带GG基因型的糖尿病患者，相比AG和AA基因型，对餐后血糖降低作用可能更差,1,,0,,,,,,李晶晶
PA166135587,rs11479,1184986818,AA,Patients with the AA genotype and cancer may have an increased risk of drug toxicity when administered capecitabine and/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer. ,携带AA基因型的癌症患者，相比GG基因型，药物毒性风险可能增加,1,,,2,,,,plus,李晶晶
PA166135587,rs11479,1184986819,AG,Patients with the AG genotype and cancer may have an increased risk of drug toxicity when administered capecitabine and/or fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer. ,携带AG基因型的癌症患者，相比GG基因型，药物毒性风险可能增加,1,,,2,,,,plus,李晶晶
PA166135587,rs11479,1184986820,GG,Patients with the GG genotype and cancer may have a decreased risk of drug toxicity when administered capecitabine and/or fluorouracil as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the risk of drug toxicity in patients with cancer. ,携带GG基因型的癌症患者，相比AG和AA基因型，药物毒性风险可能降低,1,,,0,,,,plus,李晶晶
PA166134342,rs1142345,1448616406,CC,"Children with the CC genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",携带CC基因型的癌症儿童，相比TT基因型，听力损失的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134342,rs1142345,1448616407,CT,"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",携带CT基因型的癌症儿童，相比TT基因型，听力损失的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134342,rs1142345,1448616408,TT,"Children with the TT genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the TC or CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",携带TT基因型的癌症儿童，相比CT或CC基因型，听力损失的风险可能降低,1,,,0,,,,plus,李晶晶
PA166136397,rs1142345,1448275772,CC,Pediatric patients with the CC genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.,携带CC基因型的前体淋巴细胞白血病患儿，相比CT或TT基因型，胃肠道毒性风险可能增加，可能需要减少剂量,1,,,2,,0,,plus,李晶晶
PA166136397,rs1142345,1448275773,CT,"Pediatric patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience increased GI toxicity when treated with mercaptopurine and may require a decreased dose as compared to patients with the TT genotypes. However, they may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.",携带CT基因型的前体淋巴细胞白血病患儿，相比TT基因型，胃肠道毒性风险可能增加，可能需要减少剂量；相比CC基因型，胃肠道毒性风险可能降低，可能需要增加剂量,1,,,1,,1,,plus,李晶晶
PA166136397,rs1142345,1448275774,TT,Pediatric patients with the TT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may experience decreased GI toxicity when treated with mercaptopurine and may require an increased dose as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence the likelihood of GI toxicity and dose of mercaptopurine in pediatric patients with Precursor Cell Lymphoblastic Leukemia-Lymphoma.,携带TT基因型的前体淋巴细胞白血病患儿，相比CT或CC基因型，胃肠道毒性风险可能降低，可能需要增加剂量,1,,,0,,2,,plus,李晶晶
PA166135421,rs115232898,1448097656,CC,"No patients with the CC genotype were available for analysis, but patients with the CT genotype and cancer who are treated with fluorouracil may have an increased risk for drug toxicity as compared to patients with the TT genotype. The CC genotype may also be associated with decreased DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",无CC基因型患者参与研究,1,,,,,,,plus,李晶晶
PA166135421,rs115232898,1448097657,CT,Patients with the CT genotype and cancer who are treated with fluorouracil may have an increased risk for drug toxicity as compared to patients with the TT genotype. The CT genotype is also associated with decreased DPYD activity as compared to the TT genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.,携带CT基因型的癌症患者，相比TT基因型，药物毒性风险可能增加,1,,,2,,,,plus,李晶晶
PA166135421,rs115232898,1448097658,TT,"Patients with the TT genotype and cancer who are treated with fluorouracil may have a decreased risk for drug toxicity, and increased DPYD activity, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带TT基因型的癌症患者，相比CT基因型，药物毒性风险可能降低,1,,,0,,,,plus,李晶晶
PA166134791,rs11587213,1043858681,AA,Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. ,携带AA基因型的哮喘患者，相比AG或GG基因型，药物过敏风险可能增加,1,,,2,,,,plus,李晶晶
PA166134791,rs11587213,1043858682,AG,Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. ,携带AG基因型的哮喘患者，相比AA基因型，药物过敏风险可能降低,1,,,0,,,,plus,李晶晶
PA166134791,rs11587213,1043858683,GG,Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. ,携带GG基因型的哮喘患者，相比AA基因型，药物过敏风险可能降低,1,,,0,,,,plus,李晶晶
PA166134791,rs11587213,1043858681,AA,Patients with the AA genotype and asthma may have an increased risk for aspirin sensitivity but patients with chronic urticaria may have a decreased risk for aspirin sensitivity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. ,携带AA基因型的慢性荨麻疹患者，相比AG或GG基因型，药物过敏风险可能降低,1,,,0,,,,plus,李晶晶
PA166134791,rs11587213,1043858682,AG,Patients with the AG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. ,携带AA基因型的慢性荨麻疹患者，相比AA基因型，药物过敏风险可能增加,1,,,2,,,,plus,李晶晶
PA166134791,rs11587213,1043858683,GG,Patients with the GG genotype and asthma may have a decreased risk for aspirin sensitivity but patients with chronic urticaria may have an increased risk for aspirin sensitivity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity. ,携带GG基因型的慢性荨麻疹患者，相比AA基因型，药物过敏风险可能增加,1,,,2,,,,plus,李晶晶
PA166135393,rs11600347,1183700508,AA,Patients with the AA genotype may have  increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.,携带AA基因型的高血压患者，相比CC基因型，患糖尿病的风险可能性增加,1,,,2,,,,FWD,李晶晶
PA166135393,rs11600347,1183700509,AC,Patients with the AC genotype may have  increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype CC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.,携带AC基因型的高血压患者，相比CC基因型，患糖尿病的风险可能性增加,1,,,2,,,,FWD,李晶晶
PA166135393,rs11600347,1183700510,CC,Patients with the CC genotype may have  decreased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AC. This association is more significant in white than in Hispanic. Other genetic and clinical factors may also influence a patient's risk of toxicity to hydrochlorothiazide.,携带CC基因型的高血压患者，相比AC或AA基因型，患糖尿病的风险可能性降低,1,,,0,,,,FWD,李晶晶
PA166136280,rs1160351,1444700690,AA,"Patients with the AA genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexsual dysfunction as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' response to fluvoxamine, milnacipran or paroxetine. ",携带AA基因型的重度抑郁症患者，相比CC基因型，性功能障碍风险可能增加,1,,,2,,,,plus,李晶晶
PA166136280,rs1160351,1444700691,AC,"Patients with the AA genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have an increased risk of sexsual dysfunction as compared to patients with the CC genotype or may have a decreased, but not absent, risk of sexsual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to fluvoxamine, milnacipran or paroxetine. ",携带AC基因型的重度抑郁症患者，相比CC基因型，性功能障碍风险可能增加；相比AA基因型，性功能障碍风险可能降低,1,,,1,,,,plus,李晶晶
PA166136280,rs1160351,1444700692,CC,"Patients with the CC genotype and major depression who are treated with fluvoxamine, milnacipran or paroxetine may have a decreased, but not absent, risk of sexsual dysfunction as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to fluvoxamine, milnacipran or paroxetine. ",携带CC基因型的重度抑郁症患者，相比AA基因型，性功能障碍风险可能降低,1,,,0,,,,plus,李晶晶
PA166134643,rs113993960,1447981027,CTT/CTT,Indication of ivacaftor in cystic fibrosis patients with the CTT/CTT genotype (no copies of the CFTR F508del variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ,携带CTT/CTT基因型的囊性纤维化患者，相比del/del基因型，药物更可能有效,1,,2,,,,,plus,李晶晶
PA166134643,rs113993960,1447981028,CTT/del,Indication of ivacaftor in cystic fibrosis patients with the CTT/del genotype (one copy of the CFTR F508del variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ,携带CTT/del基因型的囊性纤维化患者，相比del/del基因型，药物更可能有效,1,,2,,,,,plus,李晶晶
PA166134643,rs113993960,1447981029,del/del,"Ivacaftor is not recommended in cystic fibrosis patients with the del/del genotype (two copies of the F508del variant). A clinical trial of ivacaftor in patients with the del/del genotype showed ivacaftor was ineffective in these patients, though this study was not powered to examine efficacy. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带del/del基因型的囊性纤维化患者，相比CTT/CTT或CTT/del基因型，药物更可能无效,1,,0,,,,,plus,李晶晶
PA166152868,rs113993960,1447964144,CTT/CTT,Patients with the CTT/CTT genotype and cystic fibrosis may not respond when treated with cysteamine as compared to patients with the CTT/del or del/del genotypes. Other genetic and clinical factors may also influence the efficacy of cysteamine.,携带CTT/CTT基因型的囊性纤维化患者，相比del/del或CTT/del基因型，药物更可能无效,1,,0,,,,,plus,李晶晶
PA166152868,rs113993960,1447964145,CTT/del,Patients with the CTT/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.,携带CTT/del基基因型的囊性纤维化患者，相比CTT/CTT或因型，药物更可能有效,1,,2,,,,,plus,李晶晶
PA166152868,rs113993960,1447964146,del/del,Patients with the del/del genotype and cystic fibrosis may have an improved response when treated with cysteamine as compared to patients with the CTT/CTT genotype. Other genetic and clinical factors may also influence the efficacy of cysteamine.,携带del/del基基因型的囊性纤维化患者，相比CTT/CTT或因型，药物更可能有效,1,,2,,,,,plus,李晶晶
PA166163369,rs113993960,1448604084,CTT/CTT,Patients with cystic fibrosis and the CTT/CTT genotype may not receive benefit from cavosonstat. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.,携带CTT/CTT基因型的囊性纤维化患者，相比del/del基因型，药物更可能无效,1,,0,,,,,plus,李晶晶
PA166163369,rs113993960,1448604085,CTT/del,Patients with cystic fibrosis and the CTT/del genotype may not receive benefit from cavosonstat. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.,携带CTT/del基因型的囊性纤维化患者，相比del/del基因型，药物更可能无效,1,,0,,,,,plus,李晶晶
PA166163369,rs113993960,1448604086,del/del,Patients with cystic fibrosis and the del/del genotype may receive benefit from cavosonstat as measured in reduction of sweat chloride content but not in change of FEV1. Other clinical and genetic factors may affect whether cavosonstat is effective in these patients.,携带del/del基因型的囊性纤维化患者，相比CTT/CTT或CTT/del基因型，药物更可能有效,1,,2,,,,,plus,李晶晶
PA166134172,rs11572080,1448099259,CC,"Patients with the CC genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.",携带CC基因型的患者，相比TT基因型，神经毒性风险可能降低,1,,,0,,,,plus,李晶晶
PA166134172,rs11572080,1448099260,CT,"Patients with the CT genotype may be at decreased, but not absent, risk of neurotoxicity when treated with paclitaxel compared to patients with the TT genotype or may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.",携带CT基因型的患者，相比TT基因型，神经毒性风险可能降低；相比CC基因型，神经毒性风险可能增加,1,,,1,,,,plus,李晶晶
PA166134172,rs11572080,1448099261,TT,Patients with the TT genotype may be at increased risk of neurotoxicity  when treated with paclitaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neurotoxicity.,携带TT基因型的患者，相比CC基因型，神经毒性风险可能增加,1,,,2,,,,plus,李晶晶
PA166134647,rs11572080,982029203,CC,"Patients with the CC genotype may have increased plasma concentrations
of repaglinide in healthy volunteers as compared to patients with the TT or CT genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype. ",携带CC基因型的健康人群，相比TT或CT基因型，血药浓度可能较高,1,,,,,,2,plus,李晶晶
PA166134647,rs11572080,982029202,CT,"Patients with the CT genotype may have reduced plasma concentrations
of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype. ",携带CT基因型的健康人群，相比CC基因型，血药浓度可能较低,1,,,,,,0,plus,李晶晶
PA166134647,rs11572080,982029201,TT,"Patients with the TT genotype may have reduced plasma concentrations
of repaglinide in healthy volunteers as compared to patients with the CC genotype. Other genetic or clinical factors may influence a patient's response to repaglinide. This variant was analyzed together with rs10509681 as part of CYP2C8*3 haplotype. ",携带TT基因型的健康人群，相比CC基因型，血药浓度可能较低,1,,,,,,0,plus,李晶晶
PA166135550,rs1128503,1444695586,AA,Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels. ,携带AA基因型的患者，相比AG或GG基因型，血清肌酸磷酸激酶水平可能升高,1,,,2,,,,plus,李晶晶
PA166135550,rs1128503,1444695587,AG,Patients with the AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels. ,携带AG基因型的患者，相比AA基因型，血清肌酸磷酸激酶水平可能降低,1,,,0,,,,plus,李晶晶
PA166135550,rs1128503,1444695588,GG,Patients with the GG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence serum creatine kinase levels. ,携带GG基因型的患者，相比AA基因型，血清肌酸磷酸激酶水平可能降低,1,,,0,,,,plus,李晶晶
PA166134126,rs1128503,1447963754,AA,"Patients with the AA genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine and therefore may require a decreased dose of cyclosporine, compared to patients with the GG genotype. Patients with the AA genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.",携带AA基因型的重症肌无力或器官移植患者，相比GG基因型，药物清除率可能降低，药物剂量可能需要减少,1,,,,,0,,plus,李晶晶
PA166134126,rs1128503,1447963755,AG,"Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.",携带AG基因型的重症肌无力或器官移植患者，相比GG基因型，药物清除率可能降低，药物剂量可能需要减少；相比AA基因型，药物清除率可能增加，药物剂量可能需要增加,1,,,,,1,,plus,李晶晶
PA166134126,rs1128503,1447963756,GG,"Patients with the GG genotype and myasthenia gravis or organ transplantation may have increased clearance of cyclosporine and therefore may require an increased dose of cyclosporine, compared to patients with the AA genotype. Patients with the GG genotype may also have a decreased risk of infection as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.",携带GG基因型的重症肌无力或器官移植患者，相比AA基因型，药物清除率可能增加，药物剂量可能需要增加,1,,,,,2,,plus,李晶晶
PA166134379,rs1128503,655387230,AA,"Patients with the AA genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.",携带AA基因型的自闭症患儿，相比GG基因型，疗效可能增加,1,,2,,,,,plus,李晶晶
PA166134379,rs1128503,655387231,AG,"Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.",携带AG基因型的自闭症患儿，相比GG基因型，疗效可能增加,1,,2,,,,,plus,李晶晶
PA166134379,rs1128503,655387232,GG,"Patients with the GG genotype may have poorer response to risperidone in Children with Autism, than patients with AG or GG genotype. Other genetic and clinical factors may also influence a patient's response.",携带GG基因型的自闭症患儿，相比AG或AA基因型，疗效可能降低,1,,0,,,,,plus,李晶晶
PA166135080,rs1128503,1183614762,AA,Patients with the AA genotype who underwent kidney transplantation may have increased triglyceride levels when treated with sirolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence triglyceride levels. ,携带AA基因型的肾移植患者，相比AG或GG基因型，甘油三酯水平可能升高,1,,,2,,,,plus,李晶晶
PA166135080,rs1128503,1183614763,AG,Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels. ,携带AG基因型的肾移植患者，相比AA基因型，甘油三酯水平可能降低,1,,,0,,,,plus,李晶晶
PA166135080,rs1128503,1183614764,GG,Patients with the GG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels. ,携带GG基因型的肾移植患者，相比AA基因型，甘油三酯水平可能降低,1,,,0,,,,plus,李晶晶
PA166135131,rs1128503,1183615536,AA,Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.,携带AA基因型的患者，相比GG基因型，血药浓度可能升高,1,,,,,,2,plus,李晶晶
PA166135131,rs1128503,1183615537,AG,"Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype, or decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.",携带AG基因型的患者，相比GG基因型，血药浓度可能升高；相比AA基因型，血药浓度可能降低,1,,,,,,1,plus,李晶晶
PA166135131,rs1128503,1183615538,GG,Patients with the GG genotype may have decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.,携带GG基因型的患者，相比AA基因型，血药浓度可能降低,1,,,,,,0,plus,李晶晶
PA166134587,rs1128503,981237923,AA,Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.,携带AA基因型的患者，相比GG基因型，血药浓度可能较高,1,,,,,,2,plus,李晶晶
PA166134587,rs1128503,981237924,AG,Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.,携带AG基因型的患者，相比GG基因型，血药浓度可能较高,1,,,,,,2,plus,李晶晶
PA166134587,rs1128503,981237925,GG,Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.,携带GG基因型的患者，相比AG和AA基因型，血药浓度可能较低,1,,,,,,0,plus,李晶晶
PA166135703,rs1128503,1448573611,AA,"Patients with the AA genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the AG or GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus. ",携带AA基因型的器官移植患者，相比AG或GG基因型，药物浓度可能增加,1,,,,,,2,plus,李晶晶
PA166135703,rs1128503,1448573612,AG,"Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus. ",携带AG基因型的器官移植患者，相比GG基因型，药物浓度可能增加,1,,,,,,1,plus,李晶晶
PA166135703,rs1128503,1448573613,GG,"Patients with the GG genotype who are undergoing organ transplantation may have decreased concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus. ",携带GG基因型的器官移植患者，相比AA或AG基因型，药物浓度可能降低,1,,,,,,0,plus,李晶晶
PA166134721,rs1128503,982034870,AA,Patients with the AA genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. ,携带AA基因型的结直肠癌患者，相比GG基因型，总生存时间可能增加,1,,2,,,,,plus,李晶晶
PA166134721,rs1128503,982034871,AG,Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. ,携带AG基因型的结直肠癌患者，相比GG基因型，总生存时间可能增加,1,,2,,,,,plus,李晶晶
PA166134721,rs1128503,982034872,GG,Patients with the GG genotype and colorectal cancer may have a decreased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. ,携带GG基因型的结直肠癌患者，相比AG或AA基因型，总生存时间可能减少,1,,0,,,,,plus,李晶晶
PA166136369,rs1128503,1448612731,AA,"Patients with the AA genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype. However, studies conflict. Other genetic and clinical factors may also influence response to imatinib. ",携带AA基因型的慢性粒细胞白血病患者，相比GG基因型，药效可能较差,1,,0,,,,,plus,李晶晶
PA166136369,rs1128503,1448612732,AG,"Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype. However, studies conflict. Other genetic and clinical factors may also influence response to imatinib. ",携带AG基因型的慢性粒细胞白血病患者，相比GG基因型，药效可能较差,1,,0,,,,,plus,李晶晶
PA166136369,rs1128503,1448612733,GG,"Patients with the GG genotype and chronic myeloid leukemia may have a better response to imatinib treatment as compared to patients with the AA or AG genotype. However, studies conflict. Other genetic and clinical factors may also influence response to imatinib. ",携带GG基因型的慢性粒细胞白血病患者，相比AG或AA基因型，药效可能较好,1,,2,,,,,plus,李晶晶
PA166136371,rs1128503,1445401255,AA,Patients with the AA genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium. ,携带AA基因型的患者，相比AG或GG基因型，麻醉时药效可能增加,1,,2,,,,,plus,李晶晶
PA166136371,rs1128503,1445401256,AG,Patients with the AG genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium. ,携带AG基因型的患者，相比AA基因型，麻醉时药效可能降低,1,,0,,,,,plus,李晶晶
PA166136371,rs1128503,1445401257,GG,Patients with the GG genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium. ,携带GG基因型的患者，相比AA基因型，麻醉时药效可能降低,1,,0,,,,,plus,李晶晶
PA166135907,rs1128503,1446897992,AA,"Patients with the AA genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.",携带AA基因型的急性髓性白血病，相比GG基因型，药效可能较好,1,,2,,,,,plus,李晶晶
PA166135907,rs1128503,1446897993,AG,"Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.",携带AG基因型的急性髓性白血病，相比GG基因型，药效可能较好,1,,2,,,,,plus,李晶晶
PA166135907,rs1128503,1446897994,GG,"Patients with the GG genotype and acute myeloid leukemia may have a poorer response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the AA or AG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.",携带GG基因型的急性髓性白血病，相比AG或AA基因型，药效可能较差,1,,0,,,,,plus,李晶晶
PA166152726,rs1128503,1447960876,AA,Patients with the AA genotype and cancer may have increased exposure to tipifarnib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.,携带AA基因型的癌症患者，相比AG或GG基因型，药物代谢可能较慢,1,,,,0,,,plus,李晶晶
PA166152726,rs1128503,1447960877,AG,Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.,携带AG基因型的癌症患者，相比AA基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166152726,rs1128503,1447960878,GG,Patients with the GG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.,携带GG基因型的癌症患者，相比AA基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166153190,rs1128503,1448266848,AA,African American and white patients with the AA genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.,携带AA基因型的非裔美国人与白人癫痫患者，相比GG基因型，药物的清除可能增加,1,,,,2,,,plus,李晶晶
PA166153190,rs1128503,1448266849,AG,African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.,携带AG基因型的非裔美国人与白人癫痫患者，相比GG基因型，药物的清除可能增加,1,,,,2,,,plus,李晶晶
PA166153190,rs1128503,1448266850,GG,African American and white patients with the GG genotype and epilepsy may have decreased clearance of carbamazepine as compared to patients with the AA or AG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.,携带GG基因型的非裔美国人与白人癫痫患者，相比AG或AA基因型，药物的清除可能降低,1,,,,0,,,plus,李晶晶
PA166159002,rs1128503,1448100719,AA,Breast-feeding infants whose mothers have the AA genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants. ,携带AA基因型且服用可待因的母亲，进行母乳喂养时，相比GG基因型，婴儿患中枢神经抑郁症的风险可能增加,1,,,2,,,,plus,李晶晶
PA166159002,rs1128503,1448100720,AG,"Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants. ",携带AG基因型且服用可待因的母亲，进行母乳喂养时，相比GG基因型，婴儿患中枢神经抑郁症的风险可能增加,1,,,2,,,,plus,李晶晶
PA166159002,rs1128503,1448100721,GG,Breast-feeding infants whose mothers have the GG genotype and are taking codeine may be at decreased risk for CNS depression as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants. ,携带GG基因型且服用可待因的母亲，进行母乳喂养时，相比AA基因型，婴儿患中枢神经抑郁症的风险可能降低,1,,,0,,,,plus,李晶晶
PA166152797,rs1128503,1447962845,AA,Patients with the AA genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.,携带AA基因型的高胆固醇血症患者，相比GG基因型，LDL和总胆固醇含量降低程度可能较大,1,,2,,,,,plus,李晶晶
PA166152797,rs1128503,1447962846,AG,Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.,携带AG基因型的高胆固醇血症患者，相比GG基因型，LDL和总胆固醇含量降低程度可能较大,1,,2,,,,,plus,李晶晶
PA166152797,rs1128503,1447962847,GG,Patients with the GG genotype and hypercholesterolemia may lesser reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence cholesterol levels.,携带GG基因型的高胆固醇血症患者，相比AG或AA基因型，LDL和总胆固醇含量降低程度可能较小,1,,0,,,,,plus,李晶晶
PA166152856,rs1128503,1447963986,AA,"Patients with the AA genotype and specificially localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics. ",携带AA基因型的特定部位癫痫综合征的患者，相比GG基因型，耐药风险可能增加,1,,0,,,,,plus,李晶晶
PA166152856,rs1128503,1447963987,AG,"Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics. ",携带AG基因型的特定部位癫痫综合征的患者，相比GG基因型，耐药风险可能增加；相比AA基因型，耐药风险可能降低,1,,1,,,,,plus,李晶晶
PA166152856,rs1128503,1447963988,GG,"Patients with the GG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics. ",携带GG基因型的特定部位癫痫综合征的患者，相比AA基因型，耐药风险可能降低,1,,2,,,,,plus,李晶晶
PA166152798,rs1128503,1447962857,AA,Patients with the AA genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for myalgia.,携带AA基因型高胆固醇血症患者，相比GG基因型，肌痛的风险可能降低,1,,,0,,,,plus,李晶晶
PA166152798,rs1128503,1447962858,AG,"Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.",携带AG基因型高胆固醇血症患者，相比GG基因型，肌痛的风险可能降低,1,,,0,,,,plus,李晶晶
PA166152798,rs1128503,1447962859,GG,Patients with the GG genotype and hypercholesterolemia may have an increased risk for myalgia when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.,携带GG基因型高胆固醇血症患者，相比AG基因型，肌痛的风险可能增加,1,,,2,,,,plus,李晶晶
PA166152892,rs1128503,1447964544,AA,Patients with the AA genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.,携带AA基因型的结直肠癌患者，相比GG基因型，中性粒细胞减少症或手足综合征的风险可能降低,1,,,0,,,,plus,李晶晶
PA166152892,rs1128503,1447964545,AG,"Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.",携带AG基因型的结直肠癌患者，相比GG基因型，中性粒细胞减少症或手足综合征的风险可能降低,1,,,0,,,,plus,李晶晶
PA166152892,rs1128503,1447964546,GG,Patients with the GG genotype and colorectal cancer may have an increased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.,携带GG基因型的结直肠癌患者，相比AA基因型，中性粒细胞减少症或手足综合征的风险可能增加,1,,,2,,,,plus,李晶晶
PA166159992,rs1128503,1448256883,AA,Patients with the AA genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.,携带AA基因型的非小细胞肺癌患者，相比AG和GG基因型，药物毒性作用可能增加,1,,,2,,,,plus,李晶晶
PA166159992,rs1128503,1448256884,AG,Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.,携带AG基因型的非小细胞肺癌患者，相比AA基因型，药物毒性作用可能降低,1,,,0,,,,plus,李晶晶
PA166159992,rs1128503,1448256885,GG,Patients with the GG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.,携带GG基因型的非小细胞肺癌患者，相比AA基因型，药物毒性作用可能降低,1,,,0,,,,plus,李晶晶
PA166161227,rs1128503,1448427007,AA,Patients with the AA genotype and non-small cell lung cancer may have an increased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.,携带AA基因型的非小细胞肺癌患者，相比AG或GG基因型，腹泻和皮疹风险可能增加,1,,,2,,,,plus,李晶晶
PA166161227,rs1128503,1448427008,AG,Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.,携带AG基因型的非小细胞肺癌患者，相比AA基因型，腹泻和皮疹风险可能降低,1,,,0,,,,plus,李晶晶
PA166161227,rs1128503,1448427009,GG,Patients with the GG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.,携带GG基因型的非小细胞肺癌患者，相比AA基因型，腹泻和皮疹风险可能降低,1,,,0,,,,plus,李晶晶
PA166136421,rs1128503,1446897682,AA,"Patients with renal cell carcinoma and the AA genotype who are treated with sunitinib may have a decreased risk of  neutropenia, leukopenia, and diarrhea as compared to patients with the AG and GG genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.",携带AA基因型的肾细胞癌患者，相比AG和GG基因型，中性粒细胞减少症、白血球减少症和腹泻的风险可能降低,1,,,0,,,,plus,李晶晶
PA166136421,rs1128503,1446897683,AG,"Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of  neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.",携带AG基因型的肾细胞癌患者，相比AA基因型，中性粒细胞减少症、白血球减少症和腹泻的风险可能增加；相比GG基因型，中性粒细胞减少症、白血球减少症和腹泻的风险可能降低,1,,,1,,,,plus,李晶晶
PA166136421,rs1128503,1446897684,GG,"Patients with renal cell carcinoma and the GG genotype who are treated with sunitinib may have an increased risk of  neutropenia, leukopenia, and diarrhea as compared to patients with the AA genotypes, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.",携带GG基因型的肾细胞癌患者，相比AA基因型，中性粒细胞减少症、白血球减少症和腹泻的风险可能增加,1,,,2,,,,plus,李晶晶
PA166136510,rs1128503,1447943755,AA,Patients with AA genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.,携带AA基因型的发作性嗜睡症患者，相比AG基因型，药效可能降低,1,,0,,,,,plus,黄星
PA166136510,rs1128503,1447943756,AG,Patients with AG genotype and narcolepsy may have increased response to modafinil compared to patients with AA or GG genotype. Other clinical and genetic factors may affect response to modafinil.,携带AG基因型的发作性嗜睡症患者，相比AA或GG基因型，药效可能增加,1,,2,,,,,plus,黄星
PA166136510,rs1128503,1447943757,GG,Patients with GG genotype and narcolepsy may have decreased response to modafinil compared to patients with AG genotype. Other clinical and genetic factors may affect response to modafinil.,携带GG基因型的发作性嗜睡症患者，相比AG基因型，药效可能降低,1,,0,,,,,plus,黄星
PA166162610,rs1128503,1448573617,AA,Patients with the AA genotype and ulcerative colitis may have a decreased response when treated with tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence tacrolimus response. ,携带AA基因型的溃疡性结肠炎患者，相比AG或GG基因型，药效可能降低,1,,0,,,,,plus,黄星
PA166162610,rs1128503,1448573618,AG,Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response. ,携带AG基因型的溃疡性结肠炎患者，相比AA基因型，药效可能增加,1,,2,,,,,plus,黄星
PA166162610,rs1128503,1448573619,GG,Patients with the GG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response. ,携带GG基因型的溃疡性结肠炎患者，相比AA基因型，药效可能增加,1,,2,,,,,plus,黄星
PA166136486,rs118192116,1447992118,CC,"Individuals with the CC genotype and central core myopathy may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CG or GG genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia.",携带CC基因型的中央核肌病患者，相比CG或GG基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166136486,rs118192116,1447992119,CG,"Individuals with the CG genotype and central core myopathy may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CC genotype. Other clinical and genetic factors may also influence whether a patient develops Malignant Hyperthermia.",携带CG基因型的中央核肌病患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166136486,rs118192116,1447992120,GG,"Individuals with the GG genotype and central core myopathy may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with CC genotype. Other clinical and genetic factors may also influence whether a patient of develops Malignant Hyperthermia. Please note: the G allele is thought to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with GG genotype is not known. ",携带GG基因型的中央核肌病患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135875,rs118192124,1447992341,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带CC基因型的患者，相比TT或CT基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135875,rs118192124,1447992342,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带CT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135875,rs118192124,1447992343,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known. The T allele is also associated with central core myopathy. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带TT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135464,rs118192170,1447992401,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Please note: the C allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with CC genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CC基因型的患者，相比TT基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135464,rs118192170,1447992402,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CT基因型的患者，相比TT基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135464,rs118192170,1447992403,TT,"Patients with the TT genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带TT基因型的患者，相比CT或CC基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135459,rs118192161,1447992410,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带CC基因型的患者，相比TT或CT基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135459,rs118192161,1447992411,CT," Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带CT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135459,rs118192161,1447992412,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele confers susceptibility to MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not reported here.",携带TT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166136354,rs118192122,1447992447,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known.",携带AA基因型的患者，相比GG基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166136354,rs118192122,1447992448,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带AG基因型的患者，相比GG基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166136354,rs118192122,1447992449,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.",携带GG基因型的患者，相比AA或AG基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135465,rs118192175,1447992253,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CC基因型的患者，相比TT或CT基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135465,rs118192175,1447992254,CT ,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135465,rs118192175,1447992255,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known.",携带TT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135463,rs118192167,1447992376,AA,"Patients with the AA genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG or AG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带AA基因型的患者，相比AG或GG基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135463,rs118192167,1447992377,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带AG基因型的患者，相比AA基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135463,rs118192167,1447992378,GG,"Patients with the GG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the G allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with GG genotype is not known. ",携带GG基因型的患者，相比AA基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135466,rs118192176,1447992278,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known.",携带AA基因型的患者，相比GG基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135466,rs118192176,1447992279,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带AG基因型的患者，相比GG基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135466,rs118192176,1447992280,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带GG基因型的患者，相比AA或AG基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166158878,rs11868035,1448099102,AA,Patients with the AA genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels. ,携带AA基因型的精神分裂症患者，相比GG基因型，总胆固醇上升的幅度可能较高,1,,,2,,,,plus,黄星
PA166158878,rs11868035,1448099103,AG,Patients with the AG genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels. ,携带AG基因型的精神分裂症患者，相比GG基因型，总胆固醇上升的幅度可能较高,1,,,2,,,,plus,黄星
PA166158878,rs11868035,1448099104,GG,Patients with the GG genotype and schizophrenia may have a smaller increase or decrease in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence total cholesterol levels. ,携带GG基因型的精神分裂症患者，相比AG或AA基因型，总胆固醇上升的幅度可能较小或水平降低,1,,,0,,,,plus,黄星
PA166134629,rs118192172,1185023394,CC,Patients with CC genotype may have decreased risk to statin-related myopathy as compared patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins.,携带CC基因型的患者，相比TT或CT基因型，药物引发肌病的风险可能降低,1,,,0,,,,plus,黄星
PA166134629,rs118192172,1185023395,CT,Patients with CT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins. ,携带CT基因型的患者，相比CC基因型，药物引发肌病的风险可能增加,1,,,2,,,,plus,黄星
PA166134629,rs118192172,1185023396,TT,Patients with TT genotype may have increased risk to statin-related myopathy as compared patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to statins. ,携带TT基因型的患者，相比CC基因型，药物引发肌病的风险可能增加,1,,,2,,,,plus,黄星
PA166135458,rs118192172,1447992230,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.",携带CC基因型的患者，相比TT或CT基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135458,rs118192172,1447992231,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.",携带CT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135458,rs118192172,1447992232,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops Malignant Hyperthermia.",携带TT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135238,rs11960832,1183631407,CC,Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.,携带CC基因型的精神分裂症患者，相比TT基因型，药效可能较好,1,,2,,,,,FWD,黄星
PA166135238,rs11960832,1183631406,CT,Patients with the CT genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.,携带CT基因型的精神分裂症患者，相比TT基因型，药效可能较好,1,,2,,,,,FWD,黄星
PA166135238,rs11960832,1183631405,TT,Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to olanzapine.,携带TT基因型的精神分裂症患者，相比CT或CC基因型，药效可能较差,1,,0,,,,,FWD,黄星
PA166134240,rs119774,655385181,CC,"Patients with the CC genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.",携带CC基因型的哮喘患者，相比CT基因型，基于强力呼气容积测定（FEV1），药效可能不会提升,1,,0,,,,,plus,黄星
PA166134240,rs119774,655385180,CT,"Patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.",携带CT基因型的哮喘患者，相比CC基因型，基于强力呼气容积测定（FEV1）药效可能会提升,1,,2,,,,,plus,黄星
PA166134240,rs119774,655385182,TT,"Patients with the TT genotype were not studied. But patients with the CT genotype and Asthma may have an increased response to montelukast treatment, based on an increased Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.",无TT基因型患者参与研究,1,,,,,,,plus,黄星
PA166136283,rs12054895,1444700764,GG,Patients with the GG genotype and major depression who are treated with citalopram or escitalopram may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.,携带GG基因型的重度抑郁症患者，相比TT基因型，前2周治疗对症状改善效果可能较差,1,,0,,,,,plus,黄星
PA166136283,rs12054895,1444700763,GT,Patients with the GT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype may have less improvement over the first 2 weeks as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.,携带GT基因型的重度抑郁症患者，相比GG基因型，前2周治疗对症状改善效果可能较好；相比TT基因型，前2周治疗对症状改善效果可能较差,1,,1,,,,,plus,黄星
PA166136283,rs12054895,1444700762,TT,Patients with the TT genotype and major depression who are treated with citalopram or escitalopram may have better improvement over the first 2 weeks as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.,携带TT基因型的重度抑郁症患者，相比GG基因型，前2周治疗对症状改善效果可能较好,1,,2,,,,,plus,黄星
PA166134112,rs12050217,1447964537,AA,"Patients with the AA genotype who are treated with perindopril may have a decreased, but not absent, risk for cardiac events as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril.",携带AA基因型的患者，相比AG或GG基因型，心血管不良反应风险可能降低,1,,,0,,,,plus,黄星
PA166134112,rs12050217,1447964538,AG,Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril.,携带AG基因型的患者，相比AA基因型，心血管不良反应风险可能增加,1,,,2,,,,plus,黄星
PA166134112,rs12050217,1447964539,GG,Patients with the GG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk  for cardiac events when taking perindopril.,携带GG基因型的患者，相比AA基因型，心血管不良反应风险可能增加,1,,,2,,,,plus,黄星
PA166135486,rs121909005,1184472589,GG,"Patients with the GG genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带GG基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166135486,rs121909005,1184472590,GT,"Patients with the GG genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带GT基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166135486,rs121909005,1184472591,TT,"Patients with the TT genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带TT基因型的囊性纤维化患者，药物响应未知,1,,,,,,,plus,黄星
PA166135485,rs121908757,1184472581,AA,"Patients with the AA genotype (do not have a copy of the CFTR S549R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带AA基因型的囊性纤维化患者，药物响应未知,1,,,,,,,plus,黄星
PA166135485,rs121908757,1184472582,AC,"Patients with the AC genotype (one copy of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AC基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166135485,rs121908757,1184472583,CC,"Patients with the CC genotype (two copies of the CFTR S549R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S549R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带CC基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166135487,rs121909013,1184472593,AA,"Patients with the AA genotype (two copies of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AA基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166135487,rs121909013,1184472594,AG,"Patients with the AG genotype (one copy of the CFTR G551S variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AG基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166135487,rs121909013,1184472595,GG,"Patients with the GG genotype (do not have a copy of the CFTR G551S variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551S. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带GG基因型的囊性纤维化患者，药物响应未知,1,,,,,,,plus,黄星
PA166161190,rs121909011,1448423867,CT,Patients with cystic fibrosis and a copy of the C allele resulting in residual CFTR function may respond to ivacaftor treatment. Other genetic and clinical factors may affect response to ivacaftor.,携带CT基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166161190,rs121909011,1448423868,TT,"Patients with cystic fibrosis and without residual CFTR function, such as patients with the TT genotype, may not respond to ivacaftor treatment. Other genetic and clinical factors may affect response to ivacaftor.",携带TT基因型的囊性纤维化患者，药物可能不起效,1,,0,,,,,plus,黄星
PA166134634,rs121434569,1448108114,CC,"Advanced non-small-cell lung cancer patients with CC genotype may less likely develop acquired resistance and more likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CT or TT genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.",携带CC基因型的晚期非小细胞肺癌患者，相比CT或TT基因型，耐药的可能性更小，而且无进展生存期增加的可能性较大,1,,2,,,,,plus,黄星
PA166134634,rs121434569,1448108115,CT,"Advanced non-small-cell lung cancer patients with CT genotype may more likely develop acquired resistance and less likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CC genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.",携带CT基因型的晚期非小细胞肺癌患者，相比CC基因型，耐药的可能性更大，而且无进展生存期增加的可能性较小,1,,0,,,,,plus,黄星
PA166134634,rs121434569,1448108116,TT,"Advanced non-small-cell lung cancer patients with TT genotype may more likely develop acquired resistance and less likely have increased progression-free survival (PFS) time when treated with erlotinib or gefitinib compared to patients with CC genotypes. In these studies, patients who have EGFR activating mutations [e.g. L858R or exon 19 deletion] are treated with erlotinib or gefitinib. The T790M mutation (rs121434569) was not detected or detected in very low frequency in patients who remained sensitive to erlotinib or gefitinib treatment or in nonresponders to these drugs. This is a somatic mutation, occurred in one cell then go for clonal expansion under some circumstances. None of the studies mentioned status for heterozygosity or homozygocity.",携带TT基因型的晚期非小细胞肺癌患者，相比CC基因型，耐药的可能性更大，而且无进展生存期增加的可能性较小,1,,0,,,,,plus,黄星
PA166135470,rs121918595,1447992381,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CC基因型的患者，相比TT或CT基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135470,rs121918595,1447992382,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带CT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135470,rs121918595,1447992383,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.  Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known.",携带TT基因型的患者，相比CC基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135471,rs121918594,1447992361,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带AA基因型的患者，相比GG基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135471,rs121918594,1447992362,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia. ",携带AG基因型的患者，相比GG基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135471,rs121918594,1447992363,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia. ",携带GG基因型的患者，相比AG或AA基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166161866,rs12191877,1448522780,CC,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带CC基因型的牛皮癣患者，相比CT或TT基因型，药物可能较差,1,,0,,,,,plus,黄星
PA166161866,rs12191877,1448522781,CT,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带CT基因型的牛皮癣患者，相比CC基因型，药物可能较好,1,,2,,,,,plus,黄星
PA166161866,rs12191877,1448522782,TT,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带TT基因型的牛皮癣患者，相比CC基因型，药物可能较好,1,,2,,,,,plus,黄星
PA166135468,rs121918593,1447992331,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known.",携带AA基因型的患者，相比GG基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135468,rs121918593,1447992332,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带AG基因型的患者，相比GG基因型，可能会出现恶性高热,1,,,2,,,,plus,黄星
PA166135468,rs121918593,1447992333,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带GG基因型的患者，相比AG或AA基因型，可能不会出现恶性高热,1,,,0,,,,plus,黄星
PA166135488,rs121909041,1184472605,CC,"Patients with the CC genotype (two copies of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带CC基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166135488,rs121909041,1184472606,CT,"Patients with the CT genotype (one copy of the CFTR S1255P variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带CT基因型的囊性纤维化患者，药物可能起效,1,,2,,,,,plus,黄星
PA166135488,rs121909041,1184472607,TT,"Patients with the TT genotype (do not have a copy of the CFTR S1255P variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1255P. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带TT基因型的囊性纤维化患者，药物响应未知,1,,,,,,,plus,黄星
PA166135162,rs12208357,1183618202,CC,Patients with the CC genotype may have lower plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the TT genotype. Other genetic or clinical factors may influence the response to tramadol.,携带CC基因型的健康人群，相比TT基因型，血药浓度可能较低,1,,,,,,0,plus,黄星
PA166135162,rs12208357,1183618201,CT,Patients with the CT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the CC genotype. Other genetic or clinical factors may influence the response to tramadol.,携带CT基因型的健康人群，相比CC基因型，血药浓度可能较高,1,,,,,,2,plus,黄星
PA166135162,rs12208357,1183618200,TT,Patients with the TT genotype may have higher plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the CC genotype. Other genetic or clinical factors may influence the response to tramadol.,携带TT基因型的健康人群，相比CC基因型，血药浓度可能较高,1,,,,,,2,plus,黄星
PA166136122,rs1229984,1444607739,CC,Patients with the CC genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol. ,携带CC基因型的患者，相比TT基因型，药物代谢较慢,1,,,,0,,,plus,黄星
PA166136122,rs1229984,1444607740,CT,Patients with the CT genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol. ,携带CT基因型的患者，相比TT基因型，药物代谢较慢,1,,,,0,,,plus,黄星
PA166136122,rs1229984,1444607741,TT,Patients with the TT genotype may have a higher maximal rate (Vmax) of ethanol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence Vmax of ethanol. ,携带TT基因型的患者，相比CT或CC基因型，药物代谢较快,1,,,,2,,,plus,黄星
PA166136229,rs12505410,1444673381,GG,Patients with the GG genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib. ,携带GG基因型的慢性粒细胞性白血病患者，相比TT基因型，药效可能较好,1,,2,,,,,FWD,黄星
PA166136229,rs12505410,1444673382,GT,Patients with the GT genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib. ,携带GT基因型的慢性粒细胞性白血病患者，相比TT基因型，药效可能较好,1,,2,,,,,FWD,黄星
PA166136229,rs12505410,1444673383,TT,Patients with the TT genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to imatinib. ,携带TT基因型的慢性粒细胞性白血病患者，相比GT或GG基因型，药效可能较差,1,,0,,,,,FWD,黄星
PA166151930,rs1264457,1447952833,AA,"Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.",携带AA基因型的女性类风湿性关节炎患者，相比GG基因型，药效可能较好,1,女,2,,,,,plus,黄星
PA166151930,rs1264457,1447952834,AG,"Women with the AG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.",携带AG基因型的女性类风湿性关节炎患者，相比AA基因型，药效可能较差,1,女,0,,,,,plus,黄星
PA166151930,rs1264457,1447952835,GG,"Women with the GG genotype and rheumatoid arthritis may have a worse response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the AA genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.",携带GG基因型的女性类风湿性关节炎患者，相比AA基因型，药效可能较差,1,女,0,,,,,plus,黄星
PA166135001,rs12654264,1183533593,AA,Patients with the AA genotype may have a larger reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment. ,携带AA基因型的患者，相比TT基因型，结肠癌风险降低程度更大,1,,,0,,,,plus,黄星
PA166135001,rs12654264,1183533594,AT,Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment. ,携带AT基因型的患者，相比TT基因型，结肠癌风险降低程度更大；相比AA基因型，结肠癌风险降低程度更小,1,,,1,,,,plus,黄星
PA166135001,rs12654264,1183533595,TT,Patients with the TT genotype may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment. ,携带TT基因型的患者，相比AA基因型，结肠癌风险降低程度更小,1,,,2,,,,plus,黄星
PA166152717,rs1265112,1447960733,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CC基因型的HIV感染者，相比TT基因型，药物诱导的皮疹风险可能增加,1,,,2,,,,plus,黄星
PA166152717,rs1265112,1447960734,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CT基因型的HIV感染者，相比TT基因型，药物诱导的皮疹风险可能增加；相比CC基因型，药物诱导的皮疹风险可能降低,1,,,1,,,,plus,黄星
PA166152717,rs1265112,1447960735,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带TT基因型的HIV感染者，相比CC基因型，药物诱导的皮疹风险可能降低,1,,,0,,,,plus,黄星
PA166134134,rs12721627,655384594,CC,Patients with the CC genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.,携带CC基因型的患者，相比GG基因型，药物代谢可能较慢,1,,,,0,,,minus,黄星
PA166134134,rs12721627,655384595,CG,Patients with the CG genotype may have decreased metabolism of paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence paclitaxel metabolism.,携带CG基因型的患者，相比GG基因型，药物代谢可能较慢,1,,,,0,,,minus,黄星
PA166134134,rs12721627,655384596,GG,Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.,携带GG基因型的患者，相比CG或CC基因型，药物代谢可能较快,1,,,,2,,,minus,黄星
PA166134861,rs12720462,1043880304,AA,Patients with AA genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.,携带AA基因型的患者，相比CC基因型，剂量调整的血药浓度可能增加,1,,,,,,2,FWD,黄星
PA166134861,rs12720462,1043880305,AC,Patients with AC genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.,携带AC基因型的患者，相比CC基因型，剂量调整的血药浓度可能增加,1,,,,,,2,FWD,黄星
PA166134861,rs12720462,1043880306,CC,Patients with CC genotype may have decreased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.,携带CC基因型的患者，相比AC或AA基因型，剂量调整的血药浓度可能降低,1,,,,,,0,FWD,黄星
PA166134655,rs12777823,1447949441,AA,Patients with the AA genotype may require a lower dose of warfarin (may require a dose reduction of 9路34 mg/week) in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带AA基因型的非裔美国人，相比GG基因型，药物剂量可能需要减少,1,,,,,0,,plus,黄星
PA166134655,rs12777823,1447949442,AG,Patients with the AG genotype may require a lower dose of warfarin (may require a dose reduction of 6路92 mg/week) in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带AG基因型的非裔美国人，相比GG基因型，药物剂量可能需要减少,1,,,,,0,,plus,黄星
PA166134655,rs12777823,1447949443,GG,Patients with the GG genotype may require a higher dose of warfarin in African Americans as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带GG基因型的非裔美国人，相比AG或AA基因型，药物剂量可能需要增加,1,,,,,2,,plus,黄星
PA166136513,rs12817819,1447945960,CC,Patients with the CC genotype who are treated with antihypertensives may have a lower risk for resistant hypertension as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension. ,携带CC基因型的患者，相比CT或TT基因型，顽固性高血压风险可能降低,1,,,0,,,,FWD,黄星
PA166136513,rs12817819,1447945961,CT,Patients with the CT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension. ,携带CT基因型的患者，相比CC基因型，顽固性高血压风险可能增加,1,,,2,,,,FWD,黄星
PA166136513,rs12817819,1447945962,TT,Patients with the TT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension. ,携带TT基因型的患者，相比CC基因型，顽固性高血压风险可能增加,1,,,2,,,,FWD,黄星
PA166136023,rs1295686,1447946100,CC,"Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine. ",携带CC基因型的患者，相比TT基因型，非免疫性应答风险可能降低,1,,2,,,,,plus,黄星
PA166136023,rs1295686,1447946101,CT,"Patients with the CT genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype, or at increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine. ",携带CT基因型的患者，相比TT基因型，非免疫性应答风险可能降低；相比CC基因型，非免疫性应答风险可能增加,1,,1,,,,,plus,黄星
PA166136023,rs1295686,1447946102,TT,"Patients with the TT genotype may be at increased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine. ",携带TT基因型的患者，相比CC基因型，非免疫性应答风险可能增加,1,,0,,,,,plus,黄星
PA166135060,rs12948783,1183614548,AA,Patients with the AA genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.,携带AA基因型的癌症患者，相比GG基因型，疼痛缓解作用可能较差,1,,0,,,,,plus,黄星
PA166135060,rs12948783,1183614549,AG,Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.,携带AG基因型的癌症患者，相比GG基因型，疼痛缓解作用可能较差,1,,0,,,,,plus,黄星
PA166135060,rs12948783,1183614550,GG,Patients with the GG genotype may have better pain relief to opioids in cancer patients as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to opioids.,携带GG基因型的癌症患者，相比AA或AG基因型，疼痛缓解作用可能较好,1,,2,,,,,plus,黄星
PA166135304,rs12943590,1183680561,AA,"Patients with the AA genotype may have 1) decreased response to metformin in people with Diabetes Mellitus, 2)  increased renal and secretory clearance of metformin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin. ",携带AA基因型的糖尿病患者，相比AG或GG基因型，药效可能降低，清除率可能增加,1,,0,,,,,plus,黄星
PA166135304,rs12943590,1183680562,AG,"Patients with the AG genotype may have 1) increased response to metformin in people with Diabetes Mellitus, 2)  decreased renal and secretory clearance of metformin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin. ",携带AG基因型的糖尿病患者，相比AA基因型，药效可能增加，清除率可能降低,1,,2,,,,,plus,黄星
PA166135304,rs12943590,1183680563,GG,"Patients with the GG genotype may have 1) increased response to metformin in people with Diabetes Mellitus, 2)  decreased renal and secretory clearance of metformin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin. ",携带GG基因型的糖尿病患者，相比AA基因型，药效可能增加，清除率可能降低,1,,2,,,,,plus,黄星
PA166135305,rs12943590,1448594871,AA,"Individuals with the AA genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin. ",携带AA基因型的患者，相比GG基因型，药物清除率可能增加,1,,,,2,,,plus,黄星
PA166135305,rs12943590,1448594872,AG,"Individuals with the AG genotype may have increased renal and secretory clearance of metformin as compared to individuals with the GG genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin. ",携带AG基因型的患者，相比GG基因型，药物清除率可能增加,1,,,,2,,,plus,黄星
PA166135305,rs12943590,1448594873,GG,"Individuals with the GG genotype may have decreased renal and secretory clearance of metformin as compared to individuals with the AA genotype, however there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to metformin. ",携带GG基因型的患者，相比AA基因型，药物清除率可能降低,1,,,,0,,,plus,黄星
PA166152719,rs130072,1447960747,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CC基因型的HIV感染者，相比TT基因型，药物诱导的皮疹风险可能降低,1,,,0,,,,plus,黄星
PA166152719,rs130072,1447960748,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CT基因型的HIV感染者，相比TT基因型，药物诱导的皮疹风险可能降低,1,,,0,,,,plus,黄星
PA166152719,rs130072,1447960749,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带TT基因型的HIV感染者，相比CC基因型，药物诱导的皮疹风险可能增加,1,,,2,,,,plus,黄星
PA166136287,rs13064411,1444700826,AA,Patients with the AA genotype may have increased response to hmg coa reductase inhibitors as compared to patients with GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.,携带AA基因型的患者，相比GG或AG基因型，药效可能增加,1,,2,,,,,plus,黄星
PA166136287,rs13064411,1444700825,AG,Patients with the AG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.,携带AG基因型的患者，相比AA基因型，药效可能降低,1,,0,,,,,plus,黄星
PA166136287,rs13064411,1444700824,GG,Patients with the GG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.,携带GG基因型的患者，相比AA基因型，药效可能降低,1,,0,,,,,plus,黄星
PA166136012,rs13250975,1447943762,AA,Patients with AA genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AG and GG genotype. Other clinical and genetic factors may affect response to antipsychotics.,携带AA基因型的精神分裂症患者，相比AG和GG基因型，药效可能降低,1,,0,,,,,FWD,黄星
PA166136012,rs13250975,1447943763,AG,Patients with AG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.,携带AG基因型的精神分裂症患者，相比AA基因型，药效可能增加,1,,2,,,,,FWD,黄星
PA166136012,rs13250975,1447943764,GG,Patients with GG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.,携带GG基因型的精神分裂症患者，相比AA基因型，药效可能增加,1,,2,,,,,FWD,黄星
PA166135893,rs13253389,1445401188,AA,Patients with the AA genotype may have decreased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.,携带AA基因型的患者，相比AG或GG基因型，二手烟环境中，药物浓度可能降低,1,,,,2,,,FWD,黄星
PA166135893,rs13253389,1445401189,AG,Patients with the AG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.,携带AG基因型的患者，相比AA基因型，二手烟环境中，药物浓度可能增加,1,,,,0,,,FWD,黄星
PA166135893,rs13253389,1445401190,GG,Patients with the GG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.,携带GG基因型的患者，相比AA基因型，二手烟环境中，药物浓度可能增加,1,,,,0,,,FWD,黄星
PA166135074,rs1344706,1183630579,AA,Patients with the AA genotype and schizophrenia may have a poorer response when treated with antipsychotics as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to antipsychotics. ,携带AA基因型的精神分裂症患者，相比AC或CC基因型，疗效可能较差,1,,0,,,,,plus,黄星
PA166135074,rs1344706,1183630580,AC,Patients with the AC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics. ,携带AC基因型的精神分裂症患者，相比AA基因型，疗效可能较好,1,,2,,,,,plus,黄星
PA166135074,rs1344706,1183630581,CC,Patients with the CC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics. ,携带CC基因型的精神分裂症患者，相比AA基因型，疗效可能较好,1,,2,,,,,plus,黄星
PA166135076,rs13432159,1183619609,GG,Patients with the GG genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline. ,携带GG基因型的重度抑郁症患者，相比TT基因型，可能会承受较强的全身不良反应,1,,,2,,,,plus,黄星
PA166135076,rs13432159,1183619610,GT,"Patients with the GT genotype and major depressive disorder may experience a higher burden of general side-effects when treated with sertraline as compared to patients with the TT genotype, or a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline. ",携带GT基因型的重度抑郁症患者，相比TT基因型，可能会承受较强的全身不良反应；相比GG基因型，全身不良反应可能较弱,1,,,1,,,,plus,黄星
PA166135076,rs13432159,1183619611,TT,Patients with the TT genotype and major depressive disorder may experience a lower burden of general side-effects when treated with sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of general side-effects when treated with sertraline. ,携带TT基因型的重度抑郁症患者，相比TT基因型，全身不良反应可能较弱,1,,,0,,,,plus,黄星
PA166135301,rs13266634,1183680534,CC,"Patients with the CC genotype may have decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.",携带CC基因型的II型糖尿病患者，相比TT或CT基因型，药物反应可能较弱,1,,0,,,,,plus,黄星
PA166135301,rs13266634,1183680533,CT,"Patients with the CT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.",携带CT基因型的II型糖尿病患者，相比CC基因型，药物反应可能较强,1,,0,,,,,plus,黄星
PA166135301,rs13266634,1183680532,TT,"Patients with the TT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.",携带TT基因型的II型糖尿病患者，相比CC基因型，药物反应可能增加,1,,2,,,,,plus,黄星
PA166136207,rs13266634,1444668484,CC,Individuals with the CC genotype may have a decreased response to insulin supplemented with zinc acetate as compared to individuals with the CT and TT genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate. ,携带CC基因型的患者，相比CT和TT基因型，药物反应可能较弱,1,,0,,,,,plus,黄星
PA166136207,rs13266634,1444668485,CT,Individuals with the CT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate. ,携带CT基因型的患者，相比CC基因型，药物反应可能较强,1,,2,,,,,plus,黄星
PA166136207,rs13266634,1444668486,TT,Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate. ,携带TT基因型的患者，相比CC基因型，药物反应可能较强,1,,2,,,,,plus,黄星
PA166158976,rs13393173,1448100459,AA,Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的类风湿性关节炎患者，相比GG基因型，药物反应可能较差,1,,0,,,,,plus,黄星
PA166158976,rs13393173,1448100460,AG,"Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared with patients with genotype GG, or more likely to respond as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.",携带AG基因型的类风湿性关节炎患者，相比GG基因型，药物反应可能较差；相比AA基因型，药物反应可能较好,1,,1,,,,,plus,黄星
PA166158976,rs13393173,1448100461,GG,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的类风湿性关节炎患者，相比AA基因型，药物反应可能较好,1,,2,,,,,plus,黄星
PA166136416,rs1364805,1446897504,GG,Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.,携带GG基因型的哮喘患者，相比GT或TT基因型，药物反应可能较差,1,,0,,,,,FWD,黄星
PA166136416,rs1364805,1446897505,GT,Patients with asthma and the GT genotype may have a decreased response to montelukast as compared to patients with the TT genotypes and an increased response as compared to patients with a GG genotype. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.,携带GT基因型的哮喘患者，相比TT基因型，药物反应可能较差；相比GG基因型，药物反应可能较好,1,,1,,,,,FWD,黄星
PA166136416,rs1364805,1446897506,TT,Patients with asthma and the TT genotype may have an increased response to montelukast as compared to patients with the GG and GT genotypes genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.,携带TT基因型的哮喘患者，相比GG和GT基因型，药物反应可能较好,1,,2,,,,,FWD,黄星
PA166134348,rs13181,655386617,GG,Patients with the GG genotype may have decreased survival when treated with platinum compounds as compared to patients with the GT or TT genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.,携带GG基因型的患者，相比GT或TT基因型，生存率可能降低,1,,0,,,,,plus,黄星
PA166134348,rs13181,655386618,GT,Patients with the GT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.,携带GT基因型的患者，相比GG基因型，生存率可能提高,1,,2,,,,,plus,黄星
PA166134348,rs13181,655386619,TT,Patients with the TT genotype may have increased survival when treated with platinum compounds as compared to patients with the GG genotypes however evidence is highly contradictory. Other genetic and clinical factors may also influence survival.,携带TT基因型的患者，相比GG基因型，生存率可能提高,1,,2,,,,,plus,黄星
PA166136384,rs13181,1448263867,GG,"Patients with the GG genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia.",携带GG基因型的乳腺癌患者，相比TT基因型，嗜中性白血球减少症的风险可能降低，肌病的风险可能没有变化,1,,,0,,,,plus,黄星
PA166136384,rs13181,1448263868,GT,"Patients with the GT genotype and breast cancer may have a decreased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for neutropenia.",携带GT基因型的乳腺癌患者，相比TT基因型，嗜中性白血球减少症的风险可能降低，肌病的风险可能没有变化,1,,,0,,,,plus,黄星
PA166136384,rs13181,1448263869,TT,"Patients with the TT genotype and breast cancer may have an increased risk for neutropenia, but no difference in risk for myopathy, when treated with docetaxel as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk for neutropenia.",携带TT基因型的乳腺癌患者，相比TT基因型，嗜中性白血球减少症的风险可能增加，肌病的风险可能没有变化,1,,,2,,,,plus,黄星
PA166136168,rs13181,1444666624,GG,Patients with the GG genotype and non-small-cell lung cancer may have an increased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence risk for pneumonitis.,携带GG基因型的非小细胞肺癌患者，相比GT或TT基因型，肺炎的风险可能增加,1,,,2,,,,plus,黄星
PA166136168,rs13181,1444666625,GT,Patients with the GT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.,携带GT基因型的非小细胞肺癌患者，相比GG基因型，肺炎的风险可能降低,1,,,0,,,,plus,黄星
PA166136168,rs13181,1444666626,TT,Patients with the TT genotype and non-small-cell lung cancer may have a decreased risk for pneumonitis when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for pneumonitis.,携带TT基因型的非小细胞肺癌患者，相比GG基因型，肺炎的风险可能降低,1,,,0,,,,plus,黄星
PA166134263,rs1367117,655385371,AA,Patients with the AA genotype who are treated with irbesartan may be less likely to respond than patients with the AG or the GG genotype.  Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的患者，相比AG或GG基因型，药物的疗效可能较差,1,,0,,,,,plus,黄星
PA166134263,rs1367117,655385372,AG,Patients with the AG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response.,携带AG基因型的患者，相比AA基因型，药物的疗效可能较好,1,,2,,,,,plus,黄星
PA166134263,rs1367117,655385373,GG,Patients with the GG genotype who are treated with irbesartan may be more likely to respond than patients with the AA genotype.  Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的患者，相比AA基因型，药物的疗效可能较好,1,,2,,,,,plus,黄星
PA166135298,rs1423515,1183680517,AA,Patients with the AA genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.,携带AA基因型的哮喘患者，相比GG基因型，气道反应性可能增加,1,,0,,,,,FWD,黄星
PA166135298,rs1423515,1183680518,AG,Patients with the AG genotype may have increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.,携带AG基因型的哮喘患者，相比GG基因型，气道反应性可能增加,1,,0,,,,,FWD,黄星
PA166135298,rs1423515,1183680519,GG,Patients with the GG genotype may have decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to salbutamol.,携带GG基因型的哮喘患者，相比AA或AG基因型，气道反应性可能降低,1,,2,,,,,FWD,黄星
PA166159208,rs1470579,1448103975,AA,Patients with the AA genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to repaglinide.,携带AA基因型的II型糖尿病患者，相比AC或CC基因型，效果可能更好,1,,2,,,,,plus,黄星
PA166159208,rs1470579,1448103976,AC,Patients with the AC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.,携带AC基因型的II型糖尿病患者，相比AA基因型，效果可能降低,1,,0,,,,,plus,黄星
PA166159208,rs1470579,1448103977,CC,Patients with the CC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.,携带CC基因型的II型糖尿病患者，相比CC基因型，效果可能降低,1,,0,,,,,plus,黄星
PA166136286,rs1495741,1444700817,AA,"Patients with the AA genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease, abnormal liver-function tests and decreased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease. ",携带AA基因型的肺结核患者，使用肺结核治疗药物时，肝中毒风险增加，肝功能异常风险增加，肝脏异常发展之前异烟肼的积累降低,1,,,2,,,,plus,黄星
PA166136286,rs1495741,1444700819,AG ,"Patients with the AG genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease, abnormal liver-function tests and decreased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with GG genotype or may have decreased risk for toxic liver disease, abnormal liver-function tests and increased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease. ",携带AG基因型的肺结核患者，使用肺结核治疗药物时，肝中毒风险增加，肝功能异常风险增加，肝脏异常发展之前异烟肼的积累降低,1,,,2,,,,plus,黄星
PA166136286,rs1495741,1444700818,GG,"Patients with the GG genotype who are treated with drugs for treatment of tuberculosis may have decreased risk for toxic liver disease, abnormal liver-function tests and increased mean cumulative doses of isoniazid before the development of abnormal liver-function tests as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease. ",携带GG基因型的肺结核患者，使用肺结核治疗药物时，肝中毒风险降低，肝功能异常风险降低，肝脏异常发展之前异烟肼的积累增加,1,,,0,,,,plus,黄星
PA166135942,rs1495509,1446899738,CC,Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.,携带CC基因型的患者，相比CT和TT基因型，药物诱导的咳嗽风险可能增加,1,,,2,,,,FWD,黄星
PA166135942,rs1495509,1446899739,CT,Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.,携带CT基因型的患者，相比TT基因型，药物诱导的咳嗽风险可能增加,1,,,2,,,,FWD,黄星
PA166135942,rs1495509,1446899740,TT,Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.,携带TT基因型的患者，相比CT或CC基因型，药物诱导的咳嗽风险可能降低,1,,,0,,,,FWD,黄星
PA166135297,rs1517114,1183680512,CC,Patients with the CC genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带CC基因型的非小细胞肺癌患者，相比GG基因型，药物治疗时会增加腹泻的严重程度,1,,,2,,,,plus,黄星
PA166135297,rs1517114,1183680513,CG,Patients with the CG genotype may have increased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带CG基因型的非小细胞肺癌患者，相比GG基因型，药物治疗时可能会增加腹泻的严重程度,1,,,2,,,,plus,黄星
PA166135297,rs1517114,1183680514,GG,Patients with the GG genotype may have decreased severity of Diarrhea when treated with irinotecan in people with Non-Small-Cell Lung Carcinoma as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带GG基因型的非小细胞肺癌患者，相比CC或CG基因型，药物治疗时可能会降低腹泻的程度,1,,,0,,,,plus,黄星
PA166135391,rs1532624,1183700489,AA,Patients with the AA genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.,携带AA基因型的高血脂症患者，相比CC基因型，效果可能降低,1,,0,,,,,minus,黄星
PA166135391,rs1532624,1183700490,AC,Patients with the AC genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.,携带AC基因型的高血脂症患者，相比CC基因型，效果可能降低,1,,0,,,,,minus,黄星
PA166135391,rs1532624,1183700491,CC,Patients with the CC genotype may have increased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.,携带CC基因型的高血脂症患者，相比AA基因型，效果可能更好,1,,2,,,,,minus,黄星
PA166134790,rs1613662,1043858676,AA ,Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,无AA基因型的患者参与研究,1,,,,,,,plus,黄星
PA166134790,rs1613662,1043858677,AG,Patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带AG基因型的患者，相比GG基因型，没有药物响应的可能性增加,1,,0,,,,,plus,黄星
PA166134790,rs1613662,1043858678,GG,"Patients with the GG genotype who are treated with aspirin may have a decreased, but not absent, risk for non-response to aspirin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.",携带GG基因型的患者，相比AG基因型，没有药物响应的可能性降低,1,,2,,,,,plus,黄星
PA166135682,rs1650697,1444666772,AA,Patients with the AA genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity. ,携带AA基因型的肺癌患者，相比GG基因型，药物毒性风险可能增加,1,,,2,,,,minus,黄星
PA166135682,rs1650697,1444666773,AG,Patients with the AG genotype and lung cancer may have an increased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for drug toxicity. ,携带AG基因型的肺癌患者，相比GG基因型，药物毒性风险可能增加,1,,,2,,,,minus,黄星
PA166135682,rs1650697,1444666774,GG,Patients with the GG genotype and lung cancer may have a decreased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for drug toxicity. ,携带GG基因型的肺癌患者，相比AA或AG基因型，药物毒性风险可能降低,1,,,0,,,,minus,黄星
PA166134789,rs16851030,1448107080,CC,"Patients with the CC genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.",携带CC基因型的哮喘患者，相比TT基因型，副作用风险可能降低,1,,,0,,,,FWD,黄星
PA166134789,rs16851030,1448107081,CT,"Patients with the CT genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.",携带CT基因型的哮喘患者，相比TT基因型，副作用风险可能降低,1,,,0,,,,FWD,黄星
PA166134789,rs16851030,1448107082,TT,Patients with the TT genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.,携带TT基因型的哮喘患者，相比CC或CT基因型，副作用风险可能增加,1,,,2,,,,FWD,黄星
PA166134395,rs167771,655387877,AA,Patients with the AA genotype may have decreased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AG or GG genotype. Patients with the AA genotype may still be at risk for toxicity when taking risperidone. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带AA基因型的精神病患者，相比AG或GG基因型，锥体外系症的风险可能降低,1,,,0,,,,plus,黄星
PA166134395,rs167771,655387878,AG,Patients with the AG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带AG基因型的精神病患者，相比AA基因型，锥体外系症的风险可能增加,1,,,2,,,,plus,黄星
PA166134395,rs167771,655387879,GG,Patients with the GG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带GG基因型的精神病患者，相比AA基因型，锥体外系症的风险可能增加,1,,,2,,,,plus,黄星
PA166135750,rs16947,1444700883,AA,Patients with the AA genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.,携带AA基因型的开角青光眼患者，相比GG基因型，心动过缓的风险可能增加,1,,,2,,,,FWD,黄星
PA166135750,rs16947,1444700884,AG,Patients with the AG genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.,携带AG基因型的开角青光眼患者，相比GG基因型，心动过缓的风险可能增加,1,,,2,,,,FWD,黄星
PA166135750,rs16947,1444700885,GG,Patients with the GG genotype and open-angle glaucoma who are treated with timolol may have a decreased risk for bradycardia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.,携带GG基因型的开角青光眼患者，相比AG或AA基因型，心动过缓的风险可能降低,1,,,0,,,,FWD,黄星
PA166135070,rs16965962,1183630673,AA,Patients with the AA genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence general side-effect burden.,携带AA基因型的重度抑郁症患者，相比CC基因型，一般副作用风险可能增加,1,,,2,,,,plus,黄星
PA166135070,rs16965962,1183630674,AC,"Patients with the AC genotype and major depressive disorder may have an increased general side-effect burden when treated with citalopram as compared to patients with the CC genotype, or a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.",携带AC基因型的重度抑郁症患者，相比CC基因型，一般副作用风险可能增加,1,,,2,,,,plus,黄星
PA166135070,rs16965962,1183630675,CC,Patients with the CC genotype and major depressive disorder may have a decreased general side-effect burden when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence general side-effect burden.,携带CC基因型的重度抑郁症患者，相比AA基因型，一般副作用风险可能降低,1,,,0,,,,plus,黄星
PA166158752,rs16973225,1448097824,AA,Patients with the AA genotype may have a decreased likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AC or CC genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.,携带AA基因型的患者，相比AC或CC基因型，定期服药后，患结直肠癌的可能性降低,1,,,0,,,,plus,黄星
PA166158752,rs16973225,1448097825,AC,Patients with the AC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.,携带AC基因型的患者，相比AA基因型，定期服药后，患结直肠癌的可能性不变,1,,,2,,,,plus,黄星
PA166158752,rs16973225,1448097826,CC,Patients with the CC genotype may not have a change in likelihood of colorectal cancer with regular use of aspirin and/or non-steroidal anti-inflammatory agents as compared to patients with the AA genotype. Please note: regular use of aspirin or NSAIDs was associated with a lower likelihood of colorectal cancer in the AA genotype but not the AC or CC [AC + CC OR=0.97 (95% CI: 0.78-1.20); P=0.76]. Other clinical and genetic factors may also influence likelihood of colorectal cancer in individuals who regularly take aspirin and/or non-steroidal anti-inflammatory agents.,携带CC基因型的结直肠癌患者，相比AA基因型，定期服药后，患结直肠癌的可能性不变,1,,,2,,,,plus,黄星
PA166135290,rs17060812,1183679849,CC,Patients with the CC genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.,携带CC基因型的抑郁症患者，相比TT基因型，药物反应效果可能增加,1,,2,,,,,FWD,黄星
PA166135290,rs17060812,1183679850,CT,Patients with the CT genotype may have increased response to nortriptyline in people with Depression as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to nortriptyline.,携带CT基因型的抑郁症患者，相比TT基因型，药物反应效果可能增加,1,,2,,,,,FWD,黄星
PA166135290,rs17060812,1183679851,TT,Patients with the TT genotype may have decreased response to nortriptyline in people with Depression as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to nortriptyline.,携带TT基因型的抑郁症患者，相比CC基因型，药物反应效果可能降低,1,,0,,,,,FWD,黄星
PA166135289,rs17091162,1183679846,AA,Patients with the AA genotype may have increased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AC or CC. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.,携带AA基因型的胰腺癌患者，相比AC或CC基因型，存活率可能增加,1,,2,,,,,FWD,黄星
PA166135289,rs17091162,1183679845,AC,Patients with the AC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.,携带AC基因型的胰腺癌患者，相比AA基因型，存活率可能降低,1,,0,,,,,FWD,黄星
PA166135289,rs17091162,1183679844,CC,Patients with the CC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.,携带CC基因型的胰腺癌患者，相比AA基因型，存活率可能降低,1,,0,,,,,FWD,黄星
PA166135069,rs17135437,1183614692,CC,Patients with the CC genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.,携带CC基因型的重度抑郁症患者，相比TT基因型，听力及视觉相关的副作用可能降低,1,,,0,,,,FWD,黄星
PA166135069,rs17135437,1183614693,CT,"Patients with the CT genotype and major depressive disorder may have decreased hearing and vision-related side-effects when treated with citalopram as compared to patients with the TT genotype, or increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence hearing and vision-related side-effects.",携带CT基因型的重度抑郁症患者，相比TT基因型，听力及视觉相关的副作用可能降低，或者相比CC基因型，听力及视觉相关的副作用可能增加,1,,,1,,,,FWD,黄星
PA166135069,rs17135437,1183614694,TT,Patients with the TT genotype and major depressive disorder may have increased hearing and vision-related side-effects when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence hearing and vision-related side-effects.,携带TT基因型的重度抑郁症患者，相比CC基因型，听力及视觉相关的副作用可能增加,1,,,2,,,,FWD,黄星
PA166136394,rs17143212,1445402203,CC,Patients with the CC genotype and psychotic illnesses may be at a lower risk for haloperidol-induced toxicities as compared to patients with the CT genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.,携带CC基因型的精神疾病患者，相比CT基因型，毒副作用可能较低,1,,,0,,,,FWD,黄星
PA166136394,rs17143212,1445402204,CT,Patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.,携带CT基因型的精神疾病患者，相比CC基因型，毒副作用可能较高,1,,,2,,,,FWD,黄星
PA166136394,rs17143212,1445402205,TT,"No patients with the TT genotype were present, but patients with the CT genotype and psychotic illnesses may be at a greater risk for haloperidol-induced toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence haloperidol-induced toxicities.",TT基因型的患者参与研究,1,,,,,,,FWD,黄星
PA166135276,rs1719247,1183679127,CC,Patients with the CC genotype may be more likely to experience myopathy when treated with statins as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.,携带CC基因型的患者，相比CT或TT基因型，患肌病的可能性增加,1,,,2,,,,FWD,黄星
PA166135276,rs1719247,1183679128,CT,"Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC genotype, and more likely to experience myopathy when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.",携带CT基因型的患者，相比CC基因型，患肌病的可能性降低，或者相比TT基因型，患肌病的可能性增加,1,,,1,,,,FWD,黄星
PA166135276,rs1719247,1183679129,TT,Patients with the TT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.,携带TT基因型的患者，相比CC或CT基因型，患肌病的可能性降低,1,,,0,,,,FWD,黄星
PA166135061,rs17183814,1184999870,AA,Patients with the AA genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics. ,携带AA基因型的癫痫患者，相比GG基因型，效果可能较差,1,,0,,,,,FWD,黄星
PA166135061,rs17183814,1184999871,AG,Patients with the AG genotype and epilepsy may be less likely to respond to antiepileptic drugs as compared to patients with the GG genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics. ,携带AG基因型的癫痫患者，相比GG基因型，效果可能较差,1,,0,,,,,FWD,黄星
PA166135061,rs17183814,1184999872,GG,Patients with the GG genotype and epilepsy may be more likely to respond to antiepileptic drugs as compared to patients with the AG or AA genotype. Please note; no association was found in two large cohorts and meta-analysis. Other genetic and clinical factors may also influence a patient's response to antiepileptics. ,携带GG基因型的癫痫患者，相比AA或AG基因型，效果可能较好,1,,2,,,,,FWD,黄星
PA166135288,rs1736557,1448109547,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.",携带AA基因型的儿童肿瘤患者，相比GG基因型，毒性可能降低,1,,,0,,,,plus,黄星
PA166135288,rs1736557,1448109548,AG,"Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.",携带AG基因型的儿童肿瘤患者，相比GG基因型，毒性可能降低,1,,,0,,,,plus,黄星
PA166135288,rs1736557,1448109549,GG,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's risk for toxicity.",携带GG基因型的儿童肿瘤患者，相比AA基因型，毒性可能增加,1,,,2,,,,plus,黄星
PA166136299,rs1736557,1444703117,AA,Patients with the AA genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.,携带AA基因型的患者，相比GG基因型，低密度脂蛋白C降低幅度可能较小,1,,2,,,,,plus,黄星
PA166136299,rs1736557,1444703118,AG,Patients with the AG genotype who are treated with rosuvastatin may have decreased LDL-C reduction as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.,携带AG基因型的患者，相比GG基因型，低密度脂蛋白C降低幅度可能较小,1,,2,,,,,plus,黄星
PA166136299,rs1736557,1444703119,GG,Patients with the GG genotype who are treated with rosuvastatin may have increased LDL-C reduction as compared to patients with AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.,携带GG基因型的患者，相比AA或AG基因型，低密度脂蛋白C降低幅度可能较大,1,,0,,,,,plus,黄星
PA166136237,rs1741981,1444686798,CC,"Patients with the CC genotype and asthma may have a poorer response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.",携带CC基因型的哮喘患者，相比CT或TT基因型，反应效果可能较差,1,,0,,,,,plus,黄星
PA166136237,rs1741981,1444686799,CT,"Patients with the CT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.",携带CT基因型的哮喘患者，相比CC基因型，反应效果可能较好,1,,2,,,,,plus,黄星
PA166136237,rs1741981,1444686800,TT,"Patients with the TT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.",携带TT基因型的哮喘患者，相比CC基因型，反应效果可能较好,1,,2,,,,,plus,黄星
PA166134237,rs1751034,655385161,CC,"The CC genotype carriers had lower tenofovir renal clearance, and higher  AUC than TT genotype.",携带CC基因型者，相比TT基因型，有较低的肾清除率和较高的AUC,1,,,2,0,,,plus,黄星
PA166134237,rs1751034,655385162,CT,"The TC  genotype carriers had lower tenofovir renal clearance, and higher  AUC than TT genotype.",携带TC基因型者，相比TT基因型，有较低的肾清除率和较高的AUC,1,,,2,0,,,plus,黄星
PA166134237,rs1751034,655385163,TT,"The TT genotype is associated with higher tenofovir renal clearance, and lower AUC compared to TC and CC cariers.",携带TT基因型这，相比CC或TC基因型，有较高的肾清除率和较低的AUC,1,,,0,2,,,plus,黄星
PA166135285,rs17583889,1448109553,AA,"Patients with the AA genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.",携带AA基因型的儿童肿瘤患者，相比CC基因型，毒性可能增加,1,,,2,,,,FWD,黄星
PA166135285,rs17583889,1448109554,AC,"Patients with the AC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.",携带AC基因型的儿童肿瘤患者，相比CC基因型，毒性可能增加,1,,,2,,,,FWD,黄星
PA166135285,rs17583889,1448109555,CC,"Patients with the CC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the AA genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.",携带CC基因型的儿童肿瘤患者，相比AA基因型，毒性可能降低,1,,,0,,,,FWD,黄星
PA166134545,rs17602729,981204211,AA,Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带AA基因型的类风湿性关节炎患者，相比GG基因型，药物响应可能增加,1,,2,,,,,REV,黄星
PA166134545,rs17602729,981204212,AG,Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of CNS adverse events as compared to patients with the GG genotype. Patients with the AG genotype with Rheumatoid Arthritis who are treated with methotrexate may have an increased response to methotrexate as compared to patients with the GG genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of CNS adverse events.,携带AG基因型的类风湿性关节炎患者，相比GG基因型，药物响应可能增加，中枢神经系统不良反应风险可能会增加,1,,1,,,,,REV,黄星
PA166134545,rs17602729,981204213,GG,Patients with the GG genotype with Rheumatoid Arthritis who are treated with methotrexate may have a decreased response to methotrexate as compared to patients with the AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带GG基因型的类风湿性关节炎患者，相比AA基因型，药物响应可能会降低,1,,0,,,,,REV,黄星
PA166136524,rs17602729,1447946214,AA,Patients with the AA genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.,携带AA基因型的患者，相比GG基因型，可能收缩压增高，副反应发生率增加,1,,,2,,,,REV,黄星
PA166136524,rs17602729,1447946215,AG,Patients with the AG genotype may have a greater elevation in systolic blood pressure and a greater incidence of side effects when given regadenoson as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.,携带AG基因型的患者，相比GG基因型，可能收缩压增高，副反应发生率增加,1,,,2,,,,REV,黄星
PA166136524,rs17602729,1447946216,GG,Patients with the GG genotype may have a lower elevation in systolic blood pressure and a lower incidence of side effects when given regadenoson as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of non-immune response to regadenoson.,携带GG基因型的患者，相比AA或AG基因型，可能收缩压降低，副反应发生率降低,1,,,0,,,,REV,黄星
PA166136517,rs17671591,1447946006,CC,Patients with the CC genotype and hypercholesterolemia who are treated with atorvastatin may have a smaller drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.,携带CC基因型的高胆固醇血症患者，相比CT或TT基因型，低密度脂蛋白C可能有小幅度的降低和高密度脂蛋白C可能有小幅度的增加,1,,2,,,,,plus,黄星
PA166136517,rs17671591,1447946007,CT,Patients with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.,携带CT基因型的高胆固醇血症患者，相比CC基因型，低密度脂蛋白C可能有大幅度的降低和高密度脂蛋白C可能有大幅度的增加,1,,0,,,,,plus,黄星
PA166136517,rs17671591,1447946008,TT,Patients with the TT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.,携带TT基因型的高胆固醇血症患者，相比CC基因型，低密度脂蛋白C可能有大幅度的降低和高密度脂蛋白C可能有大幅度的增加,1,,0,,,,,plus,黄星
PA166134139,rs17238540,1183491626,GG,Patients with the GG genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.,携带GG基因型的患者，相比TT基因型，达到低密度脂蛋白目标水平的可能性较小,1,,0,,,,,FWD,黄星
PA166134139,rs17238540,1183491627,GT,Patients with the GT genotype who are treated with statins may be less likely to reach target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.,携带GT基因型的患者，相比TT基因型，达到低密度脂蛋白目标水平的可能性较小,1,,0,,,,,FWD,黄星
PA166134139,rs17238540,1183491628,TT,Patients with the TT genotype who are treated with statins may be more likely to reach target LDL levels as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's response when treated with statins.,携带TT基因型的患者，相比GG或GT基因型，达到低密度脂蛋白目标水平的可能性较大,1,,2,,,,,FWD,黄星
PA166134979,rs17238540,1183491552,GG,"Patients with the GG genotype were not studied, however patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ",无GG基因型的患者参与研究,1,,,,,,,FWD,黄星
PA166134979,rs17238540,1183491553,GT,Patients with the GT genotype may have a reduced response to pravastatin treatment (lower decreases in LDL-cholesterol and total cholesterol) as compared to patients with the TT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带GT基因型的患者，相比TT基因型，药物响应降低,1,,0,,,,,FWD,黄星
PA166134979,rs17238540,1183491554,TT,Patients with the TT genotype may have a better response to pravastatin treatment (higher decreases in LDL-cholesterol and total cholesterol) as compared to patients with the GT genotype. Several studies show no association between this variant and pravastatin response. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带TT基因型的患者，相比GT基因型，药物响应增加,1,,2,,,,,FWD,黄星
PA166134980,rs17238540,1183491622,GG,Patients with the GG genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. ,携带GG基因型的患者，相比TT基因型，药物响应降低,1,,0,,,,,FWD,黄星
PA166134980,rs17238540,1183491623,GT,Patients with the GT genotype may have a reduced response to simvastatin treatment (lower reductions in LDL cholesterol) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. ,携带GT基因型的患者，相比TT基因型，药物响应降低,1,,0,,,,,FWD,黄星
PA166134980,rs17238540,1183491624,TT,Patients with the TT genotype may have a better response to simvastatin treatment (higher reductions in LDL cholesterol) as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. ,携带TT基因型的患者，相比GT或GG基因型，药物响应增加,1,,2,,,,,FWD,黄星
PA166134996,rs17655652,1183492245,CC,Men with the CC genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to men with the CT or TT genotype. Women with the CC genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带CC基因型的男性，相比CT或TT基因型的男性，药物响应可能较好,1,男,2,,,,,FWD,黄星
PA166134996,rs17655652,1183492246,CT,Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带CT基因型的男性，相比CC基因型的男性，药物响应可能较差,1,男,0,,,,,FWD,黄星
PA166134996,rs17655652,1183492247,TT,Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带TT基因型的男性，相比CC基因型的男性，药物响应可能较差,1,男,0,,,,,FWD,黄星
PA166134996,rs17655652,1183492245,CC,Men with the CC genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to men with the CT or TT genotype. Women with the CC genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带CC基因型的女性，相比CT或TT基因型的女性，药物响应可能较差,1,女,0,,,,,FWD,黄星
PA166134996,rs17655652,1183492246,CT,Men with the CT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the CT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带CT基因型的女性，相比CC基因型的女性，药物响应可能较好,1,女,2,,,,,FWD,黄星
PA166134996,rs17655652,1183492247,TT,Men with the TT genotype who are treated with pravastatin may have a reduced response to treatment (a decreased reduction in LDL-cholesterol) as compared to men with the CC genotype. Women with the TT genotype who are treated with pravastatin may have a better response to treatment (an increased reduction in LDL-cholesterol) as compared to women with the CC genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带TT基因型的女性，相比CC基因型的女性，药物响应可能较好,1,女,2,,,,,FWD,黄星
PA166134157,rs17708472,1184996838,AA,"Patients with the AA genotype (homozygous for VKORC1*4) may require a higher dose of warfarin as compared to patients with the GG genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin.",携带AA基因型的患者，相比GG基因型，所需药物剂量可能较高,1,,,,,2,,FWD,黄星
PA166134157,rs17708472,1184996839,AG,"Patients with the AG genotype (heterozygous for VKORC1*4) may require a higher dose of warfarin as compared to patients with the GG genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin.",携带AG基因型的患者，相比GG基因型，所需药物剂量可能较高,1,,,,,2,,FWD,黄星
PA166134157,rs17708472,1184996840,GG,"Patients with the GG genotype may require a lower dose of warfarin as compared to patients with the AG and AA genotype. Some studies have not found a significant association between this variant and warfarin dose, however the majority report an association. Other genetic and clinical factors may also influence a patient's required dose of warfarin.",携带GG基因型的患者，相比AA或AG基因型，所需药物剂量可能较低,1,,,,,0,,FWD,黄星
PA166135068,rs17782313,1446899061,CC,"Patients with the CC genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of weight gain.",携带CC基因型的患者，相比TT基因型，体重增加的风险可能升高,1,,,2,,,,FWD,黄星
PA166135068,rs17782313,1446899062,CT,"Patients with the CT genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have an increased risk of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of weight gain.",携带CT基因型的患者，相比TT基因型，体重增加的风险可能升高,1,,,2,,,,FWD,黄星
PA166135068,rs17782313,1446899063,TT,"Patients with the TT genotype and disorders requiring antipsychotic treatment (amisulpride, clozapine, olanzapine, paliperidone, quetiapine or risperidone) may have a decreased risk of weight gain when treated with antipsychotics as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of weight gain.",携带TT基因型的患者，相比CC或CT基因型，体重增加的风险可能降低,1,,,0,,,,FWD,黄星
PA166159398,rs17863783,1448109580,GG,"Patients with the GG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GT or TT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.",携带GG基因型的儿童肿瘤患者，相比GT或TT基因型，毒性可能减少,1,,,0,,,,FWD,黄星
PA166159398,rs17863783,1448109581,GT,"Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG and decreased likelihood as compared to patients with the TT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.",携带GT基因型的儿童肿瘤患者，相比GG基因型，毒性可能增加，相比TT基因型，毒性可能减少,1,,,1,,,,FWD,黄星
PA166159398,rs17863783,1448109582,TT,"Patients with the TT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or GT, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.",携带TT基因型的儿童肿瘤患者，相比GT或GG基因型，毒性可能增加,1,,,2,,,,FWD,黄星
PA166134081,rs1695,1448568518,AA,"Patients with the AA genotype and cancer who are treated with oxaliplatin or platinum compounds may have an increased risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AG or GG genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AA might have a decreased, but not absent, risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.",携带AA基因型的癌症患者，相比AG或GG基因型，可能使血液毒性风险增加,1,,,2,,,,FWD,黄星
PA166134081,rs1695,1448568519,AG,"Patients with the AG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the AG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.",携带AG基因型的癌症患者，相比AA基因型，可能使血液毒性风险降低,1,,,0,,,,FWD,黄星
PA166134081,rs1695,1448568520,GG,"Patients with the GG genotype and cancer who are treated with oxaliplatin or platinum compounds may have a decreased, but not absent, risk for hematological toxicity, neurotoxicity, neutropenia, and discontinuation of treatment as compared to patients with the AA genotype. Conflicting data exist for the neurotoxicity risk showing that patients with the GG might have an increased risk. Other genetic and clinical factors may also influence a patient's risk for adverse events with oxaliplatin or platinum compounds treatment.",携带GG基因型的癌症患者，相比AA基因型，可能使血液毒性风险降低,1,,,0,,,,FWD,黄星
PA166134082,rs1695,1448519738,AA,Patients with the AA genotype and cancer who are treated with platinum-based drugs may have the highest risk of toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for  toxicity.,携带AA基因型的患者，相比AG或GG基因型，药毒性可能最高,1,,,2,,,,FWD,黄星
PA166134082,rs1695,1448519739,AG,Patients with the AG genotype and cancer who are treated with platinum-based drugs may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带AG基因型的患者，相比GG基因型，药毒性可能增加,1,,,1,,,,FWD,黄星
PA166134082,rs1695,1448519740,GG,"Patients with the GG genotype and cancer who are treated with platinum-based drugs may have a decreased, but not absent, risk of toxicity as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.",携带GG基因型的患者，相比AA和AG基因型，药毒性可能降低,1,,,0,,,,FWD,黄星
PA166134083,rs1695,1448568523,AA,"Patients with the AA genotype may have increased risk for progression and decreased survival with platinum-based treatments with cancer as compared to patients with the GG genotype, but some studies found increased survival or no association with survival. Other genetic and clinical factors may also influence a patient's response.",携带AA基因型的患者，相比GG基因型，存活期降低的风险可能增加,1,,0,,,,,FWD,黄星
PA166134083,rs1695,1448568524,AG,Patients with the AG genotype may have an average risk for progression with platinum-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.,携带AG基因型的患者，相比GG基因型，进展的风险正常,1,,1,,,,,FWD,黄星
PA166134083,rs1695,1448568525,GG,Patients with the GG genotype may have decreased risk for progression with platinum-based treatments as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的患者，相比AA基因型，进展风险可能降低,1,,2,,,,,FWD,黄星
PA166134411,rs1695,769171388,AA,Patients with the AA genotype and cancer who are treated with fluorouracil may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.,携带AA基因型的癌症患者，相比GG基因型，可能有血液毒性的风险较高,1,,,2,,,,FWD,黄星
PA166134411,rs1695,769171389,AG,"Patients with the AG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype, or may have a higher risk of hematological toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to fluorouracil.",携带AG基因型的癌症患者，相比AA基因型，可能有血液毒性的风险较低；相比GG基因型，可能有血液毒性的风险较高,1,,,0,,,,FWD,黄星
PA166134411,rs1695,769171390,GG,"Patients with the GG genotype and cancer who are treated with fluorouracil may have a lower, but not absent, risk of hematological toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for hematological toxicity when exposed to flourouracil.",携带GG基因型的癌症患者，相比AA基因型，可能有血液毒性的风险较低,1,,,0,,,,FWD,黄星
PA166134602,rs1695,981238398,AA,Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.,携带AA基因型的淋巴细胞白血病患者，相比GG基因型，药物毒性可能降低,1,,,0,,,,FWD,黄星
PA166134602,rs1695,981238399,AG,Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Drug Toxicity as compared to patients with the GG genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.,携带AG基因型的淋巴细胞白血病患者，相比GG基因型，药物毒性可能降低,1,,,0,,,,FWD,黄星
PA166134602,rs1695,981238400,GG,Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have an increased likelihood of Drug Toxicity as compared to patients with the AG and AA genotype. This finding is contradicted in other studies. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.,携带GG基因型的淋巴细胞白血病患者，相比AG和AA基因型，药物毒性可能增加,1,,,2,,,,FWD,黄星
PA166153179,rs1695,1448616392,AA,Pediatric patients with the AA genotype and medulloblastoma may have a decreased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.,携带AA基因型的成神经管细胞瘤儿童患者，相比AG或GG基因型，耳毒性风险可能降低,1,,,0,,,,FWD,黄星
PA166153179,rs1695,1448616393,AG,Pediatric patients with the AG genotype and medulloblastoma may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.,携带AG基因型的成神经管细胞瘤儿童患者，相比AA基因型，耳毒性风险可能增加,1,,,2,,,,FWD,黄星
PA166153179,rs1695,1448616394,GG,Pediatric patients with the GG genotype and medulloblastoma may have an increased risk of ototoxicity when treated with cisplatin-based regimens as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of ototoxicity in patients receiving cisplatin-based regimens.,携带GG基因型的成神经管细胞瘤儿童患者，相比AA基因型，耳毒性风险可能增加,1,,,2,,,,FWD,黄星
PA166153041,rs1695,1447982836,AA,Patients with the AA genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.,携带AA基因型的牛皮鲜患者，相比GG基因型，药物反应可能较好,1,,2,,,,,FWD,黄星
PA166153041,rs1695,1447982835,AG,Patients with the AG genotype and psoriasis who are treated with fumaric acid esters may have an increased response as patients with the GG genotype. Other genetic and clinical factors may also influence a patient's drug response.,携带AG基因型的牛皮鲜患者，相比GG基因型，药物反应可能较好,1,,2,,,,,FWD,黄星
PA166153041,rs1695,1447982834,GG ,Patients with the GG genotype and psoriasis who are treated with fumaric acid esters may have a decreased response as patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's drug response.,携带GG基因型的牛皮鲜患者，相比AG或AA基因型，药物反应可能较差,1,,0,,,,,FWD,黄星
PA166135758,rs1799722,1444701003,CC,Patients with the CC genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.,携带CC基因型的高血压患者，相比TT基因型，药物反应可能较好,1,,2,,,,,FWD,黄星
PA166135758,rs1799722,1444701002,CT,Patients with the CT genotype may have increased response to enalapril in people with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the efficacy of enalapril.,携带CT基因型的高血压患者，相比TT基因型，药物反应可能较好,1,,2,,,,,FWD,黄星
PA166135758,rs1799722,1444701001,TT,Patients with the TT genotype may have decreased response to enalapril in people with Hypertension as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the efficacy of enalapril.,携带TT基因型的高血压患者，相比CT或CC基因型，药物反应可能较差,1,,0,,,,,FWD,黄星
PA166134162,rs1799722,1000539641,CC,"Patients with the CC genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.",携带CC基因型的患者，相比CT或TT基因型，咳嗽风险可能降低,1,,,0,,,,FWD,黄星
PA166134162,rs1799722,1000539642,CT,Patients with the CT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.,携带CT基因型的患者，相比CC基因型，咳嗽风险可能增加,1,,,2,,,,FWD,黄星
PA166134162,rs1799722,1000539643,TT,Patients with the TT genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.,携带TT基因型的患者，相比CC基因型，咳嗽风险可能增加,1,,,2,,,,FWD,黄星
PA166158957,rs1799852,1448100237,CC,Patients with the CC genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.,携带CC基因型的克罗恩病患者，相比CT或TT基因型，药物反应可能降低,1,,,,,,,FWD,黄星
PA166158957,rs1799852,1448100238,CT,Patients with the CT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.,携带CT基因型的克罗恩病患者，相比TT基因型，药物反应可能降低,1,,,,,,,FWD,黄星
PA166158957,rs1799852,1448100239,TT,Patients with the TT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.,携带TT基因型的克罗恩病患者，相比CC或CT基因型，药物反应可能增加,1,,,,,,,FWD,黄星
PA166134027,rs1799807,1444698442,CC,Patients with the CC genotype have an increased risk of post anesthesia apnea  when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.,携带CC基因型的患者，相比TT基因型，麻醉后呼吸暂停的风险可能增加,1,,,2,,,,REV,黄星
PA166134027,rs1799807,1444698443,CT,Patients with the CT genotype have an increased risk of post anesthesia apnea  when treated with succinylcholine as compared to patients with the TT genotype and a decreased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.,携带CT基因型的患者，相比TT基因型，麻醉后呼吸暂停的风险可能增加，相比CC基因型，风险可能降低,1,,,1,,,,REV,黄星
PA166134027,rs1799807,1444698444,TT,Patients with the TT genotype have a decreased risk of post anesthesia apnea as compared to patients with the CC genotype when treated with succinylcholine. Other genetic and clinical factors may also influence risk of post anesthesia apnea.,携带TT基因型的患者，相比CC基因型，麻醉后呼吸暂停的风险可能降低,1,,,0,,,,REV,黄星
PA166152862,rs1799930,1447964079,AA,Patients with the AA genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. They also may have decreased clearance of isoniazid as compared to those with the AG or GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.,携带AA基因型的肺结核患者，相比GG基因型，肝中毒的风险可能增加,1,,,2,,,,FWD,黄星
PA166152862,rs1799930,1447964080,AG,"Patients with the AG genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. They also may have increased clearance of isoniazid as compared to those with the AA genotype, and decreased clearance as compared to those with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.",携带AG基因型的肺结核患者，相比GG基因型，肝中毒的风险可能增加，相比AA基因型，风险可能降低,1,,,1,,,,FWD,黄星
PA166152862,rs1799930,1447964081,GG,Patients with the GG genotype and tuberculosis (TB) may have a decreased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA genotype. They also may have increased clearance of isoniazid as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity and clearance of isoniazid.,携带GG基因型的肺结核患者，相比AA基因型，肝中毒的风险可能降低,1,,,0,,,,FWD,黄星
PA166152745,rs1799929,1447961030,CC,"Patients with the CC genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.",携带CC基因型的肺结核患者，相比CT或TT基因型，肝中毒的风险可能降低,1,,,0,,,,FWD,黄星
PA166152745,rs1799929,1447961031,CT,"Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.",携带CT基因型的肺结核患者，相比CC基因型，肝中毒的风险可能增加,1,,,2,,,,FWD,黄星
PA166152745,rs1799929,1447961032,TT,"Patients with the TT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.",携带TT基因型的肺结核患者，相比CC基因型，肝中毒的风险可能增加,1,,,2,,,,FWD,黄星
PA166135698,rs1799963,1444672768,AA,No evidence available.,无研究证据,1,,,,,,,,黄星
PA166135698,rs1799963,1444672769,AG,"Patients with the AG genotype who are taking oral contraceptives (OCs) may have an increased risk for deep vein thrombosis (DVT), as compared to patients with the GG genotype who are not taking oral contraceptives. Current evidence suggests that patients with the AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.",携带AG基因型的患者，相比GG基因型，深静脉血栓的风险可能增加,1,,,2,,,,FWD,黄星
PA166135698,rs1799963,1444672770,GG,"Patients with the GG genotype who are not taking oral contraceptives (OCs) may have a decreased risk for deep vein thrombosis (DVT), as compared to patients with the AG genotype who are taking oral contraceptives. Current evidence suggests that patients with the AG mutation who are taking oral contraceptives experience an increase risk for DVT due to the cumulative effect of both the contraceptives and the AG genotype. At the time of writing, there are no studies that show a significant increase in risk for DVT when considering only the AG genotype. Additionally, some contradictory evidence exists for this association. Other genetic and clinical factors may also influence risk for DVT in patients taking oral contraceptives.",携带GG基因型的患者，相比AG基因型，深静脉血栓的风险可能降低,1,,,0,,,,FWD,黄星
PA166136296,rs1799964,1444702766,CC,Patients with the CC genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors. ,携带CC基因型的强直性脊柱炎患者，相比TT基因型，药物反应可能较差,1,,0,,,,,FWD,黄星
PA166136296,rs1799964,1444702767,CT,Patients with the CT genotype and ankylosing spondylitis may have a poorer response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors. ,携带CT基因型的强直性脊柱炎患者，相比TT基因型，药物反应可能较差,1,,0,,,,,FWD,黄星
PA166136296,rs1799964,1444702768,TT,Patients with the TT genotype and ankylosing spondylitis may have a better response when treated with tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to TNF-alpha inhibitors. ,携带TT基因型的强直性脊柱炎患者，相比CT或CC基因型，药物反应可能较好,1,,2,,,,,FWD,黄星
PA166159044,rs1799964,1448101240,CC,Patients with the CC genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence neuropathy risk.,携带CC基因型的HIV患者，相比TT基因型，患神经病的风险可能增加,1,,,2,,,,FWD,黄星
PA166159044,rs1799964,1448101241,CT,"Patients with the CT genotype and HIV may have an increased risk for neuropathy when treated with stavudine as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.",携带CT基因型的HIV患者，相比TT基因型，患神经病的风险可能增加，相比CC基因型，风险可能降低,1,,,1,,,,FWD,黄星
PA166159044,rs1799964,1448101242,TT,Patients with the TT genotype and HIV may have a decreased risk for neuropathy when treated with stavudine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence neuropathy risk.,携带TT基因型的HIV患者，相比CC基因型，患神经病的风险可能降低,1,,,2,,,,FWD,黄星
PA166152863,rs1799931,1447964086,AA,"Patients with the AA genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity.",携带AA基因型的肺结核患者，相比GG基因型，肝中毒的风险可能增加,1,,,2,,,,FWD,黄星
PA166152863,rs1799931,1447964087,AG,"Patients with the AG genotype and tuberculosis (TB) may have an increased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity.",携带AG基因型的肺结核患者，相比GG基因型，肝中毒的风险可能增加,1,,,2,,,,FWD,黄星
PA166152863,rs1799931,1447964088,GG,"Patients with the GG genotype and tuberculosis (TB) may have a decreased risk of hepatotoxicity when treated with anti-TB drugs as compared to patients with the AA or AG genotype. However, some studies find no association with hepatotoxicity. Other genetic and clinical factors may also influence risk of hepatotoxicity.",携带GG基因型的肺结核患者，相比AG或AA基因型，肝中毒的风险可能降低,1,,,0,,,,FWD,黄星
PA166134372,rs1799983,655387010,GG,"Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.","携带GG基因型的患者，相比TT基因型,生存期可能延长 ",1,,2,,,,,FWD,黄星
PA166134372,rs1799983,655387011,GT,"Patients with the GT genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.",携带GT基因型的患者，相比TT基因型，生存期可能延长 ,1,,2,,,,,FWD,黄星
PA166134372,rs1799983,655387012,TT,"Patients with the TT genotype 1) may have shorter disease-free survival when treated with cyclophosphamide-based regimens 2) may have longer disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence disease-free survival.",携带TT基因型的患者，相比GT或GG基因型，生存期可能减少 ,1,,0,,,,,FWD,黄星
PA166135756,rs1799983,1444700987,GG,"Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.",携带GG基因型的心脏病患者，相比GT或TT基因型，可能急诊的风险降低,1,,2,,,,,FWD,黄星
PA166135756,rs1799983,1444700986,GT,"Patients with the GT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG. Other genetic or clinical factors may also influence the outcome of heart failure patients.",携带GT基因型的心脏病患者，相比GG基因型，可能急诊的风险增加,1,,1,,,,,FWD,黄星
PA166135756,rs1799983,1444700985,TT,"Patients with the TT genotype may have increased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype GG or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.",携带TT基因型的心脏病患者，相比GG或GT基因型，可能急诊的风险增加,1,,0,,,,,FWD,黄星
PA166136360,rs1799983,1445400875,GG,Patients with acute myeloid leukemia and the GG genotype may have increased survival time when treated with daunorubicin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to daunorubicin.,携带GG基因型的急性白血病患者，相比GT或TT基因型，生存时间可能增加,1,,2,,,,,FWD,黄星
PA166136360,rs1799983,1445400876,GT,Patients with acute myeloid leukemia and the GT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.,携带GT基因型的急性白血病患者，相比GG基因型，生存时间可能降低,1,,0,,,,,FWD,黄星
PA166136360,rs1799983,1445400877,TT,Patients with acute myeloid leukemia and the TT genotype may have decreased survival time when treated with daunorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to daunorubicin.,携带TT基因型的急性白血病患者，相比GG基因型，生存时间可能降低,1,,0,,,,,FWD,黄星
PA166135883,rs1799983,1445400947,GG,Patients with the GG genotype and coronary heart disease may have a better response to treatment with salvianolate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to salvianolate.,携带GG基因型的冠心病患者，相比GT或TT基因型，药物反应可能较好,1,,2,,,,,FWD,黄星
PA166135883,rs1799983,1445400948,GT,Patients with the GT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.,携带GT基因型的冠心病患者，相比GG基因型，药物反应可能较差,1,,0,,,,,FWD,黄星
PA166135883,rs1799983,1445400949,TT,Patients with the TT genotype and coronary heart disease may have a poorer response to treatment with salvianolate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salvianolate.,携带TT基因型的冠心病患者，相比GG基因型，药物反应可能较差,1,,0,,,,,FWD,黄星
PA166135917,rs1799983,1445737076,GG,"Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.",携带GG基因型的乳腺癌，胃癌及其他癌症患者，相比TT基因型，药物响应可能升高,1,,2,,,,,FWD,黄星
PA166135917,rs1799983,1445737077,GT,"Patients with the GT genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.",携带GT基因型的乳腺癌，胃癌及其他癌症患者，相比TT基因型，药物响应可能升高,1,,2,,,,,FWD,黄星
PA166135917,rs1799983,1445737078,TT,"Patients with the TT genotype and breast cancer, stomach cancer, or other cancer may have a improved response (decreased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS NOT GIVEN AS AN ADJUVANT as compared to patients with the GG and GT genotypes. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.",携带TT基因型的乳腺癌，胃癌及其他癌症患者，相比GT或GG基因型，药物响应可能降低,1,,0,,,,,FWD,黄星
PA166152927,rs1799983,1447979516,GG,Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GT or TT. Other genetic and clinical factors may also influence the response to sorafenib.,携带GG基因型的肝癌患者，相比GT或TT基因型，存活期可能降低,1,,0,,,,,FWD,黄星
PA166152927,rs1799983,1447979517,GT,Patients with the GT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.,携带GT基因型的肝癌患者，相比GG基因型，存活期可能增加,1,,2,,,,,FWD,黄星
PA166152927,rs1799983,1447979518,TT,Patients with the TT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.,携带TT基因型的肝癌患者，相比GG基因型，存活期可能增加,1,,2,,,,,FWD,黄星
PA166135063,rs1799998,1183630649,AA,Patients with the AA genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.,携带AA基因型的高血压患者，相比GG基因型，药物响应可能较差,1,,0,,,,,REV,黄星
PA166135063,rs1799998,1183630650,AG,Patients with the AG genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.,携带AG基因型的高血压患者，相比GG基因型，药物响应可能较差,1,,0,,,,,REV,黄星
PA166135063,rs1799998,1183630651,GG,Patients with the GG genotype and hypertension may be more likely to respond to treatment with candesartan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to candesartan.,携带GG基因型的高血压患者，相比AA或AG基因型，药物响应可能较好,1,,2,,,,,REV,黄星
PA166135064,rs1799998,1183630603,AA,Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.,携带AA基因型的高血压患者，相比GG基因型，舒张压可能有较大幅度的降低,1,,2,,,,,REV,黄星
PA166135064,rs1799998,1183630604,AG,Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.,携带AG基因型的高血压患者，相比GG基因型，舒张压可能有较大幅度的降低,1,,2,,,,,REV,黄星
PA166135064,rs1799998,1183630605,GG,Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the AA or AG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.,携带GG基因型的高血压患者，相比AA或AG基因型，舒张压可能有较小幅度的降低,1,,0,,,,,REV,黄星
PA166135771,rs1800469,1448107294,AA,Patients with the AA genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.,携带AA基因型的患者，相比GG基因型，慢性荨麻疹的风险可能增加,1,,,2,,,,REV,黄星
PA166135771,rs1800469,1448107295,AG,Patients with the AG genotype who are treated with aspirin may have an increased risk of aspirin-intolerant chronic urticaria as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.,携带AG基因型的患者，相比GG基因型，慢性荨麻疹的风险可能增加,1,,,2,,,,REV,黄星
PA166135771,rs1800469,1448107296,GG,Patients with the GG genotype who are treated with aspirin may have a decreased risk of aspirin-intolerant chronic urticaria as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.,携带GG基因型的患者，相比AG或AA基因型，慢性荨麻疹的风险可能降低,1,,,0,,,,REV,黄星
PA166161128,rs1800469,1448422841,AA,Patients with the AA genotype and colorectal cancer may have a decreased risk for diarrhea when treated with irinotecan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. ,携带AA基因型的结直肠癌患者，相比AG或GG基因型，腹泻风险可能降低,1,,,0,,,,REV,黄星
PA166161128,rs1800469,1448422842,AG,Patients with the AG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. ,携带AG基因型的结直肠癌患者，相比AA基因型，腹泻风险可能升高,1,,,2,,,,REV,黄星
PA166161128,rs1800469,1448422843,GG,Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan. ,携带GG基因型的结直肠癌患者，相比AA基因型，腹泻风险可能升高,1,,,2,,,,REV,黄星
PA166134345,rs1800460,1448616411,CC,"Children with the CC genotype and cancer who are treated with cisplatin may have a decreased, but not absent, risk for hearing loss as compared to children with the CT or TT genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",携带CC基因型的癌症儿童，相比CT或TT基因型，听力丧失的风险降低,1,,,0,,,,REV,黄星
PA166134345,rs1800460,1448616412,CT,"Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",携带CT基因型的癌症儿童，相比CC基因型，听力丧失的风险增加,1,,,2,,,,REV,黄星
PA166134345,rs1800460,1448616413,TT,"Children with the TT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the CC genotype. However, multiple studies have found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.",携带TT基因型的癌症儿童，相比CC基因型，听力丧失的风险增加,1,,,2,,,,REV,黄星
PA166135120,rs1800471,1183630761,CC,"No patients with the CC genotype were present in this study. However, patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.",CC基因型患者本文中尚无呈现,1,,,,,,,,黄星
PA166135120,rs1800471,1183630762,CG,Patients with the CG genotype and rheumatoid arthritis may be more likely to respond to rituximab treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rituximab.,携带CG基因型的类风湿性关节炎患者，相比GG基因型，药物响应可能更好,1,,2,,,,,REV,黄星
PA166135120,rs1800471,1183630763,GG,Patients with the GG genotype and rheumatoid arthritis may be less likely to respond to rituximab treatment as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to rituximab.,携带GG基因型的类风湿性关节炎患者，相比CG基因型，药物响应可能较差,1,,0,,,,,REV,黄星
PA166134715,rs1800532,982032766,GG,Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.,携带GG基因型的躁郁症患者，相比TT基因型，药物响应可能较好,1,,2,,,,,REV,黄星
PA166134715,rs1800532,982032765,GT,Patients with the GT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium.,携带GT基因型的躁郁症患者，相比TT基因型，药物响应可能较好,1,,2,,,,,REV,黄星
PA166134715,rs1800532,982032764,TT,Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.,携带TT基因型的躁郁症患者，相比GG基因型，药物响应可能较差,1,,0,,,,,REV,黄星
PA166134783,rs1800532,1043858635,GG,"Patients with the GG genotype and Major Depressive Disorder may be more likely to respond to citalopram treatment as compared to patients with the GT or TT genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. ",携带GG基因型的重度抑郁症患者，相比GT或TT基因型，药物响应可能较好,1,,2,,,,,REV,黄星
PA166134783,rs1800532,1043858634,GT,"Patients with the GT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. ",携带GT基因型的重度抑郁症患者，相比GG基因型，药物响应可能较差,1,,0,,,,,REV,黄星
PA166134783,rs1800532,1043858633,TT,"Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to citalopram treatment as compared to patients with the GG genotype. However, no association has been reported in studies that determined response using several antidepressants including citalopram. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment. ",携带TT基因型的重度抑郁症患者，相比GG基因型，药物响应可能较差,1,,0,,,,,REV,黄星
PA166136365,rs1800559,1445401010,CC,"Patients with the CC genotype may have decreased risk of Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT. Please note: this clinical annotation is based on two case studies and there were no individuals who were genotype TT. Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia.",携带CC基因型的患者，相比CT基因型，可能降低恶性高热的风险,1,,,0,,,,REV,黄星
PA166136365,rs1800559,1445401011,CT,"Patients with the CT genotype may have increased risk of Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC.  Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia.",携带CT基因型的患者，相比CC基因型，可能增加恶性高热的风险,1,,,2,,,,REV,黄星
PA166136365,rs1800559,1445401012,TT,"Patients with the TT genotype may have increased risk of Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: this clinical annotation is based on two case studies and there were no individuals who were genotype TT.  Other genetic or clinical factors may also influence a patient's risk of developing malignant hyperthermia.",携带TT基因型的患者，相比CC基因型，可能增加恶性高热的风险,1,,,2,,,,REV,黄星
PA166135604,rs1799971,1184987580,AA,"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics. ",携带AA基因型的戒断综合征患者，相比GG基因型，头痛可能会减少,1,,,0,,,,FWD,黄星
PA166135604,rs1799971,1184987581,AG,"Patients with the AG genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics. ",携带AG基因型的戒断综合征患者，相比GG基因型，头痛可能会减少,1,,,0,,,,FWD,黄星
PA166135604,rs1799971,1184987582,GG,"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA and AG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics. ",携带GG基因型的戒断综合征患者，相比AA或AG基因型，头痛可能会增加,1,,,2,,,,FWD,黄星
PA166134563,rs1799971,982037101,AA,"Patients with the AA genotype may have a decreased , but not absent, severity of intoxication and a decreased response when exposed to ethanol as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's ethanol response.",携带AA基因型的患者，相比AG或GG基因型，可能降低中毒的严重程度,1,,,0,,,,FWD,黄星
PA166134563,rs1799971,982037102,AG,Patients with the AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's ethanol response.,携带AG基因型的患者，相比AA基因型，可能增加中毒的严重程度,1,,,2,,,,FWD,黄星
PA166134563,rs1799971,982037103,GG,Patients with the GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's ethanol response.,携带GG基因型的患者，相比AA基因型，可能增加中毒的严重程度,1,,,2,,,,FWD,黄星
PA166134565,rs1799971,982037129,AA,"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AG and GG genotype. However, contradictory findings have been reported, with the AA genotype may be associated with a decreased likelihood of smoking cessation compared to AG and GG genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.",携带AA基因型的患者，相比AG或GG基因型，戒烟的可能增加,1,,2,,,,,FWD,黄星
PA166134565,rs1799971,982037130,AG,"Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the AG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.",携带AG基因型的患者，相比AA基因型，戒烟的可能降低,1,,0,,,,,FWD,黄星
PA166134565,rs1799971,982037131,GG,"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings have been reported, with the GG genotype may be associated with an increased likelihood of smoking cessation compared to AA genotype. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.",携带GG基因型的患者，相比AA基因型，戒烟的可能降低,1,,0,,,,,FWD,黄星
PA166136120,rs1799971,1444607725,AA,"Patients with the AA genotype who are receiving hydrocodone may have a decreased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.",携带AA基因型的患者，相比AG或GG基因型，副作用风险降低,1,,,0,,,,FWD,黄星
PA166136120,rs1799971,1444607726,AG,"Patients with the AG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.",携带AG基因型的患者，相比AA基因型，副作用风险增加,1,,,2,,,,FWD,黄星
PA166136120,rs1799971,1444607727,GG,"Patients with the GG genotype who are receiving hydrocodone may have an increased risk for experiencing side effects, including constipation, dry mouth or respiratory depression, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of side effects when receiving hydrocodone.",携带GG基因型的患者，相比AA基因型，副作用风险增加,1,,,2,,,,FWD,黄星
PA166134718,rs1799971,1446899228,AA,"Individuals with the AA genotype may experience increased efficacy of opioids for pain and opioid related drugs to treat addiction, and may require a decreased dose of opioids as compared to individuals with the AG and GG genotypes. However this has been contradicted in some studies. In some studies, the AA and AG genotypes were found to have a increased efficacy, and to require a decreased dose as compared to the GG genotype.  Other genetic and clinical factors may also influence a patient's response to opioid drugs. ",携带AA基因型的患者，相比AG或GG基因型，可能药效增加，所需剂量降低,1,,2,,,0,,FWD,黄星
PA166134718,rs1799971,1446899229,AG,"Individuals with the AG genotype may experience decreased efficacy of opioids for pain and opioid related drugs to treat addiction, and may require an increased dose of opioids as compared to individuals with the AA genotype. However this has been contradicted in some studies. In some studies, the AA and AG genotypes were found to have a increased efficacy, and to require a decreased dose as compared to the GG genotype.  Other genetic and clinical factors may also influence a patient's dependence on opioid drugs. ",携带AG基因型的患者，相比AA基因型，可能药效降低，所需剂量增加,1,,0,,,2,,FWD,黄星
PA166134718,rs1799971,1446899230,GG,"Individuals with the GG genotype may experience decreased efficacy of opioids for pain and opioid related drugs to treat addiction, and may require an increased dose of opioids as compared to individuals with the AA genotype. However this has been contradicted in some studies. In some studies, the AA and AG genotypes were found to have a increased efficacy, and to require a decreased dose as compared to the GG genotype. However this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's dependence on opioid drugs. ",携带GG基因型的患者，相比AA基因型，可能药效降低，所需剂量增加,1,,0,,,2,,FWD,黄星
PA166134242,rs1799971,1448612986,AA,Patients with the AA genotype who are treated with morphine: 1) may require a lower dose as compared to patients with the AG or GG genotype 2) may be more likely to have an increased pain relief as compared to patients with the AG or GG genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.,携带AA基因型的肿瘤患者，相比AG或GG基因型，可能所需剂量较低，药物响应增加,1,,2,,,0,,FWD,黄星
PA166134242,rs1799971,1448612987,AG,Patients with the AG genotype who are treated with morphine: 1) may require a higher dose as compared to patients with the AA genotype 2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.,携带AG基因型的肿瘤患者，相比AA基因型，可能所需剂量较高，药物响应降低,1,,0,,,2,,FWD,黄星
PA166134242,rs1799971,1448612988,GG,Patients with the GG genotype who are treated with morphine: 1) may require the highest dose as compared to patients with the AG and AA genotype  2) may be less likely to have an increased pain relief as compared to patients the AA genotype and neoplasms. Other genetic and clinical factors may also influence a patient's response when treated with morphine.,携带GG基因型的肿瘤患者，相比AA基因型，可能所需剂量最高，药物响应降低,1,,0,,,2,,FWD,黄星
PA166134246,rs1799971,655385244,AA,Patients with the AA genotype who are treated with naloxone may have lower cortisol response as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence the response to naloxone.,携带AA基因型的患者，相比AG或GG基因，药物响应可能较低,1,,0,,,,,FWD,黄星
PA166134246,rs1799971,655385243,AG,Patients with the AG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype.,携带AG基因型的患者，相比AA基因型，药物响应可能增加,1,,2,,,,,FWD,黄星
PA166134246,rs1799971,655385242,GG,Patients with the GG genotype who are treated with naloxone may have increased peak cortisol response as compared to patients with AA genotype. Other genetic and clinical factors may also influence the response to naloxone.,携带GG基因型的患者，相比AA基因型，药物响应可能增加,1,,2,,,,,FWD,黄星
PA166151951,rs1799971,1447953272,AA,Patients with the AA genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.,携带AA基因型的药物依赖患者，相比AA或GG基因型，睡眠障碍程度可能增加,1,,,2,,,,FWD,黄星
PA166151951,rs1799971,1447953273,AG,Patients with the AG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.,携带AG基因型的药物依赖患者，相比AA基因型，睡眠障碍程度可能降低,1,,,0,,,,FWD,黄星
PA166151951,rs1799971,1447953274,GG,Patients with the GG genotype and opioid dependence may have decreased severity of sleep disorders when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the severity of a patient's sleep disorders when treated with methadone.,携带GG基因型的药物依赖患者，相比AA基因型，睡眠障碍程度可能降低,1,,,0,,,,FWD,黄星
PA166135059,rs1800545,1183614512,AA,Patients with the AA genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.,携带AA基因型的左心室肥大患者，相比GG基因型，药物响应可能降低,1,,0,,,,,FWD,黄星
PA166135059,rs1800545,1183614511,AG,Patients with the AG genotype and left ventricular hypertrophy may have a decreased response when treated with atenolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to atenolol.,携带AG基因型的左心室肥大患者，相比GG基因型，药物响应可能降低,1,,0,,,,,FWD,黄星
PA166135059,rs1800545,1183614510,GG,Patients with the GG genotype and left ventricular hypertrophy may have an increased response when treated with atenolol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to atenolol.,携带GG基因型的左心室肥大患者，相比AG或AA基因型，药物响应可能增加,1,,2,,,,,FWD,黄星
PA166152789,rs1800588,1447962718,CC,Patients with the CC genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.,携带CC基因型的患者，相比TT基因型，高密度脂蛋白胆固醇可能增长较高,1,,2,,,,,FWD,黄星
PA166152789,rs1800588,1447962719,CT,Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.,携带CT基因型的患者，相比TT基因型，高密度脂蛋白胆固醇可能增长较高,1,,2,,,,,FWD,黄星
PA166152789,rs1800588,1447962720,TT,Patients with the TT genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.,携带TT基因型的患者，相比CT或CC基因型，高密度脂蛋白胆固醇可能增长较低,1,,1,,,,,FWD,黄星
PA166152790,rs1800588,1447962725,CC,"Patients with the CC genotype may have a smaller increase in HDL cholesterol when treated with pravastatin as compared to patients with the CT or TT genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.",携带CC基因型的患者，相比CT或TT基因型，高密度脂蛋白胆固醇可能增长较低,1,,1,,,,,FWD,黄星
PA166152790,rs1800588,1447962726,CT,"Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.",携带CT基因型的患者，相比CC基因型，高密度脂蛋白胆固醇可能增长较高,1,,2,,,,,FWD,黄星
PA166152790,rs1800588,1447962727,TT,"Patients with the TT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.",携带TT基因型的患者，相比CC基因型，高密度脂蛋白胆固醇可能增长较高,1,,2,,,,,FWD,黄星
PA166134870,rs1800566,1447749019,AA,Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.,携带AA基因型的患者，相比GG基因型，所需剂量可能增加,1,,,,,2,,REV,黄星
PA166134870,rs1800566,1447749020,AG,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.,携带AG基因型的患者，相比GG基因型，所需剂量可能增加,1,,,,,0,,REV,黄星
PA166134870,rs1800566,1447749021,GG,Patients with the GG genotype may require an decreased dose of warfarin as compared to patients with the AG or AA genotypes. Other clinical or genetic factors may also influence warfarin dose.,携带GG基因型的患者，相比GG或AG基因型，所需剂量可能降低,1,,,,,0,,REV,黄星
PA166134950,rs1800566,1446906858,AA,"Patients with the AA genotype and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have worse outcome (overall survival and progression-free survival) as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome.",携带AA基因型的患者，相比GG基因型，可能结果较差,1,,0,,,,,REV,黄星
PA166134950,rs1800566,1446906859,AG,"Patients with the AG genotype and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have a a better outcome (overall survival and progression-free survival) as compared to patients with the AA genotype and a worse outcome as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome.",携带AG基因型的患者，相比AA基因型，可能结果较好,1,,2,,,,,REV,黄星
PA166134950,rs1800566,1446906860,GG,"Patients with the GG genotype and Breast Neoplasms and cancer who are treated with chemotherapy regimes that include platinum compounds, anthracyclines and related substances, and nucleoside inhibitors may have a better outcome (overall survival and progression-free survival) as compared to patients with the AA genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's treatment outcome.",携带GG基因型的乳腺癌患者，相比AA基因型，可能结果较好,1,,2,,,,,REV,黄星
PA166135993,rs1800566,1447749026,AA,Patients with the AA genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence warfarin dose.,携带AA基因型的患者，相比GG基因型，所需剂量可能降低,1,,,,,0,,REV,黄星
PA166135993,rs1800566,1447749027,AG,Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.,携带AG基因型的患者，相比AA基因型，所需剂量可能增加,1,,,,,2,,REV,黄星
PA166135993,rs1800566,1447749028,GG,Patients with the GG genotype may require an increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.,携带GG基因型的患者，相比AA基因型，所需剂量可能增加,1,,,,,2,,REV,黄星
PA166134055,rs1799853,1448112404,CC,Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.,携带CC基因型的患者，相比CT或TT基因型，所需剂量可能较高,1,,,,,2,,FWD,黄星
PA166134055,rs1799853,1448112405,CT,Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.,携带CT基因型的患者，相比CC基因型，所需剂量可能较低,1,,,,,0,,FWD,黄星
PA166134055,rs1799853,1448112406,TT,Patients with the TT genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.,携带TT基因型的患者，相比CT或CC基因型，所需剂量可能较低,1,,,,,0,,FWD,黄星
PA166135117,rs1799853,1183615297,CC,Patients with the CC genotype who are taking acenocoumarol may have a decreased risk of a gastrointestinal hemorrhage as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.,携带CC基因型的患者，相比CT或TT基因型，胃肠出血的可能降低,1,,,0,,,,FWD,黄星
PA166135117,rs1799853,1183615298,CT,Patients with the CT genotype who are taking acenocoumarol may have an increased risk of a gastrointestinal hemorrhage as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.,携带CT基因型的患者，相比CC基因型，胃肠出血的可能增加,1,,,2,,,,FWD,黄星
PA166135117,rs1799853,1183615299,TT,Patients with the TT genotype who are taking acenocoumarol may have an increased risk of a gastrointestinal hemorrhage as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of gastrointestinal hemorrhage.,携带TT基因型的患者，相比CC基因型，胃肠出血的可能增加,1,,,2,,,,FWD,黄星
PA166134578,rs1799853,1448615596,CC,"Patients with the CC genotype and Epilepsy who are treated with phenytoin may have an increased metabolism of phenytoin, decreased plasma free phenytoin concentration, and a decreased, but not absent, risk of drug toxicity as compared to patients with the CT and TT genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.",携带CC基因型的癫痫患者，相比CC或CT基因型，可能增加新陈代谢，降低浓度，及降低药物中毒的风险,1,,,0,2,,,FWD,黄星
PA166134578,rs1799853,1448615597,CT,"Patients with the CT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.",携带CT基因型的癫痫患者，相比CC基因型，可能降低新陈代谢，增加浓度，及增加药物中毒的风险,1,,,2,0,,,FWD,黄星
PA166134578,rs1799853,1448615598,TT,"Patients with the TT genotype and Epilepsy who are treated with phenytoin may have a decreased metabolism of phenytoin, increased plasma free phenytoin concentration, and an increased risk of drug toxicity as compared to patients with the CC genotype. These associations have been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to phenytoin.",携带TT基因型的癫痫患者，相比CC基因型，可能降低新陈代谢，增加浓度，及增加药物中毒的风险,1,,,2,0,,,FWD,黄星
PA166134579,rs1799853,1183690927,CC,Patients with the CC genotype who are treated with celecoxib may have an increased metabolism of celecoxib and as compared to patients with the CT and TT genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.,携带CC基因型的患者，相比CT或TT基因型，新陈代谢可能加快,1,,,,2,,,FWD,黄星
PA166134579,rs1799853,1183690928,CT,Patients with the CT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.,携带CT基因型的患者，相比CC基因型，新陈代谢可能降低,1,,,,0,,,FWD,黄星
PA166134579,rs1799853,1183690929,TT,Patients with the TT genotype who are treated with celecoxib may have a decreased metabolism of celecoxib and as compared to patients with the CC genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to celecoxib.,携带TT基因型的患者，相比CC基因型，新陈代谢可能降低,1,,,,0,,,FWD,黄星
PA166134754,rs1799853,1446909043,CC,"Patients with the CC genotype may have 1) increased exposure to clopidogrel active metabolite and 2) decreased, but not absent, risk of poor responder status as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.",携带CC基因型的患者，相比CT或TT基因型，药物的暴露量可能增加，药效可以较好,1,,2,,2,,,FWD,黄星
PA166134754,rs1799853,1446909044,CT,"Patients with the CT genotype may have 1) decreased exposure to clopidogrel active metabolite and 2) an increased risk of poor responder status as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.",携带CT基因型的患者，相比CC基因型，可药物的暴露量可能降低，药效可能较差,1,,0,,0,,,FWD,黄星
PA166134754,rs1799853,1446909045,TT,"Patients with the TT genotype may have 1) decreased exposure to clopidogrel active metabolite and 2) an increased risk of poor responder status as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.",携带TT基因型的患者，相比CT或TT基因型，药物的暴露量可能降低，药效可以较差,1,,0,,0,,,FWD,黄星
PA166134289,rs1799853,655385722,CC,Patients with the CC genotype and type II diabetes who are treated with sulfonylureas: 1) May be less likely to achieve a HbA1c level of <7% as compared to patients with the TT genotype 2) May be more likely to experience treatment failure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylureas.,携带CC基因型的II型糖尿病患者，相比TT基因型，可能很难实现糖化血红蛋白水平<7%，更可能治疗失败,1,,0,,,,,FWD,黄星
PA166134289,rs1799853,655385723,CT,Results from patients with the CT genotype were not statistically significant.,CT基因型在统计学上不显著,1,,,,,,,FWD,黄星
PA166134289,rs1799853,655385724,TT,Patients with the TT genotype and type II diabetes who are treated with sulfonylureas: 1) May be more likely to achieve a HbA1c level of <7% as compared to patients with the CC genotype 2) May be less likely to experience treatment failure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to sulfonylureas.,携带TT基因型的II型糖尿病患者，相比CC基因型，可能更容易实现糖化血红蛋白水平<7%，不太可能治疗失败,1,,2,,,,,FWD,黄星
PA166136235,rs1799853,1444686785,CC,Patients with the CC (CYP2C9 *1/*1) genotype undergoing hemopoietic stem cell transplant may have increased metabolism of busulfan as compared to patients with the CT (*1/*2) or TT (*2/*2) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.,携带CC基因型进行造血干细胞移植的患者，相比CT或TT基因型，新陈代谢可能加快,1,,,,2,,,FWD,黄星
PA166136235,rs1799853,1444686786,CT,Patients with the CT (CYP2C9 *1/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.,携带CT基因型进行造血干细胞移植的患者，相比CC基因型，新陈代谢可能减慢,1,,,,0,,,FWD,黄星
PA166136235,rs1799853,1444686787,TT,Patients with the TT (CYP2C9 *2/*2) genotype undergoing hemopoietic stem cell transplant may have decreased metabolism of busulfan as compared to patients with the CC (*1/*1) genotype. Other genetic and clinical factors may also influence metabolism of busulfan.,携带TT基因型进行造血干细胞移植的患者，相比CC基因型，新陈代谢可能减慢,1,,,,0,,,FWD,黄星
PA166153429,rs1799853,1447990046,CT,Patients with the CT genotype and hypertension may have an improved response to irbesartan as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.,携带CT基因型的高血压患者，相比TT基因型，药物反应可能增加,1,,2,,,,,FWD,黄星
PA166153429,rs1799853,1447990047,TT,Patients with the TT genotype and hypertension may have a decreased response to irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence response to irbesartan in individuals with hypertension.,携带TT基因型的高血压患者，相比CT基因型，药物反应可能降低,1,,0,,,,,FWD,黄星
PA166136241,rs1800871,1444686838,AA,"Patients with the AA genotype who are undergoing kidney transplantation may have a greater chance of achieving target concentrations of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus.",携带AA基因型的肾移植患者，相比AG或GG基因型，实现靶浓度的可能较大,1,,2,,,,,REV,黄星
PA166136241,rs1800871,1444686839,AG,"Patients with the AG genotype who are undergoing kidney transplantation may have a lower chance of achieving target concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus.",携带AG基因型的肾移植患者，相比AA基因型，实现靶浓度的可能较小,1,,0,,,,,REV,黄星
PA166136241,rs1800871,1444686840,GG,"Patients with the GG genotype who are undergoing kidney transplantation may have a lower chance of achieving target concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus.",携带GG基因型的肾移植患者，相比AA基因型，实现靶浓度的可能较小,1,,0,,,,,REV,黄星
PA166136256,rs1800871,1444694576,AA,"Patients undergoing liver transplantation who receive a donor liver with the AA genotype and who are also homozygous for CYP3A5*3 may require decreased doses of tacrolimus as compared to patients with the AG or GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.",携带AA基因型的肾移植患者，相比AG或GG基因型，所需剂量可能降低,1,,,,,0,,REV,黄星
PA166136256,rs1800871,1444694577,AG,"Patients undergoing liver transplantation who receive a donor liver with the AG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.",携带AG基因型的肾移植患者，相比AA基因型，所需剂量可能增加,1,,,,,2,,REV,黄星
PA166136256,rs1800871,1444694578,GG,"Patients undergoing liver transplantation who receive a donor liver with the GG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.",携带GG基因型的肾移植患者，相比AA基因型，所需剂量可能增加,1,,,,,2,,REV,黄星
PA166134217,rs1800497,1448099299,AA,Patients with the AA genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.,携带AA基因型的精神分裂症患者，相比GG基因型，病情可能有较好的改善,1,,2,,,,,REV,黄星
PA166134217,rs1800497,1448099300,AG,Patients with the AG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the GG genotype or may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.,携带AG基因型的精神分裂症患者，相比GG基因型，病情可能有较好的改善；相比AA基因型，可能有较差的改善,1,,1,,,,,REV,黄星
PA166134217,rs1800497,1448099301,GG,Patients with the GG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.,携带GG基因型的精神分裂症患者，相比AA基因型，病情可能有较差的改善,1,,0,,,,,REV,黄星
PA166134385,rs1800497,982035403,AA,Female patients with the AA genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.,携带AA基因型的女性精神分裂症患者，相比GG基因型，可能有较好的催乳反应,1,女,,0,,,,REV,黄星
PA166134385,rs1800497,982035404,AG,Female patients with the AG genotype and schizophrenia treated with nemonapride may have a greater prolactin response to nemonapride compared to female patients with the GG genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.,携带AG基因型的女性精神分裂症患者，相比GG基因型，可能有较好的催乳反应,1,女,,0,,,,REV,黄星
PA166134385,rs1800497,982035405,GG,"Female patients with the GG genotype and schizophrenia treated with nemonapride may have a decreased, but not absent, prolactin response to nemonapride compared to female patients with the AG and AA genotype and male patients. Other genetic and clinical factors may also influence a patient's response to nemonapride.",携带GG基因型的女性精神分类症患者，相比AG或AA基因型，催乳反应可能较差,1,女,,2,,,,REV,黄星
PA166134947,rs1800497,1183490979,AA,Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.,携带AA基因型的患者，相比GG基因型，药物响应可能增加,1,,2,,,,,REV,黄星
PA166134947,rs1800497,1183490980,AG,Patients with the AG genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram.,携带AG基因型的患者，相比GG基因型，药物响应可能增加,1,,2,,,,,REV,黄星
PA166134947,rs1800497,1183490981,GG,Patients with the GG genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AG or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram.,携带GG基因型的患者，相比AA或AG基因型，药物响应可能降低,1,,0,,,,,REV,黄星
PA166134566,rs1800497,1448104251,AA,"Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.",携带AA基因型的患者，相比GG基因型，戒烟效果可能增加,1,,2,,,,,REV,黄星
PA166134566,rs1800497,1448104252,AG,"Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.",携带AG基因型的患者，相比GG基因型，戒烟效果可能增加,1,,2,,,,,REV,黄星
PA166134566,rs1800497,1448104253,GG,"Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the AG and AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation.",携带GG基因型的患者，相比AA或AG基因型，戒烟效果可能降低,1,,0,,,,,REV,黄星
PA166134569,rs1800497,981204891,AA,Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.,携带AA基因型的患者，相比GG基因型，酒精中毒风险可能增加,1,,,2,,,,REV,黄星
PA166134569,rs1800497,981204892,AG,Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.,携带AG基因型的患者，相比GG基因型，酒精中毒风险可能增加,1,,,2,,,,REV,黄星
PA166134569,rs1800497,981204893,GG,"Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. Other genetic and clinical factors may influence a patient's risk for alcohol dependency.",携带GG基因型的患者，相比AA或AG基因型，酒精中毒风险可能降低,1,,,0,,,,REV,黄星
PA166134272,rs1800497,1446898315,AA,"Patients with the AA genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.",携带AA基因型的患者，相比GG基因型，戒烟的可能性较小,1,,0,,,,,REV,黄星
PA166134272,rs1800497,1446898316,AG,"Patients with the AG genotype who are treated with bupropion may be less likely to quit smoking as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.",携带AG基因型的患者，相比GG基因型，戒烟的可能性较小,1,,0,,,,,REV,黄星
PA166134272,rs1800497,1446898317,GG,"Patients with the GG genotype who are treated with bupropion may be more likely to quit smoking as compared to patients with the AA or AG genotypes, although this has been contradicted in one study. Other genetic and clinical factors may also influence a patient's chance for quitting smoking.",携带GG基因型的患者，相比AA或AG基因型，戒烟的可能性较大,1,,2,,,,,REV,黄星
PA166134281,rs1800497,1448255889,AA,"Patients with the AA genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.",携带AA基因型的患者，相比AG或GG基因型，可能增加副作用的风险，降低迟发性运动障碍的风险,1,,,0,,,,REV,黄星
PA166134281,rs1800497,1448255890,AG,"Patients with the AG genotype may have increased risk of side effects including hyperprolactinemia and weight gain, but decreased risk of tardive dyskinesia during treatment with antipsychotic drugs as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's risk for side effects.",携带AG基因型的患者，相比GG基因型，可能增加副作用的风险，降低迟发性运动障碍的风险,1,,,0,,,,REV,黄星
PA166134281,rs1800497,1448255891,GG,"Patients with the GG genotype may have decreased but not non-existant risk of side effects including hyperprolactinemia and weight gain, but increased risk of tardive dyskinesia, during treatment with antipsychotic drugs as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for side effects.",携带GG基因型的患者，相比AA或AG基因型，可能降低副作用的风险，增加迟发型运动障碍的风险,1,,,2,,,,REV,黄星
PA166152807,rs1800497,1448106626,AA,Patients with the AA genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.,携带AA基因型的精神分裂症患者，相比GG基因型，药物响应较好,1,,2,,,,,REV,黄星
PA166152807,rs1800497,1448106627,AG,Patients with the AG genotype and schizophrenia may have a better response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to antipsychotics.,携带AG基因型的精神分裂症患者，相比GG基因型，药物响应较好,1,,2,,,,,REV,黄星
PA166152807,rs1800497,1448106628,GG,Patients with the GG genotype and schizophrenia may have a poorer response according to the Positive and Negative Syndrome Scale when treated with risperidone or aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to antipsychotics.,携带GG基因型的患者，相比AA或AG基因型，药物响应可能降低,1,,0,,,,,REV,黄星
PA166135902,rs1800497,1445401401,AA,Patients with the AA genotype and epilepsy may have lower weight gain when treated with valproic acid as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence weight gain.,携带AA基因型的癫痫患者，相比AG或GG基因型，体重增加可能较少,1,,,0,,,,REV,黄星
PA166135902,rs1800497,1445401402,AG,Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.,携带AG基因型的癫痫患者，相比AA基因型，体重增加可能较大,1,,,2,,,,REV,黄星
PA166135902,rs1800497,1445401403,GG,Patients with the GG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the AA genotype. Other genetic and clinical factors may also influence weight gain.,携带GG基因型的癫痫患者，相比AA基因型，体重增加可能较大,1,,,2,,,,REV,黄星
PA166136113,rs1800497,1444607461,AA,Individuals with the AA genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.,携带AA基因型的患者，相比GG基因型，曲线下面积可能增加,1,,,,2,,,REV,黄星
PA166136113,rs1800497,1444607462,AG,Individuals with the AG genotype may have increased area under the curve (AUC) of olanzapine as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.,携带AG基因型的患者，相比GG基因型，曲线下面积可能增加,1,,,,2,,,REV,黄星
PA166136113,rs1800497,1444607463,GG,Individuals with the GG genotype may have decreased area under the curve (AUC) of olanzapine as compared to individuals with the AA or AG genotype. Other genetic and clinical factors may also influence AUC of olanzapine.,携带GG基因型的患者，相比AG或AA基因型，曲线下面积可能降低,1,,,,0,,,REV,黄星
PA166136166,rs1800975,1444666603,CC,Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.,携带CC基因型的非小细胞肺癌患者，相比CT或TT基因型，药物响应可能较好,1,,2,,,,,REV,黄星
PA166136166,rs1800975,1444666604,CT,Patients with the CT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.,携带CT基因型的非小细胞肺癌患者，相比CC基因型，药物响应可能较差,1,,0,,,,,REV,黄星
PA166136166,rs1800975,1444666605,TT,Patients with the TT genotype and non-small-cell lung cancer may have a poorer response to treatment with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.,携带TT基因型的非小细胞肺癌患者，相比CC基因型，药物响应可能较差,1,,0,,,,,REV,黄星
PA166135058,rs1801020,1183614505,AA,Patients with the AA genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.,携带AA基因型的中风患者，相比GG基因型，住院死亡的风险降低,1,,2,,,,,REV,黄星
PA166135058,rs1801020,1183614506,AG,Patients with the AG genotype who have had a stroke may have a decreased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.,携带AG基因型的中风患者，相比GG基因型，住院死亡的风险降低,1,,2,,,,,REV,黄星
PA166135058,rs1801020,1183614507,GG,Patients with the GG genotype who have had a stroke may have an increased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.,携带GG基因型的中风患者，相比AG或AA基因型，住院死亡的风险增加,1,,0,,,,,REV,黄星
PA166134987,rs1800629,1183491818,AA,Patients with the AA genotype were not studied. Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,AA基因型尚无研究,1,,,,,,,FWD,黄星
PA166134987,rs1800629,1183491819,AG,Patients with the AG genotype and acute coronary syndrome who are treated with atorvastatin may not have an increase in lumbar bone marrow density as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,携带AG基因型的急性冠状动脉综合征患者，相比GG基因型，腰椎骨髓密度增加的可能较小,1,,0,,,,,FWD,黄星
PA166134987,rs1800629,1183491820,GG,Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,携带GG基因型的急性冠状动脉综合征患者，相比AG基因型，腰椎骨髓密度增加的可能较大,1,,2,,,,,FWD,黄星
PA166134163,rs1800629,1448099213,AA,Patients with the AA genotype and inflammatory diseases who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.,携带AA基因型的炎症疾病患者，相比GG基因型，可能不会有疾病的临床改善,1,,0,,,,,FWD,黄星
PA166134163,rs1800629,1448099214,AG,Patients with the AG genotype and inflammatory diseases who are treated with anti-TNF therapies may be less likely to have improvement in symptoms as compared to patients with the GG genotype or may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.,"携带AG基因型的炎症疾病患者，相比GG基因型，可能不会有疾病的临床改善,相比AA基因型，可能有较大的临床改善",1,,1,,,,,FWD,黄星
PA166134163,rs1800629,1448099215,GG,Patients with the GG genotype and inflammatory diseases who are treated with anti-TNF therapies may be more likely to have improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-TNF therapy.,携带GG基因型的炎症疾病患者，相比AA基因型，可能有较大的临床改善,1,,2,,,,,FWD,黄星
PA166134293,rs1800629,1448107918,AA,Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.,携带AA基因型的患者，相比GG基因型，可能增加重度过敏的机会,1,,,2,,,,FWD,黄星
PA166134293,rs1800629,1448107919,AG,There were too few patients with the AG genotype in this one small study for a conclusion to be drawn.,本研究中AG基因型人数过少,1,,,,,,,FWD,黄星
PA166134293,rs1800629,1448107920,GG,Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.,携带GG基因型的患者，相比AA基因型，可能降低重度过敏的机会,1,,,0,,,,FWD,黄星
PA166159946,rs1800629,1448255943,AA,"Patients with genotype AA may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.",携带AA基因型的肝癌患者，相比GG基因型，手足综合征的风险可能降低,1,,,0,,,,FWD,黄星
PA166159946,rs1800629,1448255942,AG,"Patients with genotype AG may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.",携带AG基因型的肝癌患者，相比GG基因型，手足综合征的风险可能降低,1,,,0,,,,FWD,黄星
PA166159946,rs1800629,1448255941,GG,"Patients with genotype GG may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients wth genotype AG or AA. Other genetic and clinical factors may also influence the response to sorafenib.",携带GG基因型的肝癌患者，相比AG或AA基因型，手足综合征的风险可能增加,1,,,2,,,,FWD,黄星
PA166134488,rs1801158,1448568508,CC,"Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) a decreased but not absent risk of toxicity and 2) increased DPYD activity as compared to patients with the CT genotype (DPYD *1/*4). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带CC基因型的癌症患者，相比CT基因型，药物中毒可能性降低，二氢嘧啶脱氢酶活性可能增加,1,,,0,,,,REV,黄星
PA166134488,rs1801158,1448568509,CT,"Patients with the CT genotype (DPYD *1/*4) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased risk of toxicity and 2) decreased DPYD activity as compared to patients with the CC genotype (DPYD *1/*1). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带CT基因型的癌症患者，相比CC基因型，药物中毒可能性增加，二氢嘧啶脱氢酶活性可能降低,1,,,2,,,,REV,黄星
PA166134488,rs1801158,1448568510,TT,"No patients with the TT genotype (DPYD *4/*4) were available for analysis, but patients with the CT genotype (DPYD *1/*4) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased risk of toxicity and 2) decreased DPYD activity as compared to patients with the CC genotype (DPYD *1/*1). However, some studies find no association with drug toxicity or DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",TT基因型尚无研究,1,,,,,,,REV,黄星
PA166135904,rs1801160,1448263011,CC,"Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased metabolism of fluorouracil and 2) decreased risk for drug toxicities as compared to patients with the CT or TT genotype (DPYD *1/*6 or *6/*6). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带CC基因型的癌症患者，相比CT或TT基因型，新陈代谢可能增加，药毒性风险可能降低,1,,,0,2,,,REV,黄星
PA166135904,rs1801160,1448263012,CT,"Patients with the CT genotype (DPYD *1/*6) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased metabolism of fluorouracil and 2) increased risk for drug toxicities as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带CT基因型的癌症患者，相比CC基因型，新陈代谢可能降低，药毒性风险可能增加,1,,,2,0,,,REV,黄星
PA166135904,rs1801160,1448263013,TT,"Patients with the TT genotype (DPYD *6/*6) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased metabolism of fluorouracil and 2) increased risk for drug toxicities when treated with as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带TT基因型的癌症患者，相比CC基因型，新陈代谢可能降低，药毒性风险可能增加,1,,,2,0,,,REV,黄星
PA166134489,rs1801159,1448522482,CC,"Patients with the CC genotype (DPYD *5/*5) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) an increased likelihood of nausea, vomiting, and leukopenia, 2) decreased response and 3) decreased clearance of fluorouracil as compared to patients with the TT genotype (DPYD *1/*1). However, other studies find no associations or contradictory associations with fluoropyrimidine-induced drug toxicity or response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带CC基因型的癌症患者，相比TT基因型，可能会表现恶心呕吐的风险增加，药物反应降低，清除能力降低,1,,0,2,,,,REV,黄星
PA166134489,rs1801159,1448522483,CT,"Patients with the CT genotype (DPYD *1/*5) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) decreased response and 2) an increased likelihood of hyperammonemia as compared to patients with the TT genotype (DPYD *1/*1). However, the vast majority of studies find no association between this diplotype and fluoropyrimidine-induced drug toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带CT基因型的癌症患者，相比TT基因型，可能会表现药物反应降低，高血氨症风险增加,1,,0,2,,,,REV,黄星
PA166134489,rs1801159,1448522484,TT,"Patients with the TT genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) a decreased likelihood of nausea, vomiting, and leukopenia, 2) increased response and 3) increased clearance of fluorouracil as compared to patients with the CT or CC genotype (DPYD *1/*5 or *5/*5). However, other studies find no associations or contradictory associations with fluoropyrimidine-induced drug toxicity or response. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带TT基因型的癌症患者，相比CT或CC基因型，可能会表现恶心呕吐风险降低，药物反应增加，清除能力增加,1,,2,0,,,,REV,黄星
PA166153407,rs1801266,1448123177,AA,Patients with the AA genotype (DPYD *8/*8) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. ,携带AA基因型的患者，相比GG基因型，二氢嘧啶脱氢酶的活性可能降低,1,,,,,,,REV,黄星
PA166153407,rs1801266,1448123178,AG,Patients with the AG genotype (DPYD *1/*8) may have decreased DPYD activity as compared to those with the GG genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. ,携带AG基因型的患者，相比GG基因型，二氢嘧啶脱氢酶的活性可能降低,1,,,,,,,REV,黄星
PA166153407,rs1801266,1448123179,GG,Patients with the GG genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the AA or AG genotype (DPYD *8/*8 or *1/*8). Other genetic and clinical factors may also affect DPYD activity. ,携带GG基因型的患者，相比AG或AA基因型，二氢嘧啶脱氢酶的活性可能增加,1,,,,,,,REV,黄星
PA166134448,rs1801272,827864180,AA,Patients with the AA genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.,携带AA基因型的患者，相比TT基因型，可能增加7-羟基化,1,,,,,,,REV,黄星
PA166134448,rs1801272,827864181,AT,Patients with the AT genotype may have increased 7-hydroxylation of coumarin compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of coumarin.,携带AT基因型的患者，相比TT基因型，可能增加7-羟基化,1,,,,,,,REV,黄星
PA166134448,rs1801272,827864182,TT,Patients with the TT genotype may have minimal 7-hydroxylation of coumarin compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of coumarin.,携带TT基因型的患者，相比AA基因型，可能有最小的7-羟基化,1,,,,,,,REV,黄星
PA166153409,rs1801268,1447989725,AA,Patients with the AA genotype (DPYD *10/*10) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. ,携带AA基因型的患者，相比CC基因型，二氢嘧啶脱氢酶的活性可能降低,1,,,,,,,REV,黄星
PA166153409,rs1801268,1447989726,AC,Patients with the AC genotype (DPYD *1/*10) may have decreased DPYD activity as compared to those with the CC genotype (DPYD *1/*1). Other genetic and clinical factors may also affect DPYD activity. ,携带AC基因型的患者，相比CC基因型，二氢嘧啶脱氢酶的活性可能降低,1,,,,,,,REV,黄星
PA166153409,rs1801268,1447989727,CC,Patients with the CC genotype (DPYD *1/*1) may have increased DPYD activity as compared to those with the AC or AA genotype (DPYD *1/*10 or *10/*10). Other genetic and clinical factors may also affect DPYD activity. ,携带CC基因型的患者，相比AA或AC基因型，二氢嘧啶脱氢酶的活性可能增加,1,,,,,,,REV,黄星
PA166135222,rs1801274,1447945754,AA,Patients with the AA genotype and rheumatoid arthritis who are with infliximab may have an increased response based on European League Against Rheumatism (EULAR) criteria and show more improvement using the Disease Activity Score 28 as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.,携带AA基因型的类风湿性关节炎患者，相比GG基因型，药物响应可能增加,1,,2,,,,,REV,黄星
PA166135222,rs1801274,1447945755,GA,Patients with the GA genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.,携带GA基因型的类风湿性关节炎患者，相比AA基因型，药物响应可能降低,1,,0,,,,,REV,黄星
PA166135222,rs1801274,1447945756,GG,Patients with the GG genotype and rheumatoid arthritis who are with infliximab may have a decreased response based on European League Against Rheumatism (EULAR) criteria and show less improvement using the Disease Activity Score 28 as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to infliximab.,携带GG基因型的类风湿性关节炎患者，相比AA基因型，药物响应可能降低,1,,0,,,,,REV,黄星
PA166136098,rs1801274,1185003578,AA,Patients with the AA genotype may have increased response to trastuzumab and longer progression-free survival in people with Breast cancer as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence the response to trastuzumab.,携带AA基因型的乳腺癌患者，相比AG或GG基因型，药物响应可能增加，存活期可能延长,1,,2,,,,,REV,黄星
PA166136098,rs1801274,1185003579,AG,Patients with the AG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.,携带AG基因型的乳腺癌患者，相比AA基因型，药物响应可能降低，存活期可能缩短,1,,0,,,,,REV,黄星
PA166136098,rs1801274,1185003580,GG,Patients with the GG genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype AA. Other genetic or clinical factors may also influence the response to trastuzumab.,携带GG基因型的乳腺癌患者，相比AA基因型，药物响应可能降低，存活期可能缩短,1,,0,,,,,REV,黄星
PA166136221,rs1801274,1448426978,AA,Patients with the AA genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.,携带AA基因型的牛皮癣患者，相比GG基因型，疾病表面积可能较小,1,,2,,,,,REV,黄星
PA166136221,rs1801274,1448426979,AG,Patients with the AG genotype and psoriasis may have a lower psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.,携带AG基因型的牛皮癣患者，相比GG基因型，疾病表面积可能较小,1,,2,,,,,REV,黄星
PA166136221,rs1801274,1448426980,GG,Patients with the GG genotype and psoriasis may have a higher psoriasis body surface area after treatment with anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.,携带GG基因型的牛皮癣患者，相比AG或AA基因型，疾病表面积可能较大,1,,0,,,,,REV,黄星
PA166134419,rs1801253,1444667359,CC,"Patients with the CC genotype 1) may have an increased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have a decreased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.",携带CC基因型的患者，相比CG或GG基因型，药物反应性可能增加，其他心力衰竭药物剂量增加的可能性降低,1,,2,,,,,plus,黄星
PA166134419,rs1801253,1444667360,CG,"Patients with the CG genotype 1) may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.",携带CG基因型的患者，相比CC基因型，药物反应性可能降低，其他心力衰竭药物剂量增加的可能性增加,1,,0,,,,,plus,黄星
PA166134419,rs1801253,1444667361,GG,"Patients with the GG genotype may have a decreased response to Beta Blocking Agents (this association has not been found in all studies and has been contradicted) 2) may have an increased likelihood for requiring increases in other heart failure medication (for example diuretics), as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Beta Blocking Agents.",携带GG基因型的患者，相比CG或GG基因型，药物反应性可能降低，其他心力衰竭药物剂量增加的可能性增加,1,,0,,,,,plus,黄星
PA166135056,rs1801253,1183614487,CC,"Healthy males with the CC genotype may have a greater increase in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CG or GG genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.",携带CC基因型的健康男性，相比CG或GG基因型，室短轴缩短率和收缩压可能有较大的增加,1,男,2,,,,,plus,黄星
PA166135056,rs1801253,1183614488,CG,"Healthy males with the CG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.",携带CG基因型的健康男性，相比CC基因型，室短轴缩短率和收缩压可能有较小的增加,1,男,0,,,,,plus,黄星
PA166135056,rs1801253,1183614489,GG,"Healthy males with the GG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.",携带GG基因型的健康男性，相比CC基因型，室短轴缩短率和收缩压可能有较小的增加,1,男,0,,,,,plus,黄星
PA166134166,rs1801253,982033836,CC,"Patients with the CC genotype and Diabetes Mellitus who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.",携带CC基因型的糖尿病患者，相比CG基因型，水肿的风险可能降低,1,,,0,,,,plus,黄星
PA166134166,rs1801253,982033837,CG,Patients with the CG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.,携带CG基因型的糖尿病患者，相比CG基因型，水肿的风险可能增加,1,,,2,,,,plus,黄星
PA166134166,rs1801253,982033838,GG,Patients with the GG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype but the results were not statistically significant. Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.,携带GG基因型的糖尿病患者，相比CC基因型，水肿的风险可能增加,1,,,2,,,,plus,黄星
PA166134254,rs1801253,655385296,CC,Patients with the  CC (Arg389) genotype may have a stronger DBP response to metoprolol with a significantly greater reduction in 24-hour and daytime DBP than was found in carriers of a G(Gly389) allele. Other genetic and clinical factors may also influence the patient's response to metoprolol.,携带CC基因型的患者，相比CG基因型，可能有较强的DBP反应（24小时内和白天，有显著的降低）,1,,2,,,,,plus,黄星
PA166134254,rs1801253,655385297,CG,Patients with the CG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.,携带CG基因型的患者，相比CG基因型，药物反应可能较弱,1,,0,,,,,plus,黄星
PA166134254,rs1801253,655385298,GG,Patients with the GG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.,携带GG基因型的患者，相比CC基因型，药物反应可能较弱,1,,0,,,,,plus,黄星
PA166152687,rs1801253,1447960438,CC,Patients with the CC genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.,携带CC基因型的冠状动脉疾病患者，相比CG或GG基因型，需要的剂量可能较少,1,,,,,0,,plus,黄星
PA166152687,rs1801253,1447960439,CG,"Patients with the CG genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the GG genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence required dose of catecholamines.",携带CG基因型的冠状动脉疾病患者，相比GG基因型，需要的剂量可能较少；相比CC基因型，需要的剂量可能较多,1,,,,,1,,plus,黄星
PA166152687,rs1801253,1447960440,GG,Patients with the GG genotype and coronary artery disease may require an increased dose of catecholamines as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence required dose of catecholamines.,携带CC基因型的冠状动脉疾病患者，相比CG或GG基因型，需要的剂量可能较多,1,,,,,2,,plus,黄星
PA166152688,rs1801253,1447960450,CC,Patients with the GG genotype and heart failure may have decreased emergency department utilization when treated with cardiovascular drugs as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.,携带GG基因型的心力衰竭患者，相比CG或GG基因型，急疹的需求可能降低,1,,2,,,,,plus,黄星
PA166152688,rs1801253,1447960451,CG,Patients with the CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.,携带CG基因型的心力衰竭患者，相比GG基因型，急疹的需求可能增加,1,,0,,,,,plus,黄星
PA166152688,rs1801253,1447960452,GG,Patients with the CC genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.,携带CC基因型的心力衰竭患者，相比GG基因型，急疹的需求可能增加,1,,0,,,,,plus,黄星
PA166152858,rs1801282,1447964004,CC,Patients with the CC genotype and schizophrenia may have lower weight gain when treated with olanzapine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence weight gain. ,携带CC基因型的精神分裂症患者，相比CG或GG基因型，体重增加可能较少,1,,,0,,,,plus,黄星
PA166152858,rs1801282,1447964005,CG,Patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain. ,携带CG基因型的精神分裂症患者，相比CC或GG基因型，体重增加可能较多,1,,,2,,,,plus,黄星
PA166152858,rs1801282,1447964006,GG,"No patients with the GG genotype were available for analysis, but patients with the CG genotype and schizophrenia may have greater weight gain when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain. ",携带GG基因型的精神分裂症患者，目前，尚无相关研究,1,,,,,,,plus,黄星
PA166134491,rs1801265,1448522487,AA,"Patients with the AA genotype (DPYD *1/*1) and cancer who are treated with fluorouracil may have 1) a decreased but not absent risk for drug toxicities, 2) increased response, 3) increased clearance of fluorouracil and 4) decreased DPYD activity as compared to patients with the AG or GG genotypes (DPYD *1/*9A or *9A/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带AA基因型的癌症患者，相比AG或GG基因型，药物毒性的风险可能降低，药物反应性可能增加，药物清除率可能增加，DPYD的活性可能降低,1,,2,0,,,,plus,黄星
PA166134491,rs1801265,1448522488,AG,"Patients with the AG genotype (DPYD *1/*9A) and cancer who are treated with fluorouracil may have 1) an increased risk for drug toxicities, 2) decreased response and 3) increased DPYD activity as compared to patients with the AA genotype (DPYD *1/*1). Patients with the AG genotype were also found to have increased clearance of fluorouracil as compared to those with the GG genotype (DPYD *9A/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance, and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带AG基因型的癌症患者，相比AA基因型，药物毒性的风险可能增加，药物反应性可能降低，DPYD的活性可能增加；相比GG基因型，药物清除率可能增加,1,,0,0,,,,plus,黄星
PA166134491,rs1801265,1448522489,GG,"Patients with the GG genotype (DPYD *9A/*9A) and cancer who are treated with fluorouracil may have 1) an increased risk for drug toxicities, 2) decreased response, 3) decreased clearance of fluorouracil and 4) increased DPYD activity as compared to patients with the AA or AG genotype (DPYD *1/*1 or *1/*9A). However, multiple studies find contradictory or negative evidence for drug toxicities, fluorouracil clearance, and DPYD activity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带GG基因型的癌症患者，相比AA或AG基因型，药物毒性的风险可能增加，药物反应性可能降低，药物清除率可能增加，DPYD的活性可能增加,1,,0,2,,,,plus,黄星
PA166136476,rs1805034,1446908681,CC,"Patients with the CC genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.",携带CC基因型的患者，相比TT基因型，荨麻疹和血管性水肿的风险可能增加,1,,,2,,,,plus,黄星
PA166136476,rs1805034,1446908682,CT,"Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.",携带CT基因型的患者，相比TT基因型，荨麻疹和血管性水肿的风险可能增加,1,,,2,,,,plus,黄星
PA166136476,rs1805034,1446908683,TT,"Patients with the TT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have a decreased, but not absent, risk of urticaria and Angioedema as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.",携带TT基因型的患者，相比CT或CC基因型，荨麻疹和血管性水肿的风险可能降低,1,,,0,,,,plus,黄星
PA166135530,rs1803274,1444698449,CC,Patients with the CC genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.,携带CC基因型的患者，相比TT基因型，麻醉后呼吸暂停的风险可能降低,1,,,0,,,,plus,黄星
PA166135530,rs1803274,1444698450,CT,Patients with the CT genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.,携带CT基因型的患者，相比TT基因型，麻醉后呼吸暂停的风险可能降低；相比CC基因型，麻醉后呼吸暂停的风险可能增加,1,,,1,,,,plus,黄星
PA166135530,rs1803274,1444698451,TT,Patients with the TT genotype have an increased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.,携带TT基因型的患者，相比CC基因型，麻醉后呼吸暂停的风险可能增加,1,,,2,,,,plus,黄星
PA166153430,rs1803274,1447990056,CC,"Patients with the CC genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, and as compared to patients with the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.",携带CC基因型的路易体痴呆病或阿尔茨海默病患者，相比TT和CT基因型，药物的反应可能增加,1,,2,,,,,plus,黄星
PA166153430,rs1803274,1447990057,CT,"Patients with the CT genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.",携带CT基因型的路易体痴呆病或阿尔茨海默病患者，相比TT基因型，药物的反应可能增加,1,,2,,,,,plus,黄星
PA166153430,rs1803274,1447990058,TT,"Patients with the TT genotype and Lewy Body disease or Alzheimer's disease may have worse response to rivastigmine as compared to patients with the CC genotype, as well as the CT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.",携带TT基因型的路易体痴呆病或阿尔茨海默病患者，相比CC和CT基因型，药物的反应可能较差,1,,0,,,,,plus,黄星
PA166158753,rs1803274,1448097839,CC,Patients with the CC genotype may be less likely to develop an addiction to cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to cocaine.,携带CC基因型的患者，相比TT基因型，可卡因成瘾的风险较低,1,,,0,,,,plus,黄星
PA166158753,rs1803274,1448097840,CT,Patients with the CT genotype may be less likely to develop an addiction to cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to cocaine.,携带CT基因型的患者，相比TT基因型，可卡因成瘾的风险较低,1,,,0,,,,plus,黄星
PA166158753,rs1803274,1448097841,TT,Patients with the TT genotype may be less likely to develop an addiction to cocaine as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also be associated with addiction to cocaine.,携带TT基因型的患者，相比CC或CT基因型，可卡因成瘾的风险较高,1,,,2,,,,plus,黄星
PA166134504,rs1801394,1448106021,AA,Pediatric ALL patients with AA genotypes may have  decreased likelihood of methotrexate induced toxicity (oral mucositis) and decreased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the GG and AG genotype. Other genetic and clinical factors may also influence response to methotrexate.,携带AA基因型的小儿ALL患者，相比GG和AG基因型，药物毒性（口腔黏膜炎）、 成淋巴细胞的胸苷酸合成酶的催化能力均可能降低,1,,0,0,,,,plus,黄星
PA166134504,rs1801394,1448106022,AG,"Pediatric ALL patients with AG genotypes may have increased likelihood of methotrexate induced toxicity (oral mucositis), increased speed of platelet recovery and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.",携带AG基因型的小儿ALL患者，相比AA基因型，药物毒性（口腔黏膜炎）、血小板恢复力和成淋巴细胞的胸苷酸合成酶的催化能力均可能增加,1,,2,2,,,,plus,黄星
PA166134504,rs1801394,1448106023,GG,Pediatric ALL patients with GG genotypes may have  increased likelihood of methotrexate induced toxicity (oral mucositis) and increased catalytic activity of TYMS in lymphoblasts when treated with methotrexate as compared to patients with the AA genotype. Allele G is not associated with decreased IQ in pediatric ALL patients treated with methotrexate. Other genetic and clinical factors may also influence response to methotrexate.,携带GG基因型的小儿ALL患者，相比AA基因型，药物毒性（口腔黏膜炎）、成淋巴细胞的胸苷酸合成酶的催化能力均可能增加,1,,2,2,,,,plus,黄星
PA166135715,rs1816702,1444686960,CC,"Patients with the CC genotype and Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.",携带CC基因型的克罗恩氏病患者，相比CT或TT基因型，药物反应可能较差,1,,0,,,,,plus,黄星
PA166135715,rs1816702,1444686961,CT,"Patients with the CT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.",携带CT基因型的克罗恩氏病患者，相比CC基因型，药物反应可能较好,1,,2,,,,,plus,黄星
PA166135715,rs1816702,1444686962,TT,"Patients with the TT genotype and Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.",携带TT基因型的克罗恩氏病患者，相比CC基因型，药物反应可能较好,1,,2,,,,,plus,黄星
PA166158997,rs1804645,1448100652,CC,Female patients with the CC genotype may have less of a decrease in bone mineral density when treated with tamoxifen as compared to patients with the CT genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen. ,携带CC基因型的女性患者，相比CT基因型，骨密度降低的幅度可能较小,1,女,,0,,,,plus,黄星
PA166158997,rs1804645,1448100653,CT,Female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen. ,携带CT基因型的女性患者，相比CC基因型，骨密度降低的幅度可能较大,1,女,,2,,,,plus,黄星
PA166158997,rs1804645,1448100654,TT,"No patients with the TT genotype were available for analysis, but female patients with the CT genotype may have a greater decrease in bone mineral density when treated with tamoxifen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density in women taking tamoxifen. ",携带TT基因型的患者，目前无相关研究,1,女,,,,,,plus,黄星
PA166159159,rs1805128,1448102348,CC,Patients with the CC genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of torsades de pointes. ,携带CC基因型的患者，相比TT基因型，药物诱导的尖端扭转风险可能降低,1,,,0,,,,plus,黄星
PA166159159,rs1805128,1448102349,CT,"Patients with the CT genotype may have a decreased risk of drug-induced torsades de pointes as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes. ",携带CT基因型的患者，相比TT基因型，药物诱导的尖端扭转风险可能降低,1,,,0,,,,plus,黄星
PA166159159,rs1805128,1448102350,TT,Patients with the TT genotype may have an increased risk of drug-induced torsades de pointes as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of torsades de pointes. ,携带TT基因型的患者，相比CC基因型，药物诱导的尖端扭转风险可能增加,1,,,2,,,,plus,黄星
PA166135776,rs1901440,1444703219,AA,"Patients with the AA genotype and Neoplasms who are treated with gemcitabine may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.",携带AA基因型的肿瘤患者，相比CC基因型，患白血球减少症的风险可能降低,1,,2,,,,,plus,黄星
PA166135776,rs1901440,1444703218,AC,"Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.",携带AC基因型的肿瘤患者，相比AA基因型，患白血球减少症的风险可能增加；相比CC基因型，患白血球减少症的风险可能降低,1,,0,,,,,plus,黄星
PA166135776,rs1901440,1444703217,CC,Patients with the CC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.,携带CC基因型的肿瘤患者，相比AA基因型，患白血球减少症的风险可能增加,1,,0,,,,,plus,黄星
PA166134135,rs1934951,655384601,CC,Patients with the CC genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.,携带CC基因型的患者，相比TT基因型，颌骨坏死的风险可能降低,1,,,0,,,,plus,黄星
PA166134135,rs1934951,655384600,CT,Patients with the CT genotype may have decreased but not non-existent risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.,携带CT基因型的患者，相比TT基因型，颌骨坏死的风险可能降低,1,,,0,,,,plus,黄星
PA166134135,rs1934951,655384599,TT,Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.,携带TT基因型的患者，相比CC或CT基因型，颌骨坏死的风险可能增加,1,,,2,,,,plus,黄星
PA166136382,rs1934951,1448263857,CC,"Patients with the CC genotype and breast cancer may have a decreased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk for anemia.",携带CC基因型的乳腺癌患者，相比CC或CT基因型，除神经病外，贫血的风险可能降低,1,,,0,,,,plus,黄星
PA166136382,rs1934951,1448263858,CT,"Patients with the CT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.",携带CT基因型的乳腺癌患者，相比CC基因型，除神经病外，贫血的风险可能增加,1,,,2,,,,plus,黄星
PA166136382,rs1934951,1448263859,TT,"Patients with the TT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.",携带TT基因型的乳腺癌患者，相比CC基因型，除神经病外，贫血的风险可能增加,1,,,2,,,,plus,黄星
PA166135489,rs193922525,1184472609,AA,"Patients with the AA genotype (two copies of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AA基因型的囊性纤维症患者，可能对药物治疗有反应,1,,2,,,,,plus,黄星
PA166135489,rs193922525,1184472610,AG,"Patients with the AG genotype (one copy of the CFTR G1349D variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AG基因型的囊性纤维症患者，可能对药物治疗有反应,1,,2,,,,,plus,黄星
PA166135489,rs193922525,1184472611,GG,"Patients with the GG genotype (do not have a copy of the CFTR G1349D variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G1349D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带GG基因型的囊性纤维症患者，可能对药物治疗有未知的反应,1,,,,,,,plus,黄星
PA166134390,rs1902023,1447963593,AA,Subjects with the AA genotype may have decreased clearance of oxazepam or lorazepam as compared to subjects with the CC genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam.,携带AA基因型的患者，相比CC基因型，药物的清除率可能降低,1,,,2,,,,plus,黄星
PA166134390,rs1902023,1447963594,AC,"Subjects with the AC genotype may have decreased clearance of oxazepam or lorazepam as compared to subjects with the CC genotype, or increased clearance as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam.",携带AC基因型的患者，相比CC基因型，药物的清除率可能降低,1,,,2,,,,plus,黄星
PA166134390,rs1902023,1447963595,CC,Subjects with the CC genotype may have increased clearance of oxazepam or lorazepam as compared to subjects with the AA genotype. Other genetic and clinical factors may also influence the oral clearance of oxazepam or lorazepam. ,携带CC基因型的患者，相比AA基因型，药物的清除率可能增加,1,,,0,,,,plus,黄星
PA166135879,rs193922747,1447992405,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带CC基因型的患者，相比TT基因型，可能会患恶性高热,1,,,2,,,,plus,黄星
PA166135879,rs193922747,1447992406,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带CT基因型的患者，相比TT基因型，可能会患恶性高热,1,,,2,,,,plus,黄星
PA166135879,rs193922747,1447992407,TT,"Patients with the TT genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT and CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带TT基因型的患者，相比CT和CC基因型，可能不会患恶性高热,1,,,0,,,,plus,黄星
PA166135975,rs193922807,1447992321,CC,"Patients with the CC genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the C allele confers MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with CC genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带CC基因型的患者，相比GG基因型，可能会患恶性高热,1,,,2,,,,plus,黄星
PA166135975,rs193922807,1447992322,CG,"Patients with the CG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带CG基因型的患者，相比GG基因型，可能会患恶性高热,1,,,2,,,,plus,黄星
PA166135975,rs193922807,1447992323,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带GG基因型的患者，相比CC基因型，可能不会患恶性高热,1,,,0,,,,plus,黄星
PA166136353,rs193922803,1448615845,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CC基因型的患者，相比CT基因型，可能不会患恶性高热,1,,,0,,,,plus,黄星
PA166136353,rs193922803,1448615846,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.  ",携带CT基因型的患者，相比CC基因型，可能患恶性高热,1,,,2,,,,plus,黄星
PA166136353,rs193922803,1448615847,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known.",携带TT基因型的患者，相比CC基因型，可能患恶性高热,1,,,2,,,,plus,黄星
PA166136356,rs193922802,1447992305,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.  Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known.",携带AA基因型的患者，相比GG基因型，可能患恶性高热,1,,,2,,,,plus,黄星
PA166136356,rs193922802,1447992306,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带AG基因型的患者，相比GG基因型，可能患恶性高热,1,,,2,,,,plus,黄星
PA166136356,rs193922802,1447992307,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带GG基因型的患者，相比AG基因型，可能不会患恶性高热,1,,,0,,,,plus,李晶晶
PA166136351,rs193922876,1447992473,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the CT or TT genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. ",携带CC基因型的患者，相比CT或TT基因型，可能不会患恶性高热,1,,,0,,,,plus,李晶晶
PA166136351,rs193922876,1447992474,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with the  the CC genotype. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia. ",携带CT基因型的患者，相比CC基因型，可能患恶性高热,1,,,2,,,,plus,李晶晶
PA166136351,rs193922876,1447992475,TT,"Patients with the TT genotype may develop of Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other clinical and genetic factors also influence whether an individual develops malignant hyperthermia.  Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known.",携带TT基因型的患者，相比CC基因型，可能患恶性高热,1,,,2,,,,plus,李晶晶
PA166134571,rs1801133,1448568563,AA,"Cancer patients with the AA genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AG or GG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.",携带AA基因型的癌症患者，相比AG或GG基因型，药物毒性的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134571,rs1801133,1448568564,AG,"Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.",携带AG基因型的癌症患者，相比GG基因型，药物毒性的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134571,rs1801133,1448568565,GG,"Cancer patients with the GG genotype may have a decreased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AA or AG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.",携带GG基因型的癌症患者，相比AG或AA基因型，药物毒性的风险可能降低,1,,,0,,,,plus,李晶晶
PA166134341,rs1801133,655386551,AA,Patients with the AA genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.,携带AA基因型的患者，相比GG基因型，代谢综合征的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134341,rs1801133,655386552,AG,Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.,携带AG基因型的患者，相比GG基因型，代谢综合征的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134341,rs1801133,655386553,GG,"Has average risk for metabolic syndrome when treated with antipsychotics.
Patients with the GG genotype treated with antipsychotics may have decreased risk for metabolic syndrome as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking antipsychotics based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.",携带GG基因型的患者，相比AA或AG基因型，代谢综合征的风险可能降低,1,,,0,,,,plus,李晶晶
PA166134393,rs1801133,655387836,AA,Patients with the AA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.,携带AA基因型的患者进行选择性外科手术时，相比GG基因型，血浆总同型半胱氨酸浓度可能更高,1,,,2,,,,plus,李晶晶
PA166134393,rs1801133,655387837,AG,Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.,携带GA基因型的患者进行选择性外科手术时，相比GG基因型，血浆总同型半胱氨酸浓度可能更高,1,,,2,,,,plus,李晶晶
PA166134393,rs1801133,655387838,GG,Patients with the GG genotype who undergo elective surgery with nitrous oxide anesthesia may have lower plasma total homocysteine concentrations as compared to patients with the GA of AA genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.,携带GG基因型的患者进行选择性外科手术时，相比GA或AA基因型，血浆总同型半胱氨酸浓度可能较低,1,,,0,,,,plus,李晶晶
PA166134429,rs1801133,1448124407,AA,"Patients with the AA genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate, and 4) may be at greater risk of folate deficiency as compared to patients with the AG or GG genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.",携带AA基因型的白血病或淋巴瘤患者，相比AG或GG基因型，疗效可能较差，药物毒性可能较高，需要剂量可能较少，叶酸缺陷的风险可能较高,1,,,2,,,,plus,李晶晶
PA166134429,rs1801133,1448124408,AG,"Patients with the AG genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have poorer response to treatment 2) may be at increased risk of toxicity 3) may require a lower dose of methotrexate, and 4) may be at greater risk of folate deficiency as compared to patients with the GG genotype, or 1) may have better response to treatment 2) may be at decreased risk of toxicity, and 3) may require a higher dose of methotrexate as compared to patients with the AA genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.",携带AG基因型的白血病或淋巴瘤患者，相比GG基因型，疗效可能较差，药物毒性可能较高，需要剂量可能较少，叶酸缺陷的风险可能较高；相比AA基因型，疗效可能较好，药物毒性可能较低，需要剂量可能较多,1,,,1,,,,plus,李晶晶
PA166134429,rs1801133,1448124409,GG,"Patients with the GG genotype and leukemia or lymphoma who are treated with methotrexate: 1) may have better response to treatment 2) may be at decreased risk of toxicity 3) may require a higher dose of methotrexate, and 4) may be at lower risk of folate deficiency as compared to patients with the AA or AG genotype. This association has been contradicted or not found in multiple studies. Other genetic and clinical factors may also influence a patient's risk for toxicity and response with methotrexate treatment.",携带GG基因型的白血病或淋巴瘤患者，相比AG或AA基因型，疗效可能较好，药物毒性可能较低，需要剂量可能较多，叶酸缺陷的风险可能较低,1,,,0,,,,plus,李晶晶
PA166134972,rs1801133,1183491367,AA,Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have an increased severity of pain lesser reduction in homocysteine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain.,携带AA基因型的女性偏头痛患者，相比AG或GG基因型，疼痛可能增加，同型半胱氨酸量可能有较小幅度减少,1,女,0,,,,,plus,李晶晶
PA166134972,rs1801133,1183491366,AG,Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain.,携带AG基因型的女性偏头痛患者，相比AA基因型，疼痛可能减轻，同型半胱氨酸量可能有较大幅度减少,1,女,2,,,,,plus,李晶晶
PA166134972,rs1801133,1183491365,GG,Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain.,携带GG基因型的女性偏头痛患者，相比AA基因型，疼痛可能减轻，同型半胱氨酸量可能有大幅度减少,1,女,2,,,,,plus,李晶晶
PA166134984,rs1801133,1183491784,AA,Patients with the AA genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带AA基因型的高血压患者，相比GG基因型，非致死性心梗和致死性冠心病的风险增加,1,,,2,,,,plus,李晶晶
PA166134984,rs1801133,1183491785,AG,Patients with the AG genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease  as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带AG基因型的高血压患者，相比GG基因型，非致死性心梗和致死性冠心病的风险增加,1,,,2,,,,plus,李晶晶
PA166134984,rs1801133,1183491786,GG,Patients with the GG genotype and Hypertension who are treated with pravastatin may have a decreased risk of nonfatal myocardial infarction and fatal coronary heart disease  as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带GG基因型的高血压患者，相比AG或AA基因型，非致死性心梗和致死性冠心病的风险降低,1,,,0,,,,plus,李晶晶
PA166135057,rs1801133,1183614500,AA,Patients with the AA genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.,携带AA基因型的可卡因成瘾患者，相比GG基因型，药物的疗效可能增加,1,,2,,,,,plus,李晶晶
PA166135057,rs1801133,1183614501,AG,Patients with the AG genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.,携带AG基因型的可卡因成瘾患者，相比GG基因型，药物的疗效可能增加,1,,2,,,,,plus,李晶晶
PA166135057,rs1801133,1183614502,GG,Patients with the GG genotype and cocaine dependence may have a decreased response when treated with disulfiram as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to disulfiram.,携带GG基因型的可卡因成瘾患者，相比AA或AG基因型，药物的疗效可能降低,1,,0,,,,,plus,李晶晶
PA166135111,rs1801133,1445402423,AA,Patients with the AA genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AG or GG genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.,携带AA基因型的高血压患者，相比AG或GG基因型，舒张压可能有较大幅度的降低,1,,2,,,,,plus,李晶晶
PA166135111,rs1801133,1445402424,AG,Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.,携带AG基因型的高血压患者，相比AA基因型，舒张压可能有较小幅度的降低,1,,0,,,,,plus,李晶晶
PA166135111,rs1801133,1445402425,GG,Patients with the GG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.,携带GG基因型的高血压患者，相比AA基因型，舒张压可能有较小幅度的降低,1,,0,,,,,plus,李晶晶
PA166134572,rs1801133,981204930,AA,Patients with the AA genotype may have increased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.,携带AA基因型的高血压患者，相比AG或GG基因型，药物毒性的概率可能增加 ,1,,,2,,,,plus,李晶晶
PA166134572,rs1801133,981204931,AG,Patients with the AG genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.,携带AG基因型的高血压患者，相比AA基因型，药物毒性的概率可能增降低,1,,,0,,,,plus,李晶晶
PA166134572,rs1801133,981204932,GG,Patients with the GG genotype may have decreased likelihood of Drug Toxicity when treated with cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to cyclophosphamide.,携带GG基因型的高血压患者，相比AA基因型，药物毒性的概率可能降低,1,,,0,,,,plus,李晶晶
PA166134574,rs1801133,981204976,AA,"Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.",携带AA基因型的前体细胞淋巴细胞白血病淋巴瘤患者，相比GG基因型，治疗中断的可能性较高,1,,,2,,,,plus,李晶晶
PA166134574,rs1801133,981204977,AG,"Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.",携带AG基因型的前体细胞淋巴细胞白血病淋巴瘤患者，相比GG基因型，治疗中断的可能性较高,1,,,2,,,,plus,李晶晶
PA166134574,rs1801133,981204978,GG,"Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.",携带GG基因型的前体细胞淋巴细胞白血病淋巴瘤患者，相比AA或AG基因型，治疗中断的可能性较低,1,,,0,,,,plus,李晶晶
PA166134575,rs1801133,981204986,AA,"Patients with the AA genotype may have: 1) increased likelihood of response to chemotherapy, 2) increased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotypes AG or GG. Other genetic and clinical factors may also influence a patient's response to cisplatin.",携带AA基因型的癌症患者，相比AG或GG基因型，对化疗的响应可能增加，药物毒性可能增加,1,,2,2,,,,plus,李晶晶
PA166134575,rs1801133,981204987,AG,"Patients with the AG genotype may have: 1) decreased likelihood of response to chemotherapy, 2) decreased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to cisplatin.",携带AG基因型的癌症患者，相比AA基因型，对化疗的响应可能降低，药物毒性可能降低,1,,0,0,,,,plus,李晶晶
PA166134575,rs1801133,981204988,GG,"Patients with the GG genotype may have: 1) decreased likelihood of response to chemotherapy, 2) decreased likelihood of Drug Toxicity when treated with cisplatin in cancer patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to cisplatin.",携带GG基因型的癌症患者，相比AA基因型，对化疗的反应可能降低，药物毒性可能降低,1,,0,0,,,,plus,李晶晶
PA166134577,rs1801133,982031653,AA,Patients with AA genotype may have 1) increased likelihood of response 2) increased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence a patient's response to carboplatin.,携带AA基因型的非小细胞肺癌患者，相比AG或GG基因型，药效可能增加，无进展生存率可能增加,1,,2,,,,,plus,李晶晶
PA166134577,rs1801133,982031654,AG,Patients with AG genotype may have 1) decreased likelihood of response 2) decreased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to carboplatin.,携带AG基因型的非小细胞肺癌患者，相比AA基因型，药物反应可能降低，无进展生存率可能降低,1,,0,,,,,plus,李晶晶
PA166134577,rs1801133,982031655,GG,Patients with GG genotype may have 1) decreased likelihood of response 2) decreased progression free survival to carboplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to carboplatin.,携带GG基因型的非小细胞肺癌患者，相比AA基因型，药物反应可能降低，无进展生存率可能降低,1,,0,,,,,plus,李晶晶
PA166135681,rs1801133,1444666765,AA,Patients with the AA genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.,携带AA基因型的肺癌患者，相比GG基因型，总存活时间可能较短,1,,0,,,,,plus,李晶晶
PA166135681,rs1801133,1444666766,AG,Patients with the AG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.,携带AG基因型的肺癌患者，相比GG基因型，总存活时间可能较短,1,,0,,,,,plus,李晶晶
PA166135681,rs1801133,1444666767,GG,Patients with the GG genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence overall survival time.,携带GG基因型的肺癌患者，相比AA或AG基因型，总存活时间可能较长,1,,2,,,,,plus,李晶晶
PA166134454,rs1801133,978608465,AA,Patients with the AA genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.,携带AA基因型的白血病患者行造血干细胞移植后，相比GG基因型，移植物抗宿主病的风险降低,1,,2,,,,,plus,李晶晶
PA166134454,rs1801133,978608466,AG,Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.,携带AG基因型的白血病患者行造血干细胞移植后，相比GG基因型，移植物抗宿主病的风险降低,1,,2,,,,,plus,李晶晶
PA166134454,rs1801133,978608467,GG,Patients with the GG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have an increased risk of Graft vs Host disease as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment.,携带GG基因型的白血病患者行造血干细胞移植后，相比AA基因型，移植物抗宿主病的风险增加,1,,0,,,,,plus,李晶晶
PA166134256,rs1801133,1448108634,AA,Patients with the AA genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.,携带AA基因型的关节炎患者，相比GG基因型，副反应和药物毒性的风险均可能增加,1,,,2,,,,plus,李晶晶
PA166134256,rs1801133,1448108635,AG,"Patients with the AG genotype and Arthritis who are treated with methotrexate may have an increased risk of adverse events and toxicity as compared to patients with the GG genotype, or may have a decreased, but not absent, risk of adverse events as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.",携带AG基因型的关节炎患者，相比GG基因型，副反应和药物毒性的风险均可能增加；相比AA基因型，副反应和药物毒性的风险均可能降低,1,,,1,,,,plus,李晶晶
PA166134256,rs1801133,1448108636,GG,"Patients with the GG genotype and Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of adverse events and toxicity as compared to patients with the AA genotype (though this association has not been found in all studies). There does not seem to be a significant association between this genotype and response to methotrexate treatment. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.",携带GG基因型的关节炎患者，相比AA基因型，副反应和药物毒性的风险均可能降低,1,,,0,,,,plus,李晶晶
PA166136357,rs193922816,1447992346,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CT. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带CC基因型的患者，相比CT基因型，可能不会发生恶性高热,1,,,0,,,,plus,李晶晶
PA166136357,rs193922816,1447992347,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带CT基因型的患者，相比CC基因型，可能会发生恶性高热,1,,,2,,,,plus,李晶晶
PA166136357,rs193922816,1447992348,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant Hyperthermia.",携带TT基因型的患者，相比CC基因型，可能会发生恶性高热,1,,,2,,,,plus,李晶晶
PA166152876,rs1947275,1447964252,CC,Patients with the CC genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.,携带CC基因型的注意力不集中症患者，相比CT和TT基因型，药物应答可能较慢,1,,0,,,,,plus,李晶晶
PA166152876,rs1947275,1447964253,CT,Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.,携带CT基因型的注意力不集中症患者，相比CC基因型，药物应答可能较快,1,,2,,,,,plus,李晶晶
PA166152876,rs1947275,1447964254,TT,Patients with the TT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.,携带TT基因型的注意力不集中症患者，相比CC基因型，药物应答可能较快,1,,2,,,,,plus,李晶晶
PA166136001,rs1967309,1448126004,AA,Patients with the AA genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo. ,携带AA基因型的急性冠脉综合征患者，相比AG和GG基因型，重度心血管事件（MACE）的风险可能降低，胆固醇外流应答可能增加,1,,2,0,,,,FWD,李晶晶
PA166136001,rs1967309,1448126005,AG,"Patients with the AG genotype may have decreased risk of major adverse cardiac events (MACE) and increased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the GG genotype, but increased risk compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo. ",携带AG基因型的急性冠脉综合征患者，相比GG基因型，重度心血管事件（MACE）的风险可能降低，胆固醇外流应答可能增加；相比AA基因型，主要心血管事件（MACE）的风险可能增加,1,,1,1,,,,FWD,李晶晶
PA166136001,rs1967309,1448126006,GG,Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo. ,携带GG基因型的急性冠脉综合征患者，相比AA和AG基因型，重度心血管事件（MACE）的风险可能增加，胆固醇外流应答可能降低,1,,0,2,,,,FWD,李晶晶
PA166134600,rs1979277,1448107640,AA,Patients with the AA genotype and with Rheumatoid Arthritis who are treated with methotrexate may have increased red blood cell folate as compared to patients with the GG genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带AA基因型的类风湿性关节炎患者，相比GG基因型，红血球叶酸盐可能增加,1,,,,,,,plus,李晶晶
PA166134600,rs1979277,1448107641,AG,Patients with the AG genotype and with Rheumatoid Arthritis who are treated with methotrexate may have increased red blood cell folate as compared to patients with the GG genotype or may have decreased red blood cell folate as compared to patients with the AA genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带AG基因型的类风湿性关节炎患者，相比GG基因型，红血球叶酸盐可能增加；相比AA基因型，红血球叶酸盐可能减少,1,,,,,,,plus,李晶晶
PA166134600,rs1979277,1448107642,GG,Patients with the GG genotype and with Rheumatoid Arthritis who are treated with methotrexate may have decreased red blood cell folate as compared to patients with the AA genotype. However this increase did not correlate with disease activity or red blood cell methotrexate metabolites. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带GG基因型的类风湿性关节炎患者，相比AA基因型，红血球叶酸盐可能降低,1,,,,,,,plus,李晶晶
PA166134601,rs1979277,981481601,AA,"Pediatric patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased catalytic activity of TYMS as compared to pediatric patients with the AG and GG genotype. Patients with the AA genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.",携带AA基因型的前体淋巴细胞白血病淋巴瘤儿童患者，相比AG和GG基因型，胸苷酸合成酶的活性可能增加；相比AG基因型，肝脏疾病毒性的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134601,rs1979277,981481602,AG,"Pediatric patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the AG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have a decreased likelihood of Toxic liver disease as compared to patients with the AA and GG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.",携带AG基因型的前体淋巴细胞白血病淋巴瘤儿童患者，相比AA基因型，胸苷酸合成酶的活性可能降低；相比AA和GG基因型，肝脏疾病毒性的风险可能降低,1,,,0,,,,plus,李晶晶
PA166134601,rs1979277,981481603,GG,"Pediatric patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have decreased catalytic activity of TYMS as compared to pediatric patients with the AA genotype. Patients with the GG genotype and with Precursor Cell Lymphoblastic Leukemia-Lymphoma who are treated with methotrexate may have increased likelihood of Toxic liver disease as compared to patients with the AG genotype. However, this association is contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to methotrexate.",携带GG基因型的前体淋巴细胞白血病淋巴瘤儿童患者，相比AA基因型，胸苷酸合成酶的活性可能降低；相比AG基因型，肝脏疾病毒性的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134656,rs1954787,1448099858,CC,Patients with the CC genotype and Depressive Disorder or Depression may be more likely to respond to antidepressant treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants. ,携带CC基因型的抑郁症患者，相比CT或TT基因型，药效可能较好,1,,2,,,,,plus,李晶晶
PA166134656,rs1954787,1448099859,CT,Patients with the CT genotype and Depressive Disorder or Depression may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants. ,携带CT基因型的抑郁症患者，相比CC基因型，药效可能较差,1,,0,,,,,plus,李晶晶
PA166134656,rs1954787,1448099860,TT,Patients with the TT genotype and Depressive Disorder or Depression may be less likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressants. ,携带TT基因型的抑郁症患者，相比CC基因型，药效可能较差,1,,0,,,,,plus,李晶晶
PA166152867,rs2031920,1447964151,CC,"Patients with the CC genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CT or TT genotype. However, the majority of studies find no association with hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.",携带CC基因型的肺结核患者，相比CT或TT基因型，肝毒性的风险可能增加,1,,,2,,,,plus,李晶晶
PA166152867,rs2031920,1447964152,CT,"Patients with the CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.",携带CT基因型的肺结核患者，相比CC基因型，肝毒性的风险可能降低,1,,,0,,,,plus,李晶晶
PA166152867,rs2031920,1447964153,TT,"Patients with the TT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. However, the majority of studies find no association with hepatotoxicity. Other genetic and clinical factors, such as variations in the NAT2 gene, may also influence risk for hepatotoxicity.",携带TT基因型的肺结核患者，相比CC基因型，肝毒性的风险可能降低,1,,,0,,,,plus,李晶晶
PA166135122,rs2066844,1183615431,CC,Patients with the CC genotype who underwent kidney transplantation may have a longer post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.,携带CC基因型的肾移植患者，相比CT或TT基因型，术后住院的时间可能较长,1,,0,,,,,plus,李晶晶
PA166135122,rs2066844,1183615432,CT,Patients with the CT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.,携带CT基因型的肾移植患者，相比CC基因型，术后住院的时间可能较短,1,,2,,,,,plus,李晶晶
PA166135122,rs2066844,1183615433,TT,Patients with the TT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.,携带TT基因型的肾移植患者，相比CC基因型，术后住院的时间可能较短,1,,2,,,,,plus,李晶晶
PA166134484,rs2069514,981201889,AA,Schizophrenia patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AA is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.,携带AA基因型吸烟的精神分裂症患者，相比GG基因型，迟发性运动障碍发生的严重程度可能增加,1,,,2,,,,plus,李晶晶
PA166134484,rs2069514,981201890,AG,Schizophrenia patients with the AG genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the GG genotype. Genotype AG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype GG. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.,携带AG基因型吸烟的精神分裂症患者，相比GG基因型，迟发性运动障碍发生的严重程度可能增加,1,,,2,,,,plus,李晶晶
PA166134484,rs2069514,981201891,GG,Schizophrenia patients with the GG genotype may have decreased severity of tardive dyskinesia when treated with antipsychotics in people who were smokers as compared to patients with the AA or AG genotype. Genotype GG is not associated with increased QT interval in Schizophrenia patients treated with antipsychotics as compared to genotype AA. Other genetic and clinical factors may also influence a patient's risk for adverse events to antipsychotics.,携带GG基因型吸烟的精神分裂症患者，相比AA或AG基因型，迟发性运动障碍发生的严重程度可能降低,1,,,0,,,,plus,李晶晶
PA166158955,rs2071303,1448100224,CC,Patients with the CC genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.,携带CC基因型的克罗恩病患者，相比TT基因型，药效可能增加,1,,2,,,,,FWD,李晶晶
PA166158955,rs2071303,1448100225,CT,Patients with the CT genotype and Crohn's Disease may have increased response to adalimumab compared to patients with the TT genotype. Other factors may affect response to adalimumab.,携带CT基因型的克罗恩病患者，相比TT基因型，药效可能增加,1,,2,,,,,FWD,李晶晶
PA166158955,rs2071303,1448100226,TT,Patients with the TT genotype and Crohn's Disease may have decreased response to adalimumab compared to patients with the CC and CT genotypes. Other factors may affect response to adalimumab.,携带TT基因型的克罗恩病患者，相比CC和CT基因型，药效可能降低,1,,0,,,,,FWD,李晶晶
PA166134458,rs2070959,981188354,AA,Patients with the AA genotype may require a decreased dose of valproic acid compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patients dose requirements.,携带AA基因型的患者，相比AG或GG基因型，可能需要减少药物的剂量,1,,,,,0,,plus,李晶晶
PA166134458,rs2070959,981188355,AG,Patients with the AG genotype may require an increased dose of valproic acid compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patients dose requirements.,携带AG基因型的患者，相比AA基因型，可能需要增加药物的剂量,1,,,,,2,,plus,李晶晶
PA166134458,rs2070959,981188356,GG,Patients with the GG genotype may require an increased dose of valproic acid compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patients dose requirements.,携带GG基因型的患者，相比AG或AA基因型，可能需要增加药物的剂量,1,,,,,2,,plus,李晶晶
PA166136217,rs2070959,1444673117,AA,"Patients with the AA genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.",携带AA基因型的结肠直肠癌患者，相比GG基因型，重度中性白细胞减少症的风险可能增加,1,,,2,,,,plus,李晶晶
PA166136217,rs2070959,1444673118,AG,"Patients with the AG genotype and colorectal cancer may have an increased risk for severe neutropenia when treated with irinotecan as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.",携带AG基因型的结肠直肠癌患者，相比GG基因型，重度中性白细胞减少症的风险可能增加；相比AA基因型，重度中性白细胞减少症的风险可能降低,1,,,1,,,,plus,李晶晶
PA166136217,rs2070959,1444673119,GG,"Patients with the GG genotype and colorectal cancer may have a decreased risk for severe neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as UGT1A1*28, may also influence the risk for neutropenia in patients taking irinotecan.",携带GG基因型的结肠直肠癌患者，相比AA基因型，重度中性白细胞减少症的风险可能降低,1,,,0,,,,plus,李晶晶
PA166136263,rs2071888,1444700470,CC,Patients with the CC genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带CC基因型的哮喘患者，相比GG基因型，药物治疗后第1秒用力肺活量（FEV1）减少风险可能增加,1,,,2,,,,minus,李晶晶
PA166136263,rs2071888,1444700469,CG,Patients with the CG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. ,携带CG基因型的哮喘患者，相比GG基因型，药物治疗后第1秒用力肺活量（FEV1）减少风险可能增加,1,,,2,,,,minus,李晶晶
PA166136263,rs2071888,1444700468,GG,Patients with the GG genotype and Asthma may have a lower aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin. ,携带GG基因型的哮喘患者，相比CG或CC基因型，药物治疗后第1秒用力肺活量（FEV1）减少风险可能降低,1,,,0,,,,minus,李晶晶
PA166152722,rs2073724,1447960777,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CC基因型的HIV感染者，相比TT基因型，发生药物诱导皮疹的风险可能降低,1,,,0,,,,plus,李晶晶
PA166152722,rs2073724,1447960778,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CT基因型的HIV感染者，相比TT基因型，发生药物诱导皮疹的风险可能降低；相比CC基因型，发生药物诱导皮疹的风险可能增加,1,,,1,,,,plus,李晶晶
PA166152722,rs2073724,1447960779,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带TT基因型的HIV感染者，相比CC基因型，发生药物诱导皮疹的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134374,rs2072671,1448099675,AA,"Patients with the AA genotype who are treated with cytarabine may have a decreased, but not absent, risk of toxicity as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.",携带AA基因型的患者，相比AC或CC基因型，药物毒性的风险可能降低,1,,,0,,,,plus,李晶晶
PA166134374,rs2072671,1448099676,AC,Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.,携带AC基因型的患者，相比AA基因型，药物毒性的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134374,rs2072671,1448099677,CC,Patients with the CC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.,携带CC基因型的患者，相比AA基因型，药物毒性的风险可能增加,1,,,2,,,,plus,李晶晶
PA166134459,rs2072671,1447960497,AA,"Patients with cancer and the AA genotype who are treated with gemcitabine may have 1) decreased expression of CDA leading to decreased clearance of gemcitabine and 2) a higher incidence of toxicity events, such as neutropenia and GI toxicity as compared to patients with the CC genotype. However current evidence is contradictory. Other genetic and clinical factors may also influence gemcitabine's risk of inducing toxicity.",携带AA基因型的癌症患者，相比CC基因型，CDA的表达减少，导致药物的清除减少；药物毒性事件，如中性白细胞减少、GI毒性，发生的可能性增加,1,,,2,,,,plus,李晶晶
PA166134459,rs2072671,1447960498,AC,"Patients with cancer and the AC genotype who are treated with gemcitabine may have 1) decreased expression of CDA leading to decreased clearance of gemcitabine and 2) a higher incidence of toxicity events, such as neutropenia and GI toxicity as compared to patients with the CC genotype. However current evidence is contradictory. Other genetic and clinical factors may also influence gemcitabine's risk of inducing toxicity.",携带AC基因型的癌症患者，相比CC基因型，CDA的表达减少，导致药物的清除减少；；药物毒性事件，如中性白细胞减少、GI毒性，发生的可能性增加,1,,,2,,,,plus,李晶晶
PA166134459,rs2072671,1447960499,CC,"Patients with the CC genotype who are treated with gemcitabine may have 1) increased expression of CDA leading to increased clearance of gemcitabine and  2) a lower incidence of toxicity events, including neutropenia and GI toxicity as compared to patients with the CC genotype. However current evidence is contradictory. Other genetic and clinical factors may also influence gemcitabine's risk of inducing toxicity.",携带CC基因型的癌症患者，相比CC基因型，CDA的表达增加，导致药物的清除增加；药物毒性事件，如中性白细胞减少、GI毒性，发生的可能性降低,1,,,0,,,,plus,李晶晶
PA166163764,rs2072671,1448616851,AA,"Patients with cancer and the AA genotype who are treated with capecitabine may have an increased incidence of adverse events, including hand-foot syndrome, as compared to patients with the AC or CC genotypes, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine. ",携带AA基因型的癌症患者，相比AC或CC基因型，副作用（如手足综合征）发生的可能性增加,1,,,2,,,,plus,李晶晶
PA166163764,rs2072671,1448616852,AG,"Patients with cancer and the AC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine. ",携带AC基因型的癌症患者，相比AA基因型，副作用（如手足综合征）发生的可能性降低,1,,,0,,,,plus,李晶晶
PA166163764,rs2072671,1448616853,CC,"Patients with cancer and the CC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine. ",携带AA基因型的癌症患者，相比AA基因型，副作用（如手足综合征）发生的可能性降低,1,,,0,,,,plus,李晶晶
PA166135596,rs2144300,1184987036,CC,Patients with the CC genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.,携带CC基因型的高血压患者，相比TT和CT基因型，HDL-C水平可能有大幅度降低,1,,,2,,,,plus,李晶晶
PA166135596,rs2144300,1184987037,CT,Patients with the CT genotype and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with the TT genotype. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.,携带CT基因型的高血压患者，相比TT基因型，HDL-C水平可能有大幅度降低,1,,,2,,,,plus,李晶晶
PA166135596,rs2144300,1184987038,TT,Patients with the TT genotype and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the CC and CT genotypes. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.,携带TT基因型的高血压患者，相比CC和CT基因型，HDL-C水平可能有小幅度降低,1,,,0,,,,plus,李晶晶
PA166134038,rs2227956,1448108727,AA,Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.,携带AA基因型的患者，相比AG或GG基因型，发生严重性过敏反应的可能性增加,1,,,2,,,,plus,李晶晶
PA166134038,rs2227956,1448108728,AG,Patients with the AG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.,携带AG基因型的患者，相比AA基因型，发生严重性过敏反应的可能性降低,1,,,0,,,,plus,李晶晶
PA166134038,rs2227956,1448108729,GG,Patients with the GG genotype may have a decreased but not non-existent chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.,携带GG基因型的患者，相比AA基因型，发生严重性过敏反应的可能性降低,1,,,0,,,,plus,李晶晶
PA166134347,rs2228001,1448616401,GG,"Patients with the GG genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.",携带GG基因型的患者，相比TT基因型，药物毒副作用（如听力损伤、中性白细胞减少）的可能性增加,1,,,2,,,,plus,李晶晶
PA166134347,rs2228001,1448616402,GT,"Patients with the GT genotype may have an increased risk for toxicity with cisplatin treatment, including hearing loss and neutropenia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.",携带GT基因型的患者，相比TT基因型，，药物毒副作用（如听力损伤、中性白细胞减少）的可能性增加,1,,,2,,,,plus,李晶晶
PA166134347,rs2228001,1448616403,TT,Patients with the TT genotype may have a decreased but not non-existent risk for toxicity with cisplatin treatment as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带TT基因型的患者，相比GT或GG基因型，，药物毒副作用（如听力损伤、中性白细胞减少）的可能性降低,1,,,0,,,,plus,李晶晶
PA166135048,rs2230808,1183607657,CC,Patients with the CC genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.,携带CC基因型的高甘油三酯血症患者，相比TT基因型，药效可能增加,1,,2,,,,,plus,李晶晶
PA166135048,rs2230808,1183607658,CT,"Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype, or a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.",携带CT基因型的高甘油三酯血症患者，相比TT基因型，药效可能增加；相比CC基因型，药效可能降低,1,,1,,,,,plus,李晶晶
PA166135048,rs2230808,1183607659,TT,Patients with the TT genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.,携带TT基因型的高甘油三酯血症患者，相比CC基因型，药效可能降低,1,,0,,,,,plus,李晶晶
PA166135420,rs2232228,1183703761,AA,Patients with genotype AA may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.,携带AA基因型的儿童肿瘤患者，相比GG基因型，服用高剂量药物后，心肌病的风险增加,1,,,2,,,,plus,李晶晶
PA166135420,rs2232228,1183703762,AG,Patients with genotype AG may have increased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype GG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.,携带AG基因型的儿童肿瘤患者，相比GG基因型，服用高剂量药物后，心肌病的风险增加,1,,,2,,,,plus,李晶晶
PA166135420,rs2232228,1183703763,GG,Patients with genotype GG may have decreased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.,携带GG基因型的儿童肿瘤患者，相比AA或AG基因型，服用高剂量药物后，心肌病的风险降低,1,,,0,,,,plus,李晶晶
PA166134268,rs2108622,1448615833,CC,"Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the CT or TT genotype. Some studies have not found an association between genotypes of this SNP and warfarin dose, or report finding a trend that was not statistically significant. This SNP is not currently associated with time to INR, risk of hemorrhage, or risk of over-coagulation. Other genetic and clinical factors may also influence a patient's required warfarin dose.",携带CC基因型的患者，相比CT或TT基因型，可能需要较低的药物剂量,1,,,,,0,,plus,李晶晶
PA166134268,rs2108622,1448615834,CT,"Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Some studies have not found an association between genotypes of this SNP and warfarin dose, or report finding a trend that was not statistically significant. This SNP is not currently associated with time to INR, risk of hemorrhage, or risk of over-coagulation. Other genetic and clinical factors may also influence a patient's required warfarin dose.",携带CT基因型的患者，相比CC基因型，可能需要较高的药物剂量,1,,,,,2,,plus,李晶晶
PA166134268,rs2108622,1448615835,TT,"Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CT or CC genotype. Some studies have not found an association between genotypes of this SNP and warfarin dose, or report finding a trend that was not statistically significant. This SNP is not currently associated with time to INR, risk of hemorrhage, or risk of over-coagulation. Other genetic and clinical factors may also influence a patient's required warfarin dose.",携带TT基因型的患者，相比CT或CC基因型，可能需要较高的药物剂量,1,,,,,2,,plus,李晶晶
PA166160464,rs2108622,1448262905,CC,Patients with the CC genotype may have increased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype TT or CT in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.,携带CC基因型的欧美患者，相比CT或CC基因型，在药物剂量调整期后，国际标准化比值（INR-var）可能增加,1,,2,,,,,plus,李晶晶
PA166160464,rs2108622,1448262904,CT,Patients with the CT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.,携带CT基因型的欧美患者，相比CC基因型，在药物剂量调整期后，国际标准化比值（INR-var）可能降低,1,,0,,,,,plus,李晶晶
PA166160464,rs2108622,1448262903,TT,Patients with the TT genotype may have decreased international normalized ratio variability (INR-var) when treated with warfarin as compared to patients with genotype CC in European-Americans after the warfarin dose-titration phase. Other genetic and clinical factors may also influence the response to warfarin.,携带TT基因型的欧美患者，相比CC基因型，在药物剂量调整期后，国际标准化比值（INR-var）可能降低,1,,0,,,,,plus,李晶晶
PA166135041,rs2239347,1183630752,AA,Patients with the AA genotype and asthma may have a reduced frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to pitrakinra.,携带AA基因型的哮喘患者，相比AC或CC基因型，哮喘发作的频率可能降低,1,,2,,,,,FWD,李晶晶
PA166135041,rs2239347,1183630753,AC,Patients with the AC genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.,携带AC基因型的哮喘患者，相比AA基因型，哮喘发作的频率可能增加,1,,0,,,,,FWD,李晶晶
PA166135041,rs2239347,1183630754,CC,Patients with the CC genotype and asthma may have a higher frequency of asthma exacerbationswhen treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.,携带CC基因型的哮喘患者，相比AA基因型，哮喘发作的频率可能增加,1,,0,,,,,FWD,李晶晶
PA166135012,rs2241883,1183604886,CC,"Patients with the CC genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.",携带CC基因型的高甘油三酯血症患者，相比TT基因型，血浆甘油三酯浓度高于药物作用靶点浓度的风险增加,1,,,2,,,,FWD,李晶晶
PA166135012,rs2241883,1183604887,CT,"Patients with the CT genotype and hypertriglyceridemia may have an increased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the TT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.",携带CT基因型的高甘油三酯血症患者，相比CC或CT基因型，血浆甘油三酯浓度高于药物作用靶点浓度的风险增加,1,,,2,,,,FWD,李晶晶
PA166135012,rs2241883,1183604888,TT,"Patients with the TT genotype and hypertriglyceridemia may have a decreased risk of exhibiting plasma triglyceride concentrations above the therapeutic target when treated with fenofibrate, as compared to patients with the CC or CT genotype. No associations with response to fenofibrate or risk of hypercholesterolemia were seen. Other genetic and clinical factors may also influence plasma triglyceride concentrations in patients taking fenofibrate.",携带TT基因型的高甘油三酯血症患者，相比CC或CT基因型，血浆甘油三酯浓度高于药物作用靶点浓度的风险降低,1,,,0,,,,FWD,李晶晶
PA166134943,rs2244613,1448100950,GG,"Patients with the GG genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.",携带GG基因型的心房颤动患者，相比TT基因型，血药浓度和出血风险可能降低,1,,,0,,,,plus,李晶晶
PA166134943,rs2244613,1448100951,GT,"Patients with the GT genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.",携带GT基因型的心房颤动患者，相比TT基因型，血药浓度和出血风险可能降低,1,,,0,,,,plus,李晶晶
PA166134943,rs2244613,1448100952,TT,Patients with the TT genotype and Atrial Fibrillation may have an increased risk for bleeding when treated with dabigatran as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.,携带TT基因型的心房颤动患者，相比GT或GG基因型，出血风险可能增加,1,,,2,,,,plus,李晶晶
PA166163250,rs2244613,1448602873,GG,Patients with the GG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.,携带GG基因型的癌症患者，相比TT基因型，药物相关的毒性可能增加,1,,,2,,,,plus,李晶晶
PA166163250,rs2244613,1448602874,GT,Patients with the GT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.,携带GT基因型的癌症患者，相比TT基因型，药物相关的毒性可能增加,1,,,2,,,,plus,李晶晶
PA166163250,rs2244613,1448602875,TT,Patients with the TT genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.,携带TT基因型的癌症患者，相比GG基因型，药物相关的毒性可能降低,1,,,0,,,,plus,李晶晶
PA166159809,rs2257212,1448125501,CC,Patients with genotype CC have shorter progression-free survival time when treated with sorafenib as compared to patients with CT or TT genotype. Other genetic and clinical factors may also influence the response to sorafenib.,携带CC基因型的患者，相比CT或TT基因型，无进展生存期时间可能更短,1,,0,,,,,plus,李晶晶
PA166159809,rs2257212,1448125502,CT,Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.,携带CT基因型的患者，相比CC基因型，无进展生存期时间可能更长,1,,2,,,,,plus,李晶晶
PA166159809,rs2257212,1448125503,TT,Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.,携带TT基因型的患者，相比CC基因型，无进展生存期时间可能更长,1,,2,,,,,plus,李晶晶
PA166134933,rs2231142,1448612863,GG,Patients with the GG genotype and who are treated with rosuvastatin 1) may have lower plasma concentrations of rosuvastatin 2) may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics.,携带GG基因型的患者，相比TT基因型，可能有较低的血药浓度，以及较差的药物疗效,1,,0,,,,,plus,李晶晶
PA166134933,rs2231142,1448612864,GT,"Patients with the GT genotype and who are treated with rosuvastatin 1) may have lower plasma concentrations of rosuvastatin 2) may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the TT genotype, or 1) may have higher plasma concentrations of rosuvastatin 2) may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics.",携带GT基因型的患者，相比TT基因型，可能有较低的血药浓度，以及较差的药物疗效；相比GG基因型，可能有较高的血药浓度，以及较好的药物疗效,1,,1,,,,,plus,李晶晶
PA166134933,rs2231142,1448612865,TT,Patients with the TT genotype and who are treated with rosuvastatin 1) may have higher plasma concentrations of rosuvastatin 2) may have a better response to treatment as determined by a higher reduction in LDL-C as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment and rosuvastatin pharmacokinetics.,携带TT基因型的患者，相比GG基因型，可能有较高的血药浓度，以及较好的药物疗效,1,,2,,,,,plus,李晶晶
PA166134935,rs2231142,1155598161,GG,Patients with the GG genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.,携带GG基因型的患者，相比TT基因型，可能有较低的血药浓度,1,,,,,,0,plus,李晶晶
PA166134935,rs2231142,1155598164,GT,Patients with the GT genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.,携带GT基因型的患者，相比TT基因型，可能有较低的血药浓度,1,,,,,,0,plus,李晶晶
PA166134935,rs2231142,1155598167,TT,Patients with the TT genotype may have higher plasma concentrations of atorvastatin as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.,携带TT基因型的患者，相比GT或GG基因型，可能有较高的血药浓度,1,,,,,,2,plus,李晶晶
PA166134937,rs2231142,1156228668,GG,Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. ,携带GG基因型的患者，相比TT基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166134937,rs2231142,1156228673,GT,Patients with the GT genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. ,携带GT基因型的患者，相比TT基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166134937,rs2231142,1156228679,TT,Patients with the TT genotype may have increased exposure to fluvastatin as compared to patients with the GT and GG genotype. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. ,携带TT基因型的患者，相比GT和GG基因型，药物代谢可能较慢,1,,,,0,,,plus,李晶晶
PA166134939,rs2231142,1156738777,GG,Patients with the GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin. ,携带GG基因型的患者，相比TT基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166134939,rs2231142,1156738780,GT,Patients with the GT genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin. ,携带GT基因型的患者，相比TT基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166134939,rs2231142,1156738792,TT,Patients with the TT genotype may have increased exposure to simvastatin as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's exposure to simvastatin. ,携带TT基因型的患者，相比GT或GG基因型，药物代谢可能较慢,1,,,,0,,,plus,李晶晶
PA166135075,rs2231142,1183614748,GG,Patients with the GG genotype and HIV infection who are treated with efavirenz may have a reduced risk of abnormal dreams as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.,携带GG基因型的HIV感染者，相比GT或TT基因型，出现异常梦境的风险降低,1,,,0,,,,plus,李晶晶
PA166135075,rs2231142,1183614749,GT,Patients with the GT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.,携带GT基因型的HIV感染者，相比GG基因型，出现异常梦境的风险增加,1,,,2,,,,plus,李晶晶
PA166135075,rs2231142,1183614750,TT,Patients with the TT genotype and HIV infection who are treated with efavirenz may have an increased risk of abnormal dreams as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.,携带TT基因型的HIV感染者，相比GG基因型，出现异常梦境的风险增加,1,,,2,,,,plus,李晶晶
PA166136151,rs2231142,1446903235,GG,"Patients with the GG genotype and cancer may have decreased exposure to sunitinib and a decreased risk for experiencing drug toxicities, as compared to patients with the TT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence exposure to sunitinib and risk for drug toxicities. ",携带GG基因型的癌症患者，相比TT基因型，药物代谢可能较快，药物毒性风险可能降低,1,,,0,,,,plus,李晶晶
PA166136151,rs2231142,1446903236,GT,"Patients with the GT genotype and renal cell carcinoma may have decreased exposure to sunitinib and a decreased risk for experiencing drug toxicities, as compared to patients with the TT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence risk for drug toxicities when receiving sunitinib.",携带GT基因型的癌症患者，相比TT基因型，药物代谢可能较快，药物毒性风险可能降低,1,,,0,,,,plus,李晶晶
PA166136151,rs2231142,1446903237,TT,"Patients with the TT genotype and renal cell carcinoma may have increased exposure to sunitinib and an increased risk for experiencing drug toxicities, as compared to patients with the GG or GT genotype. However, this association with drug toxicities has been contradicted in some studies. Other genetic and clinical factors may also influence risk for drug toxicities when receiving sunitinib.",携带TT基因型的肾细胞癌患者，药物代谢可能较慢，药物毒性风险可能增加,1,,,2,,,,plus,李晶晶
PA166136240,rs2231142,1444686831,GG,Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.,携带GG基因型的类风湿性关节炎患者，相比GT或TT基因型，药物疗效可能较差,1,,0,,,,,plus,李晶晶
PA166136240,rs2231142,1444686832,GT,Patients with the GT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.,携带GT基因型的类风湿性关节炎患者，相比GG基因型，药物疗效可能较好,1,,2,,,,,plus,李晶晶
PA166136240,rs2231142,1444686833,TT,Patients with the TT genotype and rheumatoid arthritis may have an increased likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to sulfasalazine.,携带TT基因型的类风湿性关节炎患者，相比GG基因型，药物疗效可能较好,1,,2,,,,,plus,李晶晶
PA166136267,rs2231142,1444700516,GG,"Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. ",携带GG基因型的肿瘤患者，相比GT基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166136267,rs2231142,1444700517,GT,"Patients with the GT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype. Patients with the GT genotype are not studied for sensitivity to imatinib, but based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib, imatinib or nilotinib as compared to the G allele. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.",携带GT基因型的肿瘤患者，相比GG基因型，药物代谢可能较慢,1,,,,0,,,plus,李晶晶
PA166136267,rs2231142,1444700518,TT,"Patients with the TT genotype and Neoplasms might have a decreased metabolism of imatinib as compared to patients with the GG genotype based on the finding of the GT genotype being associated with decreased metabolism as compared to the GG genotype. Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib. ",携带TT基因型的肿瘤患者，相比GG基因型，药物代谢可能较慢,1,,,,0,,,plus,李晶晶
PA166158984,rs2231142,1448263568,GG,"Patients with the GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the GT and TT genotypes. However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations.",携带GG基因型的癫痫患者，相比GT和TT基因型，药物浓度可能降低,1,,,,,,0,plus,李晶晶
PA166158984,rs2231142,1448263569,GT,"Patients with the GT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype.  However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations.",携带GT基因型的癫痫患者，相比GG基因型，药物浓度可能增加,1,,,,,,2,plus,李晶晶
PA166158984,rs2231142,1448263570,TT,"Patients with the TT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype.  However, no difference was reported in efficacy. Other factors may affect lamotrigine concentrations.",携带TT基因型的癫痫患者，相比GG基因型，药物浓度可能增加,1,,,,,,2,plus,李晶晶
PA166152841,rs2231142,1447963669,GG,"Patients with the GG genotype and lung cancer may have a decreased risk of diarrhea when treated with gefitinib as compared to patients with the GT genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.",携带GG基因型的肺癌患者，相比GT基因型，用药后腹泻的风险降低,1,,,0,,,,plus,李晶晶
PA166152841,rs2231142,1447963670,GT,"Patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.",携带GT基因型的肺癌患者，相比GG基因型，用药后腹泻的风险增加,1,,,2,,,,plus,李晶晶
PA166152841,rs2231142,1447963671,TT,"No patients with the TT genotype were available for analysis, but patients with the GT genotype and lung cancer may have an increased risk of diarrhea when treated with gefitinib as compared to patients with the GG genotype. However, multiple studies find no association between this polymorphism, including patients with the GG genotype, and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.",携带TT基因型的肺癌患者，尚无相关研究,1,,,,,,,plus,李晶晶
PA166153014,rs2231142,1447982584,GG,Patients with the GG genotype and gout may have improved response when treated with allopurinol as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to allopurinol.,携带GG基因型的痛风患者，相比GT或TT基因型，可能有较好的疗效,1,,2,,,,,plus,李晶晶
PA166153014,rs2231142,1447982585,GT,Patients with the GT genotype and gout may have worse response when treated with allopurinol as compared to patients with the GG genotype and improved response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to allopurinol.,携带GT基因型的痛风患者，相比GG基因型，可能有较好的疗效；相比TT基因型，可能有较好的疗效,1,,1,,,,,plus,李晶晶
PA166153014,rs2231142,1447982586,TT,Patients with the TT genotype and gout may have worse response when treated with allopurinol as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence response to allopurinol.,携带TT基因型的痛风患者，相比GT或GG基因型，可能有较差的疗效,1,,0,,,,,plus,李晶晶
PA166135937,rs2231142,1448612858,GG,Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.,携带GG基因型的患者，相比GT或TT基因型，可能有较好的药物清除率和药物代谢,1,,,,2,,,plus,李晶晶
PA166135937,rs2231142,1448612859,GT,Patients with the GT genotype may have improved clearance of sulfasalazine as compared to patients with the TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.,携带GT基因型的患者，相比TT基因型，可能有较好的药物清除率,1,,,,2,,,plus,李晶晶
PA166135937,rs2231142,1448612860,TT,Patients with the TT genotype may have decreased clearance and metabolism of sulfasalazine as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.,携带TT基因型的患者，相比GG基因型，可能有较差的药物清除率和药物代谢,1,,,,0,,,plus,李晶晶
PA166134862,rs2266780,1043880311,AA,Patients with AA genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.,携带AA基因型的患者，相比GG基因型，可能有较高的血药浓度,1,,,,,,2,plus,李晶晶
PA166134862,rs2266780,1043880310,AG,Patients with AG genotype may have increased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the GG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.,携带AG基因型的患者，相比GG基因型，可能有较高的血药浓度,1,,,,,,2,plus,李晶晶
PA166134862,rs2266780,1043880309,GG,Patients with GG genotype may have decreased dose-adjusted serum olanzapine N-oxide concentrations when treated with olanzapine as compared to patients with the AA or AG genotype. Other clinical or genetic factors may also influence olanzapine metabolism.,携带GG基因型的患者，相比AA或AG基因型，可能有较低的血药浓度,1,,,,,,0,plus,李晶晶
PA166135611,rs2266780,1184987920,AA,Patients with the AA genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.,携带AA基因型的患者，相比GG基因型，可能有较高的药物代谢速率,1,,,,2,,,plus,李晶晶
PA166135611,rs2266780,1184987921,AG,The AG genotype has not been evaluated.,携带AA基因型的患者，目前尚无相关研究,1,,,,,,,plus,李晶晶
PA166135611,rs2266780,1184987922,GG,Patients with the GG genotype may have a decreased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride.,携带GG基因型的患者，相比AA基因型，可能有较低的药物代谢速率,1,,,,0,,,plus,李晶晶
PA166163527,rs2266780,1448613040,AA,People with the AA genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.,携带AA基因型的患者，相比GG基因型，药物代谢可能较快,1,,,,2,,0,plus,李晶晶
PA166163527,rs2266780,1448613041,AG,People with the AG genotype may have decreased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.,携带AG基因型的患者，相比GG基因型，药物代谢可能较快,1,,,,2,,0,plus,李晶晶
PA166163527,rs2266780,1448613042,GG,People with the GG genotype may have increased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.,携带GG基因型的患者，相比AA基因型，药物代谢可能较慢,1,,,,0,,2,plus,李晶晶
PA166135610,rs2266782,1184987913,AA,Patients with the AA genotype may have a decreased metabolism of itopride as compared to patients with the GG genotype. Other clinical and genetic factors may also influence metabolism of itopride. ,携带AA基因型的患者，相比GG基因型，药物代谢可能较慢,1,,,,0,,,plus,李晶晶
PA166135610,rs2266782,1184987914,AG,The AG genotype has not been evaluated. ,携带AA基因型的患者，目前尚无相关研究,1,,,,,,,plus,李晶晶
PA166135610,rs2266782,1184987915,GG,Patients with the GG genotype may have increased metabolism of itopride as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of itopride. ,携带GG基因型的患者，相比AA基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166163526,rs2266782,1448613034,AA,People with the AA genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.,携带AA基因型的患者，相比GG基因型，药物代谢可能较慢,1,,,,0,,,plus,李晶晶
PA166163526,rs2266782,1448613035,AG,People with the AG genotype may have increased exposure to sulindac compared to people with the GG genotype. Other clinical and genetic factors may affect exposure to sulindac.,携带AG基因型的患者，相比GG基因型，药物代谢可能较慢,1,,,,0,,,plus,李晶晶
PA166163526,rs2266782,1448613036,GG,People with the GG genotype may have decreased exposure to sulindac compared to people with the AA genotype. Other clinical and genetic factors may affect exposure to sulindac.,携带GG基因型的患者，相比AA基因型，药物代谢可能较快,1,,,,2,,,plus,李晶晶
PA166134767,rs2270777,1184764358,CC,Patient with CC + CT genotypes may have a decreased IGH-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. ,携带CC基因型的生长激素缺乏症儿童患者，相比TT基因型，可能有较低IGH-I反应,1,,0,,,,,FWD,李晶晶
PA166134767,rs2270777,1184764359,CT,Patient with CT + CC genotypes may have a decreased IGH-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with TT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. ,携带CT基因型的生长激素缺乏症儿童患者，相比TT基因型，可能有较低IGH-I反应,1,,0,,,,,FWD,李晶晶
PA166134767,rs2270777,1184764360,TT,Patient with TT genotypes may have an increased IGH-I response when treated with somatropin recombinant in children with growth hormone deficiency as compared to patients with CC + CT genotypes.  Other genetic and clinical factors may also influence a patient's response to therapy. ,携带TT基因型的生长激素缺乏症儿童患者，相比CC和CT基因型，可能有较高IGH-I反应,1,,2,,,,,FWD,李晶晶
PA166136220,rs2274567,1444673144,AA,Patients with the AA genotype and paroxysmal nocturnal hemoglobinuria may have a better response to treatment with eculizumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to eculizumab.,携带AA基因型的阵发性睡眠性血红蛋白尿症患者，相比AG或GG基因型，可能有较好的药物疗效,1,,2,,,,,plus,李晶晶
PA166136220,rs2274567,1444673145,AG,Patients with the AG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.,携带AG基因型的阵发性睡眠性血红蛋白尿症患者，相比AA基因型，可能有较差的药物疗效,1,,0,,,,,plus,李晶晶
PA166136220,rs2274567,1444673146,GG,Patients with the GG genotype and paroxysmal nocturnal hemoglobinuria may have a poorer response to treatment with eculizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to eculizumab.,携带GG基因型的阵发性睡眠性血红蛋白尿症患者，相比AA基因型，可能有较差的药物疗效,1,,0,,,,,plus,李晶晶
PA166163397,rs2277984,1448604318,CC,"Patients with the CC genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.",携带CC基因型的精神分裂症患者，相比CT或TT基因型，可能有较高的血药浓度，进而增加代谢综合征的易感性,1,,,,,,2,plus,李晶晶
PA166163397,rs2277984,1448604319,CT,"Patients with the CT genotype and schizophrenia may have increased fasting triglyceride levels, that may confer susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the TT genotype, and decreased fasting triglyceride levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.",携带CT基因型的精神分裂症患者，相比TT基因型，可能有较高的血药浓度，进而增加代谢综合征的易感性,1,,,,,,2,plus,李晶晶
PA166163397,rs2277984,1448604320,TT,"Patients with the TT genotype and schizophrenia may have decreased fasting triglyceride levels, that may reduce susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.",携带TT基因型的精神分裂症患者，相比CT或CC基因型，可能有较低的血药浓度，进而降低代谢综合征的易感性,1,,,,,,0,plus,李晶晶
PA166135365,rs2282143,1448594866,CC,Patients with the CC genotype may have increased clearance of metformin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of metformin. ,携带CC基因型的患者，相比CT或TT基因型，可能有较高的药物血浆清除率,1,,,,2,,,plus,李晶晶
PA166135365,rs2282143,1448594867,CT,Patients with the CT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin. ,携带CT基因型的患者，相比CC基因型，可能有较低的药物血浆清除率,1,,,,0,,,plus,李晶晶
PA166135365,rs2282143,1448594868,TT,Patients with the TT genotype may have decreased clearance of metformin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of metformin. ,携带TT基因型的患者，相比CC基因型，可能有较低的药物血浆清除率,1,,,,0,,,plus,李晶晶
PA166160031,rs2288344,1448257272,GG,Patients with the GG genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.,携带GG基因型的患者，相比TT基因型，可能需要增加药物的剂量,1,,,,,2,,plus,李晶晶
PA166160031,rs2288344,1448257273,GT,Patients with the GT genotype may require increased dose of warfarin as compared to patients with genotype TT. Other genetic and clinical factors may also influence the dose of warfarin.,携带GT基因型的患者，相比TT基因型，可能需要增加药物的剂量,1,,,,,2,,plus,李晶晶
PA166160031,rs2288344,1448257274,TT,Patients with the TT genotype may require decreased dose of warfarin as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the dose of warfarin.,携带TT基因型的患者，相比GG或GT基因型，可能需要降低药物的剂量,1,,,,,0,,plus,李晶晶
PA166136187,rs2289310,1444667324,GG,"Patients with metastasized cancer and the GG genotype may have worse response to capecitabine or fluorouracil as compared to people with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model.",携带GG基因型的转移癌患者，相比GT或TT基因型，药物疗效可能较差,1,,0,,,,,REV,李晶晶
PA166136187,rs2289310,1444667325,GT,"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model.",携带GT基因型的转移癌患者，相比GG基因型，药物疗效可能较好；相比TT基因型，药物疗效可能较差,1,,1,,,,,REV,李晶晶
PA166136187,rs2289310,1444667326,TT,"Patients with metastasized cancer and the TT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model.",携带TT基因型的转移癌患者，相比GT或TT基因型，药物疗效可能较好,1,,2,,,,,REV,李晶晶
PA166134847,rs2273697,1448100559,AA,"Patients with the AA genotype were not studied. However, patients with AG genotype and Kidney Transplantation may have a decreased metabolism of mycophenolic acid as compared to patients with the GG genotype. However, no association is reported regarding increased risk of adverse drug reactions and this has been contradicted in at least one study. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.",未有AA基因型患者参与研究,1,,,,,,,plus,李晶晶
PA166134847,rs2273697,1448100560,AG,"Patients with AG genotype and Kidney Transplantation may have a decreased metabolism of mycophenolic acid as compared to patients with the GG genotype. However, no association is reported regarding increased risk of adverse drug reactions and this has been contradicted in at least one study. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.",携带AG基因型行肾移植的患者，相比GG基因型，对药物的代谢可能降低,1,,,,0,,,plus,李晶晶
PA166134847,rs2273697,1448100561,GG,"Patients with GG genotype and Kidney Transplantation may have an increased metabolism of mycophenolic acid as comapred to patients with the AG genotype. However, no association is reported regarding increased risk of adverse drug reactions and this has been contradicted in at least one study. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.",携带GG基因型行肾移植的患者，相比GG基因型，对药物的代谢可能增加,1,,,,2,,,plus,李晶晶
PA166135118,rs2273697,1183615318,AA,Patients with the AA genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.,携带AA基因型的结肠直肠癌患者，相比GG基因型，对药物的代谢可能加快,1,,,,2,,,plus,李晶晶
PA166135118,rs2273697,1183615319,AG,Patients with the AG genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.,携带AG基因型的结肠直肠癌患者，相比GG基因型，对药物的代谢可能加快,1,,,,2,,,plus,李晶晶
PA166135118,rs2273697,1183615320,GG,Patients with the GG genotype and colorectal cancer may have decreased metabolism of irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.,携带GG基因型的结肠直肠癌患者，相比AA或AG基因型，对药物的代谢可能减慢,1,,,,0,,,plus,李晶晶
PA166136162,rs2273697,1444666552,AA,"No patients with the AA genotype were available for analysis. However, patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.",携带AA基因型的患者，尚无相关研究,1,,,,,,,plus,李晶晶
PA166136162,rs2273697,1444666553,AG,Patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.,携带AG基因型的β地中海贫血患者，相比GG基因型，可能有较高的血药浓度,1,,,,,,2,plus,李晶晶
PA166136162,rs2273697,1444666554,GG,Patients with the GG genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.,携带GG基因型的β地中海贫血患者，相比AG基因型，可能有较低的血药浓度,1,,,,,,0,plus,李晶晶
PA166134462,rs2273697,1447813528,AA,"Patients with the AA genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.",携带AA基因型的患者，相比GG基因型，患近端肾小管病的风险增加,1,,,2,,,,plus,李晶晶
PA166134462,rs2273697,1447813529,AG,"Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.",携带AG基因型的患者，相比GG基因型，患近端肾小管病的风险增加,1,,,2,,,,plus,李晶晶
PA166134462,rs2273697,1447813530,GG,"Patients with the GG genotype may have decreased but not absent risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.",携带GG基因型的患者，相比AA或AG基因型，患近端肾小管病的风险降低,1,,,0,,,,plus,李晶晶
PA166134234,rs2273697,655385146,AA,People with the AA genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.,携带AA基因型的患者，相比GG基因型，在口服药物时，有较高的残留药物清除率，以及较低的生物药效率,1,,0,,,,,plus,李晶晶
PA166134234,rs2273697,655385147,AG,People with the AG genotype may have increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol as compared to people with the GG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.,携带AG基因型的患者，相比GG基因型，在口服药物时，有较高的残留药物清除率，以及较低的生物药效率,1,,0,,,,,plus,李晶晶
PA166134234,rs2273697,655385148,GG,People with the GG genotype may have higher bioavailablilty of orally administered talinolol as compared to people with the AA or AG genotype. Other genetic and clinical factors may also influence the clearance of talinolol.,携带GG基因型的患者，相比AA或AG基因型，在口服药物时，有较高的生物药效率,1,,2,,,,,plus,李晶晶
PA166134292,rs2273697,1444666865,AA,"Patients with the AA genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.",携带AA基因型的癫痫患者，相比GG基因型，出现耐药性的可能性增加,1,,0,,,,,plus,李晶晶
PA166134292,rs2273697,1444666866,AG,"Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.",携带AG基因型的癫痫患者，相比GG基因型，出现耐药性的可能性增加,1,,0,,,,,plus,李晶晶
PA166134292,rs2273697,1444666867,GG,"Patients with the GG genotype and epilepsy who are treated with antiepileptic drugs may be less likely to be resistant to treatment as compared to patients with the AG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.",携带GG基因型的癫痫患者，相比AG基因型，出现耐药性的可能性降低,1,,2,,,,,plus,李晶晶
PA166136084,rs2273697,1185000099,AA,Patients with the AA genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions. ,携带AA基因型的癫痫患者，相比GG基因型，出现神经性药物不良反应的风险增加,1,,,2,,,,plus,李晶晶
PA166136084,rs2273697,1185000100,AG,Patients with the AG genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions. ,携带AG基因型的癫痫患者，相比GG基因型，出现神经性药物不良反应的风险增加,1,,,2,,,,plus,李晶晶
PA166136084,rs2273697,1185000101,GG,"Patients with the GG genotype and epilepsy who are treated with carbamazepine may have a reduced, but not absent, risk of neurological adverse drug reactions as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions. ",携带GG基因型的癫痫患者，相比AA或AG基因型，出现神经性药物不良反应的风险降低,1,,,0,,,,plus,李晶晶
PA166134701,rs2289658,982032397,CC,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带CC基因型的海洛因成瘾患者，相比TT基因型，可能需要较高的药物剂量,1,,,,,2,,plus,李晶晶
PA166134701,rs2289658,982032398,CT,Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带CT基因型的海洛因成瘾患者，相比TT基因型，可能需要较高的药物剂量,1,,,,,2,,plus,李晶晶
PA166134701,rs2289658,982032399,TT,Patients with the TT genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带TT基因型的海洛因成瘾患者，相比CT或CC基因型，可能需要较低的药物剂量,1,,,,,0,,plus,李晶晶
PA166136324,rs2290271,1448109738,AA,"Patients with genotype AA may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC or AC, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.",携带AA基因型的儿童肿瘤患者，相比CC或AC基因型，药物心脏毒性的可能性增加,1,,,2,,,,FWD,李晶晶
PA166136324,rs2290271,1448109739,AC,"Patients with genotype AC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.",携带AC基因型的儿童肿瘤患者，相比AA基因型，药物心脏毒性的可能性降低,1,,,0,,,,FWD,李晶晶
PA166136324,rs2290271,1448109740,CC,"Patients with genotype CC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.",携带CC基因型的儿童肿瘤患者，相比AA基因型，药物心脏毒性的可能性降低,1,,,0,,,,FWD,李晶晶
PA166135240,rs2279343,1447953012,AA,Patients with the AA genotype and HIV may have increased clearance and decreased plasma concentration of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带AA基因型的HIV患者，相比GG基因型，药物清除率可能增加，血药浓度可能较低,1,,,,,,0,plus,李晶晶
PA166135240,rs2279343,1447953013,AG,Patients with the AG genotype and HIV may have increased clearance and decreased plasma concentration of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带AG基因型的HIV患者，相比GG基因型，可药物清除率可能增加，血药浓度可能较低,1,,,,,,0,plus,李晶晶
PA166135240,rs2279343,1447953014,GG,Patients with the GG genotype and HIV may have decreased clearance and increased plasma concentration of efavirenz as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带GG基因型的HIV患者，相比AG或AA基因型，药物清除率可能降低，血药浓度可能较高,1,,,,,,2,plus,李晶晶
PA166134368,rs2279343,655386991,AA,"Patients with the AA genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have a decreased, but not absent, risk for oral mucositis as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.",携带AA基因型的患者行造血干细胞移植术，相比AG或GG基因型，发生口腔黏膜炎的风险较低,1,,,0,,,,plus,李晶晶
PA166134368,rs2279343,655386992,AG,Patients with the AG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.,携带AG基因型的患者行造血干细胞移植术，相比AA基因型，发生口腔黏膜炎的风险较高,1,,,0,,,,plus,李晶晶
PA166134368,rs2279343,655386993,GG,Patients with the GG genotype who have received a  hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.,携带GG基因型的患者行造血干细胞移植术，相比AA基因型，发生口腔黏膜炎的风险较高,1,,,2,,,,plus,李晶晶
PA166135413,rs2279343,1445402473,AA,"Patients with the AA genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the GG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone.",携带AA基因型的海洛因成瘾患者，相比GG基因型，可能需要较高的药物剂量,1,,,,,2,,plus,李晶晶
PA166135413,rs2279343,1445402474,AG,"Patients with the AG genotype who are being treated with methadone for heroin addiction may require an increased dose of the drug as compared to patients with the GG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone.",携带AG基因型的海洛因成瘾患者，相比GG基因型，可能需要较高的药物剂量,1,,,,,2,,plus,李晶晶
PA166135413,rs2279343,1445402475,GG,"Patients with the GG genotype who are being treated with methadone for heroin addiction may require a decreased dose of the drug as compared to patients with the AA or AG genotype. However, one study found no association between this variant and methadone dose. Other genetic and clinical factors may also influence dose of methadone.",携带GG基因型的海洛因成瘾患者，相比AA或AG基因型，可能需要较低的药物剂量,1,,,,,0,,plus,李晶晶
PA166136423,rs2279343,1446898326,AA,Individuals with tobacco use disorder and the AA genotype may have an improved response to bupropion as compared to individuals with the AG and GG genotypes. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder. ,携带AA基因型的烟草使用不良者，相比AA或AG基因型，可能有较好的疗效,1,,2,,,,,plus,李晶晶
PA166136423,rs2279343,1446898327,AG,Individuals with tobacco use disorder and the AG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder. ,携带AG基因型的烟草使用不良者，相比AA基因型，疗效可能较差,1,,2,,,,,plus,李晶晶
PA166136423,rs2279343,1446898328,GG,Individuals with tobacco use disorder and the GG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder. ,携带AA基因型的烟草使用不良者，相比AA基因型，疗效可能较差,1,,0,,,,,plus,李晶晶
PA166135810,rs2279343,1444704029,AA,Patients with the AA genotype may have decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of nicotine.,携带AA基因型的患者，相比GG基因型，药物代谢可能降低,1,,,,0,,,plus,李晶晶
PA166135810,rs2279343,1444704028,AG,Patients with the AG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype or may have decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of nicotine.,携带AG基因型的患者，相比AA基因型，药物代谢可能增加；相比GG基因型，药物代谢可能降低,1,,,,2,,,plus,李晶晶
PA166135810,rs2279343,1444704027,GG,Patients with the GG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of nicotine.,携带GG基因型的患者，相比AA基因型，药物代谢可能增加,1,,,,2,,,plus,李晶晶
PA166162743,rs2279343,1448594291,AA,"Patients with the AA genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.",携带AA基因型的患者行麻醉术时，相比GG基因型，药物的清除率可能较低,1,,,,0,,,plus,李晶晶
PA166162743,rs2279343,1448594292,AG,"Patients with the AG genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.",携带AG基因型的患者行麻醉术时，相比GG基因型，药物的清除率可能较低,1,,,,0,,,plus,李晶晶
PA166162743,rs2279343,1448594293,GG,"Patients with the GG genotype who undergo anesthesia with propofol may have increased clearance of the drug as compared to patients with the AA or AG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.",携带CC基因型的患者行麻醉术时，相比AA或AG基因型，药物的清除率可能增加,1,,,,2,,,plus,李晶晶
PA166160874,rs2304429,1448267399,CC,Patients with the CC genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.,携带CC基因型的行心脏瓣膜置换术患者，相比TT基因型，可能需要较低的药物剂量,1,,,,,0,,FWD,李晶晶
PA166160874,rs2304429,1448267400,CT,Patients with the CT genotype and heart valve replacement may require lower warfarin dose compared to patients with the TT genotype. Other genetic and clinical factors may affect warfarin dose.,携带CT基因型的的行心脏瓣膜置换术患者，相比TT基因型，可能需要较低的药物剂量,1,,,,,0,,FWD,李晶晶
PA166160874,rs2304429,1448267401,TT,Patients with the TT genotype and heart valve replacement may require higher warfarin dose compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect warfarin dose.,携带TT基因型的的行心脏瓣膜置换术患者，相比CC和CT基因型，可能需要较高的药物剂量,1,,,,,2,,FWD,李晶晶
PA166135008,rs2305089,1183630719,CC,Patients with the CC genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.,携带CC基因型的哮喘患者，相比TT基因型，可能有较差的疗效,1,,0,,,,,FWD,李晶晶
PA166135008,rs2305089,1183630720,CT,Patients with the CT genotype and asthma may have a poorer response when treated with flunisolide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to flunisolide.,携带CT基因型的哮喘患者，相比TT基因型，可能有较差的疗效,1,,0,,,,,FWD,李晶晶
PA166135008,rs2305089,1183630721,TT,Patients with the TT genotype and asthma may have a better response when treated with flunisolide as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to flunisolide.,携带TT基因型的哮喘患者，相比CC或CT基因型，可能有较好的疗效,1,,2,,,,,FWD,李晶晶
PA166135812,rs2306168,1444704044,CC,Patients with the CC genotype who are treated with fexofenadine may have increased area under the plasma concentration-time curve as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.,携带CC基因型的患者，相比TT或CT基因型，可能有较高的血液浓度。,1,,,,,,2,plus,李晶晶
PA166135812,rs2306168,1444704043,CT,Patients with the CT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.,携带CT基因型的患者，相比CC基因型，可能有较低的血液浓度。,1,,,,,,0,plus,李晶晶
PA166135812,rs2306168,1444704042,TT,Patients with the TT genotype who are treated with fexofenadine may have decreased area under the plasma concentration-time curve as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.,携带TT基因型的患者，相比CC基因型，可能有较低的血液浓度。,1,,,,,,0,plus,李晶晶
PA166134467,rs2297595,1448267801,CC,"Patients with the CC genotype may have 1) increased risk of severe toxicity when treated with fluoropyrimidines and 2) decreased metabolism of fluorouracil as compared to patients with the TT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带CC基因型的患者，相比TT基因型，药物不良反应风险可能增加，代谢可能较慢,1,,0,,0,,,plus,李晶晶
PA166134467,rs2297595,1448267802,CT,"Patients with the CT genotype may have 1) increased risk of severe toxicity when treated with fluoropyrimidines and 2) decreased metabolism of fluorouracil as compared to patients with the TT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带CT基因型的患者，相比TT基因型，药物不良反应风险可能增加，代谢可能较慢,1,,0,,0,,,plus,李晶晶
PA166134467,rs2297595,1448267803,TT,"Patients with the TT genotype may have 1) decreased but not absent risk of severe toxicity when treated with fluoropyrimidines and 2) increased metabolism of fluorouracil as compared to patients with the CC or CT genotype. However, contradictory or negative results exist for these associations. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) or with other drugs such as bevacizumab, cetuximab, raltitrexed. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带TT基因型的患者，相比CC和CT基因型，药物不良反应风险可能降低，代谢可能较快,1,,2,,2,,,plus,李晶晶
PA166134704,rs2378676,982032496,AA,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带AA基因型的患者，相比CC或AC基因型，可能需要较低剂量的药物,1,,,,,0,,FWD,李晶晶
PA166134704,rs2378676,982032497,AC,Patients with the AC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带AC基因型的患者，相比AA基因型，可能需要较高剂量的药物,1,,,,,2,,FWD,李晶晶
PA166134704,rs2378676,982032498,CC,Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带CC基因型的患者，相比AA基因型，可能需要较高剂量的药物,1,,,,,2,,FWD,李晶晶
PA166135815,rs2472297,1448107336,CC,Patients with the CC genotype may have decreased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.,携带CC基因型患者，相比CT或TT基因型，药物代谢率降低,1,,,,0,,,plus,李晶晶
PA166135815,rs2472297,1448107337,CT,Patients with the CT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.,携带CT基因型患者，相比CC基因型，药物代谢率增加,1,,,,2,,,plus,李晶晶
PA166135815,rs2472297,1448107338,TT,Patients with the TT genotype may have increased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.,携带TT基因型患者，相比CC基因型，药物代谢率增加,1,,,,2,,,plus,李晶晶
PA166134883,rs2306283,1043880596,AA,Patients with the AA genotype may have decreased pitavastatin plasma concentrations as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.,携带AA基因型的患者，相比AG或GG基因型，血浆中药物浓度可能降低,1,,,,,,0,plus,李晶晶
PA166134883,rs2306283,1043880597,AG,Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.,携带AG基因型的患者，相比AA基因型，血浆中药物浓度可能更高,1,,,,,,2,plus,李晶晶
PA166134883,rs2306283,1043880598,GG,Patients with the GG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.,携带GG基因型的患者，相比AA基因型，血浆中药物浓度可能更高,1,,,,,,2,plus,李晶晶
PA166134884,rs2306283,1447953140,AA,"Patients with the AA genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels and another found increased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ",携带AA基因型的高胆固醇血症患者，相比GG基因型，用药后低密度脂蛋白降低幅度可能较小,1,,0,,,,,plus,李晶晶
PA166134884,rs2306283,1447953141,AG,"Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ",携带AG基因型的高胆固醇血症患者，相比GG基因型，用药后低密度脂蛋白降低幅度可能较小,1,,0,,,,,plus,李晶晶
PA166134884,rs2306283,1447953142,GG,"Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may a larger reduction in LDL as compared to patients with the AA or AG genotype. However, one study found no association with LDL levels and another found decreased response. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ",携带GG基因型的高胆固醇血症患者，相比AA或AG基因型，用药后低密度脂蛋白降低幅度可能更大,1,,2,,,,,plus,李晶晶
PA166134906,rs2306283,1446908946,AA,"Patients with the AA genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and increased risk of intolerance to treatment as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.",携带AA基因型的患者，相比AG或GG基因型，用药后可能出现肌酸激酶水平升高，治疗不耐受的风险增加,1,,,2,,,,plus,李晶晶
PA166134906,rs2306283,1446908947,AG,"Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have  increased creatine kinase levels, and higher a higher risk of intolerance to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. ",携带AG基因型的患者，相比GG基因型，用药后可能出现肌酸激酶水平升高，治疗不耐受的风险增加,1,,,2,,,,plus,李晶晶
PA166134906,rs2306283,1446908948,GG,"Patients with the GG genotype who are treated with statins (hmg coa reductase inhibitors) may have decreased creatine kinase levels, and may have a lower risk of intolerance to treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. ",携带GG基因型的患者，相比AG或AA基因型，用药后可能出现肌酸激酶水平较低，治疗不耐受的风险较低,1,,,0,,,,plus,李晶晶
PA166135355,rs2306283,1183697545,AA,"Patients with the AA genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.",携带AA基因型的转移性结直肠癌患者，相比GG基因型，用药后可能响应更迅速；无进展生存期更长；治疗失效的时间延长,1,,2,,,,,plus,李晶晶
PA166135355,rs2306283,1183697546,AG,"Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.",携带AG基因型的转移性结直肠癌患者，相比GG基因型，用药后可能响应更迅速；无进展生存期更长；治疗失效的时间延长,1,,2,,,,,plus,李晶晶
PA166135355,rs2306283,1183697547,GG,"Patients with the GG genotype and metastatic colorectal cancer may have 1) decreased rapid response to treatment containing irinotecan, 2) shorter progression free survival, and 3) lower irinotecan-related time to treatment failure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.",携带GG基因型的转移性结直肠癌患者，相比AG或AA基因型，用药后可能响应更慢；无进展生存期更短；治疗失效的时间更短,1,,0,,,,,plus,李晶晶
PA166135359,rs2306283,1444667974,AA,Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate. ,携带AA基因型的急性淋巴细胞白血病小儿患者，相比GG基因型，药物清除率可能增加,1,,,,2,,,plus,李晶晶
PA166135359,rs2306283,1444667975,AG,Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence clearance of methotrexate. ,携带AG基因型的急性淋巴细胞白血病小儿患者，相比GG基因型，药物清除率可能增加,1,,,,2,,,plus,李晶晶
PA166135359,rs2306283,1444667976,GG,Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence clearance of methotrexate. ,携带GG基因型的急性淋巴细胞白血病小儿患者，相比AG或AA基因型，药物清除率可能降低,1,,,,0,,,plus,李晶晶
PA166134168,rs2306283,655384824,AA,Patients with the AA genotype may have higher plasma concentrations of repaglinide in people with no health problems compared to GG genotype. Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的健康人群，相比GG基因型，血药浓度可能更高,1,,,,,,2,plus,李晶晶
PA166134168,rs2306283,655384823,AG,"While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype.",没有与AG基因型相关的研究结果,1,,,,,,,plus,李晶晶
PA166134168,rs2306283,655384822,GG,Patients with the GG genotype may have reduced plasma concentrations of repaglinide and higher blood glucose concentrations after repaglinide intake in people with no health problems compared to AA genotype. Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的健康人群，相比AA基因型，用药后可能血浆药物浓度更低，血糖升高,1,,,,,,0,plus,李晶晶
PA166134214,rs2306283,1043880586,AA,Patients with the AA genotype may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics. ,携带AA基因型患者，相比GG基因型，血药浓度可能更高,1,,,,,,2,plus,李晶晶
PA166134214,rs2306283,1043880587,AG,"Patients with the AG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype, or may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics. ",携带AG基因型患者，相比AA基因型，血药浓度可能更低；相比GG基因型，血药浓度可能更高,1,,,,,,1,plus,李晶晶
PA166134214,rs2306283,1043880588,GG,Patients with the GG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics. ,携带GG基因型患者，相比AA基因型，血药浓度可能更低,1,,,,,,0,plus,李晶晶
PA166135895,rs2306283,1445401262,AA,Patients with the AA genotype who are placed under anesthesia may have a decreased response to rocuronium as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to rocuronium.,携带AA基因型的被麻醉的患者，相比AG或GG基因型，对药物的响应可能降低,1,,0,,,,,plus,李晶晶
PA166135895,rs2306283,1445401263,AG,Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.,携带AG基因型的被麻醉的患者，相比AA基因型，对药物的响应可能增加,1,,2,,,,,plus,李晶晶
PA166135895,rs2306283,1445401264,GG,Patients with the GG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.,携带GG基因型的被麻醉的患者，相比AA基因型，对药物的响应可能增加,1,,2,,,,,plus,李晶晶
PA166153465,rs2306283,1448100575,AA,Kidney transplant patients with the AA genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.,携带AA基因型的肾脏移植病人，相比GG基因型，药物的清除率可能降低,1,,,,0,,,plus,李晶晶
PA166153465,rs2306283,1448100576,AG,Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.,携带AG基因型的肾脏移植病人，相比GG基因型，药物的清除率可能降低,1,,,,0,,,plus,李晶晶
PA166153465,rs2306283,1448100577,GG,Kidney transplant patients with the GG genotype may have more rapid clearance rates of mycophenolic acid as compared to patients with the AA or AG genotypes. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.,携带GG基因型的肾脏移植病人，相比AA或AG基因型，药物的清除效率可能更高,1,,,,2,,,plus,李晶晶
PA166158881,rs2306283,1448099127,AA,Patients with the AA genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance. ,携带AA基因型的患者，相比GG基因型，药物的清除率可能更高,1,,,,2,,,plus,李晶晶
PA166158881,rs2306283,1448099128,AG,Patients with the AG genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance. ,携带AG基因型的患者，相比GG基因型，药物的清除率可能更高,1,,,,2,,,plus,李晶晶
PA166158881,rs2306283,1448099129,GG,Patients with the GG genotype may have decreased clearance of rifampin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence rifampin clearance. ,携带GG基因型的患者，相比AA或AG基因型，药物的清除率可能更低,1,,,,0,,,plus,李晶晶
PA166160272,rs2306283,1448258738,AA,Patients with the AA genotype may have increased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to sorafenib.,携带AA基因型的患者，相比GG或AG基因型，用药后发生腹泻的可能性增加,1,,,2,,,,plus,李晶晶
PA166160272,rs2306283,1448258737,AG,Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.,携带AG基因型的患者，相比AA基因型，用药后发生腹泻的可能性降低,1,,,0,,,,plus,李晶晶
PA166160272,rs2306283,1448258736,GG,Patients with the GG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.,携带GG基因型的患者，相比AA基因型，用药后发生腹泻的可能性降低,1,,,0,,,,plus,李晶晶
PA166161285,rs2306283,1448428032,AA,"Patients with the AA genotype and solid tumors may experience deceased risk of neutropenia compared to patients with the GG genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.",携带AA基因型的实体肿瘤患者，相比GG基因型，发生嗜中性粒细胞减少症的风险降低,1,,,0,,,,plus,李晶晶
PA166161285,rs2306283,1448428033,AG,"Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.",携带AG基因型的实体肿瘤患者，相比AA基因型，发生嗜中性粒细胞减少症的风险增加,1,,,2,,,,plus,李晶晶
PA166161285,rs2306283,1448428034,GG,"Patients with the GG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.",携带GG基因型的实体肿瘤患者，相比AA基因型，发生嗜中性粒细胞减少症的风险增加,1,,,2,,,,plus,李晶晶
PA166135150,rs2472304,1183617645,AA,Patients with the AA genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. ,携带AA基因型的重度抑郁症患者，相比GG基因型，用药后症状更可能得到缓解,1,,2,,,,,plus,李晶晶
PA166135150,rs2472304,1183617646,AG,Patients with the AG genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype or may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. ,携带AG基因型的重度抑郁症患者，相比GG基因型，用药后症状更可能得到缓解；相比AA基因型，用药后症状得到缓解的可能性更小,1,,1,,,,,plus,李晶晶
PA166135150,rs2472304,1183617647,GG,Patients with the GG genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment. ,携带GG基因型的重度抑郁症患者，相比AA基因型，用药后症状得到缓解的可能性更小,1,,0,,,,,plus,李晶晶
PA166136410,rs2472304,1446896598,AA,Patients with the AA genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.,携带AA基因型的患者，相比GG基因型，血药浓度可能升高,1,,,,,,2,plus,李晶晶
PA166136410,rs2472304,1446896599,AG,Patients with the AG genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.,携带AG基因型的患者，相比GG基因型，血药浓度可能升高,1,,,,,,2,plus,李晶晶
PA166136410,rs2472304,1446896600,GG,Patients with the GG genotype may have decreased concentrations of erlotinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.,携带GG基因型的患者，相比AA或AG基因型，血药浓度可能降低,1,,,,,,0,plus,李晶晶
PA166160819,rs247616,1448266667,CC,Patients with the CC genotype may have a worse response to statin therapy compared to patients with the TT genotype. Other clinical and genetic factors may affect response to statins.,携带CC基因型的患者，相比TT基因型，药效可能较差,1,,0,,,,,plus,李晶晶
PA166160819,rs247616,1448266666,CT,Patients with the CT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.,携带CT基因型的患者，相比CC基因型，药效可能较好,1,,2,,,,,plus,李晶晶
PA166160819,rs247616,1448266665,TT,Patients with the TT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.,携带TT基因型的患者，相比CC基因型，药效可能较好,1,,2,,,,,plus,李晶晶
PA166159178,rs2498804,1448102668,AA,Patients with the AA genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.,携带AA基因型的非小细胞肺癌患者，相比CC基因型，远端转移的风险可能降低,1,,2,,,,,plus,李晶晶
PA166159178,rs2498804,1448102669,AC,Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.,携带AC基因型的非小细胞肺癌患者，相比CC基因型，远端转移的风险可能降低,1,,2,,,,,plus,李晶晶
PA166159178,rs2498804,1448102670,CC,Patients with the CC genotype and non-small-cell lung cancer may have an increased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk for disease progression.,携带CC基因型的非小细胞肺癌患者，相比AA或AC基因型，远端转移的风险可能增加,1,,0,,,,,plus,李晶晶
PA166159308,rs2523864,1448107481,CC,Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease. ,携带CC基因型的视网膜疾病患者，相比CT或TT基因型，眼压可能降低,1,,2,,,,,FWD,李晶晶
PA166159308,rs2523864,1448107482,CT,Patients with retinal disease and the CT genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the TT genotypes and increased intraocular pressure as compared to patients with the CC genotype. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease. ,携带CT基因型的视网膜疾病患者，相比TT基因型，眼压可能降低；相比CC基因型，眼压可能增加,1,,1,,,,,FWD,李晶晶
PA166159308,rs2523864,1448107483,TT,Patients with retinal disease and the TT genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease. ,携带TT基因型的视网膜疾病患者，相比CT或CC基因型，眼压可能增加,1,,0,,,,,FWD,李晶晶
PA166134914,rs2500535,1127092673,AA,Patients with the AA genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.,携带AA基因型的重度抑郁症患者，相比GG基因型，用药后症状得到改善的程度可能较低,1,,0,,,,,plus,李晶晶
PA166134914,rs2500535,1127092677,AG,Patients with the AG genotype and major depressive disorder who are treated with nortriptyline may have decreased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.,携带AG基因型的重度抑郁症患者，相比GG基因型，用药后症状得到改善的程度可能较低,1,,0,,,,,plus,李晶晶
PA166134914,rs2500535,1127092680,GG,Patients with the GG genotype and major depressive disorder who are treated with nortriptyline may have increased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.,携带GG基因型的重度抑郁症患者，相比AA或AG基因型，用药后症状更可能得到改善,1,,2,,,,,plus,李晶晶
PA166159631,rs2535629,1448123836,AA,"Patients with the AA genotype and schizophrenia may have increased response to clozapine compared to patients with the AG and GG genotypes. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.",携带AA基因型的精神分裂症患者，相比GG或AG基因型，用药后效果可能更好,1,,2,,,,,plus,李晶晶
PA166159631,rs2535629,1448123837,AG,"Patients with the AG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.",携带AG基因型的精神分裂症患者，相比AA基因型，用药后效果可能较差,1,,0,,,,,plus,李晶晶
PA166159631,rs2535629,1448123838,GG,"Patients with the GG genotype and schizophrenia may have decreased response to clozapine compared to patients with the AA genotype. This association was seen in patients of European descent, but not African-American descent. Other clinical and genetic factors may affect response to clozapine.",携带GG基因型的精神分裂症患者，相比AA基因型，用药后效果可能较差,1,,0,,,,,plus,李晶晶
PA166161864,rs2546890,1448522768,AA,Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带AA基因型的牛皮癣患者，相比AG或GG基因型，药效可能较好,1,,2,,,,,plus,李晶晶
PA166161864,rs2546890,1448522769,AG,Patients with the AG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带AG基因型的牛皮癣患者，相比AA基因型，药效可能稍差,1,,0,,,,,plus,李晶晶
PA166161864,rs2546890,1448522770,GG,Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带GG基因型的牛皮癣患者，相比AA基因型，药效可能稍差,1,,0,,,,,plus,李晶晶
PA166134210,rs2359612,1448276196,AA,Patients with the AA genotype who are treated with warfarin may require the lowest dose as compared to patients with the AG or GG genotype.  Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带AA基因型的患者，相比AG或GG基因型，可能需要更低的用药剂量,1,,,,,0,,plus,李晶晶
PA166134210,rs2359612,1448276197,AG,Patients with the AG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带AG基因型的患者，相比GG基因型，可能需要更低的用药剂量,1,,,,,0,,plus,李晶晶
PA166134210,rs2359612,1448276198,GG,Patients with the GG genotype who are treated with warfarin may require a higher dose as compared to patients with the AG or AA genotype.  Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带GG基因型的患者，相比AA或AG基因型，可能需要更高的用药剂量,1,,,,,2,,plus,李晶晶
PA166158988,rs2514036,1448100516,CC,Men with the CC genotype and hypertension may have decreased response to bisoprolol compared to men with the CT and TT genotypes. Other factors may affect response to bisoprolol.,携带CC基因型的男性高血压患者，相比CT或TT基因型，药效可能降低,1,男,0,,,,,FWD,李晶晶
PA166158988,rs2514036,1448100517,CT,Men with the CT genotype and hypertension may have decreased response to bisoprolol compared to men with the TT genotype. Other factors may affect response to bisoprolol.,携带CT基因型的男性高血压患者，相比TT基因型，药效可能降低,1,男,0,,,,,FWD,李晶晶
PA166158988,rs2514036,1448100518,TT,Men with the TT genotype and hypertension may have increased response to bisoprolol compared to men with the CC and CT genotypes. Other factors may affect response to bisoprolol.,携带TT基因型的男性高血压患者，相比CC或CT基因型，药效可能增加,1,男,2,,,,,FWD,李晶晶
PA166152723,rs2562519,1447960797,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CC基因型的HIV感染患者，相比TT基因型，用药后发生药源性皮疹的可能性较低,1,,2,,,,,plus,李晶晶
PA166152723,rs2562519,1447960798,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CT基因型的HIV感染患者，相比TT基因型，用药后发生药源性皮疹的可能性较低；相比CC基因型，用药后发生药源性皮疹的可能性较高,1,,1,,,,,plus,李晶晶
PA166152723,rs2562519,1447960799,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带TT基因型的HIV感染患者，相比CC基因型，用药后发生药源性皮疹的可能性较高,1,,0,,,,,plus,李晶晶
PA166136138,rs2612091,1448568543,CC,"Patients with the CC genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.",携带CC基因型的癌症患者，相比TT基因型，发生药物毒副作用（尤其是手足综合征）的风险可能增加,1,,0,,,,,FWD,李晶晶
PA166136138,rs2612091,1448568544,CT,"Patients with the CT genotype and cancer may have an increased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype, or a decreased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.",携带CT基因型的癌症患者，相比TT基因型，发生药物毒副作用（尤其是手足综合征）的风险可能增加；但相比CC基因型，发生药物毒副作用的风险可能降低,1,,1,,,,,FWD,李晶晶
PA166136138,rs2612091,1448568545,TT,"Patients with the TT genotype and cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.",携带TT基因型的癌症患者，相比TT基因型，发生药物毒副作用（尤其是手足综合征）的风险可能降低,1,,2,,,,,FWD,李晶晶
PA166135705,rs2631367,1444673086,CC,Patients with the CC genotype and gastrointestinal stromal tumors may have a shorter time to progression when treated with imatinib as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to imatinib treatment.,携带CC基因型的胃肠道间质瘤患者，相比CG或GG基因型，用药后出现疾病恶化的时间可能更短,1,,0,,,,,minus,李晶晶
PA166135705,rs2631367,1444673087,CG,Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.,携带CG基因型的胃肠道间质瘤患者，相比CC基因型，用药后出现疾病恶化的时间可能更长,1,,2,,,,,minus,李晶晶
PA166135705,rs2631367,1444673088,GG,Patients with the GG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.,携带GG基因型的胃肠道间质瘤患者，相比CC基因型，用药后出现疾病恶化的时间可能更长,1,,2,,,,,minus,李晶晶
PA166135613,rs2647087,1184989692,AA,"Patients with the AA genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have a reduced, but not absent, risk of pancreatitis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis. ",携带AA基因型的炎症性肠病患者，相比CC基因型，用药后胰腺炎的风险可能降低,1,,2,,,,,FWD,李晶晶
PA166135613,rs2647087,1184989693,AC,Patients with the AC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis. ,携带AC基因型的炎症性肠病患者，相比AA基因型，用药后胰腺炎的风险可能增加,1,,0,,,,,FWD,李晶晶
PA166135613,rs2647087,1184989694,CC,Patients with the CC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis. ,携带CC基因型的炎症性肠病患者，相比AA基因型，用药后胰腺炎的风险可能增加,1,,0,,,,,FWD,李晶晶
PA166163225,rs2669429,1448602691,AA,Patients with the AA genotype and hypertension may be at decreased risk of developing hyperglycemia when taking atenolol compared to patients with the AG and GG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.,携带AA基因型的高血压患者，相比AG和GG基因型，发展成高血糖症的可能性降低,1,,2,,,,,FWD,李晶晶
PA166163225,rs2669429,1448602692,AG,Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.,携带AG基因型的高血压患者，相比AA基因型，发展成高血糖症的可能性增加,1,,0,,,,,FWD,李晶晶
PA166163225,rs2669429,1448602693,GG,Patients with the GG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.,携带GG基因型的高血压患者，相比AG和AA基因型，发展成高血糖症的可能性增加,1,,0,,,,,FWD,李晶晶
PA166136262,rs267606618,1444843901,C,Patients with the 1095C allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1095T allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss,携带C等位基因的患者，相比T等位基因，用药导致耳聋的风险增加,1,,0,,,,,plus,李晶晶
PA166136262,rs267606618,1444843902,T,"Patients with the 1095T allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1095C allele. Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.",携带T等位基因的患者，相比C等位基因，用药导致耳聋的风险降低,1,,,0,,,,plus,任绿枝
PA166135035,rs2742417,1183603019,CC,Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.,携带CC基因型的重度抑郁症患者，相比TT基因型，用药导致的性生活副作用可能较重,1,,,2,,,,plus,任绿枝
PA166135035,rs2742417,1183603018,CT,"Patients with the CT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype, or increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.",携带CT基因型的重度抑郁症患者，相比CC基因型，用药导致的性生活副作用可能较轻；但相比TT基因型，用药导致的性副作用可能较重,1,,,1,,,,plus,任绿枝
PA166135035,rs2742417,1183603017,TT,Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.,携带CC基因型的重度抑郁症患者，相比TT基因型，用药导致的性生活副作用可能严重,1,,,0,,,,plus,任绿枝
PA166136144,rs267606617,1448256020,A,"Patients with the 1555A allele may have a lower, but not absent, risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1555G allele.  Other genetic and clinical factors may also influence risk of aminoglycoside-induced hearing loss.",携带A等位基因的患者，相比G等位基因，用药导致耳聋的可能性较低,1,,,0,,,,plus,任绿枝
PA166136144,rs267606617,1448256021,G,"Patients with the 1555G allele may have a greater risk of experiencing aminoglycoside-induced hearing loss as compared to patients with the 1555A allele. In the majority of studies, every individual who carried the 1555G allele developed hearing loss after receiving aminoglycoside antibiotics. Most individuals studied were homoplasmic for the G allele; it is unclear how heteroplasmy affects the severity or occurrence of aminoglycoside-induced hearing loss. Other genetic and clinical factors may also influence risk of hearing loss.",携带G等位基因的患者，相比A等位基因，用药导致耳聋的可能性较高,1,,,2,,,,plus,任绿枝
PA166134795,rs2768759,1043858725,AA,Patients with the AA genotype may have a decreased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带AA基因型的患者，相比CC基因型，用药后出现残留血小板凝集的可能性较低,1,,2,,,,,plus,任绿枝
PA166134795,rs2768759,1043858724,AC,No information are provided for the AC genotype. But patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,没有与AC基因型相关的信息,1,,1,,,,,plus,任绿枝
PA166134795,rs2768759,1043858723,CC,Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带CC基因型的患者，相比AA基因型，用药后出现残留血小板凝集的可能性较高,1,,0,,,,,plus,任绿枝
PA166159236,rs2808630,1448104031,CC,Patients with the CC genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.,携带CC基因型的冠状动脉疾病患者，相比TT基因型，对心血管疾病的疗效可能更好,1,,2,,,,,plus,任绿枝
PA166159236,rs2808630,1448104032,CT,Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.,携带CT基因型的冠状动脉疾病患者，相比TT基因型，对心血管疾病的疗效可能更好,1,,2,,,,,plus,任绿枝
PA166159236,rs2808630,1448104033,TT,Patients with the TT genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.,携带TT基因型的冠状动脉疾病患者，相比CC或CT基因型，对心血管疾病的疗效可能较差,1,,0,,,,,plus,任绿枝
PA166134164,rs2781659,1448108737,AA,Patients with the AA genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.,携带AA基因型的哮喘患者，相比GG基因型，用药后肺活量可能提升更多,1,,2,,,,,plus,任绿枝
PA166134164,rs2781659,1448108738,AG,Patients with the AG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype or may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.,携带AG基因型的哮喘患者，相比GG基因型，用药后肺活量可能提升更多；相比AA基因型，用药后肺活量可能提升较少,1,,1,,,,,plus,任绿枝
PA166134164,rs2781659,1448108739,GG,Patients with the GG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.,携带GG基因型的哮喘患者，相比AA基因型，用药后肺活量可能提升较少,1,,0,,,,,plus,任绿枝
PA166134632,rs2819742,981419551,AA,Patients with the AA genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. ,携带AA基因型的患者，相比GG基因型，用药导致横纹肌溶解症的可能性降低,1,,,0,,,,plus,任绿枝
PA166134632,rs2819742,981419552,AG,Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. ,携带AG基因型的患者，相比GG基因型，用药导致横纹肌溶解症的可能性降低,1,,,0,,,,plus,任绿枝
PA166134632,rs2819742,981419553,GG,Patients with the GG genotype may have an increased risk of cerivastatin-associated rhabdomyolysis as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity. ,携带GG基因型的患者，相比AA或AG基因型，用药导致横纹肌溶解症的可能性增加,1,,,2,,,,plus,任绿枝
PA166153193,rs2819742,1447987130,AA,Patients with the AA genotype and cardiovascular disease who are taking atorvastatin or simvastatin may have an increased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin.,携带AA基因型的心血管疾病患者，相比AG或GG基因型，用药引起肌病和肌痛的可能性增加,1,,,2,,,,plus,任绿枝
PA166153193,rs2819742,1447987131,AG,Patients with the AG genotype and cardiovascular disease who are taking atorvastatin or simvastatin may have an increased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin.,携带AG基因型的心血管疾病患者，相比GG基因型，用药引起肌病和肌痛的可能性增加；相比AA基因型，用药引起肌病和肌痛的可能性降低,1,,,1,,,,plus,任绿枝
PA166153193,rs2819742,1447987132,GG,Patients with the GG genotype and cardiovascular disease who are taking atorvastatin or simvastatin may have an decreased likelihood of developing statin-associated myopathy and myalgia as compared with patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin.,携带GG基因型的心血管疾病患者，相比AG或AA基因型，用药引起肌病和肌痛的可能性降低,1,,,0,,,,plus,任绿枝
PA166134064,rs2814707,637879933,CC,Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的风湿性关节炎患者，相比CT或TT基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166134064,rs2814707,637879934,CT,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.,携带CT基因型的风湿性关节炎患者，相比CC基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134064,rs2814707,637879935,TT,Rheumatoid Arthritis patients with the TT genotype may be less likely to respond to TNF inhibitors compared to patients with the genotype CC. Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的风湿性关节炎患者，相比CC基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166136156,rs2832407,1444666310,AA,"Patients with the AA genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate. ",携带AA基因型的酗酒者，相比CC基因型，血药浓度可能更高，药物响应可能较差,1,,0,,2,,,plus,任绿枝
PA166136156,rs2832407,1444666311,AC,"Patients with the AC genotype and who are heavy drinkers or have an alcohol-use disorder may have higher concentrations of topiramate, and a poorer response to treatment with the drug, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate. ",携带AC基因型的酗酒者，相比CC基因型，血药浓度可能更高，药物响应可能较差,1,,0,,2,,,plus,任绿枝
PA166136156,rs2832407,1444666312,CC,"Patients with the CC genotype and who are heavy drinkers or have an alcohol-use disorder may have lower concentrations of topiramate, and a better response to treatment with the drug, as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence response or concentrations of topiramate. ",携带CC基因型的酗酒者，相比AA或AC基因型，血药浓度可能更低，药物响应可能更好,1,,2,,0,,,plus,任绿枝
PA166134248,rs28364006,655385261,AA,"Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.",无AA基因型患者的参与研究,1,,,,,,,plus,任绿枝
PA166134248,rs28364006,655385260,AG,Patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带GA基因型的牛皮癣患者，相比GG基因型，病情得到改善的可能性较小,1,,0,,,,,plus,任绿枝
PA166134248,rs28364006,655385259,GG,Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area and severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带GG基因型的牛皮癣患者，相比AG基因型，病情得到改善的可能性更大,1,,2,,,,,plus,任绿枝
PA166152963,rs28371706,1447980877,AA,Pediatric patients with the AA genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.,携带AA基因型的HIV小儿感染者，相比GG基因型，药物清除率可能较低,1,,,,0,,,plus,任绿枝
PA166152963,rs28371706,1447980878,AG,Pediatric patients with the AG genotype and HIV may have decreased clearance of nevirapine as compared to pediatric patients with the GG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.,携带AG基因型的HIV小儿感染者，相比GG基因型，药物清除率可能较低,1,,,,0,,,plus,任绿枝
PA166152963,rs28371706,1447980879,GG,Pediatric patients with the GG genotype and HIV may have increased clearance of nevirapine as compared to pediatric patients with the AA or AG genotype. No significant association was seen in adults. Other genetic and clinical factors may also influence clearance of nevirapine.,携带GG基因型的HIV小儿感染者，相比AA或AG基因型，药物清除率可能更高,1,,,,2,,,plus,任绿枝
PA166134058,rs28371686,1183702165,CC,Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带CC基因型的患者，相比CG或GG基因型，可能需要增加药物剂量,1,,,,,2,,plus,任绿枝
PA166134058,rs28371686,1183702166,CG,Patients with the CG genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带CG基因型的患者，相比CC基因型，可能需要减少药物剂量,1,,,,,1,,plus,任绿枝
PA166134058,rs28371686,1183702167,GG,Patients with the GG genotype who are treated with warfarin may require the lowest does as compared to patients with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带GG基因型的患者，相比CG或CC基因型，可能需要最低的药物剂量,1,,,,,0,,plus,任绿枝
PA166135368,rs28371759,1447946673,AA,"Patients with the AA genotype (CYP3A4 *1/*1) who underwent kidney transplantation may have decreased metabolism of tacrolimus as compared to patients with the AG genotype (*1/*18B). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus.",携带AA基因型的肾脏移植病人，相比AG基因型，药物代谢可能降低,1,,,,0,,,plus,任绿枝
PA166135368,rs28371759,1447946674,AG,"Patients with the AG genotype (CYP3A4 *1/*18B) who underwent kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype (*1/*1). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus.",携带AG基因型的肾脏移植病人，相比AA基因型，药物代谢可能增加,1,,,,2,,,plus,任绿枝
PA166135368,rs28371759,1447946675,GG,"No patients with this genotype were included in the analysis. However, patients with the AG genotype (CYP3A4 *1/*18B) who underwent kidney transplantation may have increased metabolism of tacrolimus as compared to patients with the AA genotype (*1/*1). Other genetic and clinical factors, such as rs776746 (CYP3A5*3), may also influence metabolism of tacrolimus.",没有此基因型的病人参与研究,1,,,,,,,plus,任绿枝
PA166135369,rs28371759,1183698800,AA,Patients with the AA genotype (CYP3A4 *1/*1) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.,携带AA基因型的肾脏移植病人，相比GG基因型，药物代谢可能降低,1,,,,0,,,plus,任绿枝
PA166135369,rs28371759,1183698801,AG,Patients with the AG genotype (CYP3A4 *1/*1B) who underwent kidney transplantation may have decreased metabolism of cyclosporine as compared to patients with the GG genotype (*18B/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.,携带AG基因型的肾脏移植病人，相比GG基因型，药物代谢可能降低,1,,,,0,,,plus,任绿枝
PA166135369,rs28371759,1183698802,GG,Patients with the GG genotype (CYP3A4 *18B/*18B) who underwent kidney transplantation may have increased metabolism of cyclosporine as compared to patients with the AA or AG genotype (*1/*1 or *1/*18B). Other genetic and clinical factors may also influence metabolism of cyclosporine.,携带GG基因型的肾脏移植病人，相比AA或AG基因型，药物代谢可能加强,1,,,,2,,,plus,任绿枝
PA166134057,rs28371685,1183703153,CC,Patients with the CC genotype who are treated with warfarin may require an increased dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带CC基因型的患者，相比CT或TT基因型，用药剂量可能需要增加,1,,,,,2,,plus,任绿枝
PA166134057,rs28371685,1183703154,CT,Patients with the CT genotype who are treated with warfarin may require a decreased dose as compared to patients with CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带CT基因型的患者，相比CC基因型，用药剂量可能需要减少,1,,,,,1,,plus,任绿枝
PA166134057,rs28371685,1183703155,TT,Patients with the TT genotype who are treated with warfarin may require the lowest dose as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带TT基因型的患者，相比CT或CC基因型，用药剂量可能需要最低,1,,,,,0,,plus,任绿枝
PA166134915,rs28365062,1127557410,AA,Patients with the AA genotype may have a dereased metabolism of zidovudine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.,携带AA基因型的患者，相比GG基因型， 药物代谢可能较慢,1,,,,0,,,plus,任绿枝
PA166134915,rs28365062,1127557436,GA,Patients with the GA genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.,携带GA基因型的患者，相比AA基因型， 药物代谢可能加强,1,,,,2,,,plus,任绿枝
PA166134915,rs28365062,1127557441,GG,Patients with the GG genotype may have an increased metabolism of zidovudine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's zidovudine metabolism.,携带GG基因型的患者，相比AA基因型， 药物代谢可能加强,1,,,,2,,,plus,任绿枝
PA166153181,rs28365062,1447987025,AA,"Patients with the AA genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","携带AA基因型且CYPB6代谢较慢（基因型为rs3745274 TT,或 rs3745274 T/rs28399499 C或 rs28399499 CC）的HIV感染者，相比GG基因型，药物代谢可能加强",1,,,,2,,,plus,任绿枝
PA166153181,rs28365062,1447987026,AG,"Patients with the AG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have increased metabolism of efavirenz as compared to patients with the GG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","携带AG基因型且CYPB6代谢较慢（基因型为rs3745274 TT,或 rs3745274 T/rs28399499 C或 rs28399499 CC）的HIV感染者，相比GG基因型，药物代谢可能加强",1,,,,2,,,plus,任绿枝
PA166153181,rs28365062,1447987027,GG,"Patients with the GG genotype who are CYPB6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC) and have HIV may have decreased metabolism of efavirenz as compared to patients with the AA or AG genotype. The majority of studies find no association, though these studies were not conducted in exclusively CYP2B6 slow metabolizers. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.","携带GG基因型且CYPB6代谢较慢（基因型为rs3745274 TT,或 rs3745274 T/rs28399499 C或 rs28399499 CC）的HIV感染者，相比AA或AG基因型，药物代谢可能降低",1,,,,0,,,plus,任绿枝
PA166136045,rs2844665,1184764190,CC,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ,携带CC基因型的患者，相比TT基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更高,1,,,2,,,,plus,任绿枝
PA166136045,rs2844665,1184764191,CT,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带CT基因型的患者，相比TT基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更高；相比CC基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更低,1,,,1,,,,plus,任绿枝
PA166136045,rs2844665,1184764192,TT,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带TT基因型的患者，相比CC基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更低,1,,,0,,,,plus,任绿枝
PA166134646,rs28399504,1446908970,AA,"Patients with the AA genotype 1) may have increased metabolism of clopidogrel and 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG and AG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.",携带AA基因型的患者，相比GG或AG基因型，药物代谢可能加强；发生次级心脑血管相关事件的风险可能更低,1,,2,,,,,plus,任绿枝
PA166134646,rs28399504,1446908971,AG,Patients with the AG genotype 1) may have poor metabolism of clopidogrel and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.,携带AG基因型的患者，相比AA基因型，药物代谢可能较慢；发生次级心脑血管相关事件的风险可能更高,1,,0,,,,,plus,任绿枝
PA166134646,rs28399504,1446908972,GG,Patients with the GG genotype 1) may have poor metabolism of clopidogrel and 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.,携带GG基因型的患者，相比AA基因型，药物代谢可能较慢；发生次级心脑血管相关事件的风险可能更高,1,,0,,,,,plus,任绿枝
PA166153066,rs28399504,1447983181,AA,Patients with the AA genotype may have a decreased metabolism of mephenytoin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带AA基因型的患者，相比AG或GG基因型，药物代谢可能加强,1,,,,2,,,plus,任绿枝
PA166153066,rs28399504,1447983180,AG,Patients with the AG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带AG基因型的患者，相比AA基因型，药物代谢可能降低,1,,,,0,,,plus,任绿枝
PA166153066,rs28399504,1447983179,GG ,Patients with the GG genotype may have a decreased metabolism of mephenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带GG基因型的患者，相比AG或GG基因型，药物代谢可能降低,1,,,,0,,,plus,任绿枝
PA166134480,rs28399499,1447952990,CC,Patients with the CC genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带CC基因型的患者，相比TT基因型，药物暴露量可能增加,1,,,,0,,,plus,任绿枝
PA166134480,rs28399499,1447952991,CT,Patients with the CT genotype may have increased plasma drug exposure when treated with efavirenz as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带CT基因型的患者，相比TT基因型，药物暴露量可能增加,1,,,,0,,,plus,任绿枝
PA166134480,rs28399499,1447952992,TT,Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带TT基因型的患者，相比CT或CC基因型，药物暴露量可能降低,1,,,,2,,,plus,任绿枝
PA166134481,rs28399499,1444666901,CC,Patients with the CC genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带CC基因型的患者，相比TT基因型，药物暴露量可能增加,1,,,,0,,,plus,任绿枝
PA166134481,rs28399499,1444666902,CT,Patients with the CT genotype may have increased plasma drug exposure when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带CT基因型的患者，相比TT基因型，药物暴露量可能增加,1,,,,0,,,plus,任绿枝
PA166134481,rs28399499,1444666903,TT,Patients with the TT genotype may have decreased plasma drug exposure when treated with nevirapine as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's drug metabolism.,携带TT基因型的患者，相比CT或CC基因型，药物暴露量可能降低,1,,,,2,,,plus,任绿枝
PA166136159,rs28399499,1444666388,CC,Patients with the CC genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.,携带CC基因型的HIV感染者，相比TT基因型，用药后发生Stevens-Johnson综合征和中毒性表皮坏死松解症的风险可能增加,1,,,2,,,,plus,任绿枝
PA166136159,rs28399499,1444666389,CT,Patients with the CT genotype and HIV may have an increased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.,携带CT基因型的HIV感染者，相比TT基因型，用药后发生Stevens-Johnson综合征和中毒性表皮坏死松解症的风险可能增加,1,,,2,,,,plus,任绿枝
PA166136159,rs28399499,1444666390,TT,Patients with the TT genotype and HIV may have a decreased risk for Stevens-Johnson Syndrome/toxic epidermal necrolysis (SJS/TEN) when treated with nevirapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk for developing SJS/TEN when receiving nevirapine.,携带TT基因型的HIV感染者，相比CC或CT基因型，用药后发生Stevens-Johnson综合征和中毒性表皮坏死松解症的风险可能降低,1,,,0,,,,plus,任绿枝
PA166135274,rs28399433,1444667556,AA,Patients with the AA genotype and HIV may have decreased plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.,携带AA基因型的HIV感染者，相比AC或CC基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166135274,rs28399433,1444667557,AC,Patients with the AC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.,携带AC基因型的HIV感染者，相比AA基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166135274,rs28399433,1444667558,CC,Patients with the CC genotype and HIV may have increased plasma concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.,携带CC基因型的HIV感染者，相比AA基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166135469,rs28933397,1447992356,CC,"Patients with the CC genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype TT or CT. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CC基因型的患者，相比TT或CT基因型，用药后出现恶性高热的可能性较低,1,,,0,,,,plus,任绿枝
PA166135469,rs28933397,1447992357,CT,"Patients with the CT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CT基因型的患者，相比CC基因型，用药后出现恶性高热的可能性较高,1,,,2,,,,plus,任绿枝
PA166135469,rs28933397,1447992358,TT,"Patients with the TT genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CC. Please note: the T allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with TT genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. ",携带CT基因型的患者，相比CC基因型，用药后出现恶性高热的可能性较高,1,,,2,,,,plus,任绿枝
PA166134727,rs2884737,1184986372,AA,Patients with the AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's warfarin dose. ,携带AA基因型的患者，相比CC基因型，用药剂量可能需要更高,1,,,,,2,,plus,任绿枝
PA166134727,rs2884737,1184986373,AC,Patients with the AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence a patient's warfarin dose. ,携带AC基因型的患者，相比CC基因型，用药剂量可能需要更高,1,,,,,2,,plus,任绿枝
PA166134727,rs2884737,1184986374,CC,Patients with the CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's warfarin dose. ,携带CC基因型的患者，相比AA基因型，用药剂量可能需要更低,1,,,,,0,,plus,任绿枝
PA166163183,rs2942857,1448602110,AA,People who smoke and have the AA genotype may have increased clearance and decreased exposure to cotinine compared to people with the AC and CC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.,携带AA基因型的吸烟人群，相比AC或CC基因型，药物清除率可能更高，药物暴露量可能更低,1,,,,2,,,plus,任绿枝
PA166163183,rs2942857,1448602111,AC,People who smoke and have the AC genotype may have increased clearance and decreased exposure to cotinine compared to people with the CC genotype. Other clinical and genetic factors may affect metabolism and exposure of cotinine.,携带AC基因型的吸烟人群，相比CC基因型，药物清除率可能更高，药物暴露量可能更低,1,,,,2,,,plus,任绿枝
PA166163183,rs2942857,1448602112,CC,People who smoke and have the CC genotype may have decreased clearance and increased exposure to cotinine compared to people with the AA and AC genotypes. Other clinical and genetic factors may affect metabolism and exposure of cotinine.,携带CC基因型的吸烟人群，相比AC或AA基因型，药物清除率可能更低，药物暴露量可能更高,1,,,,0,,,plus,任绿枝
PA166135025,rs2952768,1446905840,CC,Patients with the CC genotype may have increased opioid analgesic requirements after surgery as compared to patients with the CT or TT genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.,携带CC基因型的术后病人，相比CT或TT基因型，用药剂量可能需要增加,1,,,,,2,,plus,任绿枝
PA166135025,rs2952768,1446905841,CT,Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.,携带CT基因型的术后病人，相比CC基因型，用药剂量可能需要减少,1,,,,,0,,plus,任绿枝
PA166135025,rs2952768,1446905842,TT,Patients with the TT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.,携带TT基因型的术后病人，相比CC基因型，用药剂量可能需要减少,1,,,,,0,,plus,任绿枝
PA166135026,rs2952768,1183574181,CC,"Patients with the CC genotype may have less vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to opioids.",携带CC基因型的患者，相比TT或CT基因型，用药后出现严重药物依赖的可能性较小,1,,,0,,,,plus,任绿枝
PA166135026,rs2952768,1183574182,CT,"Patients with the CT genotype may have more vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to opioids.",携带CT基因型的患者，相比CC基因型，用药后出现严重药物依赖的可能性较大,1,,,2,,,,plus,任绿枝
PA166135026,rs2952768,1183574183,TT,"Patients with the TT genotype may have more vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to opioids.",携带TT基因型的患者，相比CC基因型，用药后出现严重药物依赖的可能性较大,1,,,2,,,,plus,任绿枝
PA166136025,rs3077,1447949092,AA,Patients with AA genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.,携带AA基因型的乙型肝炎e抗原阴性的慢性乙肝患者，相比GG基因型，引起病毒学应答的可能性降低,1,,0,,,,,plus,任绿枝
PA166136025,rs3077,1447949091,AG,Patients with AG genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.,携带AG基因型的乙型肝炎e抗原阴性的慢性乙肝患者，相比GG基因型，引起病毒学应答的可能性降低,1,,0,,,,,plus,任绿枝
PA166136025,rs3077,1447949090,GG,Patients with GG genotype may have increased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B  as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.,携带GG基因型的乙型肝炎e抗原阴性的慢性乙肝患者，相比AA或AG基因型，引起病毒学应答的可能性增加,1,,2,,,,,plus,任绿枝
PA166152885,rs2960436,1447964348,AA,Patients with the AA genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.,携带AA基因型的胃癌患者，相比GG基因型，生存率可能更高,1,,2,,,,,plus,任绿枝
PA166152885,rs2960436,1447964349,AG,Patients with the AG genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.,携带AG基因型的胃癌患者，相比GG基因型，生存率可能更高,1,,2,,,,,plus,任绿枝
PA166152885,rs2960436,1447964350,GG,Patients with the GG genotype and stomach cancer may have better poorer survival outcomes when treated with fluorouracil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival outcome.,携带GG基因型的胃癌患者，相比AA或AG基因型，生存率可能更低,1,,0,,,,,plus,任绿枝
PA166135005,rs3025000,1183630627,CC,Patients with the CC genotype and macular degeneration may have a poorer response when treated with bevacizumab or ranibizumab as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.,携带CC基因型的黄斑变性患者，相比CT或TT基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135005,rs3025000,1183630628,CT,Patients with the CT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.,携带CT基因型的黄斑变性患者，相比CC基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166135005,rs3025000,1183630629,TT,Patients with the TT genotype and macular degeneration may have a better response when treated with bevacizumab or ranibizumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bevacizumab or ranibizumab.,携带TT基因型的黄斑变性患者，相比CC基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166161170,rs3087243,1448423691,AA,Patients with the AA genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.,携带AA基因型的牛皮癣患者，相比AG或GG基因型，用药后发生副作用的风险可能较高,1,,,2,,,,plus,任绿枝
PA166161170,rs3087243,1448423692,AG,Patients with the AG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.,携带AG基因型的牛皮癣患者，相比AA基因型，用药后发生副作用的风险可能较低,1,,,0,,,,plus,任绿枝
PA166161170,rs3087243,1448423693,GG,Patients with the GG genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.,携带GG基因型的牛皮癣患者，相比AA基因型，用药后发生副作用的风险可能较低,1,,,0,,,,plus,任绿枝
PA166153482,rs2965667,1447990848,AA,Individuals with the AA genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin. ,携带AA基因型的患者，相比TT基因型，用药后发展成结直肠癌的风险较高,1,,,2,,,,plus,任绿枝
PA166153482,rs2965667,1447990849,AT,Individuals with the AT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were more likely to develop colorectal cancer as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin. ,携带AT基因型的患者，相比TT基因型，用药后发展成结直肠癌的风险可能较高,1,,,2,,,,plus,任绿枝
PA166153482,rs2965667,1447990850,TT,Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin. ,携带TT基因型的患者，相比AA或AT基因型，用药后发展成结直肠癌的风险可能较低,1,,,0,,,,plus,任绿枝
PA166136046,rs3094188,1184764195,AA,Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ,携带AA基因型的患者，相比CC基因型，用药后发生严重皮肤副反应的风险可能增加,1,,,2,,,,plus,任绿枝
PA166136046,rs3094188,1184764196,AC,"Patients with genotype AC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype or may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带AC基因型的患者，相比CC基因型，用药后发生严重皮肤副反应的风险可能增加；相比AA基因型，用药后发生严重皮肤副反应的风险可能降低,1,,,1,,,,plus,任绿枝
PA166136046,rs3094188,1184764197,CC,"Patients with genotype CC may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带CC基因型的患者，相比AA基因型，用药后发生严重皮肤副反应的风险可能降低,1,,,0,,,,plus,任绿枝
PA166136107,rs310786,1444607375,CC,Women with the CC genotype and breast cancer may have increased lumbar bone loss when treated with tamoxifen as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.,携带CC基因型的女性乳腺癌患者，相比CT或TT基因型，用药后发生腰椎骨损伤的风险可能较高,1,女,,2,,,,FWD,任绿枝
PA166136107,rs310786,1444607376,CT,Women with the CT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.,携带CT基因型的女性乳腺癌患者，相比CC基因型，用药后发生腰椎骨损伤的风险可能较低,1,女,,0,,,,FWD,任绿枝
PA166136107,rs310786,1444607377,TT,Women with the TT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.,携带TT基因型的女性乳腺癌患者，相比CC基因型，用药后发生腰椎骨损伤的风险可能较低,1,女,,0,,,,FWD,任绿枝
PA166136190,rs3097671,1444667501,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带CC基因型的哮喘患者，相比CG或GG基因型，用药引发哮喘的可能性增加,1,,,2,,,,FWD,任绿枝
PA166136190,rs3097671,1444667502,CG,Patients with asthma and the CG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带CG基因型的哮喘患者，相比GG基因型，用药引发哮喘的可能性增加,1,,,2,,,,FWD,任绿枝
PA166136190,rs3097671,1444667503,GG,Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the CG or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带GG基因型的哮喘患者，相比CG或CC基因型，用药引发哮喘的可能性降低,1,,,0,,,,FWD,任绿枝
PA166158985,rs3114020,1448100496,CC,Patients with the CC genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. Other factors may affect concentrations of lamotrigine.,携带CC基因型的癫痫患者，相比TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166158985,rs3114020,1448100497,CT,Patients with the CT genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the TT genotype. Other factors may affect concentrations of lamotrigine.,携带CT基因型的癫痫患者，相比TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166158985,rs3114020,1448100498,TT,Patients with the TT genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the CC and CT genotypes. Other factors may affect concentrations of lamotrigine.,携带TT基因型的癫痫患者，相比CC或CT基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166136048,rs3099844,1184986498,AA,Female patients with the AA genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine. ,携带AA基因型的女性艾滋病患者，相比CC基因型，用药后发生Stevens-Johnson综合征的可能性增加,1,女,,2,,,,plus,任绿枝
PA166136048,rs3099844,1184986499,AC,Female patients with the AC genotype and acquired immunodeficiency syndrome (AIDS) may have an increased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the CC genotype and a decreased risk of Stevens-Johnson syndrome as compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine. ,携带AC基因型的女性艾滋病患者，相比CC基因型，用药后发生Stevens-Johnson综合征的可能性增加；相比AA基因型，用药后发生Stevens-Johnson综合征的可能性降低,1,女,,1,,,,plus,任绿枝
PA166136048,rs3099844,1184986500,CC,Female patients with the CC genotype and acquired immunodeficiency syndrome (AIDS) may have a decreased risk of Stevens-Johnson syndrome when treated with nevirapine as compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of Stevens-Johnson syndrome in patients treated with nevirapine. ,携带CC基因型的女性艾滋病患者，相比AA基因型，用药后发生Stevens-Johnson综合征的可能性降低,1,女,,0,,,,plus,任绿枝
PA166135689,rs3130100,1448106306,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带CC基因型的哮喘患者，相比CT或TT基因型，用药引起哮喘的风险可能增加,1,,,2,,,,FWD,任绿枝
PA166135689,rs3130100,1448106307,CT,Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT  genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带CT基因型的哮喘患者，相比TT基因型，用药引起哮喘的风险可能增加；相比CC基因型，用药引起哮喘的风险可能降低,1,,,1,,,,FWD,任绿枝
PA166135689,rs3130100,1448106308,TT,Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带TT基因型的哮喘患者，相比CT或TT基因型，用药引起哮喘的风险可能降低,1,,,0,,,,FWD,任绿枝
PA166136193,rs3129294,1444667551,AA,Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带AA基因型的哮喘患者，相比AC或CC基因型，用药引起哮喘的风险可能降低,1,,,0,,,,FWD,任绿枝
PA166136193,rs3129294,1444667552,AC,Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带AC基因型的哮喘患者，相比AA基因型，用药引起哮喘的风险可能增加；相比CC基因型，用药引起哮喘的风险可能降低,1,,,1,,,,FWD,任绿枝
PA166136193,rs3129294,1444667553,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带CC基因型的哮喘患者，相比AC或AA基因型，用药引起哮喘的风险可能增加,1,,,2,,,,FWD,任绿枝
PA166135583,rs3130931,1184764209,CC,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ,携带CC基因型的患者，相比TT基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更高,1,,,2,,,,plus,任绿枝
PA166135583,rs3130931,1184764210,CT,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.",携带CT基因型的患者，相比TT基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更高；相比CC基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更低,1,,,1,,,,plus,任绿枝
PA166135583,rs3130931,1184764211,TT,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带TT基因型的患者，相比CC基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性较低,1,,,0,,,,plus,任绿枝
PA166135582,rs3130501,1184764202,AA,"Patients with genotype AA may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带AA基因型的患者，相比GG基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性较低,1,,,0,,,,plus,任绿枝
PA166135582,rs3130501,1184764201,AG,"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带AG基因型的患者，相比AA基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更高；相比GG基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性更低,1,,,1,,,,plus,任绿枝
PA166135582,rs3130501,1184764200,GG,Patients with genotype GG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ,携带GG基因型的患者，相比AA基因型，发生严重的皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性较高,1,,,2,,,,plus,任绿枝
PA166160670,rs3213094,1448265268,CC,Patients with the CC genotype and Psoriasis may have decreased response to ustekinumab compared to patients with the CT genotype. Other clinical and genetic factors may affect response to ustekinumab.,携带CC基因型的牛皮癣患者，相比CT基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166160670,rs3213094,1448265269,CT,Patients with the CT genotype and Psoriasis may have increased response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.,携带CT基因型的牛皮癣患者，相比CC基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166160670,rs3213094,1448265270,TT,Patients with the TT genotype and Psoriasis were not found to have different response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.,携带TT基因型的牛皮癣患者，相比CC基因型，药物响应未发现差异,1,,,,,,,plus,任绿枝
PA166136167,rs3213239,1444666617,CCGG/CCGG,Patients with the CCGG/CCGG genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.,携带CCGG/CCGG基因型的非小细胞肺癌患者，相比del/del基因型，总生存期和无进展生存期可能更短,1,,0,,,,,FWD,任绿枝
PA166136167,rs3213239,1444666618,CCGG/del,Patients with the CCGG/del genotype and non-small-cell lung cancer may have shorter overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.,携带CCGG/del基因型的非小细胞肺癌患者，相比del/del基因型，总生存期和无进展生存期可能更短,1,,0,,,,,FWD,任绿枝
PA166136167,rs3213239,1444666619,del/del,Patients with the del/del genotype and non-small-cell lung cancer may have longer overall and progression-free survival times when treated with platinum-based chemotherapy as compared to patients with the CCGG/CCGG or CCGG/del genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.,携带del/del基因型的非小细胞肺癌患者，相比CCGG/CCGG或CCGG/del基因型，总生存期和无进展生存期可能更长,1,,2,,,,,FWD,任绿枝
PA166135598,rs3213619,1184987043,AA,Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.,携带AA基因型的高血压患者，相比AG或GG基因型，发展成血胆甾醇过多的可能性降低,1,,,0,,,,plus,任绿枝
PA166135598,rs3213619,1184987044,AG,Patients with the AG genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.,携带AG基因型的高血压患者，相比GG基因型，发展成血胆甾醇过多的可能性降低,1,,,0,,,,plus,任绿枝
PA166135598,rs3213619,1184987045,GG,Patients with the GG genotype and hypertension may have an increased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and AA genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.,携带GG基因型的高血压患者，相比AG或AA基因型，发展成血胆甾醇过多的可能性增加,1,,,2,,,,plus,任绿枝
PA166134080,rs316019,637880088,AA,Patients with the AA genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带AA基因型的患者，相比CC基因型，肾脏毒性的风险可能较低,1,,,0,,,,plus,任绿枝
PA166134080,rs316019,637880089,AC,Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带AC基因型的患者，相比CC基因型，肾脏毒性的风险可能较低,1,,,0,,,,plus,任绿枝
PA166134080,rs316019,637880090,CC,Patients with the CC genotype may have increased risk of nephrotoxicity in response to cisplatin treatment as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带CC基因型的患者，相比AC或AA基因型，肾脏毒性的风险可能较高,1,,,2,,,,plus,任绿枝
PA166135239,rs316019,1183631423,AA,Patients with the AA genotype may have decreased clearance of L-tryptophan as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的患者，相比AC或CC基因型，左旋色氨酸的清除率可能降低,1,,,,0,,,plus,任绿枝
PA166135239,rs316019,1183631424,AC,"Patients with the AC genotype may have decreased clearance of L-tryptophan as compared to patients with the CC genotype, but an increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.",携带AC基因型的患者，相比CC基因型，左旋色氨酸的清除率可能降低；相比AA基因型，清除率可能增加,1,,,,1,,,plus,任绿枝
PA166135239,rs316019,1183631425,CC,Patients with the CC genotype may have increased clearance of L-tryptophan as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的患者，相比AA或AC基因型，左旋色氨酸的清除率可能增加,1,,,,2,,,plus,任绿枝
PA166135366,rs316019,1446898178,AA,"No patients with the AA genotype were seen in the study population. However, patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin. ",无AA基因型的患者参与研究,1,,,,,,,plus,任绿枝
PA166135366,rs316019,1446898179,AC,"Patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin. ",携带AC基因型的患者，相比CC基因型，药物清除率可能降低,1,,,,0,,,plus,任绿枝
PA166135366,rs316019,1446898180,CC,"Patients with the CC genotype may have increased clearance of metformin as compared to patients with the AC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin. ",携带CC基因型的患者，相比AC基因型，药物清除率可能增加,1,,,,2,,,plus,任绿枝
PA166135734,rs316019,1448616421,AA,Patients with the AA genotype may have decreased risk of cisplatin-induced ototoxicity as compared to patients with AC or CC genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.,携带AA基因型的患者，相比AC或CC基因型，用药导致耳毒性的风险可能降低,1,,,0,,,,plus,任绿枝
PA166135734,rs316019,1448616422,AC,Patients with the AC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.,携带AC基因型的患者，相比AA基因型，用药导致耳毒性的风险可能增加,1,,,2,,,,plus,任绿枝
PA166135734,rs316019,1448616423,CC,Patients with the CC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.,携带CC基因型的患者，相比AA基因型，用药导致耳毒性的风险可能增加,1,,,2,,,,plus,任绿枝
PA166159399,rs316019,1448109593,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or CC, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.",携带AA基因型的儿童肿瘤患者，相比AC或CC基因型，心脏毒性的风险可能降低,1,,,0,,,,plus,任绿枝
PA166159399,rs316019,1448109594,AC,"Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and increased likelihood as compared to patients with the AA genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.",携带AC基因型的儿童肿瘤患者，相比CC基因型，心脏毒性的风险可能降低；相比AA基因型，心脏毒性的风险可能增加,1,,,1,,,,plus,任绿枝
PA166159399,rs316019,1448109595,CC,"Patients with the CC genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AC or AA, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.",携带CC基因型的儿童肿瘤患者，相比AC或AA基因型，心脏毒性的风险可能增加,1,,,2,,,,plus,任绿枝
PA166160844,rs316019,1448266988,AA,"Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.",携带AA基因型的非小细胞肺癌患者，相比CC基因型，毒性风险（尤其是肝脏毒性风险）可能增加,1,,,2,,,,plus,任绿枝
PA166160844,rs316019,1448266989,AC,"Patients with the AA genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.",携带AC基因型的非小细胞肺癌患者，相比CC基因型，毒性风险（尤其是肝脏毒性风险）可能增加,1,,,2,,,,plus,任绿枝
PA166160844,rs316019,1448266990,CC,"Patients with the CC genotype and non-small cell lung cancer may have decreased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the AA and AC genotypes. Other clinical and genetic factors may affect risk of toxicity.",携带CC基因型的非小细胞肺癌患者，相比AA或AC基因型，毒性风险（尤其是肝脏毒性风险）可能降低,1,,,0,,,,plus,任绿枝
PA166134895,rs324420,1446898818,AA,"Patients with the AA genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.",携带AA基因型的精神分裂症患者，相比CC基因型，体重增加的可能性增加,1,,,2,,,,plus,任绿枝
PA166134895,rs324420,1446898819,AC,"Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.",携带AC基因型的精神分裂症患者，相比CC基因型，体重增加的可能性增加,1,,,2,,,,plus,任绿枝
PA166134895,rs324420,1446898820,CC,"Patients with the CC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have a decreased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the AA or AC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.",携带CC基因型的精神分裂症患者，相比AA或AC基因型，体重增加的可能性降低,1,,,0,,,,plus,任绿枝
PA166134649,rs324420,982029688,AA,Men with the AA genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects. ,携带AA基因型的男性患者，相比CC基因型，药物依赖风险可能增加,1,男,,2,,,,plus,任绿枝
PA166134649,rs324420,982029689,AC,"Men with the AC genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype, or a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects. ",携带AC基因型的男性患者，相比CC基因型，药物依赖风险可能增加；相比AA基因型，药物依赖风险可能降低,1,男,,1,,,,plus,任绿枝
PA166134649,rs324420,982029690,CC,Men with the CC genotype may have a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects. ,携带CC基因型的男性患者，相比AA基因型，药物依赖风险可能降低,1,男,,0,,,,plus,任绿枝
PA166152844,rs324420,1447963690,AA,Patients with the AA genotype may be less likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence THC dependency. ,携带AA基因型的患者，相比AC或CC基因型，导致药物依赖的可能性降低,1,,,0,,,,plus,任绿枝
PA166152844,rs324420,1447963691,AC,Patients with the AC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency. ,携带AC基因型的患者，相比AA基因型，导致药物依赖的可能性增加,1,,,2,,,,plus,任绿枝
PA166152844,rs324420,1447963692,CC,Patients with the CC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency. ,携带CC基因型的患者，相比AA基因型，导致药物依赖的可能性增加,1,,,2,,,,plus,任绿枝
PA166163297,rs324420,1448603311,AA,Children with the AA genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.,携带AA基因型的儿童扁桃腺切除术患者，相比CC基因型，术后恶心呕吐的风险可能增加,1,,,2,,,,plus,任绿枝
PA166163297,rs324420,1448603312,AC,Children with the AC genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.,携带AC基因型的儿童扁桃腺切除术患者，相比CC基因型，术后恶心呕吐的风险可能增加,1,,,2,,,,plus,任绿枝
PA166163297,rs324420,1448603313,CC,Children with the CC genotype who are undergoing a tonsillectomy may have a decreased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of PONV.,携带CC基因型的儿童扁桃腺切除术患者，相比AA或AC基因型，术后恶心呕吐的风险可能降低,1,,,0,,,,plus,任绿枝
PA166152780,rs340874,1447962615,CC,Patients with the CC genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.,携带CC基因型的高血压患者，相比CT或TT基因型，空腹血糖水平升高幅度可能较大,1,,,2,,,,plus,任绿枝
PA166152780,rs340874,1447962616,CT,"Patients with the CT genotype and hypertension may have a greater increase in fasting glucose when treated with atenolol as compared to patients with the TT genotype, and a lower increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence fasting glucose levels.",携带CT基因型的高血压患者，相比TT基因型，空腹血糖水平升高幅度可能较大；相比CC基因型，空腹血糖水平升高幅度可能较小,1,,,1,,,,plus,任绿枝
PA166152780,rs340874,1447962617,TT,Patients with the TT genotype and hypertension may have a lower increase in fasting glucose when treated with atenolol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting glucose levels.,携带TT基因型的高血压患者，相比CT或CC基因型，空腹血糖水平升高幅度可能较小,1,,,0,,,,plus,任绿枝
PA166135163,rs34130495,1183618205,AA,Patients with the AA genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.,携带AA基因型的患者，相比GG基因型，血药浓度可能更高,1,,,,,,2,plus,任绿枝
PA166135163,rs34130495,1183618206,AG,Patients with the AG genotype may have increased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the GG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.,携带AG基因型的患者，相比GG基因型，血药浓度可能更高,1,,,,,,2,plus,任绿枝
PA166135163,rs34130495,1183618207,GG,Patients with the GG genotype may have decreased plasma concentrations of O-desmethyltramadol when exposed to tramadol in healthy individuals as compared to patients with the AA or AG genotype. Other genetic or clinical factors may also influence the clearance of tramadol.,携带GG基因型的患者，相比AA或AG基因型，血药浓度可能更低,1,,,,,,0,plus,任绿枝
PA166135713,rs34231037,1444686876,AA,"Patients with the AA genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib. ",携带AA基因型的肾脏肿瘤病人，相比AG或GG基因型，可能导致KDR水平升高，药物代谢增加，药物响应降低,1,,0,,2,,,plus,任绿枝
PA166135713,rs34231037,1444686877,AG,"Patients with the AG genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the GG genotypes. Conversely, patients with the AG genotype may have decreased steady state levels of KDR, and an increased response to pazopanib as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism and response to pazopanib. ",携带AG基因型的肾脏肿瘤病人，相比GG基因型，可能导致KDR水平升高，药物代谢增加，药物响应降低；相比AA基因型，可能导致KDR水平降低，药物响应更好,1,,1,,1,,,plus,任绿枝
PA166135713,rs34231037,1444686878,GG,"Patients with the GG genotype and Kidney Neoplasms may have decreased steady state levels of KDR, possibly leading to decreased metabolism of and increased response to pazopanib as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib. ",携带GG基因型的肾脏肿瘤病人，相比AG或AA基因型，可能导致KDR水平降低，药物代谢降低，药物响应更好,1,,2,,0,,,plus,任绿枝
PA166134469,rs3215400,982033498,C/del,Patients with the C/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.,携带C/del基因型的患者，相比CC基因型，药物中毒的风险增加,1,,,2,,,,plus,任绿枝
PA166134469,rs3215400,982033499,CC,"Patients with the CC genotype who are treated with cytarabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.",携带CC基因型的患者，相比del/del基因型，药物中毒的风险降低,1,,,0,,,,plus,任绿枝
PA166134469,rs3215400,982033500,del/del,Patients with the del/del genotype who are treated with cytarabine may have an increased risk of drug toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.,携带del/del基因型的患者，相比CC基因型，药物中毒的风险增加,1,,,2,,,,plus,任绿枝
PA166134470,rs3215400,1448099930,C/del,Patients with the C/del genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.,携带C/del基因型的患者，相比del/del基因型，发生3级手足综合症的可能性降低,1,,,0,,,,plus,任绿枝
PA166134470,rs3215400,1448099931,CC,Patients with the C/C genotype and cancer who are treated with capecitabine may have a decreased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the del/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.,携带C/C基因型的患者，相比del/del基因型，发生3级手足综合症的可能性降低,1,,,0,,,,plus,任绿枝
PA166134470,rs3215400,1448099932,del/del,Patients with the del/del genotype and cancer who are treated with capecitabine may have an increased likelihood of developing grade 3 hand-foot syndrome as compared to patients with the CC or C/del genotype. This has been contradicted in another (not statistically significant) study. Other genetic and clinical factors may also influence a patient's risk for adverse drug reactions.,携带del/del基因型的患者，相比C/del或CC基因型，发生3级手足综合症的可能性增加,1,,,2,,,,plus,任绿枝
PA166136445,rs34548976,1446903544,CC,"In pediatric patients with asthma and the CC genotype may have an increased response to beta-adrenergic inhalants as compared to patients with the CT and TT genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma. ",携带CC基因型的小儿哮喘患者，相比CT或TT基因型，药物响应可能更好,1,,2,,,,,FWD,任绿枝
PA166136445,rs34548976,1446903543,CT,"In pediatric patients with asthma and the CT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CC genotypes and an increased response to beta-adrenergic inhalants as compared to patients with the TT genotype. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma. ",携带CT基因型的小儿哮喘患者，相比CC基因型，药物响应可能较差；相比TT基因型，药物响应可能更好,1,,1,,,,,FWD,任绿枝
PA166136445,rs34548976,1446903542,TT,"In pediatric patients with asthma and the TT genotype may have a decreased response to beta-adrenergic inhalants as compared to patients with the CT and CC genotypes. Other clinical and genetic factors, such as stress, may also influence response to beta-adrenergics in patients with asthma. ",携带TT基因型的小儿哮喘患者，相比CT或CC基因型，药物响应可能较差,1,,0,,,,,FWD,任绿枝
PA166134689,rs352428,982031518,AA,Patients with the AA genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram. ,携带AA基因型的抑郁症患者，相比GG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134689,rs352428,982031519,AG,Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram. ,携带AG基因型的抑郁症患者，相比GG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134689,rs352428,982031520,GG,Patients with the GG genotype and depression may be more likely to respond to citalopram or escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.,携带GG基因型的抑郁症患者，相比AA基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166135798,rs3740065,1444703623,AA,"Patients with the AA genotype and leukemia who are treated with methotrexate may have decreased plasma level and decreased, but not absent, risk for toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.",携带AA基因型的白血病患者，相比AG或GG基因型，血药浓度可能降低，药物毒性风险可能降低,1,,,0,,,0,plus,任绿枝
PA166135798,rs3740065,1444703622,AG,Patients with the AG genotype and leukemia who are treated with methotrexate may have increased plasma level and increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带AG基因型的白血病患者，相比AA基因型，血药浓度可能较高，药物毒性风险可能较高,1,,,2,,,2,plus,任绿枝
PA166135798,rs3740065,1444703621,GG,Patients with the GG genotype and leukemia who are treated with methotrexate may have increased plasma level and increased risk for toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.,携带GG基因型的白血病患者，相比AA基因型，血药浓度可能较高，药物毒性风险可能较高,1,,,2,,,2,plus,任绿枝
PA166152694,rs3740065,1447960516,AA,Patients with the AA genotype and breast cancer may have an increased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the GG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.,携带AA基因型的乳腺癌患者，相比GG基因型，疾病复发的可能性增加,1,,0,,,,,plus,任绿枝
PA166152694,rs3740065,1447960517,AG,No significant association with breast cancer disease recurrence has been seen for patients with the AG genotype as compared to the AA genotype. ,携带AG基因型的乳腺癌患者，相比AA基因型，没有发现药物使用和疾病复发相关性的显著关系,1,,,,,,,plus,任绿枝
PA166152694,rs3740065,1447960518,GG,Patients with the GG genotype and breast cancer may have a decreased likelihood of disease recurrence when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also influence breast cancer recurrence.,携带GG基因型的乳腺癌患者，相比AA基因型，疾病复发的可能性降低,1,,2,,,,,plus,任绿枝
PA166135121,rs3740556,1183630669,AA,Patients with the AA genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.,携带AA基因型的肺癌患者，相比GG基因型，药物响应可能更好,1,,2,,,,,FWD,任绿枝
PA166135121,rs3740556,1183630670,AG,Patients with the AG genotype and lung cancer may have a better response when treated with platinum-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.,携带AG基因型的肺癌患者，相比GG基因型，药物响应可能更好,1,,2,,,,,FWD,任绿枝
PA166135121,rs3740556,1183630671,GG,Patients with the GG genotype and lung cancer may have a poorer response when treated with platinum-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.,携带GG基因型的肺癌患者，相比AA或AG基因型，药物响应可能较差,1,,0,,,,,FWD,任绿枝
PA166152947,rs3735451,1447980693,CC,Patients with the CC genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.,携带CC基因型的海洛因依赖者，相比TT基因型，副作用及阿片类药物戒断症状可能更严重,1,,,2,,,,FWD,任绿枝
PA166152947,rs3735451,1447980694,CT,"Patients with the CT genotype who are heroin dependent may have more severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the TT genotype, or less severe effects and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.",携带CT基因型的海洛因依赖者，相比TT基因型，副作用及阿片类药物戒断症状可能更严重；相比CC基因型，副作用及阿片类药物戒断症状可能更轻微,1,,,1,,,,FWD,任绿枝
PA166152947,rs3735451,1447980695,TT,Patients with the TT genotype who are heroin dependent may have less severe side effects and opioid withdrawal symptoms when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence side effects and opioid withdrawal symptoms in patients receiving methadone.,携带TT基因型的海洛因依赖者，相比CC基因型，副作用及阿片类药物戒断症状可能更轻微,1,,,0,,,,FWD,任绿枝
PA166135004,rs3740066,1183598054,CC,Patients with the CC genotype and non-small cell lung cancer may have an increased risk of diarrhea when treated with irinotecan as compared to patients with the CT or TT genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.,携带CC基因型的非小细胞肺癌患者，相比CT或TT基因型，腹泻的风险可能增加,1,,,2,,,,plus,任绿枝
PA166135004,rs3740066,1183598055,CT,Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.,携带CT基因型的非小细胞肺癌患者，相比CC基因型，腹泻的风险可能降低,1,,,0,,,,plus,任绿枝
PA166135004,rs3740066,1183598056,TT,Patients with the TT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.,携带TT基因型的非小细胞肺癌患者，相比CC基因型，腹泻的风险可能降低,1,,,0,,,,plus,任绿枝
PA166134499,rs3740066,1185000116,CC,Patients with the CC genotype and Epilepsy who are treated with antiepileptics may have a decreased risk of drug resistance as compared to patients with the CT or TT genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.,携带CC基因型的癫痫患者，相比CT或TT基因型，产生耐药的风险可能降低,1,,2,,,,,plus,任绿枝
PA166134499,rs3740066,1185000117,CT,Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.,携带CT基因型的癫痫患者，相比CC基因型，产生耐药的风险可能增加,1,,0,,,,,plus,任绿枝
PA166134499,rs3740066,1185000118,TT,Patients with the TT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.,携带TT基因型的癫痫患者，相比CC基因型，产生耐药的风险可能增加,1,,0,,,,,plus,任绿枝
PA166135834,rs3740066,1444704925,CC,Patients with the CC genotype may have increased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype TT or CT. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.,携带CC基因型的男性癫痫患者，相比TT或CT基因型，药物代谢可能增加,1,男,,,2,,,plus,任绿枝
PA166135834,rs3740066,1444704924,CT,Patients with the CT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.,携带CT基因型的男性癫痫患者，相比CC基因型，药物代谢可能降低,1,男,,,0,,,plus,任绿枝
PA166135834,rs3740066,1444704923,TT,Patients with the TT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.,携带TT基因型的男性癫痫患者，相比CC基因型，药物代谢可能降低,1,男,,,0,,,plus,任绿枝
PA166158992,rs3740066,1448100569,CC,"Patients with the CC genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.",携带CC基因型的器官移植患者，相比CT基因型，血药浓度可能更高,1,,,,,,2,plus,任绿枝
PA166158992,rs3740066,1448100570,CT,"Patients with the CT genotype and organ transplantation may have decreased concentrations of mycophenolic acid compared to patients with CC and TT genotypes. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.",携带CT基因型的器官移植患者，相比CC或TT基因型，血药浓度可能更低,1,,,,,,0,plus,任绿枝
PA166158992,rs3740066,1448100571,TT,"Patients with the TT genotype and organ transplantation may have increased concentrations of mycophenolic acid compared to patients with CT genotype. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.",携带TT基因型的器官移植患者，相比CT基因型，血药浓度可能更高,1,,,,,,2,plus,任绿枝
PA166135835,rs3758785,1444704952,AA,Patients with the AA genotype may have increased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.,携带AA基因型的高血压患者，相比GG或AG基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166135835,rs3758785,1444704953,AG,Patients with the AG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.,携带AG基因型的高血压患者，相比AA基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135835,rs3758785,1444704954,GG,Patients with the GG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.,携带GG基因型的高血压患者，相比AA基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135836,rs3758785,1444704958,AA,Patients with the AA genotype may have decreased response to candesartan in people with essential hypertension as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to candesartan.,携带AA基因型的高血压患者，相比GG或AG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135836,rs3758785,1444704959,AG,Patients with the AG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.,携带AG基因型的高血压患者，相比AA基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166135836,rs3758785,1444704960,GG,Patients with the GG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.,携带GG基因型的高血压患者，相比AA基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166135759,rs3761847,1444702668,AA,"Patients with the AA genotype may have increased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to anti-TNF treatments.",携带AA基因型的关节炎患者，相比GG或AG基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166135759,rs3761847,1444702667,AG,"Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.",携带AG基因型的关节炎患者，相比AA基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135759,rs3761847,1444702666,GG,"Patients with the GG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.",携带GG基因型的关节炎患者，相比AA基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135837,rs3764043,1444704945,CC,Patients with the CC genotype may have decreased imatinib clearance when treated with imatinib as compared to patients with genotype CT or TT. Other genetic and clinical factors may also influence the clearance of imatinib.,携带CC基因型的患者，相比CT或TT基因型，药物清除率可能较低,1,,,,0,,,FWD,任绿枝
PA166135837,rs3764043,1444704946,CT,Patients with the CT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the clearance of imatinib.,携带CT基因型的患者，相比CC基因型，药物清除率可能较高,1,,,,2,,,FWD,任绿枝
PA166135837,rs3764043,1444704947,TT,Patients with the TT genotype may have increased imatinib clearance when treated with imatinib as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the clearance of imatinib.,携带TT基因型的患者，相比CC基因型，药物清除率可能较高,1,,,,2,,,FWD,任绿枝
PA166135745,rs376817657,1444700842,CC,Patients with the CC genotype may have an increased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.,携带CC基因型的患者，相比CT基因型，药物代谢可能增加,1,,,,2,,,FWD,任绿枝
PA166135745,rs376817657,1444700841,TC,Patients with the CT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.,携带CT基因型的患者，相比CC基因型，药物代谢可能降低,1,,,,0,,,FWD,任绿枝
PA166135745,rs376817657,1444700840,TT,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.,携带TT基因型的患者，相比CC基因型，药物代谢可能降低,1,,,,0,,,FWD,任绿枝
PA166135474,rs3785161,1446909073,AA,Patients with the AA genotype and Coronary Disease who are treated with clopidogrel may have a decreased on-treatment platelet activity as compared to patients with the CC or CA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.,携带AA基因型的冠心病患者，相比CC或CA基因型，治疗期间血小板活性可能降低,1,,2,,,,,FWD,任绿枝
PA166135474,rs3785161,1446909074,CA,Patients with the CA genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.,携带CA基因型的冠心病患者，相比AA基因型，治疗期间血小板活性可能较高,1,,0,,,,,FWD,任绿枝
PA166135474,rs3785161,1446909075,CC,Patients with the CC genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.,携带CC基因型的冠心病患者，相比AA基因型，治疗期间血小板活性可能较高,1,,0,,,,,FWD,任绿枝
PA166136213,rs3786547,1444673041,CC,"Patients with the CC genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.",携带CC基因型的HIV感染者，相比TT基因型，发生严重的皮肤副反应的可能性更高,1,,,2,,,,FWD,任绿枝
PA166136213,rs3786547,1444673042,CT,"Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.",携带CT基因型的HIV感染者，相比TT基因型，发生严重的皮肤副反应的可能性更高；相比CC基因型，发生严重的皮肤副反应的可能性较低,1,,,1,,,,FWD,任绿枝
PA166136213,rs3786547,1444673043,TT,"Patients with the TT genotype and HIV may be at a decreased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.",携带TT基因型的HIV感染者，相比CC基因型，发生严重的皮肤副反应的可能性较低,1,,,0,,,,FWD,任绿枝
PA166136308,rs3775291,1444703513,CC,"Patients with the CC genotype and asthma who are treated with aspirin may have decreased, but not absent, risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.",携带CC基因型的哮喘患者，相比TT或CT基因型，用药导致呼吸系统疾病的风险降低,1,,,0,,,,plus,任绿枝
PA166136308,rs3775291,1444703511,CT,Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带CT基因型的哮喘患者，相比CC基因型，用药导致呼吸系统疾病的风险增加,1,,,2,,,,plus,任绿枝
PA166136308,rs3775291,1444703512,TT,Patients with the TT genotype and asthma who are treated with aspirin may have increased risk for Aspirin-Exacerbated Respiratory Disease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带TT基因型的哮喘患者，相比CC基因型，用药导致呼吸系统疾病的风险增加,1,,,2,,,,plus,任绿枝
PA166134187,rs3775291,655384915,CC,Children with the CC genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.,携带CC基因型的患者，相比CT基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166134187,rs3775291,655384916,CT,Children with the CT genotype may have a decreased response to measles vaccination as compared to patients with the CC and TT genotype. Other genetic and clinical factors may also influence response to measles vaccination.,携带CT基因型的患者，相比CC或TT基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134187,rs3775291,655384917,TT,Children with the TT genotype may have an increased response to measles vaccination as compared to patients with the CT genotype. Other genetic and clinical factors may also influence response to measles vaccination.,携带TT基因型的患者，相比CT基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166134657,rs3810651,982030420,AA,Patients with the AA genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. ,携带AA基因型的重度抑郁症患者，相比TT基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166134657,rs3810651,982030421,AT,Patients with the AT genotype and Major Depressive Disorder may be more likely to respond to venlafaxine treatment as compared to those with the TT genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. ,携带AT基因型的重度抑郁症患者，相比TT基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166134657,rs3810651,982030422,TT,Patients with the TT genotype and Major Depressive Disorder may be less likely to respond to venlafaxine treatment as compared to those with the AA or AT  genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment. ,携带TT基因型的重度抑郁症患者，相比AA或AT基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134682,rs3794271,1448099852,AA,"Patients with the AA genotype and rheumatoid arthritis may be more likely to respond to anti-TNF treatment as compared to patients with the GG or AG genotype. However, those with the AA genotype and psoriatic arthritis may be less likely to respond to anti-TNF treatment as compared to those with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.",携带AA基因型的类风湿性关节炎患者，相比GG或AG基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166134682,rs3794271,1448099853,AG,"Patients with the AG genotype and Rheumatoid Arthritis may be more likely to respond to anti-TNF treatment as compared to patients with the GG genotype but may be less likely to respond to anti-TNF treatment as compared to patients with the AA genotype. However, those with the AG genotype and psoriatic arthritis may be more likely to respond to anti-TNF treatment as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. ",携带AG基因型的类风湿性关节炎患者，相比GG基因型，药物响应可能更好；相比AA基因型，药物响应可能较差,1,,1,,,,,plus,任绿枝
PA166134682,rs3794271,1448099854,GG,"Patients with the GG genotype and Rheumatoid Arthritis may be less likely to respond to anti-TNF treatment as compared to patients with the AA genotype. However, those with the GG genotype and psoriatic arthritis may be more likely to respond to anti-TNF treatment as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. ",携带GG基因型的类风湿性关节炎患者，相比AA基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134682,rs3794271,1448099852,AA,"Patients with the AA genotype and rheumatoid arthritis may be more likely to respond to anti-TNF treatment as compared to patients with the GG or AG genotype. However, those with the AA genotype and psoriatic arthritis may be less likely to respond to anti-TNF treatment as compared to those with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.",但携带AA基因型的银屑病关节炎患者，相比GG或AG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134682,rs3794271,1448099853,AG,"Patients with the AG genotype and Rheumatoid Arthritis may be more likely to respond to anti-TNF treatment as compared to patients with the GG genotype but may be less likely to respond to anti-TNF treatment as compared to patients with the AA genotype. However, those with the AG genotype and psoriatic arthritis may be more likely to respond to anti-TNF treatment as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. ",但携带AG基因型的银屑病关节炎患者，相比AA基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166134682,rs3794271,1448099854,GG,"Patients with the GG genotype and Rheumatoid Arthritis may be less likely to respond to anti-TNF treatment as compared to patients with the AA genotype. However, those with the GG genotype and psoriatic arthritis may be more likely to respond to anti-TNF treatment as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. ",但携带GG基因型的银屑病关节炎患者，相比AA基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166135584,rs3815087,1184764214,AA,Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ,携带AA基因型的患者，相比GG基因型，用药后发生严重皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性增加,1,,,2,,,,plus,任绿枝
PA166135584,rs3815087,1184764215,AG,"Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype.  This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.",携带AG基因型的患者，相比GG基因型，用药后发生严重皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性增加；相比AA基因型，用药后发生严重皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性降低,1,,,1,,,,plus,任绿枝
PA166135584,rs3815087,1184764216,GG,"Patients with genotype GG may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带GG基因型的患者，相比AA基因型，用药后发生严重皮肤副反应（如Stevens Johnson综合征或毒性表皮坏死松解症）的可能性降低,1,,,0,,,,plus,任绿枝
PA166158989,rs3814995,1448100523,CC,Men with the CC genotype and hypertension may have reduced response to losartan compared to men with the CT and TT genotypes. Other factors may affect response to losartan.,携带CC基因型的男性高血压患者，相比CT或TT基因型，药物响应可能降低,1,男,0,,,,,plus,任绿枝
PA166158989,rs3814995,1448100524,CT,Men with the CT genotype and hypertension may have reduced response to losartan compared to men with the TT genotype. Other factors may affect response to losartan.,携带CT基因型的男性高血压患者，相比TT基因型，药物响应可能降低,1,男,0,,,,,plus,任绿枝
PA166158989,rs3814995,1448100525,TT,Men with the TT genotype and hypertension may have increased response to losartan compared to men with the CC and CT genotypes. Other factors may affect response to losartan.,携带TT基因型的男性高血压患者，相比CT或CC基因型，药物响应可能更好,1,男,2,,,,,plus,任绿枝
PA166135687,rs3818822,1444667439,AA,Patients with asthma and the AA genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带AA基因型的哮喘患者，相比AG或GG基因型，用药引起哮喘的可能性增加,1,,,2,,,,plus,任绿枝
PA166135687,rs3818822,1444667440,AG,Patients with asthma and the AG genotype may have an increased risk of aspirin induced asthma as compared to patients with the GG genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带AG基因型的哮喘患者，相比GG基因型，用药引起哮喘的可能性增加；相比AA基因型，用药引起哮喘的可能性降低,1,,,1,,,,plus,任绿枝
PA166135687,rs3818822,1444667441,GG,Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带GG基因型的哮喘患者，相比AG或AA基因型，用药引起哮喘的可能性降低,1,,,0,,,,plus,任绿枝
PA166134155,rs4086116,655384728,CC,Patients with the CC genotype may require an increased dose of acenocoumarol as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,携带CC基因型的患者，相比CT或TT基因型，用药剂量可能需要增加,1,,,,,2,,plus,任绿枝
PA166134155,rs4086116,655384727,CT,Patients with the CT genotype may require a lower dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,携带CT基因型的患者，相比CC基因型，用药剂量可能需要降低,1,,,,,0,,plus,任绿枝
PA166134155,rs4086116,655384726,TT,Patients with the TT genotype may require the lowest dose of acenocoumarol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence acenocoumarol dose.,携带TT基因型的患者，相比CC基因型，用药剂量可能需要减少,1,,,,,0,,plus,任绿枝
PA166136269,rs4086116,1444700560,CC,Patients with the CC genotype may require an increased dose of phenprocoumon as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence phenprocoumon dose.,携带CC基因型的患者，相比CT或TT基因型，可能需要增加用药剂量,1,,,,,2,,plus,任绿枝
PA166136269,rs4086116,1444700561,CT,Patients with the CT genotype may require a lower dose of phenprocoumon as compared to patients with the CC genotype and may require an increased dose of phenprocoumon as compared to patients with the TT. Other genetic and clinical factors may also influence phenprocoumon dose.,携带CT基因型的患者，相比CC基因型，可能需要减少用药剂量；相比TT基因型，可能需要增加用药剂量,1,,,,,1,,plus,任绿枝
PA166136269,rs4086116,1444700562,TT,Patients with the TT genotype may require the lowest dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.,携带TT基因型的患者，相比CC基因型，可能需要减少用药剂量,1,,,,,0,,plus,任绿枝
PA166135376,rs4124874,1444666086,GG,"Cancer patients with the GG genotype who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype. However, several subsequent studies have found no association between the GG genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.",携带GG基因型的癌症患者，相比TT基因型，用药后发生嗜中性粒细胞减少症的风险可能增加,1,,,2,,,,plus,任绿枝
PA166135376,rs4124874,1444666087,GT,"Cancer patients with the GT genotype who are treated with irinotecan may have an increased risk of Neutropenia as compared to patients with the TT genotype, or may have a decreased risk of Neutropenia as compared to patients with the GG genotype. However, several subsequent studies have found no association between the GT genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.",携带GT基因型的癌症患者，相比TT基因型，用药后发生嗜中性粒细胞减少症的风险可能增加；相比GG基因型，用药后发生嗜中性粒细胞减少症的风险可能降低,1,,,1,,,,plus,任绿枝
PA166135376,rs4124874,1444666088,TT,"Cancer patients with the TT genotype who are treated with irinotecan may have a decreased risk of Neutropenia as compared to patients with the GG genotype. However, several subsequent studies have found no association between the TT genotype and neutropenia, diarrhea or tumor response. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.",携带TT基因型的癌症患者，相比GG基因型，用药后发生嗜中性粒细胞减少症的风险可能降低,1,,,0,,,,plus,任绿枝
PA166135338,rs41303343,1183699867,A/del,"Transplant recipients with the A/del (CYP3A5 *1/*7) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the del/del (*1/*1) genotype, and have increased metabolism and require a higher dose of the drug as compared to patients with the AA (*7/*7) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.",携带A/del的移植受者，相比del/del基因型，可能需要减少药物剂量；相比AA基因型，代谢较快，用药剂量可能需要增加,1,,,,,1,,plus,任绿枝
PA166135338,rs41303343,1183699868,AA,"Transplant recipients with the AA (CYP3A5 *7/*7) genotype may have decreased metabolism of tacrolimus and require a lower dose of the drug as compared to patients with the A/del or del/del (*1/*7 or *1/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.",携带AA的移植受者，相比del/del或A/del基因型，用药剂量可能需要减少,1,,,,,0,,plus,任绿枝
PA166135338,rs41303343,1183699869,del/del,"Transplant recipients with the del/del (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus and require a higher dose of the drug as compared to patients with the A/del or AA (*1/*7 or *7/*7) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's tacrolimus dose requirements.",携带del/del的移植受者，相比A/del或AA基因型，用药剂量可能需要增加,1,,,,,2,,plus,任绿枝
PA166135371,rs4148323,1183698860,AA,"Patients with the AA (i.e. UGT1A1 *6/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.",携带AA基因型的心绞痛或心力衰竭患者，相比GG基因型，葡萄苷酸化作用可能降低,1,,,,0,,,plus,任绿枝
PA166135371,rs4148323,1183698861,AG,"Patients with the AG (i.e. UGT1A1 *1/*6) genotype and angina or heart failure may have decreased glucuronidation of carvedilol as compared to patients with the GG (*1/*1) genotype, or increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.",携带AG基因型的心绞痛或心力衰竭患者，相比GG基因型，葡萄苷酸化作用可能降低；相比AA基因型，葡萄苷酸化作用可能增加,1,,,,1,,,plus,任绿枝
PA166135371,rs4148323,1183698862,GG,"Patients with the GG (i.e. UGT1A1 *1/*1) genotype and angina or heart failure may have increased glucuronidation of carvedilol as compared to patients with the AA (*6/*6) genotype. UGT1A1 is responsible for the glucuronidation of target substrates, rendering them water soluble and allowing for their biliary or renal elimination. Other genetic and clinical factors may also influence metabolism of carvedilol.",携带GG基因型的心绞痛或心力衰竭患者，相比AA基因型，葡萄苷酸化作用可能增加,1,,,,2,,,plus,任绿枝
PA166135372,rs4148323,1183698827,AA,"No patients with this genotype were present in the study. However, patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk. ",携带AA基因型的患者没有参与此项研究,1,,,,,,,plus,任绿枝
PA166135372,rs4148323,1183698828,AG,"Patients with the AG genotype and HIV may have an increased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk. ",携带AG基因型的HIV感染者，相比GG基因型，发生高胆红素血症的可能性增加,1,,,2,,,,plus,任绿枝
PA166135372,rs4148323,1183698829,GG,"Patients with the GG genotype and HIV may have a decreased risk of developing hyperbilirubinemia during treatment with indinavir, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence hyperbilirubinemia risk. ",携带GG基因型的HIV感染者，相比AG基因型，发生高胆红素血症的可能性降低,1,,,0,,,,plus,任绿枝
PA166134473,rs4148323,1448422947,AA,Patients with the AA genotype with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia.,携带AA基因型的癌症患者，相比AG或GG基因型，发生嗜中性粒细胞减少症的可能性增加,1,,,2,,,,plus,任绿枝
PA166134473,rs4148323,1448422948,AG,"Patients with the AG genotype with cancer who are treated with irinotecan-based regimens may have an increased risk of neutropenia as compared to patients with the GG genotype, or a decreased risk of neutropenia compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia.",携带AG基因型的癌症患者，相比GG基因型，发生嗜中性粒细胞减少症的可能性增加；相比AA基因型，发生嗜中性粒细胞减少症的可能性降低,1,,,1,,,,plus,任绿枝
PA166134473,rs4148323,1448422949,GG,Patients with the GG genotype with cancer who are treated with irinotecan-based regimens may have a decreased risk of neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia.,携带GG基因型的癌症患者，相比AA基因型，发生嗜中性粒细胞减少症的可能性降低,1,,,0,,,,plus,任绿枝
PA166134771,rs4148323,1448422953,AA,"Patients with the AA (UGT1A1 *6/*6) genotype with cancer who are treated with irinotecan-based regimens may have 1) an increased risk of thrombocytopenia or diarrhea as compared to patients with the GG (*1/*1) genotype, and 2) may have decreased tumor response, progression-free survival or overall survival, as compared to patients with the AG (*1/*6) or GG (*1/*1) genotype. However, one study found increased progression-free survival or overall survival for patients who carried the A (*6) allele. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea.",携带AA基因型的癌症患者，相比GG基因型，发生血小板减少症和腹泻的风险可能增加；相比AG或GG基因型，无进展生存期和总生存期可能缩短,1,,,2,,,,plus,任绿枝
PA166134771,rs4148323,1448422954,AG,"Patients with the AG (*1/*6) genotype with cancer who are treated with irinotecan-based regimens may have 1) an increased risk of thrombocytopenia or diarrhea as compared to patients with the GG (*1/*1) genotype, and 2) may have increased tumor response, progression-free survival or overall survival as compared to patients with the AA (*6/*6) genotype. However, some studies have found no association with diarrhea, tumor response, progression-free survival or overall survival for this genotype as compared to those with the GG genotype. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea.",携带AG基因型的癌症患者，相比GG基因型，发生血小板减少症和腹泻的风险可能增加；相比AA基因型，无进展生存期和综生存期可能延长,1,,,1,,,,plus,任绿枝
PA166134771,rs4148323,1448422955,GG,"Patients with the GG (*1/*1) genotype with cancer who are treated with irinotecan-based regimens may have 1) a decreased risk of thrombocytopenia or diarrhea as compared to patients with the AA (*6/*6) or AG (*1/*6) genotype, and 2) may have increased tumor response, progression-free survival or overall survival, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's tumor response and survival, and risk of thrombocytopenia and diarrhea.",携带GG基因型的癌症患者，相比AA或AG基因型，发生血小板减少症和腹泻的风险可能降低；相比AA基因型，无进展生存期和综生存期可能延长,1,,,0,,,,plus,任绿枝
PA166134780,rs4148323,1184747132,AA,"Patients with the AA genotype and cancer may have decreased metabolism of SN-38 when treated with irinotecan as compared to patients with the AG or GG genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found decreased enzyme activity for the A allele compared to the G allele. Other genetic and clinical factors may also influence metabolism of SN-38.",携带AA基因型的癌症患者，相比AG或GG基因型，药物代谢可能较慢,1,,,,0,,,plus,任绿枝
PA166134780,rs4148323,1184747133,AG,"Patients with the AG genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the AA genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found decreased enzyme activity for the A allele compared to the G allele. Other genetic and clinical factors may also influence metabolism of SN-38.",携带AG基因型的癌症患者，相比AA基因型，药物代谢可能较快,1,,,,2,,,plus,任绿枝
PA166134780,rs4148323,1184747134,GG,"Patients with the GG genotype and cancer may have increased metabolism of SN-38 when treated with irinotecan as compared to patients with the AA genotype. SN-38 is the active metabolite of irinotecan, and is glucuronidated by UGT1A1. One in vitro study found increased enzyme activity for the G allele compared to the A allele. Other genetic and clinical factors may also influence metabolism of SN-38.",携带GG基因型的癌症患者，相比AA基因型，药物代谢可能较快,1,,,,2,,,plus,任绿枝
PA166134421,rs3918290,1448605555,CC,"Patients with the CC genotype (DPYD *1/*1) and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased clearance of fluoropyrimidine drugs and 2) decreased, but not non-existent, risk for drug toxicity as compared to patients with the CT or TT genotype (DPYD *1/*2A or *2A/*2A). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy.",携带CC基因型的癌症患者，相比CT或TT基因型，药物清除可能加快，药物中毒风险可能降低,1,,,0,2,,,plus,任绿枝
PA166134421,rs3918290,1448605556,CT,"Patients with the CT genotype (DPYD *1/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may 1) have DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) be at risk for severe or even fatal drug toxicity as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy.",携带CT基因型的癌症患者，相比CC基因型，药物清除可能较慢，药物中毒风险可能增加,1,,,2,0,,,plus,任绿枝
PA166134421,rs3918290,1448605557,TT,"Patients with the TT genotype (DPYD *2A/*2A) and cancer who are treated with fluoropyrimidine-based chemotherapy may 1) have complete DPYD deficiency and decreased clearance of fluoropyrimidine drugs and 2) be at risk for severe or even fatal drug toxicity as compared to patients with the CC genotype (DPYD *1/*1). Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil,  leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine based chemotherapy.",携带TT基因型的癌症患者，相比CC基因型，药物清除可能较慢，药物中毒风险可能增加,1,,,2,0,,,plus,任绿枝
PA166134141,rs4149015,655384628,AA,Patients carrying the AA genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. This variant is part of the SLCO1B1*17 haplotype. Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的患者，相比GG基因型，血药浓度可能较高，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134141,rs4149015,655384629,AG,Patients carrying the AG genotype may have increased pravastatin plasma AUC and decreased response to pravastatin compared with patients carrying the GG genotype. Other genetic and clinical factors may also influence a patient's response.,携带AG基因型的患者，相比GG基因型，血药浓度可能较高，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134141,rs4149015,655384630,GG,Patients carrying the GG genotype may have increased chance of response to pravastatin compared to patients carrying the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的患者，相比AA或AG基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166135003,rs4149015,1183595193,AA,Patients with the AA genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.,携带AA基因型的非小细胞肺癌患者，相比GG基因型，发生嗜中性粒细胞减少症的风险可能增加,1,,,2,,,,plus,任绿枝
PA166135003,rs4149015,1183595194,AG,Patients with the AG genotype and non-small cell lung cancer may have an increased risk of neutropenia when treated with irinotecan as compared to patients with the GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.,携带AG基因型的非小细胞肺癌患者，相比GG基因型，发生嗜中性粒细胞减少症的风险可能增加,1,,,2,,,,plus,任绿枝
PA166135003,rs4149015,1183595195,GG,Patients with the GG genotype and non-small cell lung cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AG or GG genotype. No association has been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia.,携带AA基因型的非小细胞肺癌患者，相比GG基因型，发生嗜中性粒细胞减少症的风险可能降低,1,,,0,,,,plus,任绿枝
PA166163770,rs4149178,1448616906,AA,Patients with the AA genotype and Cancer who are treated with Capecitabine may have an increased risk of Diarrhea as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine,携带AA基因型的癌症患者，相比AG或GG基因型，发生腹泻的风险可能增加,1,,,2,,,,plus,任绿枝
PA166163770,rs4149178,1448616907,AG,"Patients with the AG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine",携带AG基因型的癌症患者，相比AA基因型，发生腹泻的风险可能降低,1,,,0,,,,plus,任绿枝
PA166163770,rs4149178,1448616908,GG,"Patients with the GG genotype and Cancer who are treated with Capecitabine may have a decreased, but not absent, risk of Diarrhea as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of Diarrhea in patients with Cancer who are treated with Capecitabine",携带GG基因型的癌症患者，相比AA基因型，发生腹泻的风险可能降低,1,,,0,,,,plus,任绿枝
PA166134397,rs4149081,655387939,AA,"Patients with the AA genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have decreased clearance of methotrexate as compared to patients with the AG or GG genotype 2) may have a decreased, but not absent, risk of GI toxicity as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.",携带AA基因型的前体细胞成淋巴细胞白血病-淋巴瘤患者，相比AG或GG基因型，药物清除率可能降低，胃肠道毒性可能降低,1,,,0,0,,,plus,任绿枝
PA166134397,rs4149081,655387940,AG,Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.,携带AG基因型的前体细胞成淋巴细胞白血病-淋巴瘤患者，相比AA基因型，药物清除率可能增加，胃肠道毒性可能增加,1,,,2,2,,,plus,任绿枝
PA166134397,rs4149081,655387941,GG,Patients with the GG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate as compared to patients with the AA genotype 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.,携带GG基因型的前体细胞成淋巴细胞白血病-淋巴瘤患者，相比AA基因型，药物清除率可能增加，胃肠道毒性可能增加,1,,,2,2,,,plus,任绿枝
PA166134942,rs4149081,1158843286,AA,Patients with the AA genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.,携带AA基因型的冠心病患者，相比GG或AG基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166134942,rs4149081,1158843292,AG,Patients with the AG genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the GG genotype and a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.,携带AG基因型的冠心病患者，相比GG基因型，药物响应可能较好；相比AA基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134942,rs4149081,1158843298,GG,Patients with the GG genotype and Coronary Disease may have a decreased response to rosuvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.,携带GG基因型的冠心病患者，相比AG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135806,rs4149081,1444703871,AA,Patients with the AA genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.,携带AA基因型的冠心病患者，相比GG基因型，低密度脂蛋白胆固醇可能降低更多,1,,2,,,,,plus,任绿枝
PA166135806,rs4149081,1444703872,AG,Patients with the AG genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.,携带AG基因型的冠心病患者，相比GG基因型，低密度脂蛋白胆固醇可能降低更多,1,,2,,,,,plus,任绿枝
PA166135806,rs4149081,1444703873,GG,Patients with the GG genotype and Coronary Disease who are treated with simvastatin may have less LDL-C reduction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin,携带GG基因型的冠心病患者，相比AA基因型，低密度脂蛋白胆固醇可能降低较少,1,,0,,,,,plus,任绿枝
PA166135723,rs4149570,1444687041,AA,"Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.",携带AA基因型的炎症性肠病或克罗恩病患者，相比AC或CC基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166135723,rs4149570,1444687042,AC,"Patients with the AC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.",携带AC基因型的炎症性肠病或克罗恩病患者，相比AA基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135723,rs4149570,1444687043,CC,"Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.",携带CC基因型的炎症性肠病或克罗恩病患者，相比AA基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134815,rs4238001,1183594904,CC,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to fenofibrate. ,携带CC基因型的高甘油三酯血症患者，相比CT或TT基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134815,rs4238001,1183594905,CT,Patients with the CT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate. ,携带CT基因型的高甘油三酯血症患者，相比CC基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166134815,rs4238001,1183594906,TT,Patients with the TT genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate. ,携带TT基因型的高甘油三酯血症患者，相比CC基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166135145,rs3892097,1446905363,CC,Patients with the CC genotype (CYP2D6*1/*1) and depression who are treated with tricyclic antidepressants 1) may have a decreased likelihood of switching treatment indicating a reduced risk of side effects 2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects. ,携带CC基因型的抑郁症患者，相比TT基因型，因为副作用风险降低因此转换治疗方案的风险可能降低，可能需要增加剂量使用,1,,,0,,2,,minus,任绿枝
PA166135145,rs3892097,1446905364,CT,Patients with the CT genotype (CYP2D6*1/*4) and depression who are treated with tricyclic antidepressants 1) may have an increased likelihood of switching treatment indicating an increased risk of side effects as compared to patients with the CC genotype (CYP2D6*1/*1) 2) may require an increased dose of drug as compared to patients with the TT genotype (CYP2D6*4/*4) or may require a decreased dose of drug as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects. ,携带CT基因型的抑郁症患者，相比CC基因型，因为副作用风险增加因此转换治疗方案的风险可能增加，可能需要降低剂量使用；相比TT基因型，可能需要增加剂量使用,1,,,2,,1,,minus,任绿枝
PA166135145,rs3892097,1446905365,TT,Patients with the TT genotype (CYP2D6*4/*4) and depression who are treated with tricyclic antidepressants 1) may have an increased likelihood of switching treatment indicating an increased risk of side effects 2) may require a decreased dose of drug as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's metabolism of tricyclic antidepressants and risk of adverse effects. ,携带TT基因型的抑郁症患者，相比CC基因型，因为副作用风险增加因此转换治疗方案的风险可能增加，可能需要降低剂量使用,1,,,2,,0,,minus,任绿枝
PA166134150,rs3892097,655384702,CC,"Patients with the CC genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse.",携带CC基因型的患者，相比TT基因型，复发风险可能降低，潮热严重性可能增加,1,,2,2,,,,minus,任绿枝
PA166134150,rs3892097,655384701,CT,"Patients with the CT genotype who are treated with tamoxifen: 1) may have a decreased, but not absent, risk of relapse as compared to patients with the TT genotype 2) may have an increased severity in hot flashes as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of relapse.",携带CT基因型的患者，相比TT基因型，复发风险可能降低，潮热严重性可能增加,1,,2,2,,,,minus,任绿枝
PA166134150,rs3892097,655384700,TT,Patients with the TT genotype who are treated with tamoxifen: 1) may have an increased risk of relapse as compared to patients with the CT or CC genotype 2) may have a decreased severity in hot flashes as compared to patients with the CT or CC genotype.,携带TT基因型的患者，相比CT或CC基因型，复发风险可能增加，潮热严重性可能降低,1,,0,0,,,,minus,任绿枝
PA166134153,rs3892097,982030493,CC,Patients with the CC genotype who are treated with venlafaxine may have 1) average venlafaxine plasma concentration 2) an average risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CT or TT genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.,携带CC基因型的患者，相比CT或TT基因型，血药浓度可能达到平均值，副作用风险可能一般,1,,,1,,,1,minus,任绿枝
PA166134153,rs3892097,982030494,CT,Patients with the CT genotype who are treated with venlafaxine may have an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.,携带CT基因型的患者，相比CC基因型，副作用风险可能增加,1,,,2,,,,minus,任绿枝
PA166134153,rs3892097,982030495,TT,Patients with the TT genotype who are treated with venlafaxine may have 1)  increased venlafaxine plasma concentration 2) an increased risk of adverse effects (but check other variants for PM phenotype) as compared to patients with the CC genotype. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also influence a patient's response to venlafaxine.,携带TT基因型的患者，相比CC基因型，血药浓度可能增加，副作用风险可能增加,1,,,2,,,2,minus,任绿枝
PA166135171,rs3892097,1183619084,CC,"Patients with the CC genotype (CYP2D6*1/*1) and depression may require a higher dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's dose requirement. ",携带CC基因型的抑郁症患者，相比TT基因型，可能需要更高的药物剂量,1,,,,,2,,minus,任绿枝
PA166135171,rs3892097,1183619085,CT,"Patients with the CT genotype (CYP2D6*1/*4) and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the CC genotype (CYP2D6*1/*1) or may require a higher dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the TT genotype (CYP2D6*4/*4). Other genetic and clinical factors may also influence a patient's dose requirement. ",携带CT基因型的抑郁症患者，相比CC基因型，可能需要更低的药物剂量；相比TT基因型，可能需要更高的药物剂量,1,,,,,1,,minus,任绿枝
PA166135171,rs3892097,1183619086,TT,"Patients with the TT genotype (CYP2D6*4/*4) and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the CC genotype (CYP2D6*1/*1). Other genetic and clinical factors may also influence a patient's dose requirement. ",携带TT基因型的抑郁症患者，相比CC基因型，可能需要更低的药物剂量,1,,,,,0,,minus,任绿枝
PA166134261,rs3892097,982030643,CC,"Patients with CC genotype may have lower plasma concentrations of metoprolol and have smaller reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.",携带CC基因型的患者，相比TT基因型，血药浓度可能较低，心率、舒张压、平均动脉血压可能小幅度降低,1,,2,,,,0,minus,任绿枝
PA166134261,rs3892097,982030644,CT,"Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.",携CT基因型的患者，相比CC基因型，血药浓度可能较高，心率、舒张压、平均动脉血压可能降低较大,1,,0,,,,2,minus,任绿枝
PA166134261,rs3892097,982030645,TT,"Patients with TT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with CC genotype.  Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.",携TT基因型的患者，相比CC基因型，血药浓度可能较高，心率、舒张压、平均动脉血压可能大幅度降低,1,,0,,,,2,minus,任绿枝
PA166134506,rs4149601,1183633754,AA,Asian patients with the AA genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients.  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.,携带AA基因型的高血压亚洲患者，相比GG基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166134506,rs4149601,1183633755,AG,Asian patients with the AG genotype and Hypertension who are treated with hydrochlorothiazide may have a better response to treatment as compared to patients with the GG genotype. The opposite has been found in White patients. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.,携带AG基因型的高血压亚洲患者，相比GG基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166134506,rs4149601,1183633756,GG,Asian patients with the GG genotype and Hypertension who are treated with hydrochlorothiazide may have a poorer response to treatment as compared to patients with the AA or AG genotype.  The opposite has been found in White patients.  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.,携带GG基因型的高血压亚洲患者，相比AA或AG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135245,rs4149601,1447961309,AA,White patients with the AA genotype and hypertension who are treated with hydrochlorothiazide  may have poorer response as compared with patients with genotype GG.  The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.,携带AA基因型的高血压白种人患者，相比GG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166135245,rs4149601,1447961310,AG,White patients with the AG genotype and hypertension who are treated with hydrochlorothiazide may have better response  as compared with patients with genotype AA.  The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.,携带AG基因型的高血压白种人患者，相比AA基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166135245,rs4149601,1447961311,GG,White patients with the GG genotype and hypertension who are treated with hydrochlorothiazide  may have better response as compared with patients with genotype AA.    The opposite result has been seen in Asians (at a lower level of evidence).  Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide or other diuretic treatment.,携带GG基因型的高血压白种人患者，相比AA基因型，药物响应可能更好,1,,2,,,,,plus,任绿枝
PA166134888,rs4267385,1043880655,CC,"Patients with the CC genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.",携带CC基因型及rs4343为同型纯合子GG的患者，相比TT基因型，咳嗽风险可能降低,1,,,0,,,,plus,任绿枝
PA166134888,rs4267385,1043880656,CT,"Patients with the CT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.",携带CT基因型及rs4343为同型纯合子GG的患者，相比TT基因型，咳嗽风险可能降低,1,,,0,,,,plus,任绿枝
PA166134888,rs4267385,1043880657,TT,Patients with the TT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for cough.,携带TT基因型及rs4343为同型纯合子GG的患者，相比CT或CC基因型，咳嗽风险可能增加,1,,,2,,,,plus,任绿枝
PA166160743,rs4273729,1448266181,CC,"Patients with genotype CC may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.",携带CC基因型的丙型肝炎患者，相比GG基因型，迅速的和持续的病毒性应答可能较差,1,,0,,,,,plus,任绿枝
PA166160743,rs4273729,1448266180,CG,"Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.",携带CG基因型的丙型肝炎患者，相比GG基因型，迅速的和持续的病毒性应答可能较差,1,,0,,,,,plus,任绿枝
PA166160743,rs4273729,1448266179,GG,"Patients with genotype GG may have better rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.",携带GG基因型的丙型肝炎患者，相比CG或CC基因型，迅速的和持续的病毒性应答可能较好,1,,2,,,,,plus,任绿枝
PA166159197,rs4305746,1448106829,AA,Patients with the AA genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.,携带AA基因型的精神分裂症患者，相比GG基因型，简明精神病评定量表的分值可能有更大的提升,1,,2,,,,,plus,任绿枝
PA166159197,rs4305746,1448106830,AG,Patients with the AG genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.,携带AG基因型的精神分裂症患者，相比GG基因型，简明精神病评定量表的分值可能有更大的提升,1,,2,,,,,plus,任绿枝
PA166159197,rs4305746,1448106831,GG,Patients with the GG genotype and schizophrenia may have slower improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.,携带GG基因型的精神分裂症患者，相比AG或AA基因型，简明精神病评定量表的分值可能有更小的提升,1,,0,,,,,plus,任绿枝
PA166134813,rs430397,1183593446,CC,"Patients with the CC genotype and non-small cell lung cancer may have decreased resistance, decreased likelihood of early relapse, increased progression free survival and decreased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or non-small cell lung cancer-related death. ",携带CC基因型的非小细胞肺癌患者，相比TT基因型，耐药性、早期复发率和死亡率可能降低，无进展生存期可能增加,1,,2,,,,,plus,任绿枝
PA166134813,rs430397,1183593447,CT,"Patients with the CT genotype and non-small cell lung cancer may have decreased resistance, decreased likelihood of early relapse, increased progression free survival and decreased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or non-small cell lung cancer-related death. ",携带CT基因型的非小细胞肺癌患者，相比TT基因型，耐药性、早期复发率和死亡率可能降低，无进展生存期可能增加,1,,2,,,,,plus,任绿枝
PA166134813,rs430397,1183593448,TT,"Patients with the TT genotype and non-small cell lung cancer may have increased resistance, increased likelihood of early relapse, decreased progression free survival and increased risk of non-small cell lung cancer-related death when treated with platinum compounds (cisplatin or carboplatin) as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence resistance to platinum compounds, relapse, progression-free survival or carcinoma, non-smal cell lung cancer-related death. ",携带TT基因型的非小细胞肺癌患者，相比CT或CC基因型，耐药性、早期复发率和死亡率可能增加，无进展生存期可能降低,1,,0,,,,,plus,任绿枝
PA166134145,rs429358,655384667,CC,"Patients with the CC genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.",携带CC基因型的患者，相比TT基因型，治疗HIV时血脂升高可能性较大,1,,,2,,,,plus,任绿枝
PA166134145,rs429358,655384668,CT,"Patients with the CT genotype who are treated with antiretrovirals for HIV such as ritonavir may have an increased risk for elevated plasma lipids as compared to patients with the TT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.",携带CT基因型的患者，相比TT基因型，治疗HIV时血脂升高可能性较大,1,,,2,,,,plus,任绿枝
PA166134145,rs429358,655384669,TT,"Patients with the TT genotype who are treated with antiretrovirals for HIV such as ritonavir may have a decreased but not non-existent risk for elevated plasma lipids as compared to patients with the CC or CT genotype. Other genetic and clinical factors, in particular rs7412, may also influence a patient's risk for adverse events with ritonavir treatment.",携带CC基因型的患者，相比CT或CC基因型，治疗HIV时血脂升高可能性降低,1,,,0,,,,plus,任绿枝
PA166134149,rs4343,655384697,AA,Patients with the AA genotype and erectile dysfunction who are treated with sildenafil may have an increased chance of positive erectile response as compared to patient's with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.,携带AA基因型的勃起功能障碍患者，相比AG或GG基因型，药物响应可能增加,1,男,2,,,,,plus,任绿枝
PA166134149,rs4343,655384696,AG,Patients with the AG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.,携带AG基因型的勃起功能障碍患者，相比AA基因型，药物响应可能降低,1,男,0,,,,,plus,任绿枝
PA166134149,rs4343,655384695,GG,Patients with the GG genotype and erectile dysfunction who are treated with sildenafil may have a decreased chance of positive erectile response as compared to patient's with the AA genotype. Other genetic and clinical factors may also influence a patient's response to sildenafil.,携带GG基因型的勃起功能障碍患者，相比AA基因型，药物响应可能降低,1,男,0,,,,,plus,任绿枝
PA166134410,rs4343,982036382,AA,"Patients with the AA genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.",携带AA基因型的慢性心力衰竭患者，相比GG基因型，药物治疗与改善左心室射血分数、收缩末期和舒张末期的容积的作用相关,1,,2,,,,,plus,任绿枝
PA166134410,rs4343,982036383,AG,"Patients with the AG genotype are associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.",携带AG基因型的慢性心力衰竭患者，相比GG基因型，药物治疗与改善左心室射血分数、收缩末期和舒张末期的容积的作用相关,1,,2,,,,,plus,任绿枝
PA166134410,rs4343,982036384,GG,"Patients with the GG genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response.",携带GG基因型的慢性心力衰竭患者，相比AG或AA基因型，药物治疗与改善左心室射血分数、收缩末期和舒张末期的容积的作用可能较小,1,,0,,,,,plus,任绿枝
PA166135642,rs4363657,1444706247,CC,Patients with the CC genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.,携带CC基因型的患者，相比TT基因型，肌病风险可能增加,1,,,2,,,,plus,任绿枝
PA166135642,rs4363657,1444706248,CT,Patients with the CT genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.,携带CT基因型的患者，相比TT基因型，肌病风险可能增加,1,,,2,,,,plus,任绿枝
PA166135642,rs4363657,1444706249,TT,Patients with the TT genotype may be at decreased risk of myopathy when treated with simvastatin as compared to patients with the CC genotype.  Other genetic and clinical factors may influence also a patient's risk of myopathy.,携带TT基因型的患者，相比CC基因型，肌病风险可能降低,1,,,0,,,,plus,任绿枝
PA166135816,rs4410790,1444704078,CC,Patients with the CC genotype may have increased metabolism of olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.,携带CC基因型的患者，相比CT或TT基因型，药物代谢可能较快,1,,,,2,,,plus,任绿枝
PA166135816,rs4410790,1444704077,CT,Patients with the CT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.,携带CT基因型的患者，相比CC基因型，药物代谢可能较慢,1,,,,0,,,plus,任绿枝
PA166135816,rs4410790,1444704076,TT,Patients with the TT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.,携带TT基因型的患者，相比CC基因型，药物代谢可能较慢,1,,,,0,,,plus,任绿枝
PA166159207,rs4402960,1448103965,GG,Patients with the GG genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to repaglinide.,携带GG基因型的II型糖尿病患者，相比GT或TT基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166159207,rs4402960,1448103966,GT,Patients with the GT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.,携带GT基因型的II型糖尿病患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166159207,rs4402960,1448103967,TT,Patients with the TT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.,携带TT基因型的II型糖尿病患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166136206,rs445925,1444668470,AA,Patients with the AA genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. ,携带AA基因型的患者，相比AG或GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166136206,rs445925,1444668471,AG,Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. ,携带AG基因型的患者，相比GG基因型，药物响应可能增加；相比AA基因型，药物响应可能降低,1,,1,,,,,plus,任绿枝
PA166136206,rs445925,1444668472,GG,Patients with the GG genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors. ,携带GG基因型的患者，相比AA或AG基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166134509,rs4444903,1444665977,AA,Patients with the AA genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.,携带AA基因型的患者，相比GG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134509,rs4444903,1444665978,AG,Patients with the AG genotype who are treated with cetuximab may have a poorer response as compared to patients with the GG genotype or may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.,携带AG基因型的患者，相比GG基因型，药物响应可能较差；相比AA基因型，药物响应可能较好,1,,1,,,,,plus,任绿枝
PA166134509,rs4444903,1444665979,GG,Patients with the GG genotype who are treated with cetuximab may have a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cetuximab treatment.,携带GG基因型的患者，相比AA基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166159005,rs4516035,1448100788,CC,"Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. ",携带CC基因型的患者，相比CT或TT基因型，药物清除可能减少,1,,,,0,,,FWD,任绿枝
PA166159005,rs4516035,1448100789,CT,"Patients with the CT genotype may have decreased clearance of midazolam as compared to patients with the TT genotype, and increased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. ",携带CT基因型的患者，相比TT基因型，药物清除可能减少，相比CC基因型，药物清除可能增加,1,,,,1,,,FWD,任绿枝
PA166159005,rs4516035,1448100790,TT,"Patients with the TT genotype may have increased clearance of midazolam as compared to patients with the CC or CT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam. ",携带TT基因型的患者，相比CC或CT基因型药物清除可能增加,1,,,,2,,,FWD,任绿枝
PA166136170,rs4541111,1444666697,AA,Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.,携带AA基因型的非小细胞肺癌患者，相比CC基因型，生存期可能较长,1,,2,,,,,REV,任绿枝
PA166136170,rs4541111,1444666698,AC,Patients with the AC genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.,携带AC基因型的非小细胞肺癌患者，相比CC基因型，生存期可能较长,1,,2,,,,,REV,任绿枝
PA166136170,rs4541111,1444666699,CC,Patients with the CC genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.,携带CC基因型的非小细胞肺癌患者，相比AA或AC基因型，生存期可能较短,1,,0,,,,,REV,任绿枝
PA166134300,rs45511401,655385982,GG,"Patients with the GG genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.",携带GG基因型的非霍奇金氏淋巴瘤患者，相比TT基因型，药物中毒风险可能降低,1,,,0,,,,FWD,任绿枝
PA166134300,rs45511401,655385983,GT,"Patients with the GT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxocity as compared to patients with the GG genotype or may have a decreased, but not absent, risk for cardiotoxocity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.",携带GT基因型的非霍奇金氏淋巴瘤患者，相比GG基因型，药物中毒风险可能增加，相比TT基因型，药物中毒风险可能降低,1,,,1,,,,FWD,任绿枝
PA166134300,rs45511401,655385984,TT,Patients with the TT genotype and non-Hodgkin lymphoma who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.,携带TT基因型的非霍奇金氏淋巴瘤患者，相比GG基因型，药物中毒风险可能增加,1,,,2,,,,FWD,任绿枝
PA166134683,rs4532,982031316,CC,Patients with the CC genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.,携带CC基因型的躁郁症患者，相比TT基因型，药物响应可能降低,1,,0,,,,,FWD,任绿枝
PA166134683,rs4532,982031317,CT,Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.,携带CT基因型的躁郁症患者，相比TT基因型，药物响应可能降低,1,,0,,,,,FWD,任绿枝
PA166134683,rs4532,982031318,TT,Patients with the TT genotype and Bipolar Disorder may have an increased response to lithium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to treatment.,携带TT基因型的躁郁症患者，相比CC基因型，药物响应可能增加,1,,2,,,,,FWD,任绿枝
PA166158952,rs4532,1448100203,CC,Patients with the CC genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.,携带CC基因型的患者，相比TT基因型，尼古丁依赖风险可能降低,1,,,0,,,,FWD,任绿枝
PA166158952,rs4532,1448100204,CT,"Patients with the CT genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype, or increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.",携带CT基因型的患者，相比TT基因型，尼古丁依赖风险降低，相比CC基因型，风险可能增加,1,,,1,,,,FWD,任绿枝
PA166158952,rs4532,1448100205,TT,Patients with the TT genotype may be at increased risk for nicotine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.,携带TT基因型的患者，相比CC基因型，尼古丁依赖的风险可能增加,1,,,2,,,,FWD,任绿枝
PA166135662,rs4532,1444608245,CC,"Patients with the CC genotype and attention deficit hyperactivity disorder (ADHD) may have an increased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine. ",携带CC基因型的多动症患者，相比CT或TT基因型，不合群或恶心风险可能增加,1,,,2,,,,FWD,任绿枝
PA166135662,rs4532,1444608246,CT,"Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine. ",携带CT基因型的多动症患者，相比CC基因型，不合群或恶心的风险可能降低,1,,,0,,,,FWD,任绿枝
PA166135662,rs4532,1444608247,TT,"Patients with the TT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine. ",携带TT基因型的多动症患者，相比CC基因型，不合群或恶心的风险可能降低,1,,,0,,,,FWD,任绿枝
PA166136264,rs45605536,1444700483,CC,Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib. ,携带CC基因型患者，相比TT基因型，药物敏感性可能降低,1,,0,,,,,REV,任绿枝
PA166136264,rs45605536,1444700484,CT,Patients with the CT genotype are not studied. But based on in-vitro experiments the T allele may have an association with increased sensitivity to dasatinib or imatinib as compared to the C allele. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.,携带CT基因型患者尚无研究,1,,,,,,,REV,任绿枝
PA166136264,rs45605536,1444700485,TT,Patients with TT genotype may have an increased sensitivity to dasatinib or imatinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib. ,携带TT基因型患者，相比CC基因型，药物敏感性可能增加,1,,2,,,,,REV,任绿枝
PA166134186,rs4646,655384911,AA,Patients with the AA genotype who are treated with letrozole may have improved treatment efficacy compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的患者，相比CC基因型，可能治疗效果较好,1,,2,,,,,FWD,任绿枝
PA166134186,rs4646,655384912,AC,Patients with the AC genotype who are treated with letrozole may have improved treatment efficacy compared to patients with the CC genotype.  Other genetic and clinical factors may also influence a patient's response.,携带AC基因型的患者，相比CC基因型，可能治疗效果较好,1,,2,,,,,FWD,任绿枝
PA166134186,rs4646,655384913,CC,Patients with the CC genotype who are treated with letrozole may have decreased treatment efficacy compared to patients with the AA or AC genotype.  Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的患者，相比AC或AA基因型，可能治疗效果较差,1,,0,,,,,FWD,任绿枝
PA166136413,rs4646,1446897378,AA,"Post-menopausal women with breast cancer and the AA genotype may have a reduced response to anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, tamoxifen, or radiotherapy as compared to post-menopausal women with the AC and CC genotypes. ",携带AA基因型的绝经后乳腺癌患者，相比AC或CC基因型，药物响应可能降低,1,女,0,,,,,FWD,任绿枝
PA166136413,rs4646,1446897379,AC,"Post-menopausal women with breast cancer and the AC genotype may have an improved response to anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, tamoxifen, or radiotherapy as compared to post-menopausal women with the AA genotypes. ",携带AC基因型的绝经后乳腺癌患者，相比AA基因型，药物响应可能增加,1,女,2,,,,,FWD,任绿枝
PA166136413,rs4646,1446897380,CC,"Post-menopausal women with breast cancer and the CC genotype may have an improved response to anastrozole, cyclophosphamide, docetaxel, doxorubicin, epirubicin, exemestane, fluorouracil, letrozole, paclitaxel, tamoxifen, or radiotherapy as compared to post-menopausal women with the AA genotypes. ",携带CC基因型的绝经后乳腺癌患者，相比AA基因型，药物响应可能增加,1,女,2,,,,,FWD,任绿枝
PA166135982,rs4646,1447681826,AA,"Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin. ",携带AA基因型的绝经后乳腺癌患者，相比AC或CC基因型，血浆高密度脂蛋白胆固醇浓度可能降低,1,女,,2,,,,FWD,任绿枝
PA166135982,rs4646,1447681827,AC,"Post-menopausal women with the AC genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of hdl cholesterol as compared to women with the CC genotype and increased plasma concentrations as compared to women with the AA genotype. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin. ",携带AC基因型的绝经后乳腺癌患者，相比CC基因型，血浆高密度脂蛋白胆固醇浓度可能降低，相比AA基因型，血浆高密度脂蛋白胆固醇浓度可能升高,1,女,,1,,,,FWD,任绿枝
PA166135982,rs4646,1447681828,CC,"Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AA or AC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin. ",携带CC基因型的绝经后乳腺癌患者，相比AC或AA基因型，血浆高密度脂蛋白胆固醇浓度可能升高,1,女,,0,,,,FWD,任绿枝
PA166134898,rs4149056,1183685550,CC,"Patients with the CC genotype who are treated with pravastatin may have a smaller reduction in total cholesterol as compared to patients with the TT genotype. This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ",携带CC基因型的患者，相比TT基因型，总胆固醇可能有较小程度的降低,1,,0,,,,,plus,任绿枝
PA166134898,rs4149056,1183685551,CT,"Patients with the CT genotype who are treated with pravastatin may have a smaller reduction in total cholesterol as compared to patients with the TT genotype.  This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ",携带CT基因型的患者，相比TT基因型，总胆固醇可能有较小程度的降低,1,,0,,,,,plus,任绿枝
PA166134898,rs4149056,1183685552,TT,"Patients with the TT genotype who are treated with pravastatin may have a larger reduction in total cholesterol as compared to patients with the CC or CT genotype.  This has not been found in all studies, and the association between this variant and pravastatin response remains unclear. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ",携带TT基因型的患者，相比CC或CT基因型，总胆固醇可能有较大程度的降低,1,,2,,,,,plus,任绿枝
PA166134900,rs4149056,1448525343,CC,"Patients with the CC genotype and who are treated with atorvastatin may have 1) lower oral clearance and higher plasma concentrations of atorvastatin 2) an increased risk of composite adverse events but not an increased risk of myalgia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.  ",携带CC基因型的患者，相比TT基因型，可能有较高的血药浓度和较低的清除能力，副作用风险可能增加,1,,,2,0,,2,plus,任绿枝
PA166134900,rs4149056,1448525344,CT,"Patients with the CT genotype and who are treated with atorvastatin may have 1) lower oral clearance and higher plasma concentrations of atorvastatin 2) an increased risk of composite adverse events but not an increased risk of myalgia, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.  ",携带CT基因型的患者，相比TT基因型，可能有较高的血药浓度和较低的清除能力，副作用风险可能增加,1,,,2,0,,2,plus,任绿枝
PA166134900,rs4149056,1448525345,TT,"Patients with the TT genotype and who are treated with atorvastatin may have 1) higher oral clearance and lower plasma concentrations of atorvastatin 2) a decreased risk of composite adverse events but not a decreased risk of myalgia, as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment and atorvastatin pharmacokinetics.  ",携带TT基因型的患者，相比CT和CC基因型，可能有较低的血药浓度和较高的清除能力，副作用风险可能降低,1,,,0,2,,0,plus,任绿枝
PA166134143,rs4149056,655384646,CC,Patients with the CC genotype may have increased mean plasma AUC of repaglinide and greater blood glucose-lowering effect in response to repaglinide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的患者，相比CT或TT基因型，平均血浆药物暴露量（AUC）可能较高，降血糖效应可能较好,1,,2,,,,,plus,任绿枝
PA166134143,rs4149056,655384647,CT,Patients with the CT genotype may have decreased mean plasma AUC of repaglinide and lower blood glucose-lowering effect in response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.,携带CT基因型的患者，相比CC基因型，平均血浆药物暴露量（AUC）可能较低，降血糖效应可能较差,1,,0,,,,,plus,任绿枝
PA166134143,rs4149056,655384648,TT,Patients with the TT genotype may have decreased mean plasma AUC of repaglinide and lower blood glucose-lowering effect in response to repaglinide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的患者，相比CC基因型，平均血浆药物暴露量（AUC）可能较低，降血糖效应可能较差,1,,0,,,,,plus,任绿枝
PA166135826,rs4149056,1444704361,CC,Patients with the CC genotype may have increased plasma level of lopinavir as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.,携带CC基因型的患者，相比CT或TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166135826,rs4149056,1444704362,CT,Patients with the CT genotype may have decreased plasma level of lopinavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.,携带CT基因型的患者，相比CC基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166135826,rs4149056,1444704363,TT,Patients with the TT genotype may have decreased plasma level of lopinavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir.,携带TT基因型的患者，相比CC基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166134118,rs4149056,1447983129,CC,Patients with the CC genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带CC基因型的患者，相比CT或TT基因型，肌病的风险可能较高,1,,,2,,,,plus,任绿枝
PA166134118,rs4149056,1447983130,CT,Patients with the CT genotype may have a higher risk of simvastatin-related myopathy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带CT基因型的患者，相比TT基因型，肌病的风险可能较高,1,,,2,,,,plus,任绿枝
PA166134118,rs4149056,1447983131,TT,Patients with the TT genotype may have a lower risk of simvastatin-related myopathy as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.,携带TT基因型的患者，相比CT或CC基因型，肌病的风险可能较低,1,,,0,,,,plus,任绿枝
PA166134399,rs4149056,1444666725,CC,Pediatric patients with the CC genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.,携带CC基因型的儿童急性成淋巴细胞性白血病患者，相比TT基因型，药物清除可能较低,1,,,,0,,,plus,任绿枝
PA166134399,rs4149056,1444666726,CT,Pediatric patients with the CT genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.,携带CT基因型的儿童急性成淋巴细胞性白血病患者，相比TT基因型，药物清除可能较低,1,,,,0,,,plus,任绿枝
PA166134399,rs4149056,1444666727,TT,Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have increased clearance of methotrexate as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of methotrexate.,携带TT基因型的儿童急性成淋巴细胞性白血病患者，相比CC或CT基因型，药物清除可能较高,1,,,,2,,,plus,任绿枝
PA166135108,rs4149056,1183615195,CC,"Patients with the CC genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.",携带CC基因型的癌症患者，相比TT基因型，嗜中性白血球减少症的风险可能较高,1,,,2,,,,plus,任绿枝
PA166135108,rs4149056,1183615196,CT,"Patients with the CT genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. However, a different study of similar size found no association between the CT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.",携带CT基因型的癌症患者，相比TT基因型，嗜中性白血球减少症的风险可能较高,1,,,2,,,,plus,任绿枝
PA166135108,rs4149056,1183615197,TT,"Patients with the TT genotype and cancer may have a decreased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the CC or CT genotype. However, a different study of similar size found no association between the TT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.",携带TT基因型的癌症患者，相比CC或CT基因型，嗜中性白血球减少症的风险可能较低,1,,,0,,,,plus,任绿枝
PA166134617,rs4149056,982031455,CC,Patients with the CC genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.,携带CC基因型的患者，相比CT或TT基因型，药物诱导的横纹肌溶解风险可能较高,1,,,2,,,,plus,任绿枝
PA166134617,rs4149056,982031456,CT,Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.,携带CT基因型的患者，相比TT基因型，药物诱导的横纹肌溶解风险可能较高,1,,,2,,,,plus,任绿枝
PA166134617,rs4149056,982031457,TT,Patients with the TT genotype may have a lower risk of cerivastatin-related rhabdomyolysis as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.,携带TT基因型的患者，相比CC或CT基因型，药物诱导的横纹肌溶解风险可能较低,1,,,0,,,,plus,任绿枝
PA166134620,rs4149056,1447947008,CC,Patients with the CC genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.,携带CC基因型的患者，相比TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166134620,rs4149056,1447947009,CT,Patients with the CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.,携带CT基因型的患者，相比TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166134620,rs4149056,1447947010,TT,Patients with the TT genotype may have decreased plasma concentrations of pravastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin.,携带TT基因型的患者，相比CC或CT基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166134621,rs4149056,1447947066,CC,Patients with the CC genotype may have decreased plasma concentration of  atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.,携带CC基因型的患者，相比TT基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166134621,rs4149056,1447947067,CT,Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.,携带CT基因型的患者，相比TT基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166134621,rs4149056,1447947068,TT,Patients with the TT genotype may have increased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.,携带TT基因型的患者，相比CC或CT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166134622,rs4149056,1446898004,CC,Patients with the CC genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.,携带CC基因型的患者，相比TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166134622,rs4149056,1446898005,CT,Patients with the CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.,携带CT基因型的患者，相比TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166134622,rs4149056,1446898006,TT,Patients with the TT genotype may have lower plasma concentrations of rosuvastatin as compared to patients with the CC genotype. No association is seen between genotypes of this variant and change in LDL-cholesterol levels in response to rosuvastatin treatment. Other genetic and clinical factors may also influence a patient's metabolism and response to rosuvastatin.,携带TT基因型的患者，相比CC基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166134623,rs4149056,1448100041,CC,Patients with the CC genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.,携带CC基因型的患者，相比TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166134623,rs4149056,1448100042,CT,Patients with the CT genotype may have increased plasma drug concentrations of particular statins as compared to patients with the TT genotype. For some statins this is associated with increased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.,携带CT基因型的患者，相比TT基因型，血药浓度可能较高,1,,,,,,2,plus,任绿枝
PA166134623,rs4149056,1448100043,TT,Patients with the TT genotype may have decreased plasma drug concentrations of particular statins as compared to patients with the CC or CT genotype. For some statins this is associated with decreased risk of adverse events - see individual drug annotations particularly for simvastatin. Other genetic and clinical factors may also influence a patient's metabolism and response to statins.,携带TT基因型的患者，相比CC或CT基因型，血药浓度可能较低,1,,,,,,0,plus,任绿枝
PA166135654,rs4149056,1444607786,CC,Patients with the CC genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.,携带CC基因型的患者行肾移植术，相比TT基因型，不良药物反应的风险可能降低,1,,,0,,,,plus,任绿枝
PA166135654,rs4149056,1444607785,CT,Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.,携带CT基因型的患者行肾移植术，相比CC基因型，不良药物反应的风险可能增加；相比TT基因型，不良药物反应的风险可能降低,1,,,1,,,,plus,任绿枝
PA166135654,rs4149056,1444607784,TT,Patients with the TT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.,携带TT基因型的患者行肾移植术，相比CC基因型，不良药物反应的风险可能增加,1,,,2,,,,plus,任绿枝
PA166134817,rs4149056,1183630765,CC,Patients with the CC genotype and non-small cell lung cancer may have receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38. ,携带CC基因型的非小细胞肺癌患者，相比TT基因型，药物剂量可能增加,1,,,,,2,,plus,任绿枝
PA166134817,rs4149056,1183630766,CT,Patients with the CT genotype and non-small cell lung cancer may receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38. ,携带CT基因型的非小细胞肺癌患者，相比TT基因型，药物剂量可能增加,1,,,,,2,,plus,任绿枝
PA166134817,rs4149056,1183630767,TT,Patients with the TT genotype and non-small cell lung cancer may have a decreased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the CC or CT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38. ,携带TT基因型的非小细胞肺癌患者，相比CC或CT基因型，药物剂量可能降低,1,,,,,0,,plus,任绿枝
PA166151942,rs4149056,1447953132,CC,Patients with the CC genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.,携带CC基因型的原发性高血压患者，相比TT基因型，咳嗽的可能性增加,1,,,2,,,,plus,任绿枝
PA166151942,rs4149056,1447953133,CT,Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.,携带CT基因型的原发性高血压患者，相比TT基因型，咳嗽的可能性增加,1,,,2,,,,plus,任绿枝
PA166151942,rs4149056,1447953134,TT,Patients with the TT genotype and essential hypertension may have a decreased likelihood of cough when treated with enalapril as compared to patients with the CC and CT genotypes. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.,携带TT基因型的原发性高血压患者，相比CC或CT基因型，咳嗽的可能性降低,1,,,0,,,,plus,任绿枝
PA166160273,rs4149056,1448258745,CC,Patients with the CC genotype may have decreased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to sorafenib.,携带CC基因型的患者，相比TT或CT基因型，血小板减少症的可能性降低,1,,,0,,,,plus,任绿枝
PA166160273,rs4149056,1448258744,CT,Patients with the CT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.,携带CT基因型的患者，相比CC基因型，血小板减少症的可能性增加,1,,,2,,,,plus,任绿枝
PA166160273,rs4149056,1448258743,TT,Patients with the TT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.,携带TT基因型的患者，相比CC基因型，血小板减少症的可能性增加,1,,,2,,,,plus,任绿枝
PA166161004,rs4149056,1448276475,CC,Patients with the CC genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.,携带CC基因型的II型糖尿病患者，相比TT基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166161004,rs4149056,1448276476,CT,Patients with the CT genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.,携带CT基因型的II型糖尿病患者，相比TT基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166161004,rs4149056,1448276477,TT,Patients with the TT genotype may have decreased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the response to rosiglitazone.,携带TT基因型的II型糖尿病患者，相比CC和CT基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166158969,rs4149056,1448100349,CC,Patients with the CC genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the CT and TT genotypes. Other factors may affect concentrations of ticagrelor.,携带CC基因型的急性冠脉综合征患者，相比CT和TT基因型，药物的浓度可能增加,1,,,,2,,,plus,任绿枝
PA166158969,rs4149056,1448100350,CT,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.,携带CT基因型的急性冠脉综合征患者，相比TT基因型，药物的浓度可能增加,1,,,,2,,,plus,任绿枝
PA166158969,rs4149056,1448100351,TT,Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CC and CT genotypes. Other factors may affect concentrations of ticagrelor.,携带TT基因型的急性冠脉综合征患者，相比CC和CT基因型，药物的浓度可能降低,1,,,,0,,,plus,任绿枝
PA166135860,rs472660,1444706913,AA,"Patients with the AA genotype and Schizophrenia may have increased clearance of olanzapine as compared to patients with the AG or GG genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.",携带AA基因型的精神分裂症患者，相比AG或GG基因型，药物清除可能增加,1,,,,2,,,FWD,任绿枝
PA166135860,rs472660,1444706914,AG,"Patients with the AG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.",携带AG基因型的精神分裂症患者，相比AA基因型，药物清除可能降低,1,,,,0,,,FWD,任绿枝
PA166135860,rs472660,1444706915,GG,"Patients with the GG genotype and Schizophrenia may have decreased clearance of olanzapine as compared to patients with the AA genotype. However, contradictory findings for no association are reported. Other genetic and clinical factors may also influence a patient's response to olanzapine.",携带GG基因型的精神分裂症患者，相比AA基因型，药物清除可能降低,1,,,,0,,,FWD,任绿枝
PA166136323,rs4702484,1444704269,CC,Patients with the CC genotype and Colorectal Neoplasms who are treated with capecitabine may have decreased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.,携带CC基因型的结直肠癌患者，相比CT基因型，无进展生存期可能较短,1,,0,,,,,plus,任绿枝
PA166136323,rs4702484,1444704270,CT,Patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.,携带CT基因型的结直肠癌患者，相比CT基因型，无进展生存期可能较长,1,,2,,,,,plus,任绿枝
PA166136323,rs4702484,1444704271,TT,"Patients with the TT genotype were not studied. However, patients with the CT genotype and Colorectal Neoplasms who are treated with capecitabine may have increased progression-free survival as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine.",无TT基因型的患者参与研究,1,,,,,,,plus,任绿枝
PA166134971,rs4783961,1183491362,AA,Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. ,携带AA基因型的高胆固醇血症患者，相比GG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134971,rs4783961,1183491361,AG,Patients with the AG genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. ,携带AG基因型的高胆固醇血症患者，相比GG基因型，药物响应可能较差,1,,0,,,,,plus,任绿枝
PA166134971,rs4783961,1183491360,GG,Patients with the GG genotype and Hypercholesterolemia may have a better response to fluvastatin treatment (determined by higher change in HDL-C levels) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. ,携带GG基因型的高胆固醇血症患者，相比AG或AA基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166136108,rs478437,1444607361,CC,"In lymphoblastoid cell lines, the CC genotype was associated with increased sensitivity to tamoxifen, as compared to the CT or TT genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.",携带CC基因型的类原始淋巴细胞系，相比CT或TT基因型，药物敏感性可能增加,1,,2,,,,,FWD,任绿枝
PA166136108,rs478437,1444607362,CT,"In lymphoblastoid cell lines, the CT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.",携带CT基因型的类原始淋巴细胞系，相比CC基因型，药物敏感性可能降低,1,,0,,,,,FWD,任绿枝
PA166136108,rs478437,1444607363,TT,"In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.",携带TT基因型的类原始淋巴细胞系，相比CC基因型，药物敏感性可能降低,1,,0,,,,,FWD,任绿枝
PA166152843,rs4790694,1448106654,AA,Patients with the AA genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methamphetamine addiction.,携带AA基因型的患者，相比CC基因型，上瘾的可能性较低,1,,,0,,,,FWD,任绿枝
PA166152843,rs4790694,1448106655,AC,"Patients with the AC genotype who take methamphetamine may have a decreased likelihood of addiction as compared to patients with the CC genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.",携带AC基因型的患者，相比CC基因型，上瘾的可能性较低；相比AA基因型，上瘾的可能性较高,1,,,1,,,,FWD,任绿枝
PA166152843,rs4790694,1448106656,CC,Patients with the CC genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.,携带CC基因型的患者，相比AA基因型，上瘾的可能性较高,1,,,2,,,,FWD,任绿枝
PA166158937,rs4796793,1448100069,CC,Patients with the CC genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy. ,携带CC基因型的肾细胞癌患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166158937,rs4796793,1448100070,CG,Patients with the CG genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy. ,携带CG基因型的肾细胞癌患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166158937,rs4796793,1448100071,GG,Patients with the GG genotype and renal cell carcinoma may have an increased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy. ,携带GG基因型的肾细胞癌患者，相比CC或CG基因型，药物响应可能提高,1,,2,,,,,plus,任绿枝
PA166134180,rs4799915,655384889,CC,"Patients with the CC genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.",携带CC基因型的患者，相比TT基因型，不良心血管事件可能降低,1,,,0,,,,plus,任绿枝
PA166134180,rs4799915,655384888,CT,Patients with the CT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.,携带CT基因型的患者，相比CC基因型，不良心血管事件可能增加,1,,,2,,,,plus,任绿枝
PA166134180,rs4799915,655384887,TT,Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的患者，相比CC基因型，不良心血管事件可能增加,1,,,2,,,,plus,任绿枝
PA166135242,rs4823613,1183631468,AA,Patients with the AA genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. ,携带AA基因型的患者，相比GG基因型，药物响应可能减弱,1,,0,,,,,plus,任绿枝
PA166135242,rs4823613,1183631467,AG,Patients with the AG genotype may have a reduced response to simvastatin treatment (a lower  reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. ,携带AG基因型的患者，相比GG基因型，药物响应可能减弱,1,,0,,,,,plus,任绿枝
PA166135242,rs4823613,1183631466,GG,Patients with the GG genotype may have a better response to simvastatin treatment (an increased reduction in total cholesterol and LDL-cholesterol) as compared to patients with the AA genotype. A seperate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. ,携带GG基因型的患者，相比AA基因型，药物响应可能较好,1,,2,,,,,plus,任绿枝
PA166136050,rs4823613,1184986493,AA,Patients with the AA genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus. ,携带AA基因型的患者行器官移植时，相比GG基因型，药物代谢可能增加,1,,,,2,,,plus,任绿枝
PA166136050,rs4823613,1184986494,AG,Patients with the AG genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype and decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus. ,携带AG基因型的患者行器官移植时，相比GG基因型，药物代谢可能增加；相比AA基因型，药物代谢可能降低,1,,,,1,,,plus,任绿枝
PA166136050,rs4823613,1184986495,GG,Patients with the GG genotype and organ transplantation administered tacrolimus may have decreased metabolism of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus. ,携带GG基因型的患者行器官移植时，相比AA基因型，药物代谢可能降低,1,,,,0,,,plus,任绿枝
PA166134842,rs4680,1043880042,AA,Patients with the AA genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.,携带AA基因型的重度抑郁症患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166134842,rs4680,1043880041,AG,Patients with the AG genotype and major Depressive Disorder may have an increased response to fluvoxamine treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.,携带AG基因型的重度抑郁症患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166134842,rs4680,1043880040,GG,Patients with the GG genotype and major Depressive Disorder may have a decreased response to fluvoxamine treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.,携带GG基因型的重度抑郁症患者，相比AG或AA基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166134850,rs4680,1043880168,AA,Patients with the AA genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.,携带AA基因型的焦虑症患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166134850,rs4680,1043880167,AG,Patients with the AG genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.,携带AG基因型的焦虑症患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166134850,rs4680,1043880166,GG,Patients with the GG genotype may have increased response to venlafaxine in people with Depressive Disorder but a decreased response to venlafaxine in people with Anxiety Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.,携带GG基因型的焦虑症患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166134850,rs4680,1043880168,AA,Patients with the AA genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.,携带AA基因型的抑郁症患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166134850,rs4680,1043880167,AG,Patients with the AG genotype may have increased response to venlafaxine in people with Anxiety Disorder but a decreased response to venlafaxine in people with Depressive Disorders as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.,携带AA基因型的抑郁症患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166134850,rs4680,1043880166,GG,Patients with the GG genotype may have increased response to venlafaxine in people with Depressive Disorder but a decreased response to venlafaxine in people with Anxiety Disorders as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine treatment.,携带AA基因型的抑郁症患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166135548,rs4680,1448099687,AA,Patients with the AA genotype may be less likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. ,携带AA基因型的患者行增殖腺扁桃体切除术后，相比AG或GG基因型，术后干预的需求可能较小,1,,2,,,,,plus,任绿枝
PA166135548,rs4680,1448099688,AG,Patients with the AG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. ,携带AG基因型的患者行增殖腺扁桃体切除术后，相比AA基因型，术后干预的需求可能较大,1,,0,,,,,plus,任绿枝
PA166135548,rs4680,1448099689,GG,Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management. ,携带GG基因型的患者行增殖腺扁桃体切除术后，相比AA基因型，术后干预的需求可能较大,1,,0,,,,,plus,任绿枝
PA166135609,rs4680,1184987575,AA,"Patients with the AA genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.",携带AA基因型的物质禁断综合征患者，相比AG和GG基因型，停药后头痛的可能性降低,1,,,0,,,,plus,任绿枝
PA166135609,rs4680,1184987576,AG,"Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.",携带AG基因型的物质禁断综合征患者，相比AA基因型，停药后头痛的可能性增加,1,,,2,,,,plus,任绿枝
PA166135609,rs4680,1184987577,GG,"Patients with the GG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.",携带GG基因型的物质禁断综合征患者，相比AA基因型，停药后头痛的可能性增加,1,,,2,,,,plus,任绿枝
PA166135850,rs4680,1444706789,AA,Patients with the AA genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.,携带AA基因型的重性抑郁患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166135850,rs4680,1444706790,AG,Patients with the AG genotype and major depression may have an increased response to paroxetine as compared to patients with the GG genotype or may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.,携带AG基因型的重性抑郁患者，相比GG基因型，药物响应可能增加；相比AA基因型，药物响应可能降低,1,,1,,,,,plus,任绿枝
PA166135850,rs4680,1444706791,GG,Patients with the GG genotype and major depression may have a decreased response to paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.,携带GG基因型的重性抑郁患者，相比AA基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166134511,rs4680,1448099957,AA,"Patients with the AA genotype who are treated with nicotine replacement therapy may have an increased likelihood of smoking cessation and decreased risk of relapse as compared to patients with the GG genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.",携带AA基因型的患者行尼古丁替代治疗，相比GG基因型，戒烟的可能性较高，复发的风险可能降低,1,,2,,,,,plus,任绿枝
PA166134511,rs4680,1448099958,AG,"Patients with the AG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.",携带AG基因型的患者行尼古丁替代治疗，相比AA基因型，戒烟的可能性较低，复发的风险可能降高,1,,0,,,,,plus,任绿枝
PA166134511,rs4680,1448099959,GG,"Patients with the GG genotype who are treated with nicotine replacement therapy may have a decreased likelihood of smoking cessation and increased risk of relapse as compared to patients with the AA genotype. However, some contradictory evidence exists. Other genetic and clinical factors may also influence a patient's response to nicotine replacement therapy.",携带GG基因型的患者行尼古丁替代治疗，相比AA基因型，戒烟的可能性较低，复发的风险可能降高,1,,0,,,,,plus,任绿枝
PA166134512,rs4680,981202647,AA,Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.,携带AA基因型的精神分裂症患者，相比GG基因型，迟发性运动障碍的风险可能降低,1,,,0,,,,plus,任绿枝
PA166134512,rs4680,981202648,AG,Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have a decreased risk of tardive dyskinesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.,携带AG基因型的精神分裂症患者，相比GG基因型，迟发性运动障碍的风险可能降低,1,,,0,,,,plus,任绿枝
PA166134512,rs4680,981202649,GG,Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have an increased risk of tardive dyskinesia as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for tardive dyskinesia.,携带GG基因型的精神分裂症患者，相比AA或AG基因型，迟发性运动障碍的风险可能增加,1,,,2,,,,plus,任绿枝
PA166134513,rs4680,981202675,AA,Patients with the AA genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype. Metabolic syndrome was also associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AA genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.,携带AA基因型的精神分裂症患者，相比GG基因型，COMT基因启动子区域甲基化水平可能提高，代谢综合征的风险可能相应增加,1,,0,,,,,plus,任绿枝
PA166134513,rs4680,981202676,AG,Patients with the AG genotype and Schizophrenia who are treated with antipsychotics may have increased methylation at sites within the COMT gene promoter as compared to patients with the GG genotype or decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. No significant difference was seen in levels of methylation of the COMT gene promoter in patients with or without metabolic syndrome with the AG genotype. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.,携带AG基因型的精神分裂症患者，相比GG基因型，COMT基因启动子区域甲基化水平可能提高；相比AA基因型，COMT基因启动子区域甲基化水平可能降低,1,,1,,,,,plus,任绿枝
PA166134513,rs4680,981202677,GG,Patients with the GG genotype and Schizophrenia who are treated with antipsychotics may have decreased methylation at sites within the COMT gene promoter as compared to patients with the AA genotype. Metabolic syndrome was associated with increased methylation. Patients with the GG genotype who are treated with antipsychotics and have metabolic syndrome may have similar levels of methylation at sites within the COMT gene promoter to those seen in patients with the AA genotype without metabolic syndrome. Other genetic and clinical factors may also influence methylation of the COMT gene promoter. Other genetic and clinical factors may also influence a patient's level of methylation of the COMT gene promoter when treated with antipsychotics.,携带GG基因型的精神分裂症患者，相比AA基因型，COMT基因启动子区域甲基化水平可能降低，代谢综合征的风险可能相应降低,1,,2,,,,,plus,任绿枝
PA166134243,rs4680,1448612991,AA,Patients with the AA genotype who are treated with morphine may require a lower dose as compared to patients with the AG or GG genotype. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's response when treated with morphine.,携带AA基因型的患者，相比AG或GG基因型，所需药物剂量可能降低,1,,,,,0,,plus,任绿枝
PA166134243,rs4680,1448612992,AG,Patients with the AG genotype who are treated with morphine may require a higher dose as compared to patients with the AA genotype. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's response when treated with morphine.,携带AG基因型的患者，相比AA基因型，所需药物剂量可能增加,1,,,,,2,,plus,任绿枝
PA166134243,rs4680,1448612993,GG,Patients with the GG genotype who are treated with morphine may require a higher dose as compared to patients with the AA genotype. Contradictory studies exist for this association. Other genetic and clinical factors may also influence a patient's response when treated with morphine.,携带GG基因型的患者，相比AA基因型，所需药物剂量可能增加,1,,,,,2,,plus,任绿枝
PA166136218,rs4680,1444673125,AA,Patients with the AA genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.,携带AA基因型的精神分裂症患者，相比AG基因型，锥体束外综合征的风险可能降低,1,,,0,,,,plus,任绿枝
PA166136218,rs4680,1444673126,AG,Patients with the AG genotype and schizophrenia may have an increased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.,携带AG基因型的精神分裂症患者，相比AA或GG基因型，锥体束外综合征的风险可能增加,1,,,2,,,,plus,任绿枝
PA166136218,rs4680,1444673127,GG,Patients with the GG genotype and schizophrenia may have a decreased risk for developing extrapyramidal symptoms when treated with haloperidol as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk for extrapyramidal symptoms when taking haloperidol.,携带GG基因型的精神分裂症患者，相比AG基因型，锥体束外综合征的风险可能降低,1,,,0,,,,plus,任绿枝
PA166135831,rs4680,1444704404,AA,Patients with the AA genotype and Parkinson Disease may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.,携带AA基因型的帕金森病患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,任绿枝
PA166135831,rs4680,1444704403,AG,Patients with the AG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype or may have decreased response to entacapone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.,携带AG基因型的帕金森病患者，相比AA基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166135831,rs4680,1444704402,GG,Patients with the GG genotype and Parkinson Disease may have increased response to entacapone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to entacapone.,携带GG基因型的帕金森病患者，相比AA基因型，药物响应可能增加,1,,2,,,,,plus,任绿枝
PA166136366,rs4680,1445401144,AA,Patients with the AA genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.,携带AA基因型的患者，相比GG基因型，血压可能升高,1,,,2,,,,plus,任绿枝
PA166136366,rs4680,1445401145,AG,Patients with the AG genotype may have increased blood pressure when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.,携带AG基因型的患者，相比GG基因型，血压可能升高,1,,,2,,,,plus,任绿枝
PA166136366,rs4680,1445401146,GG,Patients with the GG genotype may have decreased blood pressure when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence blood pressure in patients receiving antipsychotics.,携带GG基因型的患者，相比AA或AG基因型，血压可能降低,1,,,0,,,,plus,任绿枝
PA166136367,rs4680,1445401151,AA,Patients with the AA genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.,携带AA基因型的患者，相比GG基因型，空腹血糖水平可能增加,1,,,2,,,,plus,任绿枝
PA166136367,rs4680,1445401152,AG,Patients with the AG genotype may have increased fasting glucose levels when treated with antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.,携带AG基因型的患者，相比GG基因型，空腹血糖水平可能增加,1,,,2,,,,plus,任绿枝
PA166136367,rs4680,1445401153,GG,Patients with the GG genotype may have reduced fasting glucose levels when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence fasting glucose in patients taking antipsychotics.,携带GG基因型的患者，相比AA或AG基因型，空腹血糖水平可能降低,1,,,0,,,,plus,任绿枝
PA166136390,rs4680,1445402113,AA,Patients with the AA genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.,携带AA基因型的精神分裂症患者，相比GG基因型，药物疗效可能较差,1,,0,,,,,plus,任绿枝
PA166136390,rs4680,1445402114,AG,Patients with the AG genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.,携带AG基因型的精神分裂症患者，相比GG基因型，药物疗效可能较差,1,,0,,,,,plus,任绿枝
PA166136390,rs4680,1445402115,GG,Patients with the GG genotype and schizophrenia may have a better response when treated with clozapine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to clozapine.,携带GG基因型的精神分裂症患者，相比AA或AG基因型，药物疗效可能较好,1,,2,,,,,plus,任绿枝
PA166159495,rs4910008,1448112495,CC,Patients with the CC genotype and rheumatoid arthritis may have increased response to tocilizumab compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect response to tocilizumab.,携带CC基因型的类风湿性关节炎，相比CT和TT基因型，药物响应可能提高,1,,2,,,,,FWD,任绿枝
PA166159495,rs4910008,1448112496,CT,Patients with the CT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.,携带CT基因型的类风湿性关节炎，相比CC基因型，药物响应可能降低,1,,0,,,,,FWD,任绿枝
PA166159495,rs4910008,1448112497,TT,Patients with the TT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.,携带TT基因型的类风湿性关节炎，相比CC基因型，药物响应可能降低,1,,0,,,,,FWD,任绿枝
PA166136425,rs489693,1448106334,AA,"Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype AA may have an increased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AC and CC genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. ",携带AA基因型的精神分裂症，分裂情感性障碍，或自闭症谱系障碍患者，相比AC和CC基因型，体重增加和高三酸甘油脂血症发生的可能性增加,1,,,2,,,,plus,任绿枝
PA166136425,rs489693,1448106335,AC,"Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype AC may have a decreased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AA genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. ",携带AC基因型的精神分裂症，分裂情感性障碍，或自闭症谱系障碍患者，相比AA基因型，体重增加和高三酸甘油脂血症发生的可能性降低,1,,,0,,,,plus,任绿枝
PA166136425,rs489693,1448106336,CC,"Patients with schizophrenia, schizoaffective disorder, or autism spectrum disorder and genotype CC may have a decreased likelihood of weight gain and hypertriglyceridemia when taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone as compared to patients with the AA genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of weight gain in patients taking amisulpride, aripiprazole, clozapine, olanzapine, haloperidol, paliperidone, quetiapine, ziprasidone, or risperidone. ",携带AC基因型的精神分裂症，分裂情感性障碍，或自闭症谱系障碍患者，相比AA基因型，体重增加和高三酸甘油脂血症发生的可能性降低,1,,,0,,,,plus,任绿枝
PA166158941,rs49411,1448100119,CC,Patients with major depressive disorder and the CC genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.,携带CC基因型的重度抑郁症患者，相比TT基因型，药物的反应性可能降低,1,,0,,,,,FWD,任绿枝
PA166158941,rs49411,1448100120,CT,Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.,携带CT基因型的重度抑郁症患者，相比TT基因型，药物的反应性可能降低,1,,0,,,,,FWD,任绿枝
PA166158941,rs49411,1448100121,TT,Patients with major depressive disorder and the TT genotype may have increased response to antidepressants compared to patients with the CC and CT genotypes. Other factors may affect response to antidepressants.,携带TT基因型的重度抑郁症患者，相比CC和CT基因型，药物的反应性可能增加,1,,2,,,,,FWD,任绿枝
PA166136172,rs4948496,1444666719,CC,Patients with the CC genotype and acute lymphoblastic leukemia may have increased concentrations of methotrexate as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.,携带CC基因型的急性成淋巴细胞性白血病患者，相比CT或TT基因型，药物浓度可能增加,1,,,,2,,,plus,任绿枝
PA166136172,rs4948496,1444666720,CT,Patients with the CT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.,携带CT基因型的急性成淋巴细胞性白血病患者，相比CC基因型，药物浓度可能降低,1,,,,0,,,plus,任绿枝
PA166136172,rs4948496,1444666721,TT,Patients with the TT genotype and acute lymphoblastic leukemia may have decreased concentrations of methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of methotrexate.,携带CT基因型的急性成淋巴细胞性白血病患者，相比CC基因型，药物浓度可能降低,1,,,,0,,,plus,任绿枝
PA166134178,rs4933824,655384879,GG,Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype.  Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的患者，相比TT或GT基因型，恶性心血管事件发生风险可能增加,1,,,2,,,,plus,任绿枝
PA166134178,rs4933824,655384880,GT,"Patients with the GT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's response.",携带GT基因型的患者，相比GG基因型，恶性心血管事件发生风险可能降低,1,,,0,,,,plus,任绿枝
PA166134178,rs4933824,655384881,TT,"Patients with the TT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype.  Other genetic and clinical factors may also influence a patient's response.",携带TT基因型的患者，相比GG基因型，恶性心血管事件发生风险可能降低,1,,,0,,,,plus,任绿枝
PA166134886,rs495828,1043880647,GG,"Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.",携带GG基因型的患者，相比TT或TG基因型，咳嗽发生风险可能降低,1,,,0,,,,plus,任绿枝
PA166134886,rs495828,1043880646,TG,Patients with the TG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.,携带TG基因型的患者，相比GG基因型，咳嗽发生风险可能增加,1,,,2,,,,plus,任绿枝
PA166134886,rs495828,1043880645,TT,Patients with the TT genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.,携带TT基因型的患者，相比GG基因型，咳嗽发生风险可能增加,1,,,2,,,,plus,任绿枝
PA166136319,rs495828,1444703955,GG,"Patients with the GG genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.",携带GG基因型的高血压患者，相比TT基因型，咳嗽发生风险可能降低,1,,,0,,,,plus,任绿枝
PA166136319,rs495828,1444703954,GT,"Patients with the GT genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.",携带GT基因型的患者，相比TT基因型，咳嗽发生风险可能降低,1,,,0,,,,plus,任绿枝
PA166136319,rs495828,1444703953,TT,Patients with the TT genotype and Hypertension who are treated with enalapril may have increased risk for Cough as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.,携带TT基因型的患者，相比GG或GT基因型，咳嗽发生风险可能增加,1,,,2,,,,plus,任绿枝
PA166152788,rs4986910,1447962705,AA,Patients with the AA genotype may have a smaller increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence HDL cholesterol response.,携带AA基因型的患者，相比AG基因型，高密度脂蛋白胆固醇可能有少量增加,1,,0,,,,,minus,任绿枝
PA166152788,rs4986910,1447962706,AG,Patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.,携带AG基因型的患者，相比AA基因型，高密度脂蛋白胆固醇可能有明显增加,1,,0,,,,,minus,任绿枝
PA166152788,rs4986910,1447962707,GG,"No patients with the GG genotype were available for analysis, but patients with the AG genotype may have a greater increase in HDL cholesterol when treated with fluvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence HDL cholesterol response.",无GG基因患者参与研究,1,,,,,,,minus,任绿枝
PA166152786,rs4986910,1447962683,AA,"Patients with the AA genotype who are undergoing kidney transplantation may require an increased dose of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.",携带AA基因型的肾脏移植患者，相比GG基因型，药物剂量可能需要增加,1,,,,,2,,minus,任绿枝
PA166152786,rs4986910,1447962684,AG,"Patients with the AG genotype who are undergoing kidney transplantation may require an increased dose of tacrolimus as compared to patients with the GG genotype, or a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.",携带AG基因型的肾脏移植患者，相比GG基因型，药物剂量可能需要增加,1,,,,,2,,minus,任绿枝
PA166152786,rs4986910,1447962685,GG,"Patients with the GG genotype who are undergoing kidney transplantation may require a decreased dose of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.",携带GG基因型的肾脏移植患者，相比AA基因型，药物剂量可能需要降低,1,,,,,0,,minus,任绿枝
PA166134879,rs4986790,1043880460,AA,Patients with AA genotype and Coronary Artery Disease who are treated with pravastatin may have a higher risk of cardiovascular events as compared to patients with the AG or GG genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带AA基因型的冠状动脉疾病患者，相比AG或GG基因型，发生心血管事件的风险可能较高,1,,,2,,,,plus,任绿枝
PA166134879,rs4986790,1043880461,AG,Patients with AG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带AG基因型的冠状动脉疾病患者，相比AA基因型，发生心血管事件的风险可能较低,1,,,0,,,,plus,任绿枝
PA166134879,rs4986790,1043880462,GG,Patients with the GG genotype and Coronary Artery Disease who are treated with pravastatin may have a lower risk of cardiovascular events as compared to patients with the AA genotype. Changes in angiographic measurements and lipid/ lipoprotein levels were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment. ,携带GG基因型的冠状动脉疾病患者，相比AA基因型，发生心血管事件的风险可能较低,1,,,0,,,,plus,任绿枝
PA166135877,rs4986790,1445400705,AA,Patients with the AA genotype may have a better response to the pertussis vaccine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.,携带AA基因型的患者，相比AG或GG基因型，可能有更好的药物响应,1,,2,,,,,plus,任绿枝
PA166135877,rs4986790,1445400706,AG,Patients with the AG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.,携带AG基因型的患者，相比AA基因型，可能有较差的药物响应,1,,0,,,,,plus,任绿枝
PA166135877,rs4986790,1445400707,GG,Patients with the GG genotype may have a poorer response to the pertussis vaccine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.,携带GG基因型的患者，相比AA基因型，可能有较差的药物响应,1,,0,,,,,plus,任绿枝
PA166134198,rs4994,655384961,AA,"Patients with the AA genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.",携带AA基因型的精神分裂症患者，相比GG基因型，体重增加的风险可能降低,1,,,0,,,,minus,任绿枝
PA166134198,rs4994,655384960,AG,"Patients with the AG genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.",携带AG基因型的精神分裂症患者，相比GG基因型，体重增加的风险可能降低,1,,,0,,,,minus,任绿枝
PA166134198,rs4994,655384959,GG,Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.,携带GG基因型的精神分裂症患者，相比AG或AA基因型，体重增加的风险可能增加,1,,,2,,,,minus,任绿枝
PA166134514,rs4961,981202715,GG,Patients with the GG genotype may have a poorer response to hydrochlorothiazide treatment as compared to patients with the TT or GT genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.,携带GG基因型的患者，相比TT或GT基因型，可能有较差的药物响应,1,,0,,,,,plus,任绿枝
PA166134514,rs4961,981202716,GT,Patients with the GT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.,携带GT基因型的患者，相比GG基因型，可能有更好的药物响应,1,,2,,,,,plus,任绿枝
PA166134514,rs4961,981202717,TT,Patients with the TT genotype may have a better response to hydrochlorothiazide treatment as compared to patients with the GG genotype. This association has not been found in all studies. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.,携带TT基因型的患者，相比GG基因型，可能有更好的药物响应,1,,2,,,,,plus,任绿枝
PA166134515,rs4961,981202791,GG,"Patients with the GG genotype and Hypertension who are treated with diuretics may have an increased likelihood of Myocardial Infarction as compared to patients with the GT or TT genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.",携带GG基因型的高血压患者，相比TT或GT基因型，心肌梗塞的可能性增加,1,,,2,,,,plus,任绿枝
PA166134515,rs4961,981202792,GT,"Patients with the GT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.",携带GT基因型的高血压患者，相比GG基因型，心肌梗塞的可能性降低,1,,,0,,,,plus,任绿枝
PA166134515,rs4961,981202793,TT,"Patients with the TT genotype and Hypertension who are treated with diuretics may have a decreased likelihood of Myocardial Infarction as compared to patients with the GG genotype. However, this association was not found in a large cohort of patients. Other genetic and clinical factors may also influence a patient's response to diuretics.",携带TT基因型的高血压患者，相比GG基因型，心肌梗塞的可能性降低,1,,,0,,,,plus,任绿枝
PA166136309,rs5050,1444703523,GG,Patients with the GG genotype who are treated with aspirin may have increased risk for Peptic Ulcer Hemorrhage as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带GG基因型的肝硬化患者，相比GT或TT基因型，消化性溃疡出血的风险增加,1,,,2,,,,plus,任绿枝
PA166136309,rs5050,1444703524,GT,"Patients with the GT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.",携带GT基因型的肝硬化患者，相比GG基因型，消化性溃疡出血的风险降低,1,,,0,,,,plus,任绿枝
PA166136309,rs5050,1444703525,TT,"Patients with the TT genotype who are treated with aspirin may have decreased, but not absent, risk for Peptic Ulcer Hemorrhage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.",携带TT基因型的肝硬化患者，相比GG基因型，消化性溃疡出血的风险降低,1,,,0,,,,plus,任绿枝
PA166134812,rs5051,1183565712,CC,Patients with the CC genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol as compared to patients with the CT or TT genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.,携带CC基因型的高血压患者，相比CT或TT基因型，收缩压可能小幅降低,1,,0,,,,,plus,任绿枝
PA166134812,rs5051,1183565713,CT,Patients with the CT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.,携带CT基因型的高血压患者，相比CC基因型，收缩压可能大幅降低,1,,2,,,,,plus,任绿枝
PA166134812,rs5051,1183565714,TT,Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.,携带TT基因型的高血压患者，相比CC基因型，收缩压可能大幅降低,1,,2,,,,,plus,任绿枝
PA166136158,rs5051,1444666378,CC,Patients with the CC genotype and hypertension may have a better response to treatment with benazepril or imidapril as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.,携带CC基因型的高血压患者，相比CT或TT基因型，可能有更好的药物响应,1,,2,,,,,plus,任绿枝
PA166136158,rs5051,1444666379,CT,Patients with the CT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.,携带CT基因型的高血压患者，相比CC基因型，可能有较差的药物响应,1,,0,,,,,plus,任绿枝
PA166136158,rs5051,1444666380,TT,Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.,携带TT基因型的高血压患者，相比CC基因型，可能有较差的药物响应,1,,0,,,,,plus,任绿枝
PA166134152,rs5030655,982030512,A/del,Patients with the A/del genotype who are treated with venlafaxine may have an increased risk of adverse effects (check other variants for PM phenotype) as compared to patients with the A/A genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.,携带A/del基因型的患者，相比A/A基因型，不良反应的风险可能增加,1,,,2,,,,minus,任绿枝
PA166134152,rs5030655,982030513,AA,Patients with the A/A genotype who are treated with venlafaxine may have average risk of adverse effects (check other variants for PM phenotype) as compared to patients with the del/del or A/del genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.,携带A/A基因型的患者，相比A/del或del/del基因型，不良反应的风险可能一般,1,,,1,,,,minus,任绿枝
PA166134152,rs5030655,982030514,del/del,Patients with the del/del genotype who are treated with venlafaxine may have an increased risk of adverse effects (check other variants for PM phenotype) as compared to patients with the A/A genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.,携带del/del基因型的患者，相比A/A基因型，不良反应的风险可能增加,1,,,2,,,,minus,任绿枝
PA166134892,rs5030655,1043880683,AA,"Patients with the AA genotype who are treated with antipsychotics may have a decreased, but not absent, risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the DEL/A or DEL/DEL genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.",携带AA基因型的患者，相比del/A或del/del基因型，锥体束外症状发生的风险可能降低,1,,,0,,,,minus,任绿枝
PA166134892,rs5030655,1043880682,DEL/A,Patients with the DEL/A genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.,携带del/A基因型的患者，相比AA基因型，锥体束外症状发生的风险可能增加,1,,,2,,,,minus,任绿枝
PA166134892,rs5030655,1043880681,DEL/DEL,Patients with the DEL/DEL genotype who are treated with antipsychotics may have an increased risk for antipsychotic-induced extrapyramidal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment with antipsychotics.,携带del/del基因型的患者，相比AA基因型，锥体束外症状发生的风险可能增加,1,,,2,,,,minus,任绿枝
PA166134260,rs5030655,982030502,A/del,Patients with the A/del genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.,携带A/del基因型的患者，相比del/del基因型，药物响应可能处于平均值,1,,1,,,,,minus,任绿枝
PA166134260,rs5030655,982030503,AA,Patients with the AA genotype who are treated with metoprolol may have average reponse to metoprolol (check other variants for PM phenotype) as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.,携带AA基因型的患者，相比del/del基因型，药物响应可能处于平均值,1,,1,,,,,minus,任绿枝
PA166134260,rs5030655,982030504,del/del,"Patients with the del/del genotype who are treated with metoprolol may have an greater reduction in heart rate, diastolic blood pressure, and mean arterial pressure as compared to patients with the A/del or A/A genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol.",携带del/del基因型的患者，相比A/del或A/A基因型，心率、心脏舒张压及平均动脉压可能有较大的下降,1,,0,,,,,minus,任绿枝
PA166134200,rs518147,982034850,CC,"Patients with the CC genotype and schizophrenia who are treated with olanzapine may have a decreased, but not absent, risk of weight gain as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment.",携带CC基因型的精神分裂症患者，相比GG基因型，体重增加的风险可能降低,1,,,0,,,,minus,任绿枝
PA166134200,rs518147,982034851,CG,"Patients with the CG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment.",携带CG基因型的精神分裂症患者，相比CC基因型，体重增加的风险可能增加,1,,,2,,,,minus,任绿枝
PA166134200,rs518147,982034852,GG,"Patients with the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine treatment.",携带GG基因型的精神分裂症患者，相比CC基因型，体重增加的风险可能增加,1,,,2,,,,minus,任绿枝
PA166152760,rs518350,1447961153,CC,Patients with the CC genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to salbutamol.,携带CC基因型的哮喘患者，相比TT基因型，药物响应可能较差,1,,0,,,,,REV,王兴悦
PA166152760,rs518350,1447961154,CT,"Patients with the CT genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.",携带CT基因型的哮喘患者，相比TT基因型，药物响应可能较差；相比CC基因型，药物响应可能较好,1,,1,,,,,REV,王兴悦
PA166152760,rs518350,1447961155,TT,Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.,携带TT基因型的哮喘患者，相比CC基因型，药物响应可能较好,1,,2,,,,,REV,王兴悦
PA166134616,rs5219,1444666371,CC,Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.,携带CC基因型的Ⅱ型糖尿病患者，相比CT或TT基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134616,rs5219,1444666372,CT,"Patients with CT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC, or a poorer response (smaller decrease in HbA1c) as compared to patients with genotype TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.",携带CT基因型的Ⅱ型糖尿病患者，相比CC基因型，药物响应可能较好；相比TT基因型，药物响应可能较差,1,,1,,,,,plus,王兴悦
PA166134616,rs5219,1444666373,TT,Patients with TT genotype and Type 2 diabetes may have better response (higher decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CC or CT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.,携带TT基因型的Ⅱ型糖尿病患者，相比CT或CC基因型，药物响应可能较好,1,,2,,,,,plus,王兴悦
PA166134233,rs5219,1448105951,CC,Patients with the CC genotype are less likely to respond to repaglinide  than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的Ⅱ型糖尿病患者，相比CT或TT基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134233,rs5219,1448105952,CT,Patients with the CT genotype are more likely to respond to repaglinide  than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.,携带CT基因型的Ⅱ型糖尿病患者，相比CC基因型，药物响应可能较好,1,,2,,,,,plus,王兴悦
PA166134233,rs5219,1448105953,TT,Patients with the TT genotype are more likely to respond to repaglinide  than patients with the CC genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的Ⅱ型糖尿病患者，相比CC基因型，药物响应可能较好,1,,2,,,,,plus,王兴悦
PA166135023,rs5370,1183564891,GG,"Men with the GG genotype and hypertension may have a smaller decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GT genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.",携带GG基因型的高血压男性患者，相比GT基因型，收缩压可能小幅降低,1,男,0,,,,,plus,王兴悦
PA166135023,rs5370,1183564892,GT,"Men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women. Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.",携带GT基因型的高血压男性患者，相比GG基因型，收缩压可能大幅降低,1,男,2,,,,,plus,王兴悦
PA166135023,rs5370,1183564893,TT,"No men with the TT genotype were present in the study analysis. However, men with the GT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol or irbesartan as compared to men with the GG genotype. No significant associations were seen for diastolic blood pressure, or in women (n=2 with TT genotype). Other genetic and clinical factors may also influence systolic and diastolic blood pressure response to atenolol and irbesartan.",TT基因型男性高血压患者未参与本研究,1,男,,,,,,plus,王兴悦
PA166134167,rs5370,1043737608,GG,"Patients with the GG genotype and type 2 diabetes who are treated with muraglitazar may have a decreased, but not absent, risk of edema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.",携带GG基因型的Ⅱ型糖尿病患者，相比TT基因型，水肿风险可能降低,1,,,0,,,,plus,王兴悦
PA166134167,rs5370,1043737609,GT,No conclusive results were found for patients with the GT genotype. But patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.,GT基因型患者无研究结论,1,,,,,,,plus,王兴悦
PA166134167,rs5370,1043737610,TT,Patients with the TT genotype and type 2 diabetes who are treated with muraglitazar may have an increased risk of edema as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of edema with muraglitazar treatment.,携带TT基因型的Ⅱ型糖尿病患者，相比TT基因型，水肿风险可能增加,1,,,2,,,,plus,王兴悦
PA166161231,rs5370,1448427400,GG,Patients with the GG genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.,携带GG基因型的乳腺癌患者，相比TT基因型，总生存期更长,1,,2,,,,,plus,王兴悦
PA166161231,rs5370,1448427401,GT,Patients with the GT genotype and breast cancer may have better overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bevacizumab.,携带GT基因型的乳腺癌患者，相比TT基因型，总生存期更长,1,,2,,,,,plus,王兴悦
PA166161231,rs5370,1448427402,TT,Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence response to bevacizumab.,携带TT基因型的乳腺癌患者，相比GG或GT基因型，总生存期较短,1,,0,,,,,plus,王兴悦
PA166134902,rs55754655,1043880831,AA,Patients with the AA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.,携带AA基因型的炎症性肠病患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166134902,rs55754655,1043880830,GA,Patients with the GA genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.,携带GA基因型的炎症性肠病患者，相比AA基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166134902,rs55754655,1043880829,GG,Patients with the GG genotype and Inflammatory Bowel Disease who are treated with azathioprine may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to azathioprine.,携带GG基因型的炎症性肠病患者，相比AA基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166134486,rs4986893,1444667271,AA,"Patients with the AA genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.",携带AA基因型的患者，相比GG基因型：药物代谢程度和代谢产物的活性可能降低，导致药物响应可能降低；继发性心血管事件的发生风险可能增加,1,,0,2,,,,plus,王兴悦
PA166134486,rs4986893,1444667272,AG,"Patients with the AG genotype 1) may have poor metabolism of clopidogrel and decreased formation of active drug metabolite, resulting in decreased response 2) may have an increased risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.",携带AG基因型的患者，相比GG基因型：药物代谢程度和代谢产物的活性可能降低，导致药物响应可能降低；继发性心血管事件的发生风险可能增加,1,,0,2,,,,plus,王兴悦
PA166134486,rs4986893,1444667273,GG,"Patients with the GG genotype 1) may have increased metabolism of clopidogrel and formation of active drug metabolite, resulting in increased response 2) may have a decreased, but not absent, risk for secondary cardiovascular events when treated with clopidogrel as compared to patients with the AA or AG genotype. Other genetic and clinical factors may influence a patient's risk for secondary cardiovascular events and response to clopidogrel.",携带GG基因型的患者，相比GG基因型：药物代谢程度和代谢产物的活性可能增加，导致药物响应可能增加；继发性心血管事件的发生风险可能降低,1,,2,0,,,,plus,王兴悦
PA166135852,rs4986893,1444706803,AA,Patients with the AA genotype and Mental disorders may have increased serum concentration of escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.,携带AA基因型的精神障碍患者，相比GG基因型，血清浓度可能增加,1,,,,,,2,plus,王兴悦
PA166135852,rs4986893,1444706804,AG,Patients with the AG genotype and Mental disorders may have increased serum concentration of escitalopram as compared to patients with the GG genotype or may have decreased serum concentration of escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.,携带AG基因型的精神障碍患者，相比GG基因型，血清浓度可能增加；相比AA基因型，血清浓度可能降低,1,,,,,,1,plus,王兴悦
PA166135852,rs4986893,1444706805,GG,Patients with the GG genotype and Mental disorders may have decreased serum concentration of escitalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.,携带GG基因型的精神障碍患者，相比AA基因型，血清浓度可能降低,1,,,,,,0,plus,王兴悦
PA166163682,rs4986893,1448615591,AA,Patients with the AA genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and GG genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin. ,携带AA基因型的患者，相比AG和GG基因型，伴嗜酸性粒细胞增多和系统症状的药物反应可能增加,1,,,2,,,,plus,王兴悦
PA166163682,rs4986893,1448615592,AG,"Patients with the AG genotype who are treated with phenytoin may have an increased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the GG genotypes, and a decreased likelihood as compared to patients with the AA genotype. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin. ",携带AG基因型的患者，相比GG基因型，伴嗜酸性粒细胞增多和系统症状的药物反应可能增加；相比AA基因型，伴嗜酸性粒细胞增多和系统症状的药物反应可能降低,1,,,1,,,,plus,王兴悦
PA166163682,rs4986893,1448615593,GG,Patients with the GG genotype who are treated with phenytoin may have an decreased likelihood of drug reaction with eosinophilia and systemic symptoms (DRESS) as compared to patients with the AG and AA genotypes. There is no association with Stevens-Johnson syndrome (SJS). Other clinical and genetic factors may also influence likelihood of DRESS in patients administered phenytoin. ,携带GG基因型的患者，相比AG和AA基因型，伴嗜酸性粒细胞增多和系统症状的药物反应可能降低,1,,,0,,,,plus,王兴悦
PA166136446,rs56113850,1446903558,CC,"Individuals who smoke and have the CC genotype may have increased rates of nicotine clearance, and as a consequence, may smoke more when compared to individuals who smoke and have the CT or TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers. ",携带CC基因型的吸烟者，相比CT或TT基因型，尼古丁清除率可能增加，因此吸烟可能相对较多,1,,,,2,,,plus,王兴悦
PA166136446,rs56113850,1446903559,CT,"Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke and have the TT genotypes, and decreased rates of metabolism as compared to patients with the CC genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers. ",携带CT基因型的吸烟者，相比TT基因型，尼古丁清除率可能增加，因此吸烟可能相对较多；相比CC基因型，尼古丁清除率可能降低,1,,,,1,,,plus,王兴悦
PA166136446,rs56113850,1446903560,TT,"Individuals who smoke and have the TT genotype may have decreased rates of nicotine clearance, and as a consequence, may smoke less when compared to individuals who smoke and have the CC or CT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers. ",携带TT基因型的吸烟者，相比CC或CT基因型，尼古丁清除率可能降低，因此吸烟可能相对较少,1,,,,0,,,plus,王兴悦
PA166158967,rs56324128,1448100336,CC,Patients with the CC genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.,携带CC基因型的急性冠脉综合征患者，相比CT基因型，药物浓度可能降低,1,,,,0,,,plus,王兴悦
PA166158967,rs56324128,1448100337,CT,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.,携带CT基因型的急性冠脉综合征患者，相比TT基因型，药物浓度可能升高,1,,,,2,,,plus,王兴悦
PA166134808,rs5985,1043858971,AA,Male patients with the AA genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带AA基因型的男性患者，相比CC基因型，对FXIII激活作用的抑制可能增加,1,男,0,,,,,minus,王兴悦
PA166134808,rs5985,1043858972,AC,Male patients with the AC genotype may have an increased inhibition of FXIII activation by aspirin as compared to the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带AC基因型的男性患者，相比CC基因型，对FXIII激活作用的抑制可能增加,1,男,0,,,,,minus,王兴悦
PA166134808,rs5985,1043858973,CC,Male patients with the CC genotype may have a decreased inhibition of FXIII activation by aspirin as compared to the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带CC基因型的男性患者，相比AA或AC基因型，对FXIII激活作用的抑制可能降低,1,男,2,,,,,minus,王兴悦
PA166158928,rs5985,1448099910,AA,Patients with choroidal neovascularization and the AA genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.,携带AA基因型的脉络膜新生血管性疾病患者，相比CC基因型，药物响应可能降低,1,,0,,,,,minus,王兴悦
PA166158928,rs5985,1448099911,AC,Patients with choroidal neovascularization and the AC genotype may have decreased response to photodynamic therapy compared to patients with the CC genotype. Other factors may affect response to photodynamic therapy.,携带AC基因型的脉络膜新生血管性疾病患者，相比CC基因型，药物响应可能降低,1,,0,,,,,minus,王兴悦
PA166158928,rs5985,1448099912,CC,Patients with choroidal neovascularization and the CC genotype may have increased response to photodynamic therapy compared to patients with the AA and AC genotypes. Other factors may affect response to photodynamic therapy.,携带CC基因型的脉络膜新生血管性疾病患者，相比AA和AC基因型，药物响应可能增加,1,,2,,,,,minus,王兴悦
PA166161178,rs5993883,1448423770,GG,Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence quetiapine response. ,携带GG基因型的精神分裂症患者，相比TT基因型，药物响应可能较好,1,,2,,,,,FWD,王兴悦
PA166161178,rs5993883,1448423771,GT,"Patients with the GT genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response. ",携带GT基因型的精神分裂症患者，相比TT基因型，药物响应可能较好；相比GG基因型，药物响应可能较差,1,,1,,,,,FWD,王兴悦
PA166161178,rs5993883,1448423772,TT,Patients with the TT genotype and schizophrenia may have a poorer response to treatment with quetiapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response. ,携带TT基因型的精神分裂症患者，相比GG基因型，药物响应可能较差,1,,0,,,,,FWD,王兴悦
PA166136430,rs6021191,1446899690,AA,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AA genotype may have a decreased risk of hypersensitivity to asparaginase as compared to patients with the AT and TT genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.,携带AA基因型的前体细胞淋巴细胞白血病-淋巴瘤儿科患者，相比AT和TT基因型，发生过敏反应的风险可能降低,1,,,0,,,,FWD,王兴悦
PA166136430,rs6021191,1446899691,AT,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AA genotype and a decreased risk as compared to patients with the TT genotype. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.,携带AT基因型的前体细胞淋巴细胞白血病-淋巴瘤儿科患者，相比AA基因型，发生过敏反应的风险可能增加；相比TT基因型，发生过敏反应的风险可能降低,1,,,1,,,,FWD,王兴悦
PA166136430,rs6021191,1446899692,TT,Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of hypersensitivity to asparaginase as compared to patients with the AT and AA genotypes. Other clinical and genetic factors may also affect risk of hypersensitivity to asparaginase in patients with precursor cell lymphoblastic leukemia-lymphoma.,携带TT基因型的前体细胞淋巴细胞白血病-淋巴瘤儿科患者，相比AT和AA基因型，发生过敏反应的风险可能增加,1,,,2,,,,FWD,王兴悦
PA166135331,rs6025,1183689590,CC,"Patients with the CC genotype (normal Factor V) may have a decreased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CT or TT genotype (carriers of Factor V Leiden). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. ",携带CC基因型的患者，相比CT或TT基因型，血栓形成的风险降低,1,,,0,,,,REV,王兴悦
PA166135331,rs6025,1183689591,CT,"Patients with the CT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. ",携带CT基因型的患者，相比CC基因型，血栓形成的风险增加,1,,,2,,,,REV,王兴悦
PA166135331,rs6025,1183689592,TT,"Patients with the TT genotype (heterozygote for Factor V Leiden) may have an increased risk of experiencing thrombosis when receiving oral contraceptives as compared to patients with the CC genotype (normal Factor V). Both Factor V Leiden and oral contraceptives have been found to independently increase the risk for thrombosis, but together they may have a cumulative effect on thrombosis risk. Other genetic and clinical factors may also influence risk of thrombosis. ",携带TT基因型的患者，相比CC基因型，血栓形成的风险增加,1,,,2,,,,REV,王兴悦
PA166134874,rs60282872,1043880422,C/del,"Patients with the CC/del genotype who are treated with fluvastatin may have a smaller change in apolipoprotein  A1 and C3 levels as compared to patients with the C/C genotype, or may have a larger  change in apolipoprotein  A1 and C3 levels as compared to patients with the del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.  ",携带CC/del基因型的患者，相比C/C基因型，载脂蛋白A1和C3水平改变可能较小；相比del/del基因型，载脂蛋白A1和C3水平改变可能较大,1,,1,,,,,FWD,王兴悦
PA166134874,rs60282872,1043880423,CC,"Patients with the CC genotype who are treated with fluvastatin may have a larger  change in apolipoprotein  A1 and C3 levels, as compared to patients with the C/del or del/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. ",携带CC基因型的患者，相比C/del或del/del基因型，载脂蛋白A1和C3水平改变可能较大,1,,2,,,,,FWD,王兴悦
PA166134874,rs60282872,1043880424,del/del,"Patients with the del/del genotype who are treated with fluvastatin may have a smaller  change in apolipoprotein  A1 and C3 levels, as compared to patients with the CC or C/del genotype. Changes with treatment in other lipids were not significantly different between genotypes. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. ",携带del/del基因型的患者，相比CC或C/del基因型，载脂蛋白A1和C3水平改变可能较小,1,,0,,,,,FWD,王兴悦
PA166134072,rs6028945,637879973,GG,Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared with patients with the genotypes GT or TT.  Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的风湿性关节炎患者，相比GT或TT基因型，对药物响应的可能性可能更大,1,,2,,,,,plus,王兴悦
PA166134072,rs6028945,637879974,GT,Rheumatoid Arthritis patients with the genotype GT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patient's response.,携带GT基因型的风湿性关节炎患者，相比GG基因型，对药物响应的可能性可能较小,1,,0,,,,,plus,王兴悦
PA166134072,rs6028945,637879975,TT,Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype GG.  Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的风湿性关节炎患者，相比GG基因型，对药物响应的可能性可能较小,1,,0,,,,,plus,王兴悦
PA166134810,rs6065,1043858981,CC,Patients with the CC genotype may have an increased risk for aspirin resistance as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.,携带CC基因型的患者，相比CT或TT基因型，耐药的风险可能增加,1,,0,,,,,plus,王兴悦
PA166134810,rs6065,1043858982,CT,"Patients with the CT genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.",携带CT基因型的患者，相比CC基因型，耐药的风险可能降低,1,,2,,,,,plus,王兴悦
PA166134810,rs6065,1043858983,TT,"Patients with the TT genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.",携带TT基因型的患者，相比CC基因型，耐药的风险可能降低,1,,2,,,,,plus,王兴悦
PA166134356,rs60369023,1184136447,AA,Patients with the AA genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity of Neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.,携带AA基因型的肿瘤患者，相比GG基因型，药物清除率可能降低；嗜中性粒细胞减少症的严重性可能增加,1,,,2,,,,plus,王兴悦
PA166134356,rs60369023,1184136448,AG,"Patients with the AG genotype and cancer who are treated with gemcitabine 1) may have decreased clearance of gemcitabine 2) may have increased severity Neutropenia as compared to patients with the GG genotype, or 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.",携带AG基因型的肿瘤患者，相比GG基因型，药物清除率可能降低，嗜中性粒细胞减少症的严重性可能增加；相比AA基因型，药物清除率可能增加，嗜中性粒细胞减少症的严重性可能降低,1,,,1,,,,plus,王兴悦
PA166134356,rs60369023,1184136449,GG,Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.,携带GG基因型的肿瘤患者，相比AA基因型，药物清除率可能增加；嗜中性粒细胞减少症的严重性可能降低,1,,,0,,,,plus,王兴悦
PA166135356,rs602950,1183697566,AA,Cancer patients with the AA genotype may have a decreased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.,携带AA基因型的肿瘤患者，相比AG或GG基因型，腹泻或脱水的风险可能降低,1,,2,,,,,REV,王兴悦
PA166135356,rs602950,1183697567,AG,Cancer patients with the AG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.,携带AG基因型的肿瘤患者，相比AA基因型，腹泻或脱水的风险可能增加,1,,0,,,,,REV,王兴悦
PA166135356,rs602950,1183697568,GG,Cancer patients with the GG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.,携带GG基因型的肿瘤患者，相比AA基因型，腹泻或脱水的风险可能增加,1,,0,,,,,REV,王兴悦
PA166134518,rs602950,982033475,AA,Patients with the AA genotype who are treated with cytarabine may have lower levels of toxicity as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.,携带AA基因型的患者，相比AG或GG基因型，药物毒性风险可能较低,1,,,0,,,,REV,王兴悦
PA166134518,rs602950,982033476,AG,Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.,携带AG基因型的患者，相比AA基因型，药物毒性风险可能较高,1,,,2,,,,REV,王兴悦
PA166134518,rs602950,982033477,GG,Patients with the GG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.,携带GG基因型的患者，相比AA基因型，药物毒性风险可能较高,1,,,2,,,,REV,王兴悦
PA166158959,rs6092,1448100251,AA,Pediatric patients with the AA genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk. ,携带AA基因型的急性淋巴细胞白血病儿科患者，相比GG基因型，骨坏死风险可能增加,1,,,2,,,,plus,王兴悦
PA166158959,rs6092,1448100252,AG,Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk. ,携带AG基因型的急性淋巴细胞白血病儿科患者，相比GG基因型，骨坏死风险可能增加,1,,,2,,,,plus,王兴悦
PA166158959,rs6092,1448100253,GG,Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk of osteonecrosis when treated with dexamethasone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence osteonecrosis risk. ,携带GG基因型的急性淋巴细胞白血病儿科患者，相比AA或AG基因型，骨坏死风险可能降低,1,,,0,,,,plus,王兴悦
PA166158965,rs61361928,1448100328,CT,Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.,携带CT基因型的急性冠脉综合征患者，相比TT基因型，药物浓度可能增加,1,,,,2,,,plus,王兴悦
PA166158965,rs61361928,1448100329,TT,Patients with the TT genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the CT genotype. Other factors may affect concentrations of ticagrelor.,携带TT基因型的急性冠脉综合征患者，相比CT基因型，药物浓度可能降低,1,,,,0,,,plus,王兴悦
PA166134067,rs6138150,637879948,CC,Rheumatoid Arthritis patients with the genotype CC may be more likely to respond to TNF inhibitors compared with patients with genotypes TT or CT .  Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的风湿性关节炎患者，相比TT或CT基因型，药物响应可能更好,1,,2,,,,,plus,王兴悦
PA166134067,rs6138150,637879949,CT,Rheumatoid Arthritis patients with the genotype CT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC .  Other genetic and clinical factors may also influence a patient's response.,携带CT基因型的风湿性关节炎患者，相比CC基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134067,rs6138150,637879950,TT,Rheumatoid Arthritis patients with the genotype TT may be less likely to respond to TNF inhibitors compared with a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的风湿性关节炎患者，相比CC基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166136176,rs61734430,1444666791,CC,Patients with the CC genotype and lung cancer may have a better response to treatment with pemetrexed as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to pemetrexed.,携带CC基因型的肺癌患者，相比CT或TT基因型，药物响应可能更好,1,,2,,,,,plus,王兴悦
PA166136176,rs61734430,1444666792,CT,Patients with the CT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.,携带CT基因型的肺癌患者，相比CC基因型，药物响应可能更差,1,,0,,,,,plus,王兴悦
PA166136176,rs61734430,1444666793,TT,Patients with the TT genotype and lung cancer may have a poorer response to treatment with pemetrexed as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to pemetrexed.,携带TT基因型的肺癌患者，相比CC基因型，药物响应可能更差,1,,0,,,,,plus,王兴悦
PA166134207,rs61750900,1448105331,GG,Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine.,携带GG基因型的患者，相比TT基因型，药物代谢可能增加,1,,,,2,,,plus,王兴悦
PA166134207,rs61750900,1448105332,GT,Patients with the GT genotype may have a decreased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine.,携带GT基因型的患者，相比TT基因型，药物代谢可能降低,1,,,,0,,,plus,王兴悦
PA166134207,rs61750900,1448105333,TT,Patients with the TT genotype may have a decreased metabolism of nicotine as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' response to nicotine.,携带TT基因型的患者，相比GG基因型，药物代谢可能降低,1,,,,0,,,plus,王兴悦
PA166136095,rs61742245,1185002359,AA,Patients with the AA genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.,携带AA基因型的患者，相比CC基因型，药物剂量可能需要增加,1,,,,,2,,plus,王兴悦
PA166136095,rs61742245,1185002360,AC,Patients with the AC genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.,携带AC基因型的患者，相比CC基因型，药物剂量可能需要增加,1,,,,,2,,plus,王兴悦
PA166136095,rs61742245,1185002361,CC,Patients with the CC genotype may require decreased dose of acenocoumarol as compared to patients with the AA or AC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.,携带CC基因型的患者，相比AA或AC基因型，药物剂量可能需要降低,1,,,,,0,,plus,王兴悦
PA166135419,rs61742245,1448105766,AA,Patients with the AA genotype may have increased dose of warfarin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of warfarin.,携带AA基因型的患者，相比CC基因型，药物剂量可能需要增加,1,,,,,2,,plus,王兴悦
PA166135419,rs61742245,1448105767,AC,Patients with the AC genotype may have increased dose of warfarin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the dose of warfarin.,携带AC基因型的患者，相比CC基因型，药物剂量可能需要增加,1,,,,,2,,plus,王兴悦
PA166135419,rs61742245,1448105768,CC,Patients with the CC genotype may have decreased dose of warfarin as compared to patients with genotype AA or AC. Other genetic and clinical factors may also influence the dose of warfarin.,携带CC基因型的患者，相比AA或AC基因型，药物剂量可能需要降低,1,,,,,0,,plus,王兴悦
PA166151944,rs619586,1447953173,AA,Patients with the AA genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.,携带AA基因型的肺癌患者，相比AG和GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166151944,rs619586,1447953174,AG,Patients with the AG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.,携带AG基因型的肺癌患者，相比AA基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166151944,rs619586,1447953175,GG,Patients with the GG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.,携带GG基因型的肺癌患者，相比AA基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166158968,rs62471956,1448106586,AA,Patients with the AA genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the AG or GG genotypes. Other factors may affect concentrations of ticagrelor.,携带AA基因型的急性冠脉综合征患者，相比AG或GG基因型，药物浓度可能增加,1,,,,2,,,plus,王兴悦
PA166158968,rs62471956,1448106587,AG,Patients with the AG genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the GG genotypes. Other factors may affect concentrations of ticagrelor.,携带AG基因型的急性冠脉综合征患者，相比GG基因型，药物浓度可能增加,1,,,,2,,,plus,王兴悦
PA166158968,rs62471956,1448106588,GG,Patients with the GG genotype and acute coronary syndrome may have decreased concentrations of ticagrelor compared to patients with the AA or AG genotypes. Other factors may affect concentrations of ticagrelor.,携带GG基因型的急性冠脉综合征患者，相比AA或AG基因型，药物浓度可能降低,1,,,,0,,,plus,王兴悦
PA166158890,rs62576288,1448099311,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to patients with the GG genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.,携带AA基因型的鼻咽癌患者，相比GG基因型，可能会有轻微的贫血,1,,,0,,,,FWD,王兴悦
PA166158890,rs62576288,1448099312,GG,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.,携带GG基因型的鼻咽癌患者，相比AA基因型，可能会有严重的贫血,1,,,2,,,,FWD,王兴悦
PA166158791,rs62576288,1448098346,AA,Patients with nasopharyngeal cancer and the AA genotype who are treated with docetaxel may have less severe anemia as compared to the GG genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel. ,携带AA基因型的鼻咽癌患者，相比GG基因型，可能会有轻微的贫血,1,,,0,,,,FWD,王兴悦
PA166158791,rs62576288,1448098347,GG,Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel. ,携带GG基因型的鼻咽癌患者，相比AA基因型，可能会有严重的贫血,1,,,2,,,,FWD,王兴悦
PA166134735,rs5918,1184989726,CC,"Patients with the CC genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. ",携带CC基因型的患者，相比TT基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134735,rs5918,1184989727,CT,"Patients with the CT genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. ",携带CT基因型的患者，相比TT基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134735,rs5918,1184989728,TT,"Patients with the TT genotype may be more likely to respond to aspirin as compared to patients with the CC or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. ",携带TT基因型的患者，相比CC或CT基因型，药物响应可能较好,1,,2,,,,,plus,王兴悦
PA166134736,rs5918,1184989732,CC,Patients with the CC genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel. ,携带CC基因型的患者，相比TT基因型，抗血小板效果可能下降,1,,0,,,,,plus,王兴悦
PA166134736,rs5918,1184989733,CT,Patients with the CT genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel. ,携带CT基因型的患者，相比TT基因型，抗血小板效果可能增加,1,,2,,,,,plus,王兴悦
PA166134736,rs5918,1184989734,TT,Patients with the TT genotype may have an increased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with CC or CT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogrel. ,携带TT基因型的患者，相比CC或CT基因型，抗血小板效果可能增加,1,,2,,,,,plus,王兴悦
PA166135402,rs6265,1448099731,CC,"Patients with the CC genotype may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin. ",携带CC基因型的患者，相比TT基因型，药物依赖风险可能较低,1,,,0,,,,minus,王兴悦
PA166135402,rs6265,1448099732,CT,"Patients with the CT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype or may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin. ",携带CT基因型的患者，相比CC基因型，药物依赖风险可能较高；相比TT基因型，药物依赖风险可能较低,1,,,1,,,,minus,王兴悦
PA166135402,rs6265,1448099733,TT,"Patients with the TT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin. ",携带TT基因型的患者，相比CC基因型，药物依赖风险可能较高,1,,,2,,,,minus,王兴悦
PA166135410,rs6265,1183702965,CC,Patients with the CC genotype and schizophrenia may show less resistance to treatment with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.,携带CC基因型的精神分裂症患者，相比CT或TT基因型，药物耐药程度可能较低,1,,2,,,,,minus,王兴悦
PA166135410,rs6265,1183702966,CT,Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.,携带CT基因型的精神分裂症患者，相比CC基因型，药物耐药程度可能较高,1,,0,,,,,minus,王兴悦
PA166135410,rs6265,1183702967,TT,Patients with the TT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.,携带TT基因型的精神分裂症患者，相比CC基因型，药物耐药程度可能较高,1,,0,,,,,minus,王兴悦
PA166135606,rs6265,1184987590,CC,"Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.",携带CC基因型的物质戒断综合征患者，相比TT基因型，头痛的可能性可能增加,1,,,2,,,,minus,王兴悦
PA166135606,rs6265,1184987591,CT,"Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.",携带CT基因型的物质戒断综合征患者，相比CC基因型，头痛的可能性可能降低,1,,,0,,,,minus,王兴悦
PA166135606,rs6265,1184987592,TT,"Patients with the TT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.",携带TT基因型的物质戒断综合征患者，相比CC基因型，头痛的可能性可能降低,1,,,0,,,,minus,王兴悦
PA166136412,rs6265,1446897193,CC,Patients with the CC genotype and schizophrenia may have greater weight gain when treated with antipsychotics as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. ,携带CC基因型的精神分裂症患者，相比CT或TT基因型，体重增加可能较多,1,,,2,,,,minus,王兴悦
PA166136412,rs6265,1446897194,CT,Patients with the CT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. ,携带CT基因型的精神分裂症患者，相比CC基因型，体重增加可能较小,1,,,0,,,,minus,王兴悦
PA166136412,rs6265,1446897195,TT,Patients with the TT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics. ,携带TT基因型的精神分裂症患者，相比CC基因型，体重增加可能较小,1,,,0,,,,minus,王兴悦
PA166135174,rs6265,1183619232,CC,Patients with the CC genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.,携带CC基因型的重度抑郁症患者，相比TT基因型，出现副作用可能性较大,1,,,2,,,,minus,王兴悦
PA166135174,rs6265,1183619233,CT,Patients with the CT genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype or may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.,携带CT基因型的重度抑郁症患者，相比TT基因型，出现副作用可能性较大；相比CC基因型，出现副作用可能性较小,1,,,1,,,,minus,王兴悦
PA166135174,rs6265,1183619234,TT,Patients with the TT genotype and major depressive disorder who are treated with fluoxetine may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects. ,携带TT基因型的重度抑郁症患者，相比CC基因型，出现副作用可能性较小,1,,,0,,,,minus,王兴悦
PA166134750,rs6265,982040541,CC,"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. ",携带CC基因型的抑郁症患者，相比TT基因型，药物响应可能较好,1,,2,,,,,minus,王兴悦
PA166134750,rs6265,982040542,CT,"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. ",携带CT基因型的抑郁症患者，相比TT基因型，药物响应可能较好,1,,2,,,,,minus,王兴悦
PA166134750,rs6265,982040543,TT,"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine as compared to patients with the CT or CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine. ",携带TT基因型的抑郁症患者，相比CT或CC基因型，药物响应可能较差,1,,0,,,,,minus,王兴悦
PA166134781,rs6265,1444608035,CC,"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.",PA450801:携带CC基因型的抑郁症患者，相比CT或TT基因型，药物响应可能较好,1,,2,,,,,minus,王兴悦
PA166134781,rs6265,1444608036,CT,"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.",PA450801:携带CT基因型的抑郁症患者，相比CC或TT基因型，药物响应可能较好,1,,2,,,,,minus,王兴悦
PA166134781,rs6265,1444608037,TT,"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine or antidepressants but more likely to respond to citalopram as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.",PA450801:携带TT基因型的抑郁症患者，相比CT或CC基因型，药物响应可能较差,1,,0,,,,,minus,王兴悦
PA166134781,rs6265,1444608035,CC,"Patients with the CC genotype and Depressive Disorder may be more likely to respond to paroxetine but less likely to respond to citalopram or antidepressants as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.",PA449015:携带CC基因型的抑郁症患者，相比CT或TT基因型，药物响应可能较差,1,,0,,,,,minus,王兴悦
PA166134781,rs6265,1444608036,CT,"Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.",PA449015:携带CT基因型的抑郁症患者，相比CC或TT基因型，药物响应可能较好,1,,2,,,,,minus,王兴悦
PA166134781,rs6265,1444608037,TT,"Patients with the TT genotype and Depressive Disorder may be less likely to respond to paroxetine or antidepressants but more likely to respond to citalopram as compared to patients with the CT or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.",PA449015:携带TT基因型的抑郁症患者，相比CT或CC基因型，药物响应可能较好,1,,2,,,,,minus,王兴悦
PA166135919,rs6265,1446896646,CC,Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to olanzapine.,携带CC基因型的精神分裂症患者，相比CT或TT基因型，药物响应可能较好,1,,2,,,,,minus,王兴悦
PA166135919,rs6265,1446896647,CT,Patients with the CT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.,携带CT基因型的精神分裂症患者，相比CC基因型，药物响应可能较差,1,,0,,,,,minus,王兴悦
PA166135919,rs6265,1446896648,TT,Patients with the TT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.,携带TT基因型的精神分裂症患者，相比CC基因型，药物响应可能较差,1,,0,,,,,minus,王兴悦
PA166160513,rs628031,1448263580,AA,"Patients with the AA genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine.",携带AA基因型的癫痫患者，相比GG基因型，药物浓度可能增加,1,,,,2,,,plus,王兴悦
PA166160513,rs628031,1448263581,AG,"Patients with the AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine.",携带AG基因型的癫痫患者，相比GG基因型，药物浓度可能增加,1,,,,2,,,plus,王兴悦
PA166160513,rs628031,1448263582,GG,"Patients with the GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the AA and AG genotypes. However, no difference was found in dose or efficacy. Other genetic and clinical factors may affect response to lamotrigine.",携带GG基因型的癫痫患者，相比AA和AG基因型，药物浓度可能降低,1,,,,0,,,plus,王兴悦
PA166136115,rs628031,1444607636,AA,Patients with the AA genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to metformin.,携带AA基因型的患者，相比GG基因型，药物响应可能降低，胃肠道副作用风险可能增加,1,,0,,,,,plus,王兴悦
PA166136115,rs628031,1444607637,AG,Patients with the AG genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype and increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.,携带AG基因型的患者，相比GG基因型，药物响应可能降低，胃肠道副作用风险可能增加；相比AA基因型，药物响应可能增加，胃肠道副作用风险可能降低,1,,1,,,,,plus,王兴悦
PA166136115,rs628031,1444607638,GG,Patients with the GG genotype who are treated with metformin may have a increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.,携带GG基因型的患者，相比AA基因型，药物响应可能增加，胃肠道副作用风险可能降低,1,,2,,,,,plus,王兴悦
PA166135881,rs63749869,1447992481,AA,"Patients with the AA genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Please note: the A allele is considered to confer MH in an autosomal dominant manner and is almost always reported in heterozygotes therefore the phenotype of an individual with AA genotype is not known. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带AA基因型的患者，相比GG基因型，可能会有恶性高热,1,,,2,,,,plus,王兴悦
PA166135881,rs63749869,1447992482,AG,"Patients with the AG genotype may develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带AG基因型的患者，相比GG基因型，可能会有恶性高热,1,,,2,,,,plus,王兴悦
PA166135881,rs63749869,1447992483,GG,"Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype AG or GG. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia.",携带GG基因型的患者，相比AG或AA基因型，可能不会有恶性高热,1,,,0,,,,plus,王兴悦
PA166135449,rs6427528,1448265250,AA,"Patients with the AA genotype may have increased response to etanercept in people with Arthritis, Rheumatoid as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.",携带AA基因型的风湿性关节炎患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166135449,rs6427528,1448265251,AG,"Patients with the AG genotype may have increased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.",携带AG基因型的风湿性关节炎患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166135449,rs6427528,1448265252,GG,"Patients with the GG genotype may have decreased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to etanercept.",携带GG基因型的风湿性关节炎患者，相比AA或AG基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166135680,rs6467136,1444666758,AA,Patients with the AA genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone.,携带AA基因型的Ⅱ型糖尿病患者，相比GG基因型，药物响应可能更好,1,,2,,,,,plus,王兴悦
PA166135680,rs6467136,1444666759,AG,Patients with the AG genotype and type 2 diabetes may have a better response when treated with rosiglitazone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosiglitazone,携带AG基因型的Ⅱ型糖尿病患者，相比GG基因型，药物响应可能更好,1,,2,,,,,plus,王兴悦
PA166135680,rs6467136,1444666760,GG,Patients with the GG genotype and type 2 diabetes may have a poorer response when treated with rosiglitazone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to rosiglitazone,携带GG基因型的Ⅱ型糖尿病患者，相比AA或AG基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166136203,rs646776,1444668404,CC,Patients with the CC genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.,携带CC基因型的患者，相比CT或TT基因型，药物响应可能增加,1,,2,,,,, minus,王兴悦
PA166136203,rs646776,1444668405,CT,Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.,携带CT基因型的患者，相比TT基因型，药物响应可能增加；相比CC基因型，药物响应可能降低,1,,1,,,,, minus,王兴悦
PA166136203,rs646776,1444668406,TT,Patients with the TT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.,携带TT基因型的患者，相比CT或CC基因型，药物响应可能降低,1,,0,,,,, minus,王兴悦
PA166152724,rs6545803,1447960805,GG,Patients with the GG genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带GG基因型的HIV感染患者，相比TT基因型，药物导致皮疹的风险增加,1,,,2,,,, plus,王兴悦
PA166152724,rs6545803,1447960806,GT,Patients with the GT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带GT基因型的HIV感染患者，相比TT基因型，药物导致皮疹的风险增加；相比GG基因型，药物导致皮疹的风险降低,1,,,1,,,, plus,王兴悦
PA166152724,rs6545803,1447960807,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带TT基因型的HIV感染患者，相比GG基因型，药物导致皮疹的风险降低,1,,,0,,,, plus,王兴悦
PA166159161,rs671,1448102370,AA,Patients with the AA genotype may have an increased risk for heroin addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.,携带AA基因型的患者，相比GG基因型，海洛因成瘾的风险可能增加,1,,,2,,,, plus,王兴悦
PA166159161,rs671,1448102371,AG,Patients with the AG genotype may have an increased risk for heroin addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.,携带AG基因型的患者，相比GG基因型，海洛因成瘾的风险可能增加,1,,,2,,,, plus,王兴悦
PA166159161,rs671,1448102372,GG,Patients with the GG genotype may have a decreased risk for heroin addiction as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for heroin addiction.,携带GG基因型的患者，相比AA或AG基因型，海洛因成瘾的风险可能降低,1,,,0,,,, plus,王兴悦
PA166134991,rs662799,1183492044,AA,"Patients with the AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. ",携带AA基因型的高血脂患者，相比AG或GG基因型，低密度脂蛋白胆固醇可能大幅降低,1,,2,,,,, plus,王兴悦
PA166134991,rs662799,1183492045,AG,"Patients with the AG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. ",携带AG基因型的高血脂患者，相比AA基因型，低密度脂蛋白胆固醇可能小幅幅降低,1,,0,,,,, plus,王兴悦
PA166134991,rs662799,1183492046,GG,"Patients with the GG genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have less reduction in LDL-cholesterol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. ",携带GG基因型的高血脂患者，相比AA基因型，低密度脂蛋白胆固醇可能小幅幅降低,1,,0,,,,, plus,王兴悦
PA166134877,rs6755571,1043880443,AA,"Patients with AA genotype were not studied. However, patients with the AC genotype and neoplasms may have a decreased  plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.",AA基因型患者未参与研究,1,,,,,,,FWD,王兴悦
PA166134877,rs6755571,1043880444,AC,Patients with the AC genotype and neoplasms may have a decreased  plasma predose concentration as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.,携带AC基因型的肿瘤患者，相比CC基因型，血浆初始剂量浓度可能降低,1,,,,,,0,FWD,王兴悦
PA166134877,rs6755571,1043880445,CC,Patients with the CC genotype and neoplasms may have an increased  plasma predose concentration as compared to patients with the AC genotype. Other genetic and clinical factors may also influence a patient's ABT-751 metabolism.,携带CC基因型的肿瘤患者，相比AC基因型，血浆初始剂量浓度可能增加,1,,,,,,2,FWD,王兴悦
PA166135445,rs6749447,1183704377,GG,Patients with the GG genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.,携带GG基因型的男性高血压患者，相比TT基因型，动态血压的下降可能减少,1,男,0,,,,,plus,王兴悦
PA166135445,rs6749447,1183704378,GT,Patients with the GT genotype may have decreased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to losartan.,携带GT基因型的男性高血压患者，相比TT基因型，动态血压的下降可能减少,1,男,0,,,,,plus,王兴悦
PA166135445,rs6749447,1183704379,TT,Patients with the TT genotype may have increased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to losartan.,携带TT基因型的男性高血压患者，相比GG或GT基因型，动态血压的下降可能增加,1,男,2,,,,,plus,王兴悦
PA166159034,rs676210,1448101116,AA,Patients with the AA genotype and hypertriglyceridemia may have greater decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate. ,携带AA基因型的高甘油三酯血症患者，相比AG或GG基因型，甘油三酯水平可能大幅下降,1,,2,,,,, plus,王兴悦
PA166159034,rs676210,1448101117,AG,Patients with the AG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate. ,携带AG基因型的高甘油三酯血症患者，相比AA基因型，甘油三酯水平可能小幅下降,1,,0,,,,, plus,王兴悦
PA166159034,rs676210,1448101118,GG,Patients with the GG genotype and hypertriglyceridemia may have smaller decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fenofibrate. ,携带GG基因型的高甘油三酯血症患者，相比AA基因型，甘油三酯水平可能小幅下降,1,,0,,,,, plus,王兴悦
PA166134749,rs6785930,1446909037,AA,"Patients with the AA genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. ",携带AA基因型的患者，相比GG基因型，神经学事件发生风险增加,1,,,2,,,, plus,王兴悦
PA166134749,rs6785930,1446909038,AG,"Patients with the AG genotype who are treated with clopidogrel may have an increased risk of neurological events as compared to patients with the GG genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. ",携带AG基因型的患者，相比GG基因型，神经学事件发生风险增加,1,,,2,,,, plus,王兴悦
PA166134749,rs6785930,1446909039,GG,"Patients with the GG genotype who are treated with clopidogrel may have a decreased, but not absent, risk of neurological events as compared to patients with the AA genotype. However, no association with differences in risk of cardiovascular events was reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel. ",携带GG基因型的患者，相比AA基因型，神经学事件发生风险降低,1,,,0,,,, plus,王兴悦
PA166136132,rs6822844,1444607974,GG,"Patients with the GG genotype and systemic lupus erythematosus may be more likely to respond to treatment with rituximab, as compared to patients with the GT genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.",携带GG基因型的系统性红斑狼疮患者，相比GT基因型，对药物响应的可能性增加,1,,2,,,,, plus,王兴悦
PA166136132,rs6822844,1444607975,GT,"Patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.",携带GT基因型的系统性红斑狼疮患者，相比GG基因型，对药物响应的可能性降低,1,,0,,,,, plus,王兴悦
PA166136132,rs6822844,1444607976,TT,"No patients with the TT genotype were present in the study. However, patients with the GT genotype and systemic lupus erythematosus may be less likely to respond to treatment with rituximab, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with rituximab.",无TT基因型患者参与研究,1,,,,,,, plus,王兴悦
PA166161865,rs6908425,1448522774,CC,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带CC基因型的牛皮癣患者，相比CT或TT基因型，可能对药物响应较差,1,,0,,,,, plus,王兴悦
PA166161865,rs6908425,1448522775,CT,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带CT基因型的牛皮癣患者，相比CC基因型，可能对药物响应较好,1,,2,,,,, plus,王兴悦
PA166161865,rs6908425,1448522776,TT,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带TT基因型的牛皮癣患者，相比CC基因型，可能对药物响应较好,1,,2,,,,, plus,王兴悦
PA166135442,rs6920220,1183704354,AA,Patients with the AA genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.,携带AA基因型的关节炎患者，相比GG基因型，药物停药可能性增加,1,,0,,,,, plus,王兴悦
PA166135442,rs6920220,1183704355,AG,Patients with the AG genotype may have increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to methotrexate.,携带AG基因型的关节炎患者，相比GG基因型，药物停药可能性增加,1,,0,,,,, plus,王兴悦
PA166135442,rs6920220,1183704356,GG,Patients with the GG genotype may have decreased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to methotrexate.,携带GG基因型的关节炎患者，相比AA或AG基因型，药物停药可能性降低,1,,2,,,,, plus,王兴悦
PA166134523,rs67376798,1448605550,AA,"Patients with the AA genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) complete DYPD deficiency and decreased clearance of fluoropyrimidine drugs and 2) increased risk and increased severity of drug toxicity, in particular diarrhea, as compared to patients with the TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带AA基因型的肿瘤患者，相比TT基因型，可能有DPYD完全缺陷，且药物清除能力可能下降；药物严重毒副作用的风险及严重性可能增加,1,,,2,0,,, plus,王兴悦
PA166134523,rs67376798,1448605551,AT,"Patients with the AT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) DYPD deficiency and decreased clearance of fluoropyrimidine drugs and 2) increased risk and increased severity of drug toxicity, in particular diarrhea, as compared to patients with the TT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带AT基因型的肿瘤患者，相比TT基因型，可能有DPYD缺陷，且药物清除能力可能下降；药物严重毒副作用的风险及严重性可能增加,1,,,2,0,,, plus,王兴悦
PA166134523,rs67376798,1448605552,TT,"Patients with the TT genotype and cancer who are treated with fluoropyrimidine-based chemotherapy may have 1) increased clearance of the drug and 2) decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AT genotype. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin), FOLFIRI (fluorouracil, leucovorin and irinotecan) or FEC (fluorouracil, epirubicin and cyclophosphamide) or with other drugs such as bevacizumab, cetuximab, raltitrexed. The combination and delivery of the drug may influence risk for toxicity. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.",携带TT基因型的肿瘤患者，相比AT基因型，药物清除能力可能增加；药物严重毒副作用的风险及严重性可能下降,1,,,0,2,,, plus,王兴悦
PA166135441,rs6977820,1183704344,CC,Patients with the CC genotype may have decreased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.,携带CC基因型的精神分裂症患者，相比TT或CT基因型，发生迟发性运动障碍的可能性可能下降,1,,,0,,,, plus,王兴悦
PA166135441,rs6977820,1183704345,CT,Patients with the CT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.,携带CT基因型的精神分裂症患者，相比CC基因型，发生迟发性运动障碍的可能性可能增加,1,,,2,,,, plus,王兴悦
PA166135441,rs6977820,1183704346,TT,Patients with the TT genotype may have increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype CC. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.,携带TT基因型的精神分裂症患者，相比CC基因型，发生迟发性运动障碍的可能性可能增加,1,,,2,,,, plus,王兴悦
PA166151948,rs6983267,1447953225,GG,Patients with the GG genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.,携带GG基因型的肺癌患者，相比TT基因型，对药物的响应可能增加,1,,2,,,,, plus,王兴悦
PA166151948,rs6983267,1447953226,GT,Patients with the GT genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.,携带GT基因型的肺癌患者，相比TT基因型，对药物的响应可能增加,1,,2,,,,, plus,王兴悦
PA166151948,rs6983267,1447953227,TT,Patients with the TT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG and GT genotypes. Other genetic and clinical factors may also influence a patient's response to platinum compounds.,携带TT基因型的肺癌患者，相比GG和GT基因型，对药物的响应可能降低,1,,0,,,,, plus,王兴悦
PA166134761,rs6988229,982045085,CC,Patients with CC genotypes may have decreased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带CC基因型的哮喘患者，相比TT基因型，支气管扩张剂反应可能降低,1,,0,,,,, plus,王兴悦
PA166134761,rs6988229,982045084,TC,Patients with TC genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带TC基因型的哮喘患者，相比CC基因型，支气管扩张剂反应可能增加,1,,2,,,,, plus,王兴悦
PA166134761,rs6988229,982045083,TT,Patients with TT genotypes may have increased bronchodilator response (FEV1) when treated with salbutamol in asthma when compared to patients with CC genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带TT基因型的哮喘患者，相比CC基因型，支气管扩张剂反应可能增加,1,,2,,,,, plus,王兴悦
PA166135992,rs700518,1447682295,AA,"Post-menopausal women with breast cancer and the AA genotype may have increased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or CC genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer. ",携带AA基因型的绝经后期乳腺癌女性患者，相比AC或CC基因型，血浆甘油三酯的浓度可能增加,1,女,,,,,2, minus,王兴悦
PA166135992,rs700518,1447682296,AC,"Post-menopausal women with breast cancer and the AC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AA genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer. ",携带AC基因型的绝经后期乳腺癌女性患者，相比AA基因型，血浆甘油三酯的浓度可能降低；相比CC基因型，血浆甘油三酯的浓度可能增加,1,女,,,,,1, minus,王兴悦
PA166135992,rs700518,1447682297,CC,"Post-menopausal women with breast cancer and the CC genotype may have decreased concentrations of plasma triglycerides when taking letrozole, alone or with a statin, as compared to women with the AC or AA genotypes. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer. ",携带CC基因型的绝经后期乳腺癌女性患者，相比AC或AA基因型，血浆甘油三酯的浓度可能降低,1,女,,,,,0, minus,王兴悦
PA166134068,rs7046653,1183703652,AA,Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的风湿性关节炎患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166134068,rs7046653,1183703653,AG,Rheumatoid Arthritis patients with the AG genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype GG. Other genetic and clinical factors may also influence a patient's response.,携带AG基因型的风湿性关节炎患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166134068,rs7046653,1183703654,GG,Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的风湿性关节炎患者，相比AA或AG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166134706,rs7118900,982032568,AA,Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带AA基因型的海洛因成瘾患者，相比GG基因型，药物维持治疗时，所需的药物剂量可能更低,1,,,,,0,,FWD,王兴悦
PA166134706,rs7118900,982032569,AG,Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带AG基因型的海洛因成瘾患者，相比GG基因型，药物维持治疗时，所需的药物剂量可能更低,1,,,,,0,,FWD,王兴悦
PA166134706,rs7118900,982032570,GG,Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. ,携带GG基因型的海洛因成瘾患者，相比AA或AG基因型，药物维持治疗时，所需的药物剂量可能更高,1,,,,,2,,FWD,王兴悦
PA166135659,rs7103411,1444608042,CC,Patients with the CC genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.,携带CC基因型的重度抑郁症患者，相比TT基因型，药物响应可能更好,1,,2,,,,, plus,王兴悦
PA166135659,rs7103411,1444608043,CT,"Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype, or a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.",携带CT基因型的重度抑郁症患者，相比TT基因型，药物响应可能更好；相比CC基因型，药物响应可能较差,1,,1,,,,, plus,王兴悦
PA166135659,rs7103411,1444608044,TT,Patients with the TT genotype and major depressive disorder may have a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.,携带TT基因型的重度抑郁症患者，相比CC基因型，药物响应可能较差,1,,0,,,,, plus,王兴悦
PA166152820,rs7142143,1447963263,CC,"Pediatric patients with the CC genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.",携带CC基因型的急性淋巴细胞白血病患者，相比TT基因型，复发风险可能较大,1,,0,,,,, plus,王兴悦
PA166152820,rs7142143,1447963264,CT,"Pediatric patients with the CT genotype and acute lymphoblastic leukemia (ALL) may have a greater risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of relapse.",携带CT基因型的急性淋巴细胞白血病患者，相比TT基因型，复发风险可能较大,1,,0,,,,, plus,王兴悦
PA166152820,rs7142143,1447963265,TT,"Pediatric patients with the TT genotype and acute lymphoblastic leukemia may have a smaller risk of relapse when treated with asparaginase, dexamethasone, methotrexate or other ALL regimen drugs, as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of relapse.",携带TT基因型的急性淋巴细胞白血病患者，相比CC或CT基因型，复发风险可能较小,1,,2,,,,, plus,王兴悦
PA166134179,rs7142881,655384885,AA,Patients with the AA genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的患者，相比GG基因型，恶性心血管事件发生风险可能增加,1,,,2,,,, plus,王兴悦
PA166134179,rs7142881,655384884,AG,Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.,携带AG基因型的患者，相比GG基因型，恶性心血管事件发生风险可能增加,1,,,2,,,, plus,王兴悦
PA166134179,rs7142881,655384883,GG,"Patients with the GG genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.",携带GG基因型的患者，相比AA和AG基因型，恶性心血管事件发生风险可能降低,1,,,0,,,, plus,王兴悦
PA166134088,rs712829,1447961315,GG,Patients with the GG genotype who are treated with gefitinib may be less likely to respond compared to a patient with one or more T alleles.  Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的患者，相比单个或多个T等位基因基因型，药物响应可能降低,1,,0,,,,, plus,王兴悦
PA166134088,rs712829,1447961316,GT,Patients with the GT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.,携带GT基因型的患者，相比GG基因型，药物响应可能更好,1,,2,,,,, plus,王兴悦
PA166134088,rs712829,1447961317,TT,Patients with the TT genotype who are treated with gefitinib may be more likely to respond compared to such a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的患者，相比GG基因型，药物响应可能更好,1,,2,,,,, plus,王兴悦
PA166134416,rs712829,827831124,GG,Patients with the GG genotype and cancer who are treated with erlotinib may have increased severity of Diarrhea compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.,携带GG基因型的肿瘤患者，相比GT或TT基因型，腹泻的严重性可能增加,1,,,2,,,, plus,王兴悦
PA166134416,rs712829,827831125,GT,Patients with the GT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.,携带GT基因型的肿瘤患者，相比GG基因型，腹泻的严重性可能降低,1,,,0,,,, plus,王兴悦
PA166134416,rs712829,827831126,TT,Patients with the TT genotype and cancer who are treated with erlotinib may have decreased severity of Diarrhea compared to patients with the GG genotype. Other genetic and clinical factors may also influence severity of Diarrhea when treated with erlotinib.,携带TT基因型的肿瘤患者，相比GG基因型，腹泻的严重性可能降低,1,,,0,,,, plus,王兴悦
PA166163252,rs7187684,1448602887,CC,Patients with the CC genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.,携带CC基因型的肿瘤患者，相比TT基因型，药物总毒性风险可能下降,1,,,0,,,,FWD,王兴悦
PA166163252,rs7187684,1448602886,CT,Patients with the CT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.,携带CT基因型的肿瘤患者，相比CC基因型，药物总毒性风险可能增加,1,,,2,,,,FWD,王兴悦
PA166163252,rs7187684,1448602885,TT,Patients with the TT genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.,携带TT基因型的肿瘤患者，相比CC基因型，药物总毒性风险可能增加,1,,,2,,,,FWD,王兴悦
PA166134662,rs71647871,1446908994,CC,Patients with the CC genotype who are treated with clopidogrel may have higher on-treatment ADP-induced platelet aggregation and lower levels of clopidogrel active metabolite as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.,携带CC基因型的肿瘤患者，相比CT或TT基因型，血小板聚集可能性较高，活性代谢物水平可能较低,1,,0,,,,,minus,王兴悦
PA166134662,rs71647871,1446908995,CT,Patients with the CT genotype who are treated with clopidogrel may have lower on-treatment ADP-induced platelet aggregation and higher levels of clopidogrel active metabolite as compared to patients with the CC genotype. The T allele is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel. Other genetic and clinical factors may also influence a patient's response to clopidogrel.,携带CT基因型的肿瘤患者，相比CC基因型，血小板聚集可能性较低，活性代谢物水平可能较高,1,,2,,,,,minus,王兴悦
PA166134662,rs71647871,1446908996,TT,Patients with the TT genotype who are treated with clopidogrel may have lower on-treatment ADP-induced platelet aggregation and higher levels of clopidogrel active metabolite as compared to patients with the CC genotype. The T allele is associated with impaired catalytic activity towards hydrolysis of clopidogrel and 2-oxo-clopidogrel. Other genetic and clinical factors may also influence a patient's response to clopidogrel.,携带TT基因型的肿瘤患者，相比CC基因型，血小板聚集可能型较低，活性代谢物水平可能较高,1,,2,,,,,minus,王兴悦
PA166134495,rs71647871,1448573562,CC,Patients with the CC genotype and Attention Deficit Disorder may require an increased dose of methylphenidate as compared to patients with the CT genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.,携带CC基因型的注意力缺陷障碍患者，相比CT基因型，药物剂量可能需要增加,1,,,,,2,,minus,王兴悦
PA166134495,rs71647871,1448573563,CT,Patients with the CT genotype and Attention Deficit Disorder may require a decreased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.,携带CT基因型的注意力缺陷障碍患者，相比CC基因型，药物剂量可能需要减少,1,,,,,0,,minus,王兴悦
PA166134495,rs71647871,1448573564,TT,"Patients with the TT genotype were not studied, however patients with the CT genotype and Attention Deficit Disorder may require a decreased dose of methylphenidate as compared to patients with the CC genotype. This was not associated with response. Other genetic and clinical factors may also influence methylphenidate dose and response.",无TT基因型患者参与研究,1,,,,,,,minus,王兴悦
PA166136428,rs71647871,1446899482,CC,Patients with the CC genotype may have increased metabolism of enalapril as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of enalapril.,携带CC基因型的患者，相比CT基因型，药物代谢可能增加,1,,,,2,,,minus,王兴悦
PA166136428,rs71647871,1446899483,CT,Patients with the CT genotype may have decreased metabolism of enalapril as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of enalapril.,携带CT基因型的患者，相比CC基因型，药物代谢可能降低,1,,,,0,,,minus,王兴悦
PA166134828,rs72551330,1043859387,CC,Patients with the CC genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.,携带CC基因型的肾移植患者，相比TT基因型，手术移植后的第一和第二个月，肾小球滤过率和瞬时蛋白尿的风险可能增加,1,,,2,,,,FWD,王兴悦
PA166134828,rs72551330,1043859388,CT,Patients with the CT genotype and Kidney Transplantation may have an increased risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the TT genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.,携带CT基因型的肾移植患者，相比TT基因型，手术移植后的第一和第二个月，肾小球滤过率和瞬时蛋白尿的风险可能增加,1,,,2,,,,FWD,王兴悦
PA166134828,rs72551330,1043859389,TT,"Patients with the TT genotype and Kidney Transplantation may have a decreased, but not absent, risk for a diminished estimated glomerular filtration rate and transient proteinuria in the first (p=0.07) and second month (p=0.03) after transplantation when treated with mycophenolate mofetil as compared to patients with the CC genotype. Studies found no association with increased risk for acute allograft rejection within 3 month after transplantation. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil and risk for acute allograft rejection.",携带TT基因型的肾移植患者，相比CC基因型，手术移植后的第一和第二个月，肾小球滤过率和瞬时蛋白尿的风险可能降低,1,,,0,,,,FWD,王兴悦
PA166136123,rs72552763,1444607746,GAT/DEL,Patients with the GAT/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.,携带GAT/del基因型的患者，相比GAT/GAT基因型，药物稳态浓度可能下降,1,,,,2,,,FWD,王兴悦
PA166136123,rs72552763,1444607747,GAT/GAT,Patients with the GAT/GAT genotype who are treated with metformin may have an increased trough metformin steady-state concentration as compared to patients with the GAT/DEL genotype. Other genetic and clinical factors may also influence a patient's response to metformin.,携带GAT/GAT基因型的患者，相比GAT/del基因型，药物稳态浓度可能增加,1,,,,0,,,FWD,王兴悦
PA166136123,rs72552763,1444607748,del/del,Patients with the del/del genotype were not studied but patients with the GAT/DEL genotype who are treated with metformin may have a decreased trough metformin steady-state concentration as compared to patients with the GAT/GAT genotype. Other genetic and clinical factors may also influence a patient's response to metformin.,未有del/del基因型的患者参与研究,1,,,,,,,FWD,王兴悦
PA166135527,rs717620,1444705491,CC,Patients with the CC genotype may have decreased clearance and distribution of volume of methotrexate as compared to patients with the TT genotype. Please note: the opposite effect was observed in a study done in an Asian population with various types of lymphomas. The T allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate. ,携带CC基因型的患者，相比TT基因型，药物清除率及体内分布量可能降低,1,,,,0,,, minus,王兴悦
PA166135527,rs717620,1444705492,CT,Patients with the CT genotype may have increased clearance and distribution of volume of methotrexate as compared to patients with the CC genotype. Please note: the opposite effect was observed in a study done in an Asian population with various types of lymphomas. The T allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate. ,携带CT基因型的患者，相比CC基因型，药物清除率及体内分布量可能增加,1,,,,2,,, minus,王兴悦
PA166135527,rs717620,1444705493,TT,Patients with the TT genotype may have increased clearance and distribution of volume of methotrexate as compared to patients with the CC genotype. Please note: the opposite effect was observed in a study done in an Asian population with various types of lymphomas. The C allele was associated with increased clearance of methotrexate. Other clinical and genetic factors may also affect clearance and distribution of volume of methotrexate. ,携带TT基因型的患者，相比CC基因型，药物清除率及体内分布量可能增加,1,,,,2,,, minus,王兴悦
PA166135528,rs717620,1444705497,CC,Patients with lymphoblastic leukemia-lymphoma and the CC genotype may have a decreased risk of drug toxicity and increased clearance of methotrexate when treated with methotrexate as compared to patients with the TT genotype. Please note: the opposite effect was observed in a study done in a French population with various types of lymphomas. The C allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate. ,携带CC基因型的成淋巴细胞白血病-淋巴瘤患者，相比TT基因型，药物毒性风险可能降低，药物清除率可能增加,1,,,,2,,, minus,王兴悦
PA166135528,rs717620,1444705498,CT,Patients with lymphoblastic leukemia-lymphoma and the CT genotype may have an increased risk of drug toxicity and decreased clearance of methotrexate when treated with methotrexate as compared to patients with the CC genotype. Please note: the opposite effect was observed in a study done in a French population with various types of lymphomas. The C allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate. ,携带CT基因型的成淋巴细胞白血病-淋巴瘤患者，相比TT基因型，药物毒性风险可能增加，药物清除率可能下降,1,,,,0,,, minus,王兴悦
PA166135528,rs717620,1444705499,TT,Patients with lymphoblastic leukemia-lymphoma and the TT genotype may have an increased risk of drug toxicity and decreased clearance of methotrexate when treated with methotrexate as compared to patients with the CC genotype. Please note: the opposite effect was observed in a study done in a French population with various types of lymphomas. The C allele was associated with decreased clearance of methotrexate. Other clinical and genetic factors may also influence risk of drug toxicity when treated with methotrexate. ,携带TT基因型的成淋巴细胞白血病-淋巴瘤患者，相比CC基因型，药物毒性风险可能增加，药物清除率可能下降,1,,,,0,,, minus,王兴悦
PA166134526,rs717620,1447813534,CC,"Patients with the CC genotype and HIV infection who are treated with tenofovir may have an increased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.",携带CC基因型的HIV感染患者，相比CT和TT基因型，肾小管功能障碍风险可能增加，但可能与肾小球滤过率的变化无关,1,,,2,,,, minus,王兴悦
PA166134526,rs717620,1447813535,CT,"Patients with the CT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.",携带CT基因型的HIV感染患者，相比CC基因型，肾小管功能障碍风险可能降低，但可能与肾小球滤过率的变化无关,1,,,0,,,, minus,王兴悦
PA166134526,rs717620,1447813536,TT,"Patients with the TT genotype and HIV infection who are treated with tenofovir may have a decreased risk of kidney tubular dysfunction, but may not be associated with changes in glomerular filtration rate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced kidney tubular dysfunction.",携带TT基因型的HIV感染患者，相比CC基因型，肾小管功能障碍风险可能降低，但可能与肾小球滤过率的变化无关,1,,,0,,,, minus,王兴悦
PA166134527,rs717620,1448426845,CC,Patients with the CC genotype and Epilepsy who are treated with antiepileptics may be less likely to be resistant to treatment as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.,携带CC基因型的癫痫患者，相比CT或TT基因型，治疗耐药性可能下降,1,,2,,,,, minus,王兴悦
PA166134527,rs717620,1448426846,CT,Patients with the CT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.,携带CT基因型的癫痫患者，相比CC基因型，治疗耐药性可能增加,1,,0,,,,, minus,王兴悦
PA166134527,rs717620,1448426847,TT,Patients with the TT genotype and Epilepsy who are treated with antiepileptics may be more likely to be resistant to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antiepileptics.,携带TT基因型的癫痫患者，相比CC基因型，治疗耐药性可能增加,1,,0,,,,, minus,王兴悦
PA166134804,rs717620,1043858890,CC,Patients with the CC genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.,携带CC基因型的患者，相比TT基因型，药物代谢水平可能下降,1,,,,0,,, minus,王兴悦
PA166134804,rs717620,1043858889,CT,Patients with the CT genotype may have decreased metabolism of erythromycin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.,携带CT基因型的患者，相比TT基因型，药物代谢水平可能下降,1,,,,0,,, minus,王兴悦
PA166134804,rs717620,1043858888,TT,Patients with the TT genotype may have increased metabolism of erythromycin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of erythromycin.,携带TT基因型的患者，相比CC或CT基因型，药物代谢水平可能增加,1,,,,2,,, minus,王兴悦
PA166153034,rs717620,1447982783,CC,"Patients with the CC genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have a decreased, but not absent, risk for Drug Toxicity as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.",携带CC基因型的患者，相比CT或TT基因型，药物毒性风险可能下降,1,,,0,,,, minus,王兴悦
PA166153034,rs717620,1447982782,CT,"Patients with the CT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.",携带CT基因型的患者，相比CC基因型，药物毒性风险可能增加,1,,,2,,,, minus,王兴悦
PA166153034,rs717620,1447982781,TT,"Patients with the TT genotype who are treated with atazanavir, lopinavir, ritonavir or tenofovir may have an increased risk for Drug Toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for Drug Toxicity.",携带TT基因型的患者，相比CC基因型，药物毒性风险可能增加,1,,,2,,,, minus,王兴悦
PA166160279,rs717620,1448258927,CC,"Patients with the CC genotype may have increased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.",携带CC基因型的肾细胞癌患者，相比CT基因型，皮疹风险可能增加,1,,,2,,,, minus,王兴悦
PA166160279,rs717620,1448258928,CT,"Patients with the CT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.",携带CT基因型的肾细胞癌患者，相比CC基因型，皮疹风险可能降低,1,,,0,,,, minus,王兴悦
PA166160279,rs717620,1448258929,TT,"Patients with the TT genotype may have decreased risk of skin rash when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CT. Other genetic and clinical factors may also influence the toxicity to sorafenib.",携带TT基因型的肾细胞癌患者，相比CT基因型，皮疹风险可能降低,1,,,0,,,, minus,王兴悦
PA166153451,rs72558187,1447990241,CT,Individuals with the CT genotype may have decreased metabolism and clearance of irbesartan which may result may in increased exposure as compared to patients with the TT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.,携带CT基因型的患者，相比TT基因型，药物代谢及药物清除率可能下降,1,,,,0,,,plus,王兴悦
PA166153451,rs72558187,1447990242,TT,Individuals with the TT genotype may have increased metabolism and clearance of irbesartan which may result may in decreased exposure of irbesartan as compared to patients with the CT genotype. Other clinical and genetic factors may also influence metabolism of irbesartan.,携带TT基因型的患者，相比CT基因型，药物代谢及药物清除率可能增加,1,,,,2,,,plus,王兴悦
PA166134496,rs7297610,981202104,CC,Patients with the CC genotype and hypertension who are treated with hydrochlorothiazide may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.,携带CC基因型的高血压患者，相比CT或TT基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166134496,rs7297610,981202105,CT,Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.,携带CT基因型的高血压患者，相比CC基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166134496,rs7297610,981202106,TT,Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.,携带TT基因型的高血压患者，相比CC基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166135431,rs729147,1448109586,AA,"Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG or AG, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.",携带AA基因型的儿童肿瘤患者，相比GG或AG基因型，心脏中毒发生可能性降低,1,,,0,,,,FWD,王兴悦
PA166135431,rs729147,1448109587,AG,"Patients with the AG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.",携带AG基因型的儿童肿瘤患者，相比AA基因型，心脏中毒发生可能性增加,1,,,2,,,,FWD,王兴悦
PA166135431,rs729147,1448109588,GG,"Patients with the GG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.",携带GG基因型的儿童肿瘤患者，相比AA基因型，心脏中毒发生可能性增加,1,,,2,,,,FWD,王兴悦
PA166134848,rs7311358,1043880099,AA,"Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.",携带AA基因型的肾移植患者，相比GG基因型，药物清除率可能降低,1,,0,,,,,plus,王兴悦
PA166134848,rs7311358,1043880100,AG,"Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.",携带AG基因型的肾移植患者，相比GG基因型，药物清除率可能降低,1,,0,,,,,plus,王兴悦
PA166134848,rs7311358,1043880101,GG,"Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.",携带GG基因型的肾移植患者，相比AG或AA基因型，药物清除率可能增加,1,,2,,,,,plus,王兴悦
PA166135430,rs7311358,1183704273,AA,Patients with the AA genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.,携带AA基因型的鼻咽癌患者，相比GG基因型，药时曲线下面积(AUC)可能增加，药物清除率可能降低,1,,,,0,,2,plus,王兴悦
PA166135430,rs7311358,1183704274,AG,Patients with the AG genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.,携带AG基因型的鼻咽癌患者，相比GG基因型，药时曲线下面积(AUC)可能增加，药物清除率可能降低,1,,,,0,,2,plus,王兴悦
PA166135430,rs7311358,1183704275,GG,Patients with the GG genotype may have decreased AUC and increased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the clearance of docetaxel.,携带GG基因型的鼻咽癌患者，相比AG或AA基因型，药时曲线下面积(AUC)可能减少，药物清除率可能增加,1,,,,2,,0,plus,王兴悦
PA166135913,rs7387065,1445594567,AA,Patients with the AA genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.,携带AA基因型的原发性高血压患者，相比AG或GG基因型，药物响应可能降低,1,,0,,,,,FWD,王兴悦
PA166135913,rs7387065,1445594568,AG,Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.,携带AG基因型的原发性高血压患者，相比GG基因型，药物响应可能降低；相比AA基因型，药物响应可能增加,1,,1,,,,,FWD,王兴悦
PA166135913,rs7387065,1445594569,GG,Patients with the GG genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.,携带GG基因型的原发性高血压患者，相比AG和AA基因型，药物响应可能增加,1,,2,,,,,FWD,王兴悦
PA166134156,rs7294,1448276190,CC,Patients with the CC genotype who are treated with warfarin may require a lower dose as compared to patients with the TC or TT genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带CC基因型的患者，相比TC或TT基因型，可能需要更低的药物剂量,1,,,,,0,,minus,王兴悦
PA166134156,rs7294,1448276191,CT,Patients with the CT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带CT基因型的患者，相比CC基因型，可能需要更高的药物剂量,1,,,,,2,,minus,王兴悦
PA166134156,rs7294,1448276192,TT,Patients with the TT genotype who are treated with warfarin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带TT基因型的患者，相比CC基因型，可能需要更高的药物剂量,1,,,,,2,,minus,王兴悦
PA166136399,rs7294,1445585750,CC,"Patients with the CC genotype may require a decreased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or TT genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.",携带CC基因型的患者，相比CT或TT基因型，可能需要减少药物剂量,1,,,,,0,,minus,王兴悦
PA166136399,rs7294,1445585751,CT,"Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence  a patient's phenprocoumon or acenocoumarol dose requirement.",携带CT基因型的患者，相比CC基因型，可能需要增加药物剂量；相比TT基因型，可能需要减少药物剂量；,1,,,,,1,,minus,王兴悦
PA166136399,rs7294,1445585752,TT,"Patients with the TT genotype may require an increased dose of phenprocoumon or acenocoumarol as compared to patients with the CT or CC genotypes, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.",携带TT基因型的患者，相比CT或CC基因型，可能需要增加药物剂量,1,,,,,2,,minus,王兴悦
PA166135491,rs74503330,1184472601,AA,"Patients with the AA genotype (two copies of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AA基因型的囊性纤维症患者，可能对药物有响应,1,,2,,,,,plus,王兴悦
PA166135491,rs74503330,1184472602,AG,"Patients with the AG genotype (one copy of the CFTR S1251N variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AG基因型的囊性纤维症患者，可能对药物有响应,1,,2,,,,,plus,王兴悦
PA166135491,rs74503330,1184472603,GG,"Patients with the GG genotype (do not have a copy of the CFTR S1251N variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including S1251N. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带GG基因型的囊性纤维症患者，药物响应未知,1,,0,,,,,plus,王兴悦
PA166135280,rs746647,1183679788,AA,Patients with the AA genotype may have decreased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.,携带AA基因型的HIV患者，相比GG基因型，药物引起皮疹的风险可能降低,1,,,0,,,,minus,王兴悦
PA166135280,rs746647,1183679787,AG,Patients with the AG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.,携带AG基因型的HIV患者，相比AA基因型，药物引起皮疹的风险可能增加,1,,,2,,,,minus,王兴悦
PA166135280,rs746647,1183679786,GG,Patients with the GG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.,携带GG基因型的HIV患者，相比AA基因型，药物引起皮疹的风险可能增加,1,,,2,,,,minus,王兴悦
PA166134997,rs7412,1447947145,CC,Patients with the CC genotype who are treated with atorvastatin may have a reduced response (less reduction in LDL-cholesterol) as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,携带CC基因型的患者，相比TT或CT基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166134997,rs7412,1447947146,CT,Patients with the CT genotype who are treated with atorvastatin may have a better response (higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,携带CT基因型的患者，相比CC基因型，药物响应可能较好,1,,2,,,,,plus,王兴悦
PA166134997,rs7412,1447947147,TT,Patients with the TT genotype who are treated with atorvastatin may have a better response (higher reduction in LDL-cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,携带TT基因型的患者，相比CC基因型，药物响应可能较好,1,,2,,,,,plus,王兴悦
PA166134642,rs75527207,1448423775,AA,"Ivacaftor is indicated in cystic fibrosis patients with the AA genotype (two copies of the CFTR G551D variant). FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带AA基因型的囊性纤维症患者，可以使用该药物,1,,2,,,,,plus,王兴悦
PA166134642,rs75527207,1448423776,AG,"Ivacaftor is indicated in cystic fibrosis patients with the AG genotype (one copy of the CFTR G551D variant). FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带AG基因型的囊性纤维症患者，可以使用该药物,1,,2,,,,,plus,王兴悦
PA166134642,rs75527207,1448423777,GG,"Indication of ivacaftor in cystic fibrosis patients with the GG genotype (no copies of the CFTR G551D variant) is dependent on the presence of other variants within the CFTR gene. FDA-approved drug labeling information indicates use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G551D. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带GG基因型的囊性纤维症患者，是否可以使用该药物未知,1,,0,,,,,plus,王兴悦
PA166135534,rs7582141,1184514212,GG,Patients with the GG genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. ,携带GG基因型的前列腺癌患者，相比TT基因型，晚期毒性风险可能降低,1,男,,0,,,,plus,王兴悦
PA166135534,rs7582141,1184514211,GT,"Patients with the GT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype, or may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. ",携带GT基因型的前列腺癌患者，相比GG基因型，晚期毒性风险可能增加；相比TT基因型，晚期毒性风险可能降低,1,男,,1,,,,plus,王兴悦
PA166135534,rs7582141,1184514210,TT,Patients with the TT genotype and prostate cancer who are treated with radiotherapy may have an increased risk of late stage toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity. ,携带TT基因型的前列腺癌患者，相比GG基因型，晚期毒性风险可能增加,1,男,,2,,,,plus,王兴悦
PA166135279,rs7588295,1183679868,AA,Patients with the AA genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.,携带AA基因型的患者，相比GG基因型，可能发生骨坏死的可能性增加,1,,,2,,,,FWD,王兴悦
PA166135279,rs7588295,1183679869,AG,Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.,携带AG基因型的患者，相比GG基因型，可能发生骨坏死的可能性增加,1,,,2,,,,FWD,王兴悦
PA166135279,rs7588295,1183679870,GG,Patients with the GG genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.,携带GG基因型的患者，相比AA或AG基因型，可能发生骨坏死的可能性降低,1,,,0,,,,FWD,王兴悦
PA166134691,rs7439366,1184472961,CC,Patients with the CC genotype may have decreased response to valproic acid as compared to patients with TT or TC genotype. The association was found in individuals with no disease and was not reported in cohort of patients with Epilepsy. Other genetic and clinical factors may also influence response to valproic acid.,携带CC基因型的患者，相比TT或TC基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166134691,rs7439366,1184472962,TC,Patients with the TC genotype may have increased response to valproic acid as compared to patients with CC genotype. The association was found in individuals with no disease and was not reported in cohort of patients with Epilepsy. Other genetic and clinical factors may also influence response to valproic acid.,携带TC基因型的患者，相比CC基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166134691,rs7439366,1184472963,TT,Patients with the TT genotype may have increased response to valproic acid as compared to patients with CC genotype. The association was found in individuals with no disease and was not reported in cohort of patients with Epilepsy. Other genetic and clinical factors may also influence response to valproic acid.,携带TT基因型的患者，相比CC基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166134536,rs7439366,1447945880,CC,Patients with the CC genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带CC基因型的HIV感染患者，相比TT基因型，血药浓度可能更高,1,,,,,,2,plus,王兴悦
PA166134536,rs7439366,1447945881,CT,Patients with the CT genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带CT基因型的HIV感染患者，相比TT基因型，血药浓度可能更高,1,,,,,,2,plus,王兴悦
PA166134536,rs7439366,1447945882,TT,Patients with the TT genotype and HIV infection who are treated with efavirenz may have lower plasma concentrations of the drug as compared to patients with the CC and CT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带TT基因型的HIV感染患者，相比CC和CT基因型，血药浓度可能更低,1,,,,,,0,plus,王兴悦
PA166136443,rs7439366,1446903009,CC,Patients with the CC genotype may require an increased dose of codeine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of codeine. ,携带CC基因型的患者，相比TT基因型，药物剂量可能增加,1,,,,,2,,plus,王兴悦
PA166136443,rs7439366,1446903010,CT,No information is available for the CT genotype. ,无CT基因型患者参与研究,1,,,,,,,plus,王兴悦
PA166136443,rs7439366,1446903011,TT,Patients with the TT genotype may require a decreased dose of codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of codeine. ,携带TT基因型的患者，相比CC基因型，药物剂量可能减少,1,,,,,0,,plus,王兴悦
PA166152997,rs7439366,1447981284,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带CC基因型的患者，相比CT或TT基因型，阿片类戒断症状严重性可能增加,1,,,2,,,,plus,王兴悦
PA166152997,rs7439366,1447981285,CT,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带CT基因型的患者，相比CC基因型，阿片类戒断症状严重性可能降低,1,,,0,,,,plus,王兴悦
PA166152997,rs7439366,1447981286,TT,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带TT基因型的患者，相比CC基因型，阿片类戒断症状严重性可能降低,1,,,0,,,,plus,王兴悦
PA166135270,rs760370,1444932376,AA,"Patients with cancer and the AA genotype may have increased response to gemcitabine as compared to patients with the AG and GG genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine. ",携带AA基因型的肿瘤患者，相比AG和GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166135270,rs760370,1444932377,AG,"Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine. ",携带AG基因型的肿瘤患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166135270,rs760370,1444932378,GG,"Patients with cancer and the GG genotype may have decreased response to gemcitabine as compared to patients with the AG and AA genotypes. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine. ",携带GG基因型的肿瘤患者，相比AG和AA基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166152995,rs7662029,1447981270,AA,Patients with the AA genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带AA基因型的患者，相比GG基因型，阿片类戒断综合征严重性可能降低,1,,,0,,,,FWD,王兴悦
PA166152995,rs7662029,1447981271,AG,Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带AG基因型的患者，相比GG基因型，阿片类戒断综合征严重性可能降低,1,,,0,,,,FWD,王兴悦
PA166152995,rs7662029,1447981272,GG,Patients with the GG genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带GG基因型的患者，相比AA或AG基因型，阿片类戒断综合征严重性可能增加,1,,,2,,,,FWD,王兴悦
PA166136431,rs7661530,1446899704,CC,Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors. ,携带CC基因型的患者，相比CT和TT基因型，可能更容易引起咳嗽,1,,,2,,,,FWD,王兴悦
PA166136431,rs7661530,1446899705,CT,Patients with the CT genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the TT genotype and less likely than patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors. ,携带CT基因型的患者，相比TT基因型，可能更容易引起咳嗽,1,,,2,,,,FWD,王兴悦
PA166136431,rs7661530,1446899706,TT,Patients with the TT genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CC and CT genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors. ,携带TT基因型的患者，相比CC和CT基因型，可能不容易引起咳嗽,1,,,0,,,,FWD,王兴悦
PA166135314,rs7668258,1448100482,CC,"Patients with the CC genotype may 1) have increased clearance (CL/F) and 2) require higher doses of lamotrigine as compared to patients with the CT or TT genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine.",携带CC基因型的患者，相比CT或TT基因型，药物清除率可能增加，可能需要更高的药物剂量,1,,,,,2,,plus,王兴悦
PA166135314,rs7668258,1448100483,CT,"Patients with the CT genotype may 1) have decreased clearance (CL/F) and 2) require lower doses of lamotrigine as compared to patients with the CC genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine.",携带CT基因型的患者，相比CC基因型，药物清除率可能降低，可能需要减少药物剂量,1,,,,,0,,plus,王兴悦
PA166135314,rs7668258,1448100484,TT,"Patients with the TT genotype may 1) have decreased clearance (CL/F) and 2) require lower doses of lamotrigine as compared to patients with the CC genotype, though not all studies show consistent results. Other genetic and clinical factors may also influence a patient's response to lamotrigine.",携带TT基因型的患者，相比CC基因型，药物清除率可能降低，可能需要减少药物剂量,1,,,,,0,,plus,王兴悦
PA166152996,rs7668258,1447981277,CC,Patients with the CC genotype who are undergoing methadone maintenance treatment may have increased severity of opiate withdrawal symptoms as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带CC基因型的患者，相比CT或TT基因型，药物治疗时阿片类戒断症状严重性可能增加,1,,,2,,,,plus,王兴悦
PA166152996,rs7668258,1447981278,CT,Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带CT基因型的患者，相比CC基因型，药物治疗时阿片类戒断症状严重性可能降低,1,,,0,,,,plus,王兴悦
PA166152996,rs7668258,1447981279,TT,Patients with the TT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.,携带TT基因型的患者，相比CC基因型，药物治疗时阿片类戒断症状严重性可能降低,1,,,0,,,,plus,王兴悦
PA166153196,rs7754840,1447987206,CC,Patients with diabetes mellitus and the CC genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus. ,携带CC基因型的糖尿病患者，相比CG和GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166153196,rs7754840,1447987207,CG,Patients with diabetes mellitus and the CG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus. ,携带CG基因型的糖尿病患者，相比GG基因型，药物响应可能增加；相比CC基因型，药物响应可能降低,1,,1,,,,,plus,王兴悦
PA166153196,rs7754840,1447987208,GG,Patients with diabetes mellitus and the GG genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the CG and CC genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus. ,携带GG基因型的糖尿病患者，相比CG和CC基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166151963,rs77010898,1447954399,AA,"Patients with the AA genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.",携带AA基因型的囊性纤维症患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166151963,rs77010898,1447954400,AG,"Patients with the AG genotype and cystic fibrosis may have increased response when treated with ataluren as compared to patients with the GG genotype. Randomized clinical trials found improvement in chloride transport, but did not find evidence for improved pulmonary function after 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.",携带AG基因型的囊性纤维症患者，相比GG基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166151963,rs77010898,1447954401,GG,Patients with the GG genotype and cystic fibrosis may not respond to treatment with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.,携带GG基因型的囊性纤维症患者，可能对药物无响应,1,,0,,,,,plus,王兴悦
PA166153197,rs7756992,1447987213,AA,Patients with diabetes mellitus and the AA genotype may have a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.,携带AA基因型的糖尿病患者，相比AG和GG基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166153197,rs7756992,1447987214,AG,Patients with diabetes mellitus and the AG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AA genotype and a worse response to dipeptidyl peptidase 4 inhibitors as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.,携带AG基因型的糖尿病患者，相比AA基因型，药物响应可能增加；相比GG基因型，药物响应可能较差,1,,1,,,,,plus,王兴悦
PA166153197,rs7756992,1447987215,GG,Patients with diabetes mellitus and the GG genotype may have an improved response to dipeptidyl peptidase 4 inhibitors as compared to patients with the AG and AA genotype. Other clinical and genetic factors may also influence response to dipeptidyl peptidase 4 inhibitors in patients with diabetes mellitus.,携带GG基因型的糖尿病患者，相比AG和AA基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166134075,rs774359,637879988,CC,Rheumatoid Arthritis patients with the CC genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的风湿性关节炎患者，相比TT基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134075,rs774359,637879989,CT,Rheumatoid Arthritis patients with the CT genotype may be less likely to respond to TNF inhibitors compared to patients with genotypes TT. Other genetic and clinical factors may also influence a patient's response.,携带CT基因型的风湿性关节炎患者，相比TT基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134075,rs774359,637879990,TT,Rheumatoid Arthritis patients with the TT genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CC or CT. Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的风湿性关节炎患者，相比CC或CT基因型，药物响应可能更好,1,,2,,,,,plus,王兴悦
PA166135914,rs77876672,1445616167,CC,Patients with the CC genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. ,携带CC基因型的原发性高血压患者，相比CT和TT基因型，药物响应可能较差,1,,0,,,,,FWD,王兴悦
PA166135914,rs77876672,1445616168,CT,Patients with the CT genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the TT genotypes and an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. ,携带CT基因型的原发性高血压患者，相比TT基因型，药物响应可能较差；相比CC基因型，药物响应可能增加,1,,1,,,,,FWD,王兴悦
PA166135914,rs77876672,1445616169,TT,Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the CT and CC genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension. ,携带TT基因型的原发性高血压患者，相比CT和CC基因型，药物响应可能增加,1,,2,,,,,FWD,王兴悦
PA166136195,rs7862221,1444667587,CC,Patients with asthma and the CC genotype may have an increased risk of aspirin induced asthma as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带CC基因型的哮喘患者，相比CT或TT基因型，药物引起哮喘的风险可能增加,1,,,2,,,,FWD,王兴悦
PA166136195,rs7862221,1444667588,CT,Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带CT基因型的哮喘患者，相TT基因型，药物引起哮喘的风险可能增加；相CC基因型，药物引起哮喘的风险可能降低,1,,,1,,,,FWD,王兴悦
PA166136195,rs7862221,1444667589,TT,Patients with asthma and the TT genotype may have a decreased risk of aspirin induced asthma as compared to people with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.,携带TT基因型的哮喘患者，相比CT或CC基因型，药物引起哮喘的风险可能降低,1,,,0,,,,FWD,王兴悦
PA166134659,rs762551,1446908982,AA,"Patients with the AA genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.",携带AA基因型的患者，相比CC基因型，血小板高反应性可能降低,1,,2,,,,,plus,王兴悦
PA166134659,rs762551,1446908983,AC,"Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.",携带AC基因型的患者，相比CC基因型，血小板高反应性可能降低,1,,2,,,,,plus,王兴悦
PA166134659,rs762551,1446908984,CC,"Patients with the CC genotype may have increased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AC or CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.",携带CC基因型的患者，相比AC或CC基因型，血小板高反应性可能增加,1,,0,,,,,plus,王兴悦
PA166134692,rs762551,982040487,AA,Patients with AA genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.,携带AA基因型的患者，相比CC基因型，药物剂量可能需要增加，疲劳风险可能增加,1,,,2,,2,,plus,王兴悦
PA166134692,rs762551,982040488,AC,Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.,携带AC基因型的患者，相比CC基因型，药物剂量可能需要增加，疲劳风险可能增加,1,,,2,,2,,plus,王兴悦
PA166134692,rs762551,982040489,CC,Patients with CC genotype may require a decreased dose of paroxetine and may have an decreased risk of fatigue when treated with paroxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.,携带CC基因型的患者，相比AA基因型，药物剂量可能需要减少，疲劳风险可能增降低,1,,,0,,0,,plus,王兴悦
PA166134184,rs762551,655384905,AA,"Patients with the AA genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.",携带AA基因型的类风湿性关节炎患者，相比CC基因型，药物毒性风险可能降低,1,,,0,,,,plus,王兴悦
PA166134184,rs762551,655384904,AC,"Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.",携带AC基因型的类风湿性关节炎患者，相比CC基因型，药物毒性风险可能降低,1,,,0,,,,plus,王兴悦
PA166134184,rs762551,655384903,CC,Patients with the CC genotype and rheumatoid arthritis who are treated with leflunomide may have an increased risk of toxicity as compared to patients with the AC or AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.,携带CC基因型的类风湿性关节炎患者，相比AC或AA基因型，药物毒性风险可能增加,1,,,2,,,,plus,王兴悦
PA166134266,rs762551,655385389,AA,"Patients with the AA genotype may have a decreased, but not absent, risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.",携带AA基因型的患者，相比AC或CC基因型，随着咖啡消耗量的增加，非致命性心肌梗死的风险可能降低,1,,,0,,,,plus,王兴悦
PA166134266,rs762551,655385390,AC,Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.,携带AC基因型的患者，相比AA基因型，随着咖啡消耗量的增加，非致命性心肌梗死的风险可能增加,1,,,2,,,,plus,王兴悦
PA166134266,rs762551,655385391,CC,Patients with the CC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.,携带CC基因型的患者，相比AA基因型，随着咖啡消耗量的增加，非致命性心肌梗死的风险可能增加,1,,,2,,,,plus,王兴悦
PA166134283,rs762551,982035378,AA,Patients with the AA genotype and psychiatric disorders who are treated with olanzapine may have decreased response to olanzapine based on decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AC and CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.,携带AA基因型的精神疾病患者，相比AC和CC基因型，在降低正常的剂量/体重药物血清浓度前提下，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166134283,rs762551,982035379,AC,Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.,携带AC基因型的精神疾病患者，相比AA基因型，在不降低正常的剂量/体重药物血清浓度前提下，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166134283,rs762551,982035380,CC,Patients with the CC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.,携带CC基因型的精神疾病患者，相比AA基因型，在不降低正常的剂量/体重药物血清浓度前提下，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166153101,rs762551,1447983942,AA,Pediatric patients with epilepsy and the AA genotype may have increased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AC or CC genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.,携带AA基因型的儿童癫痫患者，相比AC或CC基因型，药物清除率可能增加,1,,,,2,,,plus,王兴悦
PA166153101,rs762551,1447983943,AC,Pediatric patients with epilepsy and the AC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.,携带AC基因型的儿童癫痫患者，相比AA基因型，药物清除率可能降低,1,,,,0,,,plus,王兴悦
PA166153101,rs762551,1447983944,CC,Pediatric patients with epilepsy and the CC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.,携带CC基因型的儿童癫痫患者，相比AA基因型，药物清除率可能降低,1,,,,0,,,plus,王兴悦
PA166136164,rs762551,1448101458,AA,Patients with the AA genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.,携带AA基因型的β-地中海贫血患者，相比AC或CC基因型，药物浓度可能降低,1,,,,0,,,plus,王兴悦
PA166136164,rs762551,1448101459,AC,Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.,携带AC基因型的β-地中海贫血患者，相比AA基因型，药物浓度可能增加,1,,,,2,,,plus,王兴悦
PA166136164,rs762551,1448101460,CC,Patients with the CC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.,携带CC基因型的β-地中海贫血患者，相比AA基因型，药物浓度可能增加,1,,,,2,,,plus,王兴悦
PA166136252,rs7903146,1444694380,CC,"Patients with the CC genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence development of NODAT.",携带CC基因型的肾移植患者，相比TT基因型，移植后新发糖尿病的可能性可能降低,1,,,0,,,,plus,王兴悦
PA166136252,rs7903146,1444694381,CT,"Patients with the CT genotype who undergo kidney transplantation may have a decreased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence development of NODAT.",携带CT基因型的肾移植患者，相比TT基因型，移植后新发糖尿病的可能性可能降低；相比CC基因型，移植后新发糖尿病的可能性可能增加,1,,,1,,,,plus,王兴悦
PA166136252,rs7903146,1444694382,TT,"Patients with the TT genotype who undergo kidney transplantation may have an increased likelihood of developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus, sirolimus or cyclosporine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence development of NODAT.",携带TT基因型的肾移植患者，相比CC基因型，移植后新发糖尿病的可能性可能增加,1,,,2,,,,plus,王兴悦
PA166134806,rs7903146,1043858906,CC,"Patients with the CC genotype may have increased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CT or TT genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.",携带CC基因型的II型糖尿病患者，相比CT或TT基因型，药物响应及空腹血糖水平可能增加,1,,2,,,,,plus,王兴悦
PA166134806,rs7903146,1043858907,CT,"Patients with the CT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.",携带CT基因型的II型糖尿病患者，相比CC基因型，药物响应及空腹血糖水平可能降低,1,,0,,,,,plus,王兴悦
PA166134806,rs7903146,1043858908,TT,"Patients with the TT genotype may have decreased response (reductions in haemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) levels) when treated with sulfonamides, urea derivatives in people with Diabetes Mellitus, Type 2 as compared to patients with CC genotype. Other clinical and genetic factors may also influence a patient's response to sulfonamides, urea derivatives.",携带TT基因型的II型糖尿病患者，相比CC基因型，药物响应及空腹血糖水平可能降低,1,,0,,,,,plus,王兴悦
PA166135018,rs7921977,1183555572,CC,"Patients with the CC genotype and non-small cell lung cancer show no significant differences in progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. However, patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.",携带CC基因型的非小细胞肺癌患者，相比TT基因型，无进展生存期无明显差异,1,,1,,,,,FWD,王兴悦
PA166135018,rs7921977,1183555573,CT,"Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.",携带CT基因型的非小细胞肺癌患者，相比TT基因型，无进展生存期可能缩短,1,,0,,,,,FWD,王兴悦
PA166135018,rs7921977,1183555574,TT,"Patients with the TT genotype and non-small cell lung cancer may have increased progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the CT genotype. Other genetic and clinical factors may also influence progression-free survival time.",携带TT基因型的非小细胞肺癌患者，相比CT基因型，无进展生存期可能延长,1,,2,,,,,FWD,王兴悦
PA166163523,rs7968606,1448613013,CC,Patients with the CC genotype and schizophrenia may have increased response to amisulpride as measured by the PANSS general as compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect response to amisulpride.,携带CC基因型的精神分裂症患者，相比CT和TT基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166163523,rs7968606,1448613014,CT,Patients with the CT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.,携带CT基因型的精神分裂症患者，相比CC基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166163523,rs7968606,1448613015,TT,Patients with the TT genotype and schizophrenia may have decreased response to amisulpride as measured by the PANSS general as compared to patients with the CC genotype. Other clinical and genetic factors may affect response to amisulpride.,携带TT基因型的精神分裂症患者，相比CC基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166152976,rs800292,1447981077,AA,Patients with the AA genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to bevacizumab. ,携带AA基因型的老年性黄斑变性患者，相比GG基因型，视力改善可能更好,1,,2,,,,,minus,王兴悦
PA166152976,rs800292,1447981078,AG,"Patients with the AG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype, and a poorer improvement as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab. ",携带AG基因型的老年性黄斑变性患者，相比GG基因型，视力改善可能更好；相比AA基因型，视力改善可能较差,1,,1,,,,,minus,王兴悦
PA166152976,rs800292,1447981079,GG,Patients with the GG genotype and age-related macular degeneration may have a poorer improvement in visual acuity when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab. ,携带GG基因型的老年性黄斑变性患者，相比AA基因型，视力改善可能较差,1,,0,,,,,minus,王兴悦
PA166134408,rs8012552,699639352,CC,Patients with the CC genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.,携带CC基因型的高血压患者，相比TT基因型，咳嗽的风险增加,1,,,2,,,,FWD,王兴悦
PA166134408,rs8012552,699639353,CT,Patients with the CT genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. (please note that patients with this genotype were not studied directly). Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.,携带CT基因型的高血压患者，相比TT基因型，咳嗽的风险增加,1,,,2,,,,FWD,王兴悦
PA166134408,rs8012552,699639354,TT,"Patients with the TT genotype and hypertension who are treated with ACE-inhibitors may have a decreased, but not absent, risk of cough as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.",携带TT基因型的高血压患者，相比CC基因型，咳嗽的风险降低,1,,,0,,,,FWD,王兴悦
PA166135492,rs80282562,1184472572,AA,"Patients with the AA genotype (two copies of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AA基因型的囊性纤维症患者，对药物治疗可能有响应,1,,2,,,,,minus,王兴悦
PA166135492,rs80282562,1184472573,AG,"Patients with the AG genotype (one copy of the CFTR G178R variant) and cystic fibrosis may respond to ivacaftor treatment. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor. ",携带AG基因型的囊性纤维症患者，对药物治疗可能有响应,1,,2,,,,,minus,王兴悦
PA166135492,rs80282562,1184472574,GG,"Patients with the GG genotype (do not have a copy of the CFTR G178R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 10 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence a patient's response to ivacaftor.",携带GG基因型的囊性纤维症患者，对药物治疗响应未知,1,,0,,,,,minus,王兴悦
PA166136103,rs806368,1444607311,CC,Individuals with the CC genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.,携带CC基因型的高血压患者，相比TT基因型，可卡因成瘾风险可能降低,1,,,0,,,,plus,王兴悦
PA166136103,rs806368,1444607312,CT,Individuals with the CT genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.,携带CT基因型的高血压患者，相比TT基因型，可卡因成瘾风险可能降低,1,,,0,,,,plus,王兴悦
PA166136103,rs806368,1444607313,TT,Individuals with the TT genotype may have an increased risk of cocaine dependence as compared to those with the CC or CT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.,携带TT基因型的高血压患者，相比CT基因型，可卡因成瘾风险可能增加,1,,,2,,,,plus,王兴悦
PA166134211,rs8050894,1444694179,CC,Patients with the CC genotype who are treated with warfarin may require a higher dose as compared to patients with the CG or GG genotype.   Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带CC基因型的患者，相比CG或GG基因型，可能需要更高的药物剂量,1,,,,,2,,plus,王兴悦
PA166134211,rs8050894,1444694180,CG,Patients with the CG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype.   Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带CG基因型的患者，相比GG基因型，可能需要更低的药物剂量,1,,,,,0,,plus,王兴悦
PA166134211,rs8050894,1444694181,GG,Patients with the GG genotype who are treated with warfarin may require the lowest dose as compared to patients with the CG or CC genotype.   Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带GG基因型的患者，相比CG或CC基因型，可能需要更低的药物剂量,1,,,,,0,,plus,王兴悦
PA166134370,rs8192709,655387000,CC,"Recipients of HLA-identical hematopoietic stem cell transplantation with the CC genotype and leukemia may have a decreased, but not absent, risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.",携带CC基因型的白血病患者，接受HLA相合造血干细胞移植后，相比CT或TT基因型，出血性膀胱炎的风险可能降低,1,,,0,,,,plus,王兴悦
PA166134370,rs8192709,655387001,CT,Recipients of HLA-identical hematopoietic stem cell transplantation with the CT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.,携带CT基因型的白血病患者，接受HLA相合造血干细胞移植后，相比CC基因型，出血性膀胱炎的风险可能增加,1,,,2,,,,plus,王兴悦
PA166134370,rs8192709,655387002,TT,Recipients of HLA-identical hematopoietic stem cell transplantation with the TT genotype and leukemia may have an increased risk for hemorrhagic cystitis when treated with cyclophosphamide compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hemorrhagic cystitis.,携带TT基因型的白血病患者，接受HLA相合造血干细胞移植后，相比CC基因型，出血性膀胱炎的风险可能增加,1,,,2,,,,plus,王兴悦
PA166135962,rs8192709,1446906372,CC,Patients with genotype CC may have decreased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CT. Other genetic and clinical factors may also influence the metabolism of efavirenz.,携带CC基因型的HIV感染患者，相比CT基因型，药物代谢可能减慢,1,,,,0,,,plus,王兴悦
PA166135962,rs8192709,1446906373,CT,Patients with genotype CT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.,携带CT基因型的HIV感染患者，相比CC基因型，药物代谢可能加快,1,,,,2,,,plus,王兴悦
PA166135962,rs8192709,1446906374,TT,Patients with genotype TT may have increased metabolism of efavirenz in people with HIV Infections as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of efavirenz.,携带TT基因型的HIV感染患者，相比CC基因型，药物代谢可能加快,1,,,,2,,,plus,王兴悦
PA166159027,rs8192935,1448100957,AA,Patients with the AA genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.,携带AA基因型的心房颤动患者，相比GG基因型，血药浓度值可能增加,1,,,,,,2,minus,王兴悦
PA166159027,rs8192935,1448100958,AG,Patients with the AG genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.,携带AG基因型的心房颤动患者，相比GG基因型，血药浓度值可能增加,1,,,,,,2,minus,王兴悦
PA166159027,rs8192935,1448100959,GG,Patients with the GG genotype and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the AA and AG genotypes. Other clinical factors may affect plasma concentrations of dabigatran.,携带GG基因型的心房颤动患者，相比AA和AG基因型，血药浓度值可能降低,1,,,,,,0,minus,王兴悦
PA166135015,rs8330,1444667455,CC,Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带CC基因型的患者，相比CG或GG基因型，肝功能衰竭风险可能增加,1,,,2,,,,plus,王兴悦
PA166135015,rs8330,1444667456,CG,Patients with the CG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带CG基因型的患者，相比CC基因型，肝功能衰竭风险可能降低,1,,,0,,,,plus,王兴悦
PA166135015,rs8330,1444667457,GG,Patients with the GG genotype may have a decreased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.,携带GG基因型的患者，相比CC基因型，肝功能衰竭风险可能降低,1,,,0,,,,plus,王兴悦
PA166152773,rs846664,1447961346,AA,Patients with the AA genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence alcoholism risk.,携带AA基因型的非裔美国人患者，相比CC基因型，嗜酒成性可能性较小,1,,,0,,,,minus,王兴悦
PA166152773,rs846664,1447961347,AC,"Patients with the AC genotype who are African-American may be less likely to become addicted to alcohol as compared to patients with the CC genotype, or more likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.",携带AC基因型的非裔美国人患者，相比CC基因型，嗜酒成性可能性较小；比AA基因型，嗜酒成性可能性较大,1,,,1,,,,minus,王兴悦
PA166152773,rs846664,1447961348,CC,Patients with the CC genotype who are African-American may be more likely to become addicted to alcohol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence alcoholism risk.,携带CC基因型的非裔美国人患者，比AA基因型，嗜酒成性可能性较大,1,,,2,,,,minus,王兴悦
PA166134069,rs854555,1448107979,AA,Rheumatoid Arthritis patients with the AA genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.,携带AA基因型的风湿性关节炎患者，相比CC基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134069,rs854555,1448107980,AC,Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC.  Other genetic and clinical factors may also influence a patient's response.,携带AC基因型的风湿性关节炎患者，相比CC基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166134069,rs854555,1448107981,CC,Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AC.  Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的风湿性关节炎患者，相比AA或AC基因型，药物响应可能较好,1,,2,,,,,plus,王兴悦
PA166135478,rs887829,1446903300,CC,"Patients infected with the human immunodeficiency virus (HIV) and the CC genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.",携带CC基因型的HIV感染患者，相比TT基因型，高胆红素血症和胆红素相关的药物停用风险可能降低,1,,,0,,,,minus,王兴悦
PA166135478,rs887829,1446903301,CT,"Patients infected with the human immunodeficiency virus (HIV) and the CT genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.",携带CT基因型的HIV感染患者，相比TT基因型，高胆红素血症和胆红素相关的药物停用风险可能降低,1,,,0,,,,minus,王兴悦
PA166135478,rs887829,1446903302,TT,"Patients infected with the human immunodeficiency virus (HIV) and the TT genotype who are treated with atazanavir may have an increased risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.",携带TT基因型的HIV感染患者，相比CC或CT基因型，高胆红素血症和胆红素相关的药物停用风险可能增加,1,,,2,,,,minus,王兴悦
PA166136161,rs887829,1444666546,CC,Patients with the CC genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.,携带CC基因型的β-地中海贫血患者，相比TT基因型，药物浓度可能降低,1,,,,0,,,minus,王兴悦
PA166136161,rs887829,1444666547,CT,Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.,携带CT基因型的β-地中海贫血患者，相比TT基因型，药物浓度可能降低,1,,,,0,,,minus,王兴悦
PA166136161,rs887829,1444666545,TT,Patients with the TT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.,携带TT基因型的β-地中海贫血患者，相比CC或CT基因型，药物浓度可能增加,1,,,,2,,,minus,王兴悦
PA166161473,rs887829,1448431547,CC,Patients with the CC genotype and heart valve replacement may require a lower stable dose of warfarin compared to patients with the CT and TT genotypes. Other clinical and genetic factors affect stable dose of warfarin.,携带CC基因型的患者，行心脏瓣膜置换术，相比CT和TT基因型，需要的药物稳定维持量可能较低,1,,,,,0,,minus,王兴悦
PA166161473,rs887829,1448431548,CT,Patients with the CT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes. Other clinical and genetic factors affect stable dose of warfarin.,携带CT基因型的患者，行心脏瓣膜置换术，相比CC基因型，需要的药物稳定维持量可能较大,1,,,,,2,,minus,王兴悦
PA166161473,rs887829,1448431549,TT,Patients with the TT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes. Other clinical and genetic factors affect stable dose of warfarin.,携带TT基因型的患者，行心脏瓣膜置换术，相比CC基因型，需要的药物稳定维持量可能较大,1,,,,,2,,minus,王兴悦
PA166152771,rs881152,1447961331,AA,Patients with the AA genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to salbutamol.,携带AA基因型的哮喘患者，相比GG基因型，药物响应可能较差,1,,0,,,,,plus,王兴悦
PA166152771,rs881152,1447961332,AG,"Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.",携带AG基因型的哮喘患者，相比GG基因型，药物响应可能较差；相比AA基因型，药物响应可能较好,1,,1,,,,,plus,王兴悦
PA166152771,rs881152,1447961333,GG,Patients with the GG genotype and asthma may have a better response to salbutamol treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.,携带GG基因型的哮喘患者，相比AA基因型，药物响应可能较好,1,,2,,,,,plus,王兴悦
PA166134442,rs9272105,827849110,AA,Patients with the AA genotype may have decreased but not absent risk for developing neutralizing anti-IFN-beta antibodies (i.e. decreased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to interferon-beta therapy.,携带AA基因型的患者，相比AG或GG基因型，治疗失败风险可能降低,1,,2,,,,,plus,王兴悦
PA166134442,rs9272105,827849111,AG,Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.,携带AG基因型的患者，相比AA基因型，治疗失败风险可能增加,1,,0,,,,,plus,王兴悦
PA166134442,rs9272105,827849112,GG,Patients with the GG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.,携带GG基因型的患者，相比AA基因型，治疗失败风险可能增加,1,,0,,,,,plus,王兴悦
PA166135783,rs924607,1448602510,CC,"Patients with the CC genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine.",携带CC基因型的患者，相比TT基因型，周围神经系统疾病风险可能降低,1,,2,,,,,plus,王兴悦
PA166135783,rs924607,1448602511,CT,"Patients with the CT genotype may have decreased, but not absent, risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine.",携带CT基因型的患者，相比TT基因型，周围神经系统疾病风险可能降低,1,,2,,,,,plus,王兴悦
PA166135783,rs924607,1448602512,TT,Patients with the TT genotype may have increased risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vincristine.,携带TT基因型的患者，相比CC或CT基因型，周围神经系统疾病风险可能增加,1,,0,,,,,plus,王兴悦
PA166134440,rs9282861,827849080,CC,Patients with the CC genotype may have a decreased but not absent risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.,携带CC基因型的患者，相比CT或TT基因型，子宫内膜癌发生风险可能降低,1,女,,0,,,,minus,王兴悦
PA166134440,rs9282861,827849081,CT,Patients with the CT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.,携带CT基因型的患者，相比CC基因型，子宫内膜癌发生风险可能增加,1,女,,2,,,,minus,王兴悦
PA166134440,rs9282861,827849082,TT,Patients with the TT genotype may have an increased risk for endometrial neoplasms when treated with estrogen replacement therapy for greater than 3 years as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for adverse responses to hormone replacement therapy.,携带TT基因型的患者，相比CC基因型，子宫内膜癌发生风险可能增加,1,女,,2,,,,minus,王兴悦
PA166161867,rs9304742,1448522786,CC,Patients with the CC genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带CC基因型的牛皮癣患者，相比CT或TT基因型，药物响应可能较差,1,,0,,,,,FWD,王兴悦
PA166161867,rs9304742,1448522787,CT,Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带CT基因型的牛皮癣患者，相比CC基因型，药物响应可能更好,1,,2,,,,,FWD,王兴悦
PA166161867,rs9304742,1448522788,TT,Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.,携带TT基因型的牛皮癣患者，相比CC基因型，药物响应可能更好,1,,2,,,,,FWD,王兴悦
PA166134060,rs9332131,1183703115,A/del,Patients with A/del genotype may require a lower daily warfarin maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.,携带A/del基因型的患者，相比AA基因型，药物日维持剂量可能较低,1,,,,,0,,plus,王兴悦
PA166134060,rs9332131,1183703116,AA,Patients with the AA genotype who are treated with warfarin may require a higher maintenance dose as compared to patients with the del/A or del/del genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.,携带AA基因型的患者，相比del/A或del/del基因型，药物日维持剂量可能较高,1,,,,,2,,plus,王兴悦
PA166134060,rs9332131,1183703117,del/del,Patients with del/del genotype may require significantly lower daily warfarin maintenance dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's dose of warfarin.,携带del/del基因型的患者，相比AA基因型，药物日维持剂量可能较低,1,,,,,0,,plus,王兴悦
PA166134438,rs9332131,827848777,A/del,Patients with the A/del genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.,携带A/del基因型的患者，相比AA基因型，药物代谢可能降低,1,,,,0,,,plus,王兴悦
PA166134438,rs9332131,827848778,AA,Patients with the AA genotype may have increased metabolism of phenytoin as compared to patients with the A/del or del/del genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.,携带AA基因型的患者，相比A/del或del/del基因型，药物代谢可能增加,1,,,,2,,,plus,王兴悦
PA166134438,rs9332131,827848779,del/del,Patients with the del/del genotype may have decreased metabolism of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of phenytoin.,携带del/del基因型的患者，相比AA基因型，药物代谢可能增加,1,,,,2,,,plus,王兴悦
PA166135896,rs9282564,1445401269,CC,Children with the CC genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.,携带CC基因型的儿童患者，行扁桃体切除术，相比TT基因型，住院时间可能更长,1,,0,,,,,minus,王兴悦
PA166135896,rs9282564,1445401270,CT,Children with the CT genotype who are undergoing a tonsillectomy and are treated with morphine may have a longer hospital stay due to respiratory depression as compared to patients with the TT genotype. Other genetic and clinical factors may also influence respiratory depression.,携带CT基因型的儿童患者，行扁桃体切除术，相比TT基因型，住院时间可能更长,1,,0,,,,,minus,王兴悦
PA166135896,rs9282564,1445401271,TT,Children with the TT genotype who are undergoing a tonsillectomy and are treated with morphine may have a decreased chance of a prolonged hospital stay due to respiratory depression as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence respiratory depression.,携带TT基因型的儿童患者，行扁桃体切除术，相比CC或CT基因型，住院时间可能缩短,1,,2,,,,,minus,王兴悦
PA166158991,rs9282564,1448100554,CT,Patients with the CT genotype and lung transplantation may have increased concentrations of tacrolimus compared to patients with the TT genotype. Other factors may affect concentration of tacrolimus.,携带CT基因型的肺移植患者，行扁桃体切除术，相比TT基因型，药物浓度可能增加,1,,,,2,,,minus,王兴悦
PA166158991,rs9282564,1448100555,TT,Patients with the TT genotype and lung transplantation may have decreased concentrations of tacrolimus compared to patients with the CT genotype. Other factors may affect concentration of tacrolimus.,携带TT基因型的肺移植患者，行扁桃体切除术，相比CT基因型，药物浓度可能降低,1,,,,0,,,minus,王兴悦
PA166134120,rs9344,655384489,AA,"Patients with the AA genotype may have increased survival when treated with cetuximab as compared to patients with the AG or GG genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.",携带AA基因型的患者，相比AG或GG基因型，生存期可能延长,1,,2,,,,,plus,王兴悦
PA166134120,rs9344,655384488,AG,"Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.",携带AG基因型的患者，相比AA基因型，生存期可能缩短,1,,0,,,,,plus,王兴悦
PA166134120,rs9344,655384487,GG,"Patients with the GG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.",携带GG基因型的患者，相比AA基因型，生存期可能缩短,1,,0,,,,,plus,王兴悦
PA166134434,rs9344,827848733,AA,"Patients with the AA genotype may have 1) decreased but not absent risk for drug toxicity 2) decreased event free survival when treated with methotrexate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.",携带AA基因型的患者，相比AG或GG基因型，药物毒性风险可能降低，生存期可能减少,1,,0,0,,,,plus,王兴悦
PA166134434,rs9344,827848734,AG,"Patients with the AG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.",携带AG基因型的患者，相比AA基因型，药物毒性风险可能增加，生存期可能增加,1,,2,2,,,,plus,王兴悦
PA166134434,rs9344,827848735,GG,"Patients with the GG genotype may have 1) increased risk for drug toxicity 2) increased event free survival when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate, particularly rs34743033.",携带GG基因型的患者，相比AA基因型，药物毒性风险可能增加，生存期可能增加,1,,2,2,,,,plus,王兴悦
PA166134759,rs9344,982044868,AA,"Patients with the AA genotype may have decreased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AG or GG genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil.",携带AA基因型的结肠肿瘤患者，相比AG或GG基因型，肿瘤复发时间可能缩短,1,,0,,,,,plus,王兴悦
PA166134759,rs9344,982044869,AG,"Patients with the AG or GG genotypes may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil.",携带AG或GG基因型的结肠肿瘤患者，相比AA基因型，肿瘤复发时间可能延长,1,,2,,,,,plus,王兴悦
PA166134759,rs9344,982044870,GG,"Patients with the AG or GG genotypes may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotypes in Colonic Neoplasms, however the data is from one study including evaluation and validation cohorts . Other genetic and clinical factors may also influence response to fluorouracil.",携带AG或GG基因型的结肠肿瘤患者，相比AA基因型，肿瘤复发时间可能延长,1,,2,,,,,plus,王兴悦
PA166135585,rs9469003,1448115859,CC,Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ,携带CC基因型的患者，相比TT基因型，皮肤严重不良反应的风险可能增加,1,,,2,,,,plus,王兴悦
PA166135585,rs9469003,1448115860,CT,"Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.",携带CT基因型的患者，相比TT基因型，皮肤严重不良反应的风险可能增加；相比CC基因型，皮肤严重不良反应的风险可能降低,1,,,1,,,,plus,王兴悦
PA166135585,rs9469003,1448115861,TT,"Patients with genotype TT may have a decreased, but not absent, risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions. ",携带TT基因型的患者，相比CC基因型，皮肤严重不良反应的风险可能降低,1,,,0,,,,plus,王兴悦
PA166134540,rs9461684,981204081,CC,Patients with the CC genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CC基因型的HIV感染患者，相比TT基因型，药物引起皮疹风险可能降低,1,,,0,,,,FWD,王兴悦
PA166134540,rs9461684,981204082,CT,Patients with the CT genotype and HIV infection who are treated with nevirapine may have a decreased risk of drug-induced rash as compared to patients with the TT genotype or may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带CT基因型的HIV感染患者，相比TT基因型，药物引起皮疹风险可能降低；相比CC基因型，药物引起皮疹风险可能增加,1,,,1,,,,FWD,王兴悦
PA166134540,rs9461684,981204083,TT,Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.,携带TT基因型的HIV感染患者，相比CC基因型，药物引起皮疹风险可能增加,1,,,2,,,,FWD,王兴悦
PA166135592,rs9479757,1184986781,AA,The AA genotype was only present in one individual and could not be evaluated for its influence on risk of opioid dependence upon exposure to opioids. Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids. ,携带AA基因型的研究人数较少，不具有参考意义,1,,,,,,,plus,王兴悦
PA166135592,rs9479757,1184986782,AG,Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.,携带AG基因型的患者，相比GG基因型，阿片类成瘾风险可能降低,1,,,0,,,,plus,王兴悦
PA166135592,rs9479757,1184986783,GG,Patients with the GG genotype may have an increased risk of opioid dependence when exposed to opioids as compared to patients with the AG genotype. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.,携带GG基因型的患者，相比AG基因型，阿片类成瘾风险可能增加,1,,,2,,,,plus,王兴悦
PA166135013,rs964184,1183545770,CC,Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.,携带CC基因型的高甘油三酯血症患者，相比GG基因型，药物响应可能降低,1,,0,,,,,plus,王兴悦
PA166135013,rs964184,1183545769,CG,Patients with the CG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype or a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.,携带CG基因型的高甘油三酯血症患者，相比CC基因型，药物响应可能增加；相比GG基因型，药物响应可能降低,1,,1,,,,,plus,王兴悦
PA166135013,rs964184,1183545768,GG,Patients with the GG genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.,携带GG基因型的高甘油三酯血症患者，相比CC基因型，药物响应可能增加,1,,2,,,,,plus,王兴悦
PA166134532,rs776746,1444705364,CC,Patients with the CC genotype and recipients of kidney transplant who are treated with tacrolimus may have an increased risk of developing hyperlipidemia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.,携带CC基因型的肾移植患者，相比CT或TT基因型，高血脂发生风险增加,1,,,2,,,,minus,王兴悦
PA166134532,rs776746,1444705365,CT,"Patients with the CT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.",携带CT基因型的肾移植患者，相比CC基因型，高血脂发生风险降低,1,,,0,,,,minus,王兴悦
PA166134532,rs776746,1444705366,TT,"Patients with the TT genotype and recipients of kidney transplant who are treated with tacrolimus may have a decreased, but not absent, risk of of developing hyperlipidemia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.",携带TT基因型的肾移植患者，相比CC基因型，高血脂发生风险降低,1,,,0,,,,minus,王兴悦
PA166135362,rs776746,1183697629,CC,Pregnant women with the CC genotype may have decreased clearance of nifedipine as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of nifedipine.,携带CC基因型孕妇，相比CT或TT基因型，药物清除可能降低,1,女,,,0,,,minus,王兴悦
PA166135362,rs776746,1183697630,CT,Pregnant women with the CT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.,携带CT基因型孕妇，相比CC基因型，药物清除可能增加,1,女,,,2,,,minus,王兴悦
PA166135362,rs776746,1183697631,TT,Pregnant women with the TT genotype may have increased clearance of nifedipine as compared to women with the CC genotype. Other genetic and clinical factors may also influence clearance of nifedipine.,携带TT基因型孕妇，相比CC基因型，药物清除可能增加,1,女,,,2,,,minus,王兴悦
PA166135632,rs776746,1448423997,CC,"Patients undergoing a liver transplant who carry the CC (CYP3A5 *3/*3) genotype may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement.",携带CC基因型的肝移植患者，相比CT或TT基因型，药物代谢可能较慢造成药物暴露量增加，可能需要更低的药物剂量,1,,,,0,0,,minus,王兴悦
PA166135632,rs776746,1448423998,CT,"Patients undergoing a liver transplant who carry the CT (CYP3A5 *1/*3) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement.",携带CT基因型的肝移植患者，相比CC基因型，药物代谢可能增加造成药物暴露量降低，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166135632,rs776746,1448423999,TT,"Patients undergoing a liver transplant who carry the TT (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors, such as the donor liver genotype, may also influence a patient's tacrolimus dose requirement.",携带TT基因型的肝移植患者，相比CC基因型，药物代谢可能增加造成药物暴露量降低，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166135633,rs776746,1184999959,CC,"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype and are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.",携带CC基因型的肝移植患者，相比CT或TT基因型，移植排斥发生风险可能降低,1,,2,,,,,minus,王兴悦
PA166135633,rs776746,1184999960,CT,Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.,携带CT基因型的肝移植患者，相比CC基因型，移植排斥发生风险可能增加,1,,0,,,,,minus,王兴悦
PA166135633,rs776746,1184999961,TT,Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype and are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.,携带TT基因型的肝移植患者，相比CC基因型，移植排斥发生风险可能增加,1,,0,,,,,minus,王兴悦
PA166136083,rs776746,1447946946,CC,Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation may have an increased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence risk for renal dysfunction. ,携带CC基因型的肝移植患者，相比CT或TT基因型，肾脏功能异常风险可能增加,1,,,2,,,,minus,王兴悦
PA166136083,rs776746,1447946947,CT,Patients with the CT genotype (CYP3A5 *1/*3) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence risk for renal dysfunction. ,携带CT基因型的肝移植患者，相比CC基因型，肾脏功能异常风险可能降低,1,,,0,,,,minus,王兴悦
PA166136083,rs776746,1447946948,TT,Patients with the TT genotype (CYP3A5 *1/*1) undergoing liver transplantation may have a decreased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence risk for renal dysfunction. ,携带TT基因型的肝移植患者，相比CC基因型，肾脏功能异常风险可能降低,1,,,0,,,,minus,王兴悦
PA166135601,rs776746,1447946952,CC,Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CT (*1/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus. ,携带CC基因型的器官移植患者，相比CT基因型，神经毒性风险可能降低,1,,,0,,,,minus,王兴悦
PA166135601,rs776746,1447946953,CT,Patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus. ,携带CT基因型的器官移植患者，相比CC基因型，神经毒性风险可能增加,1,,,2,,,,minus,王兴悦
PA166135601,rs776746,1447946954,TT,"No individuals with the TT genotype (CYP3A5 *1/*1) were available for analysis. However, patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus. ",无TT基因型患者参与研究,1,,,,,,,minus,王兴悦
PA166136085,rs776746,1444705382,CC,"Patients with the CC genotype (CYP3A5 *3/*3) undergoing kidney transplantation may have decreased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. However, the majority of studies show no association between the CC genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.",携带CC基因型的肾移植患者，相比CT或TT基因型，收缩压及舒张压可能降低,1,,,,,,,minus,王兴悦
PA166136085,rs776746,1444705383,CT,"Patients with the CT genotype (CYP3A5 *1/*3) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, the majority of studies show no association between the CT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.",携带CT基因型的肾移植患者，相比CC基因型，收缩压及舒张压可能升高,1,,,,,,,minus,王兴悦
PA166136085,rs776746,1444705384,TT,"Patients with the TT genotype (CYP3A5 *1/*1) undergoing kidney transplantation may have increased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, the majority of studies show no association between the TT genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.",携带TT基因型的肾移植患者，相比CC基因型，收缩压及舒张压可能升高,1,,,,,,,minus,王兴悦
PA166136086,rs776746,1448255845,CC,Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for infections when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.,携带CC基因型的器官移植患者，相比CT或TT基因型，感染风险可能降低,1,,,0,,,,minus,王兴悦
PA166136086,rs776746,1448255846,CT,Patients with the CT genotype (CYP3A5 *1/*3) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.,携带CT基因型的器官移植患者，相比CC基因型，感染风险可能增加,1,,,2,,,,minus,王兴悦
PA166136086,rs776746,1448255847,TT,Patients with the TT genotype (CYP3A5 *1/*1) undergoing organ transplantation may have an increased risk for infections when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.,携带TT基因型的器官移植患者，相比CC基因型，感染风险可能增加,1,,,2,,,,minus,王兴悦
PA166136087,rs776746,1448573606,CC,"Patients with the CC genotype (CYP3A5 *3/*3) and ulcerative colitis may have an increased chance of achieving remission when treated with tacrolimus as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis. ",携带CC基因型的溃疡性结肠炎患者，相比CT基因型，缓解几率可能增加,1,,2,,,,,minus,王兴悦
PA166136087,rs776746,1448573607,CT,"Patients with the CT genotype (CYP3A5 *1/*3) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis. ",携带CT基因型的溃疡性结肠炎患者，相比CC基因型，缓解几率可能降低,1,,0,,,,,minus,王兴悦
PA166136087,rs776746,1448573608,TT,"Patients with the TT genotype (CYP3A5 *1/*1) and ulcerative colitis may have a decreased chance of achieving remission when treated with tacrolimus as compared to patients with the CC (*3/*3) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis. ",携带TT基因型的溃疡性结肠炎患者，相比CC基因型，缓解几率可能降低,1,,0,,,,,minus,王兴悦
PA166136088,rs776746,1444705394,CC,"Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation who are treated with tacrolimus may have a decreased, but not absent, risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity. ",携带CC基因型的肝转移患者，相比CT或TT基因型，神经钙调蛋白抑制剂诱发肝脏毒性的风险可能降低,1,,,0,,,,minus,王兴悦
PA166136088,rs776746,1444705395,CT,Patients with the CT genotype (CYP3A5 *1/*3) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity. ,携带CT基因型的肝转移患者，相比CC基因型，神经钙调蛋白抑制剂诱发肝脏毒性的风险可能增加,1,,,2,,,,minus,王兴悦
PA166136088,rs776746,1444705396,TT,Patients with the TT genotype (CYP3A5 *1/*1) undergoing liver transplantation who are treated with tacrolimus may have an increased risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity. ,携带TT基因型的肝转移患者，相比CC基因型，神经钙调蛋白抑制剂诱发肝脏毒性的风险可能增加,1,,,2,,,,minus,王兴悦
PA166134376,rs776746,1448422642,CC,"Patients with the CC genotype (CYP3A5 *3/*3) may require a lower dose of cyclosporine to reach target blood concentration as compared to patients with the CT (CYP3A5 *1/*3) or TT (CYP3A5 *1/*1) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine.",携带CC基因型的患者，相比CT或TT基因型，达到目标血药浓度所需的药物剂量可能更低,1,,,,0,0,,minus,王兴悦
PA166134376,rs776746,1448422643,CT,"Patients with the CT (CYP3A5 *1/*3) genotype may require a higher dose of cyclosporine to reach target blood concentration as compared to patients with the CC (CYP3A5 *3/*3) genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine.",携带CT基因型的患者，相比CC基因型，达到目标血药浓度所需的药物剂量可能更高,1,,,,2,2,,minus,王兴悦
PA166134376,rs776746,1448422644,TT,"Patients with the TT genotype (CYP3A5 *1/*1) may require a higher dose of cyclosporine to reach target blood concentration as compared to patients with the CC (CYP3A5 *3/*3) genotype,  although this is contradicted in some studies. Other genetic and clinical factors may also influence dose of cyclosporine.",携带TT基因型的患者，相比CC基因型，达到目标血药浓度所需的药物剂量可能更高,1,,,,2,2,,minus,王兴悦
PA166134402,rs776746,1448108861,CC,Patients with the CC genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.,携带CC基因型的患者，相比TT基因型，神经毒性风险可能降低,1,,,0,,,,minus,王兴悦
PA166134402,rs776746,1448108862,CT,Patients with the CT genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.,携带CT基因型的患者，相比TT基因型，神经毒性风险可能降低,1,,,0,,,,minus,王兴悦
PA166134402,rs776746,1448108863,TT,Patients with the TT genotype may have an increased risk of neurotoxicity when treated with paclitaxel as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.,携带TT基因型的患者，相比CT或CC基因型，神经毒性风险可能增加,1,,,2,,,,minus,王兴悦
PA166134941,rs776746,1444666125,CC,"Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.",携带CC基因型的肿瘤患者，相比TT基因型，因药物毒性导致剂量减少的风险可能降低,1,,,0,,,,minus,王兴悦
PA166134941,rs776746,1444666126,CT,"Patients with the CT genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.",携带CT基因型的肿瘤患者，相比TT基因型，因药物毒性导致剂量减少的风险可能降低,1,,,0,,,,minus,王兴悦
PA166134941,rs776746,1444666127,TT,Patients with the TT genotype and Carcinoma who are treated with sunitinib may have an increased risk for dose reductions due to toxicity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.,携带TT基因型的肿瘤患者，相比CT或CC基因型，因药物毒性导致剂量减少的风险可能增加,1,,,2,,,,minus,王兴悦
PA166134958,rs776746,1447947103,CC,Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,携带CC基因型的肿瘤患者，相比TT基因型，药物响应可能更好,1,,2,,,,,minus,王兴悦
PA166134958,rs776746,1447947104,CT,Patients with the CT genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,携带CT基因型的肿瘤患者，相比TT基因型，药物响应可能更好,1,,2,,,,,minus,王兴悦
PA166134958,rs776746,1447947105,TT,Patients with the TT genotype who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the CC or CT genotype. Conflicting evidence was seen by population type.  Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. ,携带TT基因型的肿瘤患者，相比CC或CT基因型，药物响应可能降低,1,,0,,,,,minus,王兴悦
PA166134959,rs776746,1447947109,CC,Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin  may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.,携带CC基因型的动脉粥样硬化患者，相比CT基因型，药物响应可能更好,1,,2,,,,,minus,王兴悦
PA166134959,rs776746,1447947110,CT,Patients with the CT genotype and Arteriosclerosis who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.,携带CT基因型的动脉粥样硬化患者，相比CC基因型，药物响应可能降低,1,,0,,,,,minus,王兴悦
PA166134959,rs776746,1447947111,TT,"Patients with the TT genotype and Arteriosclerosis were not examined in the study, however; patients with the CT genotype who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.",无TT基因型患者参与研究,1,,,,,,,minus,王兴悦
PA166134960,rs776746,1448099845,CC,Patients with the CC genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment. ,携带CC基因型的患者，相比TT基因型，血药浓度可能较高，药物清除率降低,1,,,,0,,2,minus,王兴悦
PA166134960,rs776746,1448099846,CT,"Patients with the CT genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype, or may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment. ",携带CT基因型的患者，相比TT基因型，血药浓度可能较高，药物清除率降低；相比CC基因型，血药浓度可能较低，药物清除率较高,1,,,,0,,0,minus,王兴悦
PA166134960,rs776746,1448099847,TT,Patients with the TT genotype may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment. ,携带TT基因型的患者，相比CC基因型，血药浓度可能较低，药物清除率较高,1,,,,2,,0,minus,王兴悦
PA166135020,rs776746,1183556912,CC,Patients with the CC genotype may have increased metabolism of ondansetron as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.,携带CC基因型的患者，相比TT基因型，药物代谢可能增加,1,,,,2,,,minus,王兴悦
PA166135020,rs776746,1183556913,CT,Patients with the CT genotype may have increased metabolism of ondansetron as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.,携带CT基因型的患者，相比TT基因型，药物代谢可能增加,1,,,,2,,,minus,王兴悦
PA166135020,rs776746,1183556914,TT,Patients with the TT genotype may have decreased metabolism of ondansetron as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.,携带TT基因型的患者，相比CC或CT基因型，药物代谢可能降低,1,,,,0,,,minus,王兴悦
PA166135107,rs776746,1183615182,CC,Healthy males with the CC (CYP3A5 *3/*3) genotype may have increased metabolism of amlodipine as compared to healthy males with the CT or TT (*3/*1 or *1/*1) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.,携带CC基因型的健康男性，相比CT或TT基因型，药物代谢可能增加,1,男,,,2,,,minus,王兴悦
PA166135107,rs776746,1183615183,CT,Healthy males with the CT (CYP3A5 *3/*1) genotype may have decreased metabolism of amlodipine as compared to patients with the CC (*3/*3) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.,携带CT基因型的健康男性，相比CC基因型，药物代谢可能降低,1,男,,,0,,,minus,王兴悦
PA166135107,rs776746,1183615184,TT,Healthy males with the TT (CYP3A5 *1/*1) genotype may have decreased metabolism of amlodipine as compared to patients with the CC (*3/*3) genotype. No significant associations were seen when considering clearance of amlodipine. Other genetic and clinical factors may also influence metabolism of amlodipine.,携带TT基因型的健康男性，相比CC基因型，药物代谢可能降低,1,男,,,0,,,minus,王兴悦
PA166136306,rs776746,1444703477,CC,Male patients with the CC genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.,携带CC基因型的男性患者，相比TT基因型，药物清除可能降低,1,男,,,0,,,minus,王兴悦
PA166136306,rs776746,1444703476,CT,Male patients with the CT genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.,携带CT基因型的男性患者，相比TT基因型，药物清除可能降低,1,男,,,0,,,minus,王兴悦
PA166136306,rs776746,1444703475,TT,Male patients with the TT genotype may have increased clearance of vardenafil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.,携带TT基因型的男性患者，相比CC或CT基因型，药物清除可能增加,1,男,,,2,,,minus,王兴悦
PA166134529,rs776746,1448613233,CC,"Patients with the CC genotype (CYP3A5*3/*3) who are recipients of a kidney, heart, lung or hematopoeitic stem cell transplant, or have other diseases, who are treated with tacrolimus may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.",携带CC基因型的接受肾、心、肺或血液干细胞移植或其他疾病的患者，相比CT或TT基因型，药物代谢可能降低，可能需要更低的药物剂量,1,,,,0,0,,minus,王兴悦
PA166134529,rs776746,1448613234,CT,"Patients with the CT genotype (CYP3A5*1/*3) who are recipients of a kidney, heart, lung or hematopoeitic stem cell transplant, or have other diseases, who are treated with tacrolimus may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.",携带CT基因型的接受肾、心、肺或血液干细胞移植或其他疾病的患者，相比CC基因型，药物代谢可能增加，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166134529,rs776746,1448613235,TT,"Patients with the TT genotype (CYP3A5*1/*1) who are recipients of a kidney, heart, lung or hematopoeitic stem cell transplant, or have other diseases, who are treated with tacrolimus may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's tacrolimus dose requirement.",携带TT基因型的接受肾、心、肺或血液干细胞移植或其他疾病的患者，相比CC基因型，药物代谢可能增加，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166134530,rs776746,1448427705,CC,"Patients with the CC (*3/*3) genotype and are recipients of a kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have an increased risk of nephrotoxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). However, some studies show a decreased risk of nephrotoxicity for patients with the CC genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.",携带CC基因型的接受肾或造血干细胞移植或有溃疡性结肠炎的患者，相比CT或TT基因型，肾脏毒性风险可能增加,1,,,2,,,,minus,王兴悦
PA166134530,rs776746,1448427706,CT,"Patients with the CT genotype (*1/*3) and are recipients of a kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). However, some studies show an increased risk of nephrotoxicity for patients with the CT genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.",携带CT基因型的接受肾或造血干细胞移植或有溃疡性结肠炎的患者，相比CC基因型，肾脏毒性风险可能降低,1,,,0,,,,minus,王兴悦
PA166134530,rs776746,1448427707,TT,"Patients with the TT (*1/*1) genotype and are recipients of kidney or hematopoietic stem cell transplantation or who have ulcerative colitis who are treated with tacrolimus may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the CC genotype (*3/*3). However, some studies show an increased risk of nephrotoxicity for patients with the TT genotype, and the majority of studies show no association at all. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.",携带TT基因型的接受肾或造血干细胞移植或有溃疡性结肠炎的患者，相比CC基因型，肾脏毒性风险可能降低,1,,,0,,,,minus,王兴悦
PA166134531,rs776746,1448604371,CC,"Patients with the CC (*3/*3) genotype and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.",携带CC基因型的接受肾或造血干细胞移植的患者，相比CT或TT基因型，移植排斥风险可能降低,1,,2,,,,,minus,王兴悦
PA166134531,rs776746,1448604372,CT,Patients with the CT genotype (*1/*3) and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3) or a decreased risk of transplant rejection as compared to patients with the TT genotype (*1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.,携带CT基因型的接受肾或造血干细胞移植的患者，相比CC基因型，移植排斥风险可能增加；相比TT基因型，移植排斥风险可能降低,1,,1,,,,,minus,王兴悦
PA166134531,rs776746,1448604373,TT,Patients with the TT (*1/*1) genotype and recipients of kidney or hematopoietic stem cell transplant who are treated with tacrolimus may have an increased risk of transplant rejection as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.,携带TT基因型的接受肾或造血干细胞移植的患者，相比CC基因型，移植排斥风险可能增加,1,,0,,,,,minus,王兴悦
PA166134533,rs776746,981203887,CC,"Patients with the CC genotype and HIV infection who are treated with nevirapine may have increased clearance of the drug as compared to patients with the CT and TT genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.",携带CC基因型的HIV感染患者，相比CT或TT基因型，药物清除可能增加,1,,,,2,,,minus,王兴悦
PA166134533,rs776746,981203888,CT,"Patients with the CT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.",携带CT基因型的HIV感染患者，相比CC基因型，药物清除可能降低,1,,,,0,,,minus,王兴悦
PA166134533,rs776746,981203889,TT,"Patients with the TT genotype and HIV infection who are treated with nevirapine may have decreased clearance of the drug as compared to patients with the CC genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity and genotype has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.",携带TT基因型的HIV感染患者，相比CC基因型，药物清除可能降低,1,,,,0,,,minus,王兴悦
PA166134534,rs776746,1448108239,CC,Patients with the CC genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带CC基因型的HIV感染患者，相比TT基因型，药物暴露量可能降低,1,,,,2,,,minus,王兴悦
PA166134534,rs776746,1448108240,CT,Patients with the CT genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype or may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带CT基因型的HIV感染患者，相比TT基因型，药物暴露量可能降低；相比CC基因型，药物暴露量可能增加,1,,,,1,,,minus,王兴悦
PA166134534,rs776746,1448108241,TT,Patients with the TT genotype and HIV infection who are treated with efavirenz may have increased exposure to drug as compared to patients with the CC genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.,携带TT基因型的HIV感染患者，相比CC基因型，药物暴露量可能增加,1,,,,0,,,minus,王兴悦
PA166134535,rs776746,1448567989,CC,Patients with the CC genotype (*3/*3) and who are recipients of transplants may have decreased metabolism of sirolimus and require a lower dose as compared to patients with the CT and TT genotype (*1/*3 and *3*/3). Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.,携带CC基因型的接受手术移植患者，相比CT和TT基因型，药物代谢可能降低，可能需要更低的药物剂量,1,,,,,0,,minus,王兴悦
PA166134535,rs776746,1448567990,CT,Patients with the CT genotype (*1/*3) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.,携带CT基因型的接受手术移植患者，相比CC基因型，药物代谢可能增加，可能需要更高的药物剂量,1,,,,,2,,minus,王兴悦
PA166134535,rs776746,1448567991,TT,Patients with the TT genotype (*1/*1) and who are recipients of transplants may have increased metabolism of sirolimus and require a higher dose as compared to patients with the CC genotype (*3/*3). Other genetic and clinical factors may also influence a patient's sirolimus dose requirements.,携带TT基因型的接受手术移植患者，相比CC基因型，药物代谢可能增加，可能需要更高的药物剂量,1,,,,,2,,minus,王兴悦
PA166134769,rs776746,1448568187,CC,"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype may have decreased metabolism of tacrolimus resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement. ",接受携带CC基因型的肝脏移植的患者，相比接受CT或TT基因型的肝脏移植，药物代谢可能降低，可能需要更低的药物剂量,1,,,,0,0,,minus,王兴悦
PA166134769,rs776746,1448568188,CT,"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement. ",接受携带CT基因型的肝脏移植的患者，相比接受CC基因型的肝脏移植，药物代谢可能增加，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166134769,rs776746,1448568189,TT,"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of tacrolimus resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's tacrolimus dose requirement. ",接受携带TT基因型的肝脏移植的患者，相比接受CC基因型的肝脏移植，药物代谢可能增加，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166135752,rs776746,1444700898,CC,Patients with the CC genotype may have decreased metabolism of quetiapine as compared to CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.,携带CC基因型的患者，相比CT或TT基因型，药物代谢可能降低,1,,,,0,,,minus,王兴悦
PA166135752,rs776746,1444700899,CT,Patients with the CT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.,携带CT基因型的患者，相比CC基因型，药物代谢可能增加,1,,,,2,,,minus,王兴悦
PA166135752,rs776746,1444700900,TT,Patients with the TT genotype may have increased metabolism of quetiapine as compared to CC genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.,携带TT基因型的患者，相比CC基因型，药物代谢可能增加,1,,,,2,,,minus,王兴悦
PA166135905,rs776746,1448266831,CC,"Patients with the CC genotype (CYP3A5 *3/*3) and epilepsy may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.",携带CC基因型的癫痫患者，相比CT或TT基因型，药物清除可能降低，可能需要更低的药物剂量,1,,,,0,0,,minus,王兴悦
PA166135905,rs776746,1448266832,CT,"Patients with the CT genotype (CYP3A5 *1/*3) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.",携带CT基因型的癫痫患者，相比CC基因型，药物清除可能增加，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166135905,rs776746,1448266833,TT,"Patients with the TT genotype (CYP3A5 *1/*1) and epilepsy may have increased clearance and decreased concentrations of carbamazepine, and require higher doses of the drug, as compared to patients with the CC genotype (CYP3A5 *3/*3). Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.",携带TT基因型的癫痫患者，相比CC基因型，药物清除可能增加，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166134961,rs776746,1448107630,CC,Patients with the CC genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment. ,携带CC基因型的心肌梗塞患者，相比TT基因型，达到目标低密度脂蛋白水平的可能性更高,1,,2,,,,,minus,王兴悦
PA166134961,rs776746,1448107631,CT,"Patients with the CT genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype, or may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment. ",携带CT基因型的心肌梗塞患者，相比TT基因型，达到目标低密度脂蛋白水平的可能性更高；相比CC基因型，达到目标低密度脂蛋白水平的可能性较低,1,,1,,,,,minus,王兴悦
PA166134961,rs776746,1448107632,TT,Patients with the TT genotype and Myocardial Infarction who are treated with rosuvastatin may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment. ,携带TT基因型的心肌梗塞患者，相比CC基因型，达到目标低密度脂蛋白水平的可能性较低,1,,0,,,,,minus,王兴悦
PA166159855,rs776746,1448125855,CC,Patients with the CC genotype and chronic myeloid leukemia have have increased trough concentrations of imatinib compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect concentrations of imatinib.,携带CC基因型的慢性粒细胞白血病患者，相比CT和TT基因型，药物值浓度可能增加,1,,,,0,,,minus,王兴悦
PA166159855,rs776746,1448125856,CT,Patients with the CT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.,携带CT基因型的慢性粒细胞白血病患者，相比CC基因型，药物值浓度可能较低,1,,,,2,,,minus,王兴悦
PA166159855,rs776746,1448125857,TT,Patients with the TT genotype and chronic myeloid leukemia have have decreased trough concentrations of imatinib compared to patients with the CC genotype. Other genetic and clinical factors may affect concentrations of imatinib.,携带CT基因型的慢性粒细胞白血病患者，相比CC基因型，药物值浓度可能较低,1,,,,2,,,minus,王兴悦
PA166135938,rs776746,1446899622,CC,"Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype, regardless of CYP3A4 expresser status. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.",接受携带CC基因型的肝脏移植的患者，CYP3A4低或中度表达，相比接受CT或TT基因型的肝脏移植，药物代谢可能降低，可能需要更低的药物剂量,1,,,,0,0,,minus,王兴悦
PA166135938,rs776746,1446899623,CT,"Patients who are recipients of a liver transplantation from a donor with the CT (CYP3A5 *1/*3) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype who is also a CYP3A4 low or intermediate expresser. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.",接受携带CT基因型的肝脏移植的患者，CYP3A4低或中度表达，相比接受CC基因型的肝脏移植，药物代谢可能增加，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166135938,rs776746,1446899624,TT,"Patients who are recipients of a liver transplantation from a donor with the TT (CYP3A5 *1/*1) genotype may have increased metabolism of cyclosporine resulting in decreased exposure, and may require a higher dose as compared to patients who receive a liver transplantation from a donor with the CC (*3/*3) genotype. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.",接受携带TT基因型的肝脏移植的患者，相比接受CC基因型的肝脏移植，药物代谢可能增加，可能需要更高的药物剂量,1,,,,2,2,,minus,王兴悦
PA166161465,rs776746,1448430655,CC,"Patients with the CC genotype and organ transplantation may have reduced clearance of everolimus compared to patients with the TT genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus. ",携带CC基因型的器官移植患者，相比TT基因型，药物清除可能下降,1,,,,0,,,minus,王兴悦
PA166161465,rs776746,1448430656,CT,"Patients with the CT genotype and organ transplantation may have reduced clearance of everolimus compared to patients with the TT genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus. ",携带CT基因型的器官移植患者，相比TT基因型，药物清除可能下降,1,,,,0,,,minus,王兴悦
PA166161465,rs776746,1448430657,TT,"Patients with the TT genotype and organ transplantation may have increased clearance of everolimus compared to patients with the CC genotype. However, not all studies have found a significant association. Other clinical and genetic factors may affect pharmacokinetics of everolimus. ",携带TT基因型的器官移植患者，相比CC基因型，药物清除可能增加,1,,,,2,,,minus,王兴悦
PA166134074,rs983332,637879983,GG,Rheumatoid Arthritis patients with genotype GG may be more likely to respond to TNF inhibitors as compared with patients with GT or TT genotypes .  Other genetic and clinical factors may also influence a patient's response.,携带GG基因型的风湿性关节炎患者，相比GT或TT基因型，药物响应可能较好,1,,2,,,,,minus,王兴悦
PA166134074,rs983332,637879984,GT,Rheumatoid Arthritis patients with genotype GT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.,携带GT基因型的风湿性关节炎患者，相比GG基因型，药物响应可能较差,1,,0,,,,,minus,王兴悦
PA166134074,rs983332,637879985,TT,Rheumatoid Arthritis patients with genotype TT may be less likely to respond to TNF inhibitors compared to a patient with genotype GG.  Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的风湿性关节炎患者，相比GG基因型，药物响应可能较差,1,,0,,,,,minus,王兴悦
PA166134181,rs993648,655384893,CC,Patients with the CC genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.,携带CC基因型的患者，相比CT基因型，恶性心血管事件风险可能增加,1,,,2,,,,minus,王兴悦
PA166134181,rs993648,655384892,CT,"Patients with the CT genotype who are treated with iloperidone may have decreased, but not absent, risk for adverse cardiovascular events as compared to patients with either the CC or the TT genotype.   It is unclear at this time why the heterozygous genotype would confer a different phenotype than either homozygous genotype.",携带CT基因型的患者，相比CC或TT基因型，恶性心血管事件风险可能降低,1,,,0,,,,minus,王兴悦
PA166134181,rs993648,655384891,TT,Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.,携带TT基因型的患者，相比CT基因型，恶性心血管事件风险可增加,1,,,2,,,,minus,王兴悦
PA166135479,rs9936750,1183863990,CC,Patients with the CC genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.,携带CC基因型的患者，相比TT基因型，药物毒性风险可能增加,1,,,2,,,,FWD,王兴悦
PA166135479,rs9936750,1183863991,CT,"Patients with the CT genotype who are treated with capecitabine may have an increased risk for capecitabine-induced toxicity as compared to patients with the TT genotype and may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.",携带CT基因型的患者，相比TT基因型，药物毒性风险可能增加；相比CC基因型，药物毒性风险可能降低,1,,,1,,,,FWD,王兴悦
PA166135479,rs9936750,1183863992,TT,"Patients with the TT genotype who are treated with capecitabine may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.",携带TT基因型的患者，相比CC基因型，药物毒性风险可能降低,1,,,0,,,,FWD,王兴悦
PA166135422,rs9934438,1446905852,AA,Patients with the AA genotype may have decreased dose of acenocoumarol or phenprocoumon as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.,携带AA基因型的患者，相比GG基因型，所需药物剂量可能减少,1,,,,,0,,plus,王兴悦
PA166135422,rs9934438,1446905853,AG,Patients with the AG genotype may have decreased dose of acenocoumarol or phenprocoumon as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.,携带AG基因型的患者，相比GG基因型，所需药物剂量可能减少,1,,,,,0,,plus,王兴悦
PA166135422,rs9934438,1446905854,GG,Patients with the GG genotype may have increased dose of acenocoumarol or phenprocoumon as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the dose of acenocoumarol or phenprocoumon.,携带GG基因型的患者，相比AA或AG基因型，所需药物剂量可能增加,1,,,,,2,,plus,王兴悦
PA166134762,rs9934438,1448105562,AA,Patients with AA genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带AA基因型的患者，相比GG基因型，第一次达到治疗范围内INR值所需要的时间可能缩短，过强抗凝风险时间可能缩短,1,,2,,,,,plus,王兴悦
PA166134762,rs9934438,1448105563,AG,Patients with AG genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带AG基因型的患者，相比GG基因型，第一次达到治疗范围内INR值所需要的时间可能缩短，过强抗凝风险时间可能缩短,1,,2,,,,,plus,王兴悦
PA166134762,rs9934438,1448105564,GG,Patients with GG genotypes may have increased the time to achieve a first INR within the therapeutic range and longer time to have over-anticoagulation (INR >4) risk when compared to patients with AA genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.,携带GG基因型的患者，相比AA基因型，第一次达到治疗范围内INR值所需要的时间可能增加，过强抗凝风险时间可能延长,1,,0,,,,,plus,王兴悦
PA166134267,rs9934438,1448602258,AA,Patients with the AA genotype who are treated with warfarin may require a lower dose as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带AA基因型的患者，相比AG或GG基因型，所需药物剂量可能更低,1,,,,,0,,plus,王兴悦
PA166134267,rs9934438,1448602259,AG,"Patients with the AG genotype who are treated with warfarin may require a lower dose as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient鈥檚 required dose of warfarin. ",携带AG基因型的患者，相比GG基因型，所需药物剂量可能更低；相比AA基因型，所需药物剂量可能更高,1,,,,,1,,plus,王兴悦
PA166134267,rs9934438,1448602260,GG,Patients with the GG genotype who are treated with warfarin may require higher dose as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's required dose of warfarin.,携带GG基因型的患者，相比AG或AA基因型，所需药物剂量可能更高,1,,,,,2,,plus,王兴悦
PA166136484,rs9934438,1447673034,AA,Patients with the AA genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.,携带AA基因型的患者，相比GG基因型，达到治疗范围内INR值所需要的时间可能缩短,1,,2,,,,,plus,王兴悦
PA166136484,rs9934438,1447673035,AG,Patients with the AG genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.,携带AG基因型的患者，相比GG基因型，达到治疗范围内INR值所需要的时间可能缩短,1,,2,,,,,plus,王兴悦
PA166136484,rs9934438,1447673036,GG,Patients with the GG genotype may have increased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype AG or AA. Other genetic and clinical factors may also influence the response to warfarin.,携带GG基因型的患者，相比AG或AA基因型，达到治疗范围内INR值所需要的时间可能增加,1,,0,,,,,plus,王兴悦
PA166134048,rs9937,1447963731,AA,"Patients with the AA genotype with cancer who are treated with gemcitabine 1) may be more likely to experience neutropenia and 2) may have decreased progression-free survival (PFS) as compared to patients with the AG or GG genotype. However, evidence is very contradictory for this association: one study found a decreased risk for hematological toxicity in those with the AA genotype, one study found increased PFS in those with the AA genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.",携带AA基因型的肿瘤患者，相比AG或GG基因型，嗜中性白血球减少症发生可能性增加，无进展生存期可能缩短,1,,0,2,,,,plus,王兴悦
PA166134048,rs9937,1447963732,AG,"Patients with the AG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, one study found no association with PFS for this variant. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.",携带AG基因型的肿瘤患者，相比AA基因型，嗜中性白血球减少症发生可能性降低，无进展生存期可能增加,1,,2,0,,,,plus,王兴悦
PA166134048,rs9937,1447963733,GG,"Patients with the GG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, evidence is very contradictory for this association: one study found an increased risk for hematological toxicity in those with the GG genotype, one study found decreased PFS in those with the GG genotype when assessed in a haplotype with rs1042858, one study found no association with PFS. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.",携带GG基因型的肿瘤患者，相比AA基因型，嗜中性白血球减少症发生可能性降低，无进展生存期可能增加,1,,2,0,,,,plus,王兴悦
